DESCRIPTIONS,0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49
Maternal weight measured at pregnancy week 26 GUSTO visit,"Placental weight (maternal genotype, adjusted for sex and gestational age)","Placental weight (fetal genotype, adjusted for sex and gestational age)",Birth weight,"Placental weight (maternal genotype, adjusted for sex)",Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),"Placental weight (paternal genotype, adjusted for sex and gestational age)","Placental weight (fetal genotype, adjusted for sex)",Birth weight (UKB data field 20022),Birth weight (MTAG),BMI at 6 weeks old,General glucose level in pregnancy (gestational week 30-32),"Placental weight (paternal genotype, adjusted for sex)",Glycemic traits (pregnancy),Gestational insulin sensitivity,Adiponectin levels in pregnancy,Gestational hypertension,Birth weight variance,Offspring birth weight,Gestational age (maternal effect),Gestational diabetes mellitus,Diabetes (gestational),Two-hour glucose in pregnancy (gestational week 30-32),Pelvic organ prolapse x maximum birth weight interaction,Gestational diabetes,BMI at birth,Gestational age (fetal effect),Fasting glucose in pregnancy (gestational week 14-16),BMI (weighted GWA),BMI at 6 months old,BMI at 8 months old,BMI at 3 months old,Gestational age at birth in labor-initiated deliveries (maternal effect),Gestational age at birth (maternal effect),Platelet count during  first trimester of pregnancy,Metabolite levels (pregnanediol-3-glucuronide),Intrahepatic cholestasis of pregnancy,Gestational duration,Pregnanediol-3-glucuronide levels,Preterm birth (maternal effect),Platelet count during  second trimester of pregnancy,Mean platelet volume during first trimester of pregnancy,Gynoid lean mass,Mean platelet volume during second trimester of pregnancy,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Platelet count during  third trimester of pregnancy,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Disease topic 16 (Pregnancy complications-plus),Fetal hemoglobin levels,Pregnancy zone protein levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3)
Maternal height measured at gestational week 26 GUSTO visit,"Placental weight (fetal genotype, adjusted for sex and gestational age)",Birth weight,"Placental weight (maternal genotype, adjusted for sex and gestational age)",Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),Gestational duration,Gestational age (fetal effect),Gestational hypertension,Gestational age (maternal effect),General glucose level in pregnancy (gestational week 30-32),Infant length,"Placental weight (paternal genotype, adjusted for sex and gestational age)",Birth weight (MTAG),Preeclampsia or small for gestational age infant (maternal genotype effect),"Placental weight (maternal genotype, adjusted for sex)","Placental weight (fetal genotype, adjusted for sex)",Birth weight (UKB data field 20022),BMI at 6 weeks old,Gestational age at birth (maternal effect),Gestational age at birth in labor-initiated deliveries (maternal effect),Anthropometric traits in newborns,Pelvic organ prolapse x maximum birth weight interaction,Glycemic traits (pregnancy),Birth weight variance,Gestational insulin sensitivity,"Placental weight (paternal genotype, adjusted for sex)",Gestational diabetes mellitus,Two-hour glucose in pregnancy (gestational week 30-32),BMI at birth,Gestational length in nulliparas,Gestational diabetes,Diabetes (gestational),Preterm birth (maternal effect),Offspring birth weight,Gestational age at birth in labor-initiated deliveries (child effect),Height (standard GWA),Fetal hemoglobin levels,Post-term birth,Fasting glucose in pregnancy (gestational week 14-16),Adiponectin levels in pregnancy,Height (weighted GWA),Birth length,Preterm delivery,BMI at 6 months old,Pregnanediol-3-glucuronide levels,Full scale intelligence quotient (cesarean section interaction),Height adjusted BMI,Disease topic 16 (Pregnancy complications-plus),Mean platelet volume during second trimester of pregnancy,Mean platelet volume during first trimester of pregnancy,Infant head circumference (MTAG)
"Maternal body mass index (BMI) at gestational week 26 GUSTO visit, calculated from weight and height at pw26 visit",Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),BMI at birth,"Placental weight (maternal genotype, adjusted for sex and gestational age)",BMI at 6 weeks old,Birth weight (UKB data field 20022),"Placental weight (fetal genotype, adjusted for sex and gestational age)",BMI (weighted GWA),"Placental weight (maternal genotype, adjusted for sex)","Placental weight (paternal genotype, adjusted for sex and gestational age)",Birth weight,"Placental weight (fetal genotype, adjusted for sex)",BMI at 6 months old,Birth weight (MTAG),Birth weight variance,Glycemic traits (pregnancy),BMI at 3 months old,BMI at 8 months old,BMI (standard GWA),"Placental weight (paternal genotype, adjusted for sex)",Gestational diabetes mellitus,Gestational insulin sensitivity,General glucose level in pregnancy (gestational week 30-32),Pelvic organ prolapse x maximum birth weight interaction,Height adjusted BMI,Longitudinal body mass index,Anthropometric traits in newborns,BMI-adjusted waist-hip ratio,Gestational age at birth in labor-initiated deliveries (maternal effect),Offspring birth weight,Adiponectin levels in pregnancy,Preeclampsia or small for gestational age infant (maternal genotype effect),Gestational diabetes,Diabetes (gestational),BMI at 1 year old,Critical COVID-19 or BMI (pleiotropy),COVID-19 infection or BMI (pleiotropy),BMI at 2 years old,Gestational age (maternal effect),Gestational age at birth in labor-initiated deliveries (child effect),Gestational hypertension,BMI,Modified Stumvoll Insulin Sensitivity Index (BMI interaction),Hospitalized COVID-19 or BMI (pleiotropy),Childhood body mass index,Gestational age (fetal effect),Body mass index (MTAG),Whole body fat mass (UKB data field 23100),Modified Stumvoll Insulin Sensitivity Index (adjusted for BMI),Body mass index in prediabetes,Diastolic blood pressure (BMI adjusted)
"Energy in kcal, from 24hr recall food and supplement intake",Energy expenditure (24h),Energy intake,Body mass index (dietary energy interaction),Relative carbohydrate intake,Glucose meal response (LMM),Energy expenditure,Dietary macronutrient intake (multi-trait analysis),Two-hour glucose challenge,Relative fat intake,Relative protein intake,Valine meal response (LMM),Waist-to-hip circumference ratio (dietary energy interaction),F-low caloric food liking (derived food-liking factor),Fasting glucose levels x carbohydrate intake interaction (2df),Glucose meal response (OrNLSr),Protein level change in low calorie diet obesity intervention,Lactate meal response (LMM),Low-carbohydrate diet (LCD) score,Triglycerides levels in IDL meal response (OrNLSr),Dietary macronutrient intake,Glycoprotein acetyls (mainly a1-acid glycoprotein) meal response (LMM),Fasting insulin levels x carbohydrate intake interaction (2df),Response to metfomin (Glucose levels at 60 minutes adjusted for baseline glucose levels),Citrate meal response (LMM),Principal component-derived dietary pattern 30,Metabolite risk score for predicting weight gain,Principal component-derived dietary pattern 2,F-savour/caloric food liking (derived food-liking factor),Two-hour glucose,Principal component-derived dietary pattern 24,F-healthy breakfast food liking (derived food-liking factor),Principal component-derived dietary pattern 40,Principal component-derived dietary pattern 45,Principal component-derived dietary pattern 3,Tyrosine meal response (LMM),Docosahexaenoic acid (22:6) meal response (OrNLSr),Basal metabolic rate (UKB data field 23105),Principal component-derived dietary pattern 36,Principal component-derived dietary pattern 29,Principal component-derived dietary pattern 20,Principal component-derived dietary pattern 18,Age at adiposity rebound,Principal component-derived dietary pattern 12,Principal component-derived dietary pattern 10,Principal component-derived dietary pattern 35,Principal component-derived dietary pattern 4,Resting metabolic rate,Principal component-derived dietary pattern 26,Principal component-derived dietary pattern 5,Postprandial triglyceride response to high fat diet meal
"Energy in kcal, without outliers which are less than 800 kcal from 24hr recall food and supplement intake",Energy expenditure (24h),Energy intake,Dietary macronutrient intake (multi-trait analysis),Body mass index (dietary energy interaction),Low-carbohydrate diet (LCD) score,Relative carbohydrate intake,Two-hour glucose challenge,Relative fat intake,Glucose meal response (LMM),Relative protein intake,Energy expenditure,Waist-to-hip circumference ratio (dietary energy interaction),F-low caloric food liking (derived food-liking factor),Basal metabolic rate (UKB data field 23105),Dietary macronutrient intake,Valine meal response (LMM),Glucose meal response (OrNLSr),Triglycerides levels in IDL meal response (OrNLSr),Total fatty acids levels (UKB data field 23442),Principal component-derived dietary pattern 3,Protein level change in low calorie diet obesity intervention,Plasma metabolome feature (c18_1192) (Glucose),Principal component-derived dietary pattern 2,Principal component-derived dietary pattern 30,Principal component-derived dietary pattern 24,Fasting glucose levels x carbohydrate intake interaction (2df),Principal component-derived dietary pattern 45,Principal component-derived dietary pattern 36,Omega-6 fatty acids levels (UKB data field 23445),Principal component-derived dietary pattern 40,Metabolite peak levels (QI843),Basal metabolic rate variance,Principal component-derived dietary pattern 18,Metabolite peak levels (QI5469),Principal component-derived dietary pattern 7,Principal component-derived dietary pattern 10,Principal component-derived dietary pattern 32,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Metabolite peak levels (QI8774),Principal component-derived dietary pattern 5,Two-hour glucose,Metabolite peak levels (QI9368),Principal component-derived dietary pattern 39,Principal component-derived dietary pattern 12,Principal component-derived dietary pattern 35,Principal component-derived dietary pattern 4,Principal component-derived dietary pattern 31,Principal component-derived dietary pattern 46,Principal component-derived dietary pattern 28,Principal component-derived dietary pattern 20
"Energy in kcal, without outliers which are less than 500 kcal from 24hr recall food and supplement intake",Energy expenditure (24h),Energy intake,Dietary macronutrient intake (multi-trait analysis),Body mass index (dietary energy interaction),Low-carbohydrate diet (LCD) score,Relative carbohydrate intake,Two-hour glucose challenge,Relative fat intake,Glucose meal response (LMM),Energy expenditure,Relative protein intake,Waist-to-hip circumference ratio (dietary energy interaction),F-low caloric food liking (derived food-liking factor),Basal metabolic rate (UKB data field 23105),Dietary macronutrient intake,Valine meal response (LMM),Total fatty acids levels (UKB data field 23442),Glucose meal response (OrNLSr),Metabolite peak levels (QI5469),Principal component-derived dietary pattern 3,Basal metabolic rate variance,Protein level change in low calorie diet obesity intervention,Principal component-derived dietary pattern 30,Principal component-derived dietary pattern 2,Principal component-derived dietary pattern 45,Triglycerides levels in IDL meal response (OrNLSr),Metabolite peak levels (QI843),Principal component-derived dietary pattern 24,Fasting glucose levels x carbohydrate intake interaction (2df),Principal component-derived dietary pattern 36,Tea intake (UKB data field 1488),Principal component-derived dietary pattern 40,Omega-6 fatty acids levels (UKB data field 23445),Metabolite peak levels (QI4887),Metabolite peak levels (QI6365),Metabolite peak levels (QI9368),Two-hour glucose,Metabolite peak levels (QI244),Metabolite peak levels (QI4775),Metabolite peak levels (QI648),Metabolite peak levels (QI4378),Metabolite peak levels (QI2689),Metabolite peak levels (QI6688),Metabolite peak levels (QI3785),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Metabolite peak levels (QI4708),Metabolite peak levels (QI15249),Metabolite peak levels (QI8774),Metabolite peak levels (QI3722),Metabolite peak levels (QI2435)
"Protein in g, from 24hr recall food and supplement intake",Relative protein intake,Serum levels of protein SELL,Protein MENT levels (MENT.5744.12.3),Serum levels of protein REG3G,Protein MENT levels,Serum levels of protein RECQL,Protein IMPACT levels,Serum levels of protein PREP,Serum levels of protein KIT,Serum levels of protein GLCE,Serum levels of protein DUT,Serum levels of protein MPG,Serum levels of protein SET,Serum protein levels (sST2),Serum levels of protein MLN,Serum levels of protein XG,Serum levels of protein GC,Serum levels of protein GNLY,Protein level change in low calorie diet obesity intervention,Serum levels of protein LYZ,Serum levels of protein GNPTG,Blood protein levels,Serum levels of protein RET,GMPR/PSMG3 protein level ratio,Serum levels of protein GRP,Serum levels of protein ALPL,Serum levels of protein MGA,Serum levels of protein GRAP,Serum levels of protein BTC,Serum levels of protein IGHG1;IGHG2;IGHG3;IGHG4;IGL;IGK,Serum levels of protein CTRL,Protein DEPP levels (DEPP.7178.59.3),Serum levels of protein NPW,Serum levels of protein COMP,Serum levels of protein AGT,Serum levels of protein MET,Serum levels of protein RELB,Serum levels of protein TEX29,Serum levels of protein PROC,GGT1/MME protein level ratio,Serum total protein levels,GP6/MANF protein level ratio,Serum levels of protein GGT2,Serum levels of protein AGA,Serum levels of protein FAM3D,GLOD4/GMPR protein level ratio,HAGH/HMBS protein level ratio,Serum levels of protein AGRP,Serum levels of protein PYY,COMP/ITGAV protein level ratio
"Carbohydrate in g, from 24hr recall food and supplement intake",Relative carbohydrate intake,Glucose meal response (LMM),Glycerate levels,Glycoprotein acetyls (mainly a1-acid glycoprotein) meal response (LMM),Fasting glucose levels x carbohydrate intake interaction (2df),Glucose meal response (OrNLSr),Metabolite levels (gamma-glutamylglycine),Glycerate levels in elite athletes,Metabolite levels (prolylglycine; pro-gly),N-glycan levels,HbA1c levels x carbohydrate intake interaction (2df),Fasting plasma glycodeoxycholate 3-O-glucuronide concentration,Citrate meal response (LMM),Metabolite levels (alpha-glutamylglutamate),Metabolite levels (gamma-glutamylglutamate),Metabolite levels (gamma-glutamyl-2-aminobutyrate),Metabolite levels (1-linoleoyl-GPG (18:2)),Alpha-ketoglutarate levels,Metabolite levels (glyco-beta-muricholate),Fasting plasma glycochenodeoxycholate 3-O-glucuronide concentration,Alpha-ketoglutarate levels in elite athletes,Human milk oligosaccharide concentration (lacto-N-fucopentaose-III),Gamma-glutamyl hydrolase levels (GGH.9370.69.3),Glutaroyl carnitine levels (Biocrates platform),Metabolite levels (N-acetyl-aspartyl-glutamate (NAAG)),Metabolite levels (glycocholenate sulfate),Dietary macronutrient intake (multi-trait analysis),Metabolite levels (gamma-glutamylglutamine),Change in serum metabolite levels,Metabolite levels (glycine),Human milk oligosaccharide concentration (lacto-N-fucopentaose III),Metabolite levels (glycyltyrosine),Human milk oligosaccharide concentration (lacto-N-fucopentaose-II),Human milk oligosaccharide concentration (lacto-N-fucopentaose-I),Gamma-glutamylglycine levels,Triglycerides levels in IDL meal response (OrNLSr),Two-hour glucose challenge,Two-hour glucose,Glyco-beta-muricholate levels,Human milk oligosaccharide concentration (lacto-N-fucopentaose II),Change in serum metabolite levels (CMS),Gamma glutamyltransferase levels (adjusted for BMI) x vegetarianism interaction,Relative sugar intake,Human milk oligosaccharide concentration (lacto-N-fucopentaose I),Glycohyocholate levels,Metabolite levels (linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]; C36:4 DAG),Response to metfomin (Glucose levels at 60 minutes adjusted for baseline glucose levels),Low-carbohydrate diet (LCD) score,Metabolite levels (MHPG),Relative protein intake
"Total Fat in g, from 24hr recall food and supplement intake",Relative fat intake,Total fatty acids levels (UKB data field 23442),Total fatty acid levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),"Monounsaturated fatty acids (16:1, 18:1) levels",Saturated fatty acids levels (UKB data field 23448),Very long-chain saturated fatty acid levels (fatty acid 20:0),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Monounsaturated fatty acids levels (UKB data field 23447),Fatty acids (20:5) levels,Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453),Fatty acids (15:0) levels,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Polyunsaturated fatty acids levels (UKB data field 23446),Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452),Omega-3 fatty acids to total fatty acids percentage (UKB data field 23451),Body fat percentage and fasting glucose (pairwise),Circulating odd-numbered chain saturated fatty acid levels (C23:0),"Fasting monounsaturated fatty acids (16:1, 18:1)",Postprandial triglyceride response to high fat diet meal,Circulating odd-numbered chain saturated fatty acid levels (C15:0),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Body fat percentage variance,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Omega-6 fatty acids levels (UKB data field 23445),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Omega-3 fatty acids levels (UKB data field 23444),Body fat percentage (aged 40-50 years),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Body fat rate,Monounsaturated fatty acid levels,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Body fat percentage (aged 64-69 years),Omega-6 fatty acids to omega-3 fatty acids ratio (UKB data field 23459),Saturated fatty acids to total fatty acids percentage (UKB data field 23455),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Docosahexaenoic acid to total fatty acids percentage (UKB data field 23457),Total triglycerides levels (UKB data field 23407),Fatty acid(16:1)_[M-H]1- levels,Polyunsaturated fatty acid levels,Triglycerides levels in IDL meal response (OrNLSr),Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels),Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),Fatty acids (14:0) levels,Whole body fat free mass (UKB data field 23101)
"Carbohydrate in Percentage, from 24hr recall food and supplement intake",Relative carbohydrate intake,Relative protein intake,Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453),Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),Low-carbohydrate diet (LCD) score,Dietary macronutrient intake (multi-trait analysis),Relative sugar intake,Omega-3 fatty acids to total fatty acids percentage (UKB data field 23451),Relative fat intake,"Monounsaturated fatty acids (16:1, 18:1) levels",HbA1c levels x carbohydrate intake interaction (2df),Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452),Polyunsaturated fatty acids levels (UKB data field 23446),Glucose meal response (LMM),Percentage of invited food questionnaires completed,Citrate meal response (LMM),Monounsaturated fatty acids levels (UKB data field 23447),Glycerate levels,Principal component-derived dietary pattern 30,Total fatty acids levels (UKB data field 23442),Percent glycated albumin,Dietary macronutrient intake,Saturated fatty acids to total fatty acids percentage (UKB data field 23455),Intake of total sugars,Carnitine levels (Biocrates platform),Omega-6 fatty acids to omega-3 fatty acids ratio (UKB data field 23459),Principal component-derived dietary pattern 45,Maltose levels in elite athletes,Metabolite levels (carnitine),Principal component-derived dietary pattern 29,CLEC4G/KEL protein level ratio,Principal component-derived dietary pattern 36,Principal component-derived dietary pattern 35,Principal component-derived dietary pattern 39,Principal component-derived dietary pattern 58,Human milk oligosaccharide concentration (lacto-N-fucopentaose-III),Saturated fatty acids levels (UKB data field 23448),Principal component-derived dietary pattern 40,Glutaroyl carnitine levels (Biocrates platform),Principal component-derived dietary pattern 81,Principal component-derived dietary pattern 20,Fasting glucose levels x carbohydrate intake interaction (2df),Human milk oligosaccharide concentration (lacto-N-fucopentaose-I),Principal component-derived dietary pattern 10,Principal component-derived dietary pattern 24,Human milk oligosaccharide concentration (lacto-N-fucopentaose III),Triglycerides levels in IDL meal response (OrNLSr),Human milk oligosaccharide concentration (lacto-N-fucopentaose-II),Carnitine levels
"Protein in Percentage, from 24hr recall food and supplement intake",Relative protein intake,Protein MENT levels (MENT.5744.12.3),Serum levels of protein SELL,Protein MENT levels,Protein IMPACT levels,Serum levels of protein KIT,Serum total protein levels,Serum levels of protein SET,Serum levels of protein PREP,Serum levels of protein RECQL,Serum levels of protein MLN,APP/SPARC protein level ratio,Blood protein levels,APRT/MIF protein level ratio,Serum levels of protein DUT,Serum levels of protein MAX,Total protein levels (UKB data field 30860),COMP/ITGAV protein level ratio,AHSP/HMBS protein level ratio,Total protein levels x vegetarianism interaction,REG1A/REG4 protein level ratio,Serum levels of protein ALPL,Serum levels of protein RET,Serum levels of protein LYZ,Serum protein levels (sST2),CERT/MAX protein level ratio,Serum levels of protein CTRL,HAGH/HMBS protein level ratio,Serum levels of protein PROC,Serum levels of protein MET,LAT/MANF protein level ratio,AGXT/MME protein level ratio,Serum levels of protein NPW,Total protein levels (adjusted for BMI) x vegetarianism interaction,Serum levels of protein COMP,BAX/MAX protein level ratio,REG1B/REG3A protein level ratio,FAM3B/FUT3_FUT5 protein level ratio,Protein DEPP levels (DEPP.7178.59.3),Serum levels of protein TEX29,FXN/TST protein level ratio,ADM/CLMP protein level ratio,Serum levels of protein BTC,ADAMTS15/CLMP protein level ratio,AMBP/CAPG protein level ratio,COMT/RHOC protein level ratio,Serum levels of protein FAM3D,MEPE/SOST protein level ratio,MANF/PPIB protein level ratio,FHIT/MAX protein level ratio
"Fat in Percentage, from 24hr recall food and supplement intake",Relative fat intake,Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453),Body fat percentage variance,Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),Omega-3 fatty acids to total fatty acids percentage (UKB data field 23451),Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452),Body fat percentage,Body fat percentage (aged 40-50 years),Total fatty acids levels (UKB data field 23442),Body fat percentage (aged 64-69 years),Saturated fatty acids to total fatty acids percentage (UKB data field 23455),Saturated fatty acids levels (UKB data field 23448),Polyunsaturated fatty acids levels (UKB data field 23446),Docosahexaenoic acid to total fatty acids percentage (UKB data field 23457),Linoleic acid to total fatty acids percentage (UKB data field 23456),Monounsaturated fatty acids levels (UKB data field 23447),Total fatty acid levels,Omega-6 fatty acids to omega-3 fatty acids ratio (UKB data field 23459),Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),Fatty acids (20:5) levels,Body fat rate,"Monounsaturated fatty acids (16:1, 18:1) levels",Body fat percentage and triglycerides (pairwise),Percent liver fat,Body fat percentage or coronary artery disease (MTAG),Body fat percentage and coronary artery disease (pairwise),Ratio of polyunsaturated fatty acids to total fatty acids,Fatty acids (15:0) levels,Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Body fat percentage (adjusted for testosterone and SHBG),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),Omega-6 fatty acids levels (UKB data field 23445),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Omega-3 fatty acids levels (UKB data field 23444),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Body fat percentage and fasting glucose (pairwise),Triglycerides to total lipids in IDL percentage (UKB data field 23613),Ratio of monounsaturated fatty acids to total fatty acids,"Fasting monounsaturated fatty acids (16:1, 18:1)",Ratio of omega-6 fatty acids to total fatty acids,Very long-chain saturated fatty acid levels (fatty acid 20:0),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Polyunsaturated fatty acid levels,Ratio of omega-3 fatty acids to total fatty acids,Ratio of saturated fatty acids to total fatty acids,Triglycerides to total lipids in medium VLDL percentage (UKB data field 23598),Ratio of docosahexaenoic acid to total fatty acid levels
"Saturated Fat in g, from 24hr recall food and supplement intake",Very long-chain saturated fatty acid levels (fatty acid 24:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),Saturated fatty acids levels (UKB data field 23448),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Saturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C17:0),Circulating odd-numbered chain saturated fatty acid levels (C23:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0),Saturated fatty acids,Monounsaturated fatty acids levels (UKB data field 23447),Relative fat intake,"Monounsaturated fatty acids (16:1, 18:1) levels",Postprandial saturated fatty acids,"Fasting monounsaturated fatty acids (16:1, 18:1)",Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Polyunsaturated fatty acids levels (UKB data field 23446),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Total fatty acids levels (UKB data field 23442),Monounsaturated fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Postprandial triglyceride response to high fat diet meal,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fasting saturated fatty acids,Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels),Polyunsaturated fatty acid levels,Fatty acids (15:0) levels,Saturated fatty acids to total fatty acids percentage (UKB data field 23455),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acids (20:5) levels,Ratio of saturated fatty acids to total fatty acids,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),Triglycerides levels in IDL meal response (OrNLSr),Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),Fatty acid(16:1)_[M-H]1- levels,Total fatty acid levels,Triglycerides levels in medium HDL meal response (LMM),Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453),Fatty acid(18:4)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(20:3)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Total lipids in very large HDL meal response (LMM),Fatty acid(20:4)_[M-H]1- levels,Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)
"Monounsaturated Fat in g, from 24hr recall food and supplement intake","Postprandial monounsaturated fatty acids (16:1, 18:1)","Monounsaturated fatty acids (16:1, 18:1) levels",Monounsaturated fatty acids levels (UKB data field 23447),"Fasting monounsaturated fatty acids (16:1, 18:1)",Monounsaturated fatty acid levels,Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels),Polyunsaturated fatty acids levels (UKB data field 23446),Very long-chain saturated fatty acid levels (fatty acid 24:0),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Circulating odd-numbered chain saturated fatty acid levels (C23:0),Triglycerides levels in IDL meal response (OrNLSr),Very long-chain saturated fatty acid levels (fatty acid 20:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0),Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),Postprandial triglyceride response to high fat diet meal,Delta-6 desaturase activity response to n3-polyunsaturated fat supplement,Monounsaturated fatty acids,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Delta-5 desaturase activity response to n3-polyunsaturated fat supplement,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Postprandial polyunsaturated fatty acids,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,Fasting polyunsaturated fatty acids,Serum polyunsaturated fatty acid concentration x Mediterranean diet adherence interaction in metabolic syndrome,Ratio of monounsaturated fatty acids to total fatty acids,Triglycerides levels in medium HDL meal response (LMM),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453),Relative fat intake,Postprandial saturated fatty acids,Total fatty acids levels (UKB data field 23442),Triglycerides levels in small HDL meal response (LMM),Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Saturated fatty acids levels (UKB data field 23448),Polyunsaturated fatty acids,Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)
"Polyunsaturated Fat in g, from 24hr recall food and supplement intake",Polyunsaturated fatty acids levels (UKB data field 23446),Polyunsaturated fatty acid levels,Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Postprandial polyunsaturated fatty acids,Monounsaturated fatty acids levels (UKB data field 23447),"Monounsaturated fatty acids (16:1, 18:1) levels","Fasting monounsaturated fatty acids (16:1, 18:1)",Monounsaturated fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453),Very long-chain saturated fatty acid levels (fatty acid 24:0),Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Fasting polyunsaturated fatty acids,Polyunsaturated fatty acids,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Serum polyunsaturated fatty acid concentration x Mediterranean diet adherence interaction in metabolic syndrome,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Delta-6 desaturase activity response to n3-polyunsaturated fat supplement,Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 22:0),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Delta-5 desaturase activity response to n3-polyunsaturated fat supplement,Ratio of polyunsaturated fatty acids to total fatty acids,Postprandial triglyceride response to high fat diet meal,Very long-chain saturated fatty acid levels (fatty acid 20:0),Postprandial saturated fatty acids,Other polyunsaturated fatty acid levels than 18:2,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),Circulating odd-numbered chain saturated fatty acid levels (C23:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Postprandial total fatty acids,Triglycerides levels in IDL meal response (OrNLSr),Monounsaturated fatty acids,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Total fatty acids levels (UKB data field 23442),Ratio of polyunsaturated fatty acids to monounsaturated fatty acids,Ratio of monounsaturated fatty acids to total fatty acids,Saturated fatty acids levels (UKB data field 23448)
"Cholesterol in mg, from 24hr recall food and supplement intake",Total esterified cholesterol levels (UKB data field 23415),Remnant cholesterol levels,Cholesterol levels,"Remnant cholesterol (non-HDL, non-LDL -cholesterol)",Total cholesterol in very large HDL meal response (LMM),Total cholesterol levels,"Remnant cholesterol (non-HDL, non-LDL -cholesterol) levels (UKB data field 23402)","Cholesterol, total",Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Total esterified cholesterol levels,Total cholesterol levels (MTAG),Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),Cholesterol to total lipids in small VLDL percentage (UKB data field 23600),Esterified cholesterol levels,Cholesterol to total lipids in small HDL percentage (UKB data field 23645),Serum total cholesterol levels,Total Cholesterol in IDL,Total cholesterol levels (UKB data field 23400),Cholesterol in medium HDL (UKB data field 23568),Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597),X-08402-to-cholesterol ratio,Cholesterol levels in IDL,Cholesterol to total lipids in very small VLDL percentage (UKB data field 23605),Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642),Cholesteryl ester (24:0) levels,X-11820-to-cholesterol ratio,Total cholesterol levels in medium VLDL,Cholesterol in IDL (UKB data field 23526),Cholesterol to total lipids in medium LDL percentage (UKB data field 23620),Cholesteryl ester (24:1) levels,Cholesterol to total lipids in large VLDL percentage (UKB data field 23590),Postprandial esterified cholesterol,Total cholesterol in small LDL meal response (OrNLSr),Cholesterol to total lipids in small LDL percentage (UKB data field 23625),Total cholesterol levels in VLDL,Free cholesterol in very large HDL meal response (LMM),Cholesterol in medium LDL (UKB data field 23540),Free cholesterol to total lipids in small VLDL percentage (UKB data field 23602),VLDL cholesterol levels (UKB data field 23403),Cholesterol levels (UKB data field 30690),Free cholesterol to total lipids in small HDL percentage (UKB data field 23647),Cholesteryl ester (24:6) levels,Free cholesterol in medium HDL (UKB data field 23570),Total cholesterol in very large VLDL meal response (OrNLSr),Cholesterol to total lipids in very large VLDL percentage (UKB data field 23585),Cholesteryl ester (24:5) levels,Free cholesterol levels,Postprandial total cholesterol in medium HDL,Cholesteryl ester (22:0) levels,Cholesterol esters in very large HDL meal response (LMM)
"Vitamin A in mcg, from 24hr recall food and supplement intake",Retinol (Vitamin A) levels,Vitamin levels,Retinol (Vitamin A) levels in elite athletes,Serum lycopene concentrations,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Metabolite levels (C36:4 PC-A; C36_4_PC_A),Dietary macronutrient intake,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Serum levels of protein MGA,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Change in serum metabolite levels (CMS),Vitamin D levels or COVID-19 (MTAG),Vitamin B1 intake,Metabolite levels (N-acetyl-aspartyl-glutamate (NAAG)),Response to Vitamin E supplementation,N-glycan levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Vitamin D levels (dietary vitamin D intake interaction),Metabolite levels (glyco-beta-muricholate),(S)-a-amino-omega-caprolactam levels,Glyco-beta-muricholate levels,Monounsaturated fatty acid levels,Vitamin D-binding protein levels (GC.6581.50.3),Serum levels of protein MGAT4A,Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),Dietary macronutrient intake (multi-trait analysis),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Serum metabolite levels (CMS),Change in serum metabolite levels,"Fasting monounsaturated fatty acids (16:1, 18:1)",Plasma metabolome feature (c18_538) (L-2-Hydroxyglutaric acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Vitamin C levels,Monounsaturated fatty acids levels (UKB data field 23447),Metabolite levels (MHPG),Vitamin B2 intake,2-o-methylascorbic acid levels,Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels),Very long-chain saturated fatty acid levels (fatty acid 24:0),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Metabolite levels (N-acetylglutamate; acetylglutamic acid),Metabolite levels (gamma-glutamylglutamate),Metabolite levels (NMMA),Metabolite levels (HVA/MHPG ratio),Vitamin D insufficiency,Polyunsaturated fatty acid levels,Triglycerides (48:2)A levels
"Calcium in mg, from 24hr recall food and supplement intake",Calcium levels,Serum calcium levels,Plasma calcium levels,Calcium levels (UKB data field 30680),Urinary electrolytes (magnesium/calcium ratio),Urinary calcium excretion,Calcium levels x vegetarianism interaction,Colorectal cancer (calcium intake interaction),Calcium levels (adjusted for BMI) x vegetarianism interaction,Serum levels of protein CA4,CA2/CA3 protein level ratio,Serum levels of protein CA8,Serum levels of protein CA2,CA2/HMBS protein level ratio,CA3/HMBS protein level ratio,Serum levels of protein CA6,Urinary magnesium-to-creatinine ratio,CA 15 3 plasma levels,Urinary magnesium excretion,Coronary artery calcium score,CA2/PSMG3 protein level ratio,Magnesium levels,CA1/CA3 protein level ratio,CA2/HAGH protein level ratio,Medication use (calcium channel blockers),CA6/DNER protein level ratio,Serum levels of protein CA10,CA13/LACTB2 protein level ratio,Serum magnesium levels,CA5A/KRT18 protein level ratio,Bone mineral content,Calcium-binding protein 2 levels,Calpastatin levels (CAST.3026.5.2),Serum levels of protein CA1,Valine meal response (LMM),CA1/CA2 protein level ratio,CA13/USP8 protein level ratio,Vitamin levels,Calcium-binding protein 8 levels,CA4/SELE protein level ratio,CA13/COMT protein level ratio,AGXT/CA5A protein level ratio,CA1/HMBS protein level ratio,Dietary macronutrient intake,Dietary macronutrient intake (multi-trait analysis),Relative protein intake,aparc-a2009s lh volume S-calcarine,Change in serum metabolite levels (CMS),Cholate levels,AHSP/CA2 protein level ratio
"Starch in g, from 24hr recall food and supplement intake","Glycogen [starch] synthase, muscle levels",Glycoprotein acetyls (mainly a1-acid glycoprotein) meal response (LMM),Glucose meal response (LMM),Glycerate levels,Relative carbohydrate intake,Principal component-derived dietary pattern 45,Principal component-derived dietary pattern 30,Glucose meal response (OrNLSr),Principal component-derived dietary pattern 29,Principal component-derived dietary pattern 35,Principal component-derived dietary pattern 39,Principal component-derived dietary pattern 36,Gamma-glutamyl hydrolase levels (GGH.9370.69.3),Principal component-derived dietary pattern 58,Principal component-derived dietary pattern 40,Principal component-derived dietary pattern 24,Principal component-derived dietary pattern 31,Principal component-derived dietary pattern 46,Principal component-derived dietary pattern 10,Principal component-derived dietary pattern 32,Principal component-derived dietary pattern 20,Principal component-derived dietary pattern 54,Principal component-derived dietary pattern 28,Principal component-derived dietary pattern 12,Glycerate levels in elite athletes,Principal component-derived dietary pattern 81,Principal component-derived dietary pattern 33,Principal component-derived dietary pattern 2,Principal component-derived dietary pattern 44,Principal component-derived dietary pattern 23,Principal component-derived dietary pattern 27,Principal component-derived dietary pattern 1,Principal component-derived dietary pattern 14,Principal component-derived dietary pattern 19,Principal component-derived dietary pattern 21,Dietary macronutrient intake (multi-trait analysis),Principal component-derived dietary pattern 16,Principal component-derived dietary pattern 26,C-glycosyltryptophan levels,Citrate meal response (LMM),Principal component-derived dietary pattern 52,Principal component-derived dietary pattern 3,Principal component-derived dietary pattern 43,Principal component-derived dietary pattern 18,Principal component-derived dietary pattern 4,Principal component-derived dietary pattern 11,Gamma-glutamyltryptophan levels,N-glycan levels,Principal component-derived dietary pattern 13,Principal component-derived dietary pattern 17
"Sugar in g, from 24hr recall food and supplement intake",Relative sugar intake,Intake of total sugars,Two-hour glucose challenge,Two-hour glucose,Glucose meal response (LMM),Glucose levels,Glucose meal response (OrNLSr),Response to metfomin (Glucose levels at 60 minutes adjusted for baseline glucose levels),Oral glucose tolerance test-2h,GIP levels in response to oral glucose tolerance test (120 minutes),Oral glucose tolerance test-1h,Fasting glucose levels x carbohydrate intake interaction (2df),Glucose levels (UKB data field 23470),Glucose levels (UKB data field 30740),Fasting glucose change (long-term),Fasting glucose change (short-term),Perceived intensity of glucose,Glucagon levels in response to oral glucose tolerance test (120 minutes),Glucagon levels in response to oral glucose tolerance test (30 minutes),Maltose levels in elite athletes,Glucose in urine,Postprandial glucose in prediabetes,Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-120 minutes),Glucose levels (Biocrates platform),Blood sugar levels,GLP-1 levels in response to oral glucose tolerance test (120 minutes),2-hour postprandial insulin levels in prediabetes,Insulin levels in response to oral glucose tolerance test (120 minutes),Insulin levels in response to oral glucose tolerance test (30 minutes),Relative carbohydrate intake,Never eat sugar vs no sugar restrictions (UKB data field 6144),Fructose levels in elite athletes,Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-30 minutes),Response to metfomin (Fasting glucose levels adjusted for baseline glucose levels),Random glucose levels,Fasting glucose,Blood glucose levels,Intake of sweets,Sugar-sweetened beverage consumption,Plasma metabolome feature (c18_1192) (Glucose),Glucose levels in elite athletes,Glucose levels (Metabolon platform),Maltose levels,GIP levels in response to oral glucose tolerance test (fasting),HbA1c levels x carbohydrate intake interaction (2df),Oral glucose tolerance test-0h,Glycerate levels,"Fructose-2,6-bisphosphatase TIGAR levels (TIGAR.12476.50.3)",Confectionary intake,"Never eat sugar vs no eggs, dairy, wheat or sugar restrictions (UKB data field 6144)"
"Dietary Fibre in g, from 24hr recall food and supplement intake",Dietary macronutrient intake (multi-trait analysis),Fasting plasma glycodeoxycholate 3-O-glucuronide concentration,Principal component-derived dietary pattern 30,Gamma glutamyltransferase levels (adjusted for BMI) x vegetarianism interaction,Principal component-derived dietary pattern 40,Glycerate levels,Fasting plasma glycochenodeoxycholate 3-O-glucuronide concentration,Principal component-derived dietary pattern 45,Principal component-derived dietary pattern 35,Principal component-derived dietary pattern 29,Principal component-derived dietary pattern 36,Principal component-derived dietary pattern 58,Vegetable intake (standard GWA),Principal component-derived dietary pattern 24,Principal component-derived dietary pattern 39,Principal component-derived dietary pattern 20,Principal component-derived dietary pattern 46,Principal component-derived dietary pattern 54,Principal component-derived dietary pattern 12,Principal component-derived dietary pattern 28,Principal component-derived dietary pattern 10,Principal component-derived dietary pattern 27,Principal component-derived dietary pattern 44,Principal component-derived dietary pattern 81,Principal component-derived dietary pattern 23,Principal component-derived dietary pattern 31,Principal component-derived dietary pattern 52,Principal component-derived dietary pattern 18,Principal component-derived dietary pattern 21,Principal component-derived dietary pattern 19,Glyco-beta-muricholate levels,Principal component-derived dietary pattern 33,Principal component-derived dietary pattern 32,Principal component-derived dietary pattern 14,Human milk oligosaccharide concentration (lacto-N-fucopentaose-I),Principal component-derived dietary pattern 43,Principal component-derived dietary pattern 26,"Fasting monounsaturated fatty acids (16:1, 18:1)",Principal component-derived dietary pattern 16,Human milk oligosaccharide concentration (lacto-N-fucopentaose-III),Glucose meal response (LMM),Human milk oligosaccharide concentration (lacto-N-fucopentaose-II),Principal component-derived dietary pattern 42,Principal component-derived dietary pattern 13,Human milk oligosaccharide concentration (lacto-N-fucopentaose I),Principal component-derived dietary pattern 1,Principal component-derived dietary pattern 5,Principal component-derived dietary pattern 17,Principal component-derived dietary pattern 11,Principal component-derived dietary pattern 4
"B Carotene in mcg, from 24hr recall food and supplement intake",Metabolite levels (carotene diol (1)),Carotenoid levels (alpha-carotene),Metabolite levels (carotene diol (2)),Carotene diol (2) levels in elite athletes,Carotene diol (1) levels in elite athletes,Plasma metabolome feature (hilic_5782) (2-Apo-beta-carotenal),Carotene diol (1) levels,Carotenoid levels,Carotene diol (2) levels,Carotene diol (3) levels,Metabolite levels (MHPG),Serum lycopene concentrations,Change in serum metabolite levels (CMS),Carotenoid and tocopherol levels,Citrate meal response (LMM),Metabolite levels (glyco-beta-muricholate),Carnitine levels (Metabolon platform),Metabolite levels (C36:4 PC-A; C36_4_PC_A),Metabolite levels (carnitine),"Metabolite levels (1-dihomo-linolenylglycerol (alpha, gamma); 1-dihomo-linolenylglycerol (20:3))",Change in serum metabolite levels,Glyco-beta-muricholate levels,Metabolite levels (1-linoleoyl-GPG (18:2)),Metabolite levels (oleoyl-oleoyl-glycerol (18:1/18:1)  [1]; C36:2 DAG; C36_2_DAG),Carnitine levels (Biocrates platform),Serum metabolite levels (CMS),Metabolite levels (oleoyl-linoleoyl-glycerol (18:1/18:2) [1]; C36:3 DAG),Metabolite levels (C38_5_PC),Glycoprotein acetyls (mainly a1-acid glycoprotein) meal response (LMM),Metabolite levels (linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]; C36:4 DAG),Glutaroyl carnitine levels (Metabolon platform),Glucose meal response (LMM),Plasma metabolome feature (hilic_5103) (Linoleyl carnitine),Metabolite levels (1-palmitoylglycerophosphoglycerol; 1-palmitoyl-GPG (16:0)),Plasma metabolome feature (hilic_2680) (Isobutyryl-L-carnitine),Metabolite levels (palmitoyl-linoleoyl-glycerol (16:0/18:2) [1]; C34:2 DAG; C34_2_DAG),Metabolite levels (palmitoleoyl-linoleoyl-glycerol (16:1/18:2) [1]; C34:3 DAG),Glutaroyl carnitine levels (Biocrates platform),Plasma carotene diol (3) levels in chronic kidney disease,Metabolite levels (C38:2 PC; C38_2_PC),Metabolite levels (gamma-glutamylthreonine),Hydroxyisovaleroyl carnitine levels (Metabolon platform),Plasma carotene diol (2) levels in chronic kidney disease,Metabolite levels (2-methylbutyrylcarnitine (C5)),Metabolite levels (mannose),CHGB/MOG protein level ratio,Plasma carotene diol (1) levels in chronic kidney disease,Monounsaturated fatty acids levels (UKB data field 23447),"Monounsaturated fatty acids (16:1, 18:1) levels",RBC levels of L-Carnitine
"Retinol in mcg, from 24hr recall food and supplement intake",Retinol levels,Retinol (Vitamin A) levels,Retinol dehydrogenase 16 levels (RDH16.12881.17.3),Retinol (Vitamin A) levels in elite athletes,All-trans-retinol dehydrogenase levels,4-oxo-retinoic acid levels,Retinoschisin levels,Retinol-binding protein 1 levels,Retinol dehydrogenase 16 levels,All-trans-retinol dehydrogenase [NAD levels,Retinol-binding protein 2 levels,Retinol-binding protein 5 levels,Retinol-binding protein 4 levels,Retinoic acid receptor responder protein 1 levels (RARRES1.8398.277.3),Retinoic acid receptor responder protein 3 levels (RARRES3.10961.15.3),Retinoid-binding protein 7 levels (RBP7.14208.3.3),Retinoic acid early transcript 1G protein levels,All-trans retinoic acid-induced differentiation factor levels,Metabolite levels (oleoyl-linoleoyl-glycerol (18:1/18:2) [1]; C36:3 DAG),Metabolite levels (oleoyl-oleoyl-glycerol (18:1/18:1)  [1]; C36:2 DAG; C36_2_DAG),Serum lycopene concentrations,Cellular retinoic acid-binding protein 1 levels,1-myristoylglycerol (14:0) levels,Metabolite levels (palmitoleoyl-linoleoyl-glycerol (16:1/18:2) [1]; C34:3 DAG),Metabolite levels (linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]; C36:4 DAG),Metabolite levels (palmitoyl-linoleoyl-glycerol (16:0/18:2) [1]; C34:2 DAG; C34_2_DAG),Deoxycholic acid glucuronide (X-11491) levels,Metabolite levels (deoxycholic acid glucuronide),Cellular retinoic acid-binding protein 1 levels (CRABP1.11967.23.3),Retinoid-inducible serine carboxypeptidase levels,"Metabolite levels (1-dihomo-linolenylglycerol (alpha, gamma); 1-dihomo-linolenylglycerol (20:3))",Retinoic acid receptor responder protein 1 levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Metabolite levels (1-palmitoylglycerophosphoglycerol; 1-palmitoyl-GPG (16:0)),Retinoid-binding protein 7 levels,Metabolite levels (palmitoyl-linoleoyl-glycerol (16:0/18:2) [2]),Metabolite levels (linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1]),Metabolite levels (oleoyl-linoleoyl-glycerol (18:1/18:2) [2]),Metabolite levels (1-linoleoyl-GPG (18:2)),Metabolite levels (linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2]),Metabolite levels (palmitoyl-arachidonoyl-glycerol (16:0/20:4) [1]),Palmitoyl-oleoyl-glycerol (16:0/18:1) [2] levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,"5alpha-androstan-3alpha,17beta-diol 17-glucuronide levels",Change in serum metabolite levels (CMS),Metabolite levels (oleoyl-arachidonoyl-glycerol (18:1/20:4) [1]),1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Metabolite levels (1-stearoyl-2-linoleoyl-GPC (18:0/18:2); C36:2 PC; C36_2_PC),Deoxycholic acid glucuronide levels
"Iron in mg, from 24hr recall food and supplement intake",Iron levels,Serum iron levels,Iron status biomarkers (iron levels),Iron status biomarkers (total iron binding capacity),Plasma iron levels,Iron deficiency,Iron status biomarkers,Type 2 diabetes (dietary heme iron intake interaction),Iron status biomarkers (ferritin levels),Iron deficiency anemia,Iron deficiency anaemia,Liver iron content,Pancreas iron content,Disorders of iron metabolism (PheCode 275.1),Iron status biomarkers (transferrin levels),Iron status biomarkers (transferrin saturation),Spleen iron concentration,Blood trace element (Cu levels),Urinary magnesium-to-creatinine ratio,Blood trace element (Se levels),Ferritin levels (FTH1.FTL.3031.66.1),Magnesium levels,Serum magnesium levels,Blood trace element (Zn levels),Zinc intake,Protein MENT levels (MENT.5744.12.3),Response to selenium supplementation (change in plasma selenium concentration),ESAM/FUT8 protein level ratio,Serum manganese levels,Plasma magnesium levels,Urinary electrolytes (magnesium/calcium ratio),Dietary macronutrient intake (multi-trait analysis),Plasma manganese levels,Ferritin levels,Vitamin levels,Protein FAM150B levels (FAM150B.6284.7.3),Plasma zinc levels,Serum aluminum levels,FAM3B/FUT3_FUT5 protein level ratio,Ferritin level (brain),Red blood cell folate levels,Serum zinc levels,Serum lead levels,Urinary magnesium excretion,Metabolite levels (creatine),Lead levels in blood,Serum copper levels,Plasma lead levels,Zinc levels,Plasma arsenic levels
"Vitamin C in mg, from 24hr recall food and supplement intake",Vitamin C levels,Vitamin K-dependent protein C levels,Vitamin levels,Adipoylcarnitine (C6-DC) levels,Protein C level (plasma),Protein C levels,Isovalerylcarnitine (C5) levels,Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),Response to Vitamin E supplementation,Propionylcarnitine (c3) levels,Hexanoylcarnitine (C6) levels,Glutarylcarnitine (C5) levels,Retinol (Vitamin A) levels,Glutarylcarnitine (c5-dc) levels,Serum lycopene concentrations,Nonanoylcarnitine (C9) levels,Metabolite levels (C38_5_PC),Metabolite levels (C36:4 PC-A; C36_4_PC_A),Glutaroylcarnitine (C5DC) levels,Vitamin B1 intake,2-methylbutyrylcarnitine (C5) levels,Metabolite levels (adipoylcarnitine (C6-DC)),Vitamin D levels (dietary vitamin D intake interaction),Vitamin D-binding protein levels (GC.6581.50.3),Serum calcium levels,C2/SSC5D protein level ratio,Carnitine C6 levels,Protein C level (CSF),Butyrylcarnitine (C4) levels,Octanoylcarnitine (c8) levels,FFA Eicosapentaenoic Acid c levels,Lipid levels in hepatitis C treatment,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Calcium levels,Metabolite levels (2-methylbutyrylcarnitine (C5)),Serum levels of protein C5,N-glycan levels,Serum levels of protein C3,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Serum levels of protein C5;C6,Pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels,Carnitine C8 levels,Circulating odd-numbered chain saturated fatty acid levels (C23:0),Ascorbic acid 3-sulfate (X-12206) levels,Isovalerylcarnitine (C5) levels in elite athletes,Vitamin E levels,Serum levels of protein C1QC,Plasma calcium levels,Methylglutarylcarnitine levels,Metabolite levels (C38:2 PC; C38_2_PC)
"Sodium in mg, from 24hr recall food and supplement intake",Sodium levels,Sodium intake,Urinary sodium levels,Urinary sodium excretion,Urinary sodium to creatinine ratio,Added salt consumption,Urinary sodium to potassium ratio,Sodium levels in epilepsy,Blood pressure measurement (high sodium intervention),Blood pressure measurement (low sodium intervention),Urinary electrolytes (magnesium/calcium ratio),Valine meal response (LMM),Magnesium levels,Metabolite levels (N-acetyl-aspartyl-glutamate (NAAG)),N-acetyl-aspartyl-glutamate (naag) levels,Urinary magnesium-to-creatinine ratio,Blood pressure measurement (high sodium and potassium intervention),Plasma magnesium levels,Systolic blood pressure x sodium interaction (2df test),Urinary magnesium excretion,Serum magnesium levels,Systolic blood pressure x sodium interaction (1df test),Blood osmolality (transformed sodium),Chloride levels,Diastolic blood pressure x sodium interaction (2df test),Systolic blood pressure (dietary potassium intake interaction),Diastolic blood pressure x sodium interaction (1df test),Sodium channel subunit beta-2 levels,Potassium levels,Metabolite levels (NMMA),Plasma metabolome feature (hilic_4394) (MG(18:00:00:0)),Sodium channel subunit beta-4 levels,Metabolite levels (valine),Gamma-glutamylvaline levels,N-lactoyl valine levels,Plasma metabolome feature (c18_658) (Methylarsonic acid monosodium salt),N-acetylaspartate (naa) levels,Metabolite levels (N-acetylglutamine),N-acetyl-L-glutamic acid levels,Protein MENT levels (MENT.5744.12.3),Glutamine levels (UKB data field 23461),Metabolite levels (pregnenetriol sulfate),Metabolite levels (gamma-glutamyl-2-aminobutyrate),Metabolite levels (sulfate),Metabolite levels (N-acetylglutamate; acetylglutamic acid),Metabolite levels (HVA),Serum levels of protein NAB2,2-hydroxyhippurate (salicylurate) levels,Metabolite levels (gamma-glutamyl-alpha-lysine),Blood trace element (Se levels)
"Thiamin in mg, from 24hr recall food and supplement intake",Thiamine-triphosphatase levels,Thiamin pyrophosphokinase 1 levels,Vitamin levels,Serum magnesium levels,Valine meal response (LMM),Gamma-glutamylmethionine levels,Metabolite levels (gamma-glutamylthreonine),Metabolite levels (threonylphenylalanine),Gamma-glutamylhistidine levels,Serum levels of protein THRA,Magnesium levels,Gamma-glutamylthreonine levels,Urinary magnesium-to-creatinine ratio,Protein MENT levels (MENT.5744.12.3),Histidine meal response (LMM),Metabolite levels (threonine),Serum levels of protein MGAT2,Urinary magnesium excretion,Metabolite levels (gamma-glutamylglutamate),Gamma-glutamylglutamate levels,Response to selenium supplementation (change in plasma selenium concentration),Gamma-glutamylglutamine levels,Metabolite levels (gamma-glutamylglutamine),Serum levels of protein FTMT,Vitamin D-binding protein levels (GC.6581.50.3),Response to metfomin (Glucose levels at 60 minutes adjusted for baseline glucose levels),Serum manganese levels,Serum levels of protein GNMT,Response to metfomin (Insulin levels at 60 minutes),Serum levels of protein MGA,Vitamin B1 intake,Transcobalamin-2 levels (TCN2.5584.21.3),Metabolite levels (glyco-beta-muricholate),Galanin peptides levels (GAL.13389.8.3),Gamma-glutamylvaline levels,Plasma metabolome feature (hilic_901) (Dimethylphenylenediamine),Metabolite levels (alpha-glutamylglutamate),Serum levels of protein MGAT4A,Gamma-glutamyl hydrolase levels (GGH.9370.69.3),Serum levels of protein SELL,Plasma metabolome feature (hilic_4394) (MG(18:00:00:0)),Thioredoxin levels,Glyco-beta-muricholate levels,Gamma-glutamylcitrulline levels,Serum levels of protein MGAT4B,Serum zinc levels,Plasma magnesium levels,Dietary macronutrient intake (multi-trait analysis),Change in serum metabolite levels,Threonylphenylalanine levels
"Riboflavin in mg, from 24hr recall food and supplement intake",Riboflavin kinase levels (RFK.13059.33.3),Riboflavin to 3-Indolepropionic acid ratio in coronary artery disease,Riboflavin kinase levels,Metabolite levels (ribose),Metabolite levels (ribitol),Ribonate levels in elite athletes,Valine meal response (LMM),Ribitol levels,Urine ribonate levels in chronic kidney disease,Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),Ribitol levels in elite athletes,Ribothymidine levels,Total cholesterol in chylomicron and extremely large VLDL meal response (OrNLSr),Metabolite levels (isoleucylvaline),"Metabolite levels (5alpha-androstan-3alpha,17beta-diol 17-glucuronide)",Metabolite levels (O-sulfo-L-tyrosine),Serum levels of protein LIFR,FCRL2/KLB protein level ratio,Metabolite peak levels (QI4144),"Metabolite levels (4-androsten-3beta,17beta-diol disulfate (1); androstenediol (3beta,17beta) disulfate (1))",Tyrosine meal response (LMM),Metabolite peak levels (QI409),5-methyluridine (ribothymidine) levels,Ribulonate/xylulonate/lyxonate levels,Metabolite levels (erythritol),Ribonate levels,"Metabolite levels (4-androsten-3beta,17beta-diol monosulfate (1); androstenediol (3beta,17beta) monosulfate (1))",Serum levels of protein RFFL,Metabolite levels (1-linoleoyl-GPG (18:2)),Ribavirin-induced anemia,Total cholesterol in very large VLDL meal response (OrNLSr),Metabolite peak levels (QI2435),Metabolite peak levels (QI3754),Free cholesterol in chylomicron and extremely large VLDL meal response (OrNLSr),Metabolite peak levels (QI2044),Metabolite peak levels (QI15249),Metabolite peak levels (QI3785),Metabolite levels (linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]; C36:4 DAG),Metabolite peak levels (QI15625),Metabolite peak levels (QI3513),"Metabolite levels (4-androsten-3beta,17beta-diol disulfate (2); androstenediol (3beta,17beta) disulfate (2))",Change in serum metabolite levels,"Metabolite levels (4-androsten-3alpha,17alpha-diol monosulfate (2); androstenediol (3alpha, 17alpha) monosulfate (2))",Metabolite peak levels (QI4246),Metabolite peak levels (QI4123),Metabolite peak levels (QI15385),"Metabolite levels (1-dihomo-linolenylglycerol (alpha, gamma); 1-dihomo-linolenylglycerol (20:3))",Metabolite levels (linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1]),Metabolite peak levels (QI15464),Metabolite levels (dihomo-linolenate (20:3n3 or n6); eicosatrienoate)
"Potassium in mg, from 24hr recall food and supplement intake",Potassium levels,Urinary potassium levels,Systolic blood pressure (dietary potassium intake interaction),Urinary sodium to potassium ratio,Urinary potassium excretion,Urinary potassium to creatinine ratio,Urinary electrolytes (magnesium/calcium ratio),Urinary magnesium-to-creatinine ratio,KLK11/KLK8 protein level ratio,KLK6/MOG protein level ratio,Potassium chromate levels,Valine meal response (LMM),KLK10/KLK11 protein level ratio,Blood pressure measurement (high sodium and potassium intervention),Urinary magnesium excretion,Plasma magnesium levels,KLK8 protein levels,KLK8/LY6D protein level ratio,Magnesium levels,Serum levels of protein KCNE2,Creatine kinase M-type levels (CKM.2670.67.4),BCAN/KLK6 protein level ratio,Urinary sodium to creatinine ratio,Serum levels of protein KLK8,Serum levels of protein KCNG4,K10 abundance in stool,CK-MB level (plasma),DKK1/MGLL protein level ratio,Serum magnesium levels,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Metabolite levels (valine),KLK11 protein levels,Serum levels of protein KLK12,CRKL/MGLL protein level ratio,Plasma metabolome feature (hilic_4394) (MG(18:00:00:0)),Sodium levels,Metabolite levels (creatine),Urinary sodium levels,Response to selenium supplementation (change in plasma selenium concentration),Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),Plasma metabolome feature (c18_126) (Potassium bicarbonate),Alpha-ketoglutaramate levels,Serum levels of protein KLK11,Urinary sodium excretion,Voltage-gated potassium channel subunit beta-2 levels (KCNAB2.10015.119.3),Alpha-ketoglutarate levels,Serum levels of protein KCNA10,Ketonuria (moderate to severe),Urine 6-hydroxymelatonin sulfate-to-creatinine ratio,Metabolite levels (glyco-beta-muricholate)
"Phosphorus in mg, from 24hr recall food and supplement intake",Phosphorus intake,Phosphorus levels,Serum phosphate levels,Phosphate levels,Phosphate levels (adjusted for BMI) x vegetarianism interaction,Phosphate levels x vegetarianism interaction,Phosphate levels in elite athletes,Urinary magnesium-to-creatinine ratio,Urinary magnesium excretion,Urinary electrolytes (magnesium/calcium ratio),Phosphate-to-erythronate ratio,Phospholysine phosphohistidine inorganic pyrophosphate phosphatase levels,Choline phosphate levels,Plasma pyridoxal phosphate levels,Intestinal-type alkaline phosphatase levels (ALPI.10463.23.3),Relative protein intake,Choline phosphate levels in elite athletes,Serum levels of protein MGP,Dietary macronutrient intake (multi-trait analysis),Plasma pyridoxal phosphate to pyridoxal ratio,Protein MENT levels (MENT.5744.12.3),Pyridoxal phosphate phosphatase levels,Protein DEPP levels (DEPP.7178.59.3),Dietary macronutrient intake,MPHOSPH8/USP8 protein level ratio,Plasma pyridoxic acid to pyridoxal phosphate ratio,Phosphoenolpyruvate levels in blood donors,Metabolite levels (glycyltryptophan),Principal component-derived dietary pattern 30,Alkaline phosphatase levels (adjusted for BMI) x vegetarianism interaction,Intestinal-type alkaline phosphatase levels,Metabolite levels (MHPG),Serum levels of protein PRELP,Serum levels of protein SELL,AGRP/NPY protein level ratio,Pimelate (heptanedioate) levels in elite athletes,GAL/PM20D1 protein level ratio,Principal component-derived dietary pattern 45,Pyridoxal 5'-phosphate levels,Serum magnesium levels,PPP1R2/USP8 protein level ratio,Principal component-derived dietary pattern 36,Principal component-derived dietary pattern 29,Phosphoglucomutase-1 levels (PGM1.9173.21.3),Serum levels of protein POMC,Principal component-derived dietary pattern 24,Magnesium levels,Glycerol 3-phosphate levels in elite athletes,Metabolite levels (pterin),Serum levels of protein MPG
"Zinc in mg, from 24hr recall food and supplement intake",Zinc intake,Serum zinc levels,Zinc levels,Plasma zinc levels,Zinc-alpha-2-glycoprotein levels (AZGP1.9312.8.3),Blood trace element (Zn levels),Zinc-alpha-2-glycoprotein levels,Zinc finger protein 18 levels (ZNF18.11372.2.3),Zinc finger protein 276 levels (ZNF276.14692.3.3),Plasma metabolome feature (hilic_2832) (Zinc lactate),Zinc finger protein 175 levels (ZNF175.12716.3.3),Zinc transporter 5 levels,Response to antioxidants and zinc in age-related macular degeneration (disease progression),Zinc transporter 3 levels,Zinc fingers and homeoboxes protein 3 levels (ZHX3.10036.201.3),Zinc finger protein 275 levels,Zinc transporter ZIP14 levels,Zinc finger protein 334 levels,Zinc transporter ZIP5 levels,Immunoglobulin measurement (zinc sulfate turbidity test),Serum levels of protein ZNF276,Zinc finger protein GLI2 levels,Zinc finger protein 134 levels,Serum levels of protein ZNF275,Zinc finger protein 175 levels,Serum levels of protein ZNF334,Superoxide dismutase [Cu-Zn] levels,Serum levels of protein ZP4,Zinc finger protein 180 levels,Zinc finger protein 18 levels,Zinc finger protein 329 levels,Zinc finger protein 75D levels,Zinc finger protein 276 levels,Serum levels of protein ZNF10,Zinc finger protein 774 levels,protein Z inhibitor level (plasma),Myeloid zinc finger 1 levels,Serum levels of protein ZFYVE27,Zinc finger protein 526 levels,Zinc finger protein 10 levels,Serum levels of protein ZNRF3,Zinc finger protein ZPR1 levels,Zinc finger protein 830 levels,Zinc finger protein 276 level in Chronic kidney disease with hypertension and no diabetes (14692_3),Zinc finger protein 566 levels,Zinc fingers and homeoboxes protein 3 levels,Zinc fingers and homeoboxes protein 2 levels,Serum levels of protein ZNRF4,Zinc finger protein 264 levels,Blood trace element (Cu levels)
"Selenium in mcg, from 24hr recall food and supplement intake",Response to selenium supplementation (change in plasma selenium concentration),Serum selenium levels,Plasma selenium levels,Plasma selenium concentration,Midgestational selenium levels,Blood trace element (Se levels),Blood and toenail selenium levels,Serum levels of protein SEMG2,Glyco-beta-muricholate levels,Metabolite levels (glyco-beta-muricholate),Serum levels of protein SEMG1,Toenail selenium levels,Serum levels of protein SELPLG,Selenium levels (reference vs low),"Selenide, water dikinase 1 levels (SEPHS1.14083.25.3)",Valine meal response (LMM),X-13431--nonanoylcarnitine levels,Serum levels of protein SELP,Serum levels of protein SELE,Selenoprotein S levels (VIMP.11286.78.3),Change in serum metabolite levels (CMS),Serum manganese levels,Serum levels of protein SEMA3G,Dietary macronutrient intake (multi-trait analysis),Serum levels of protein MUSK,Serum metabolite levels (CMS),Tauro-beta-muricholate levels,Blood trace element (Cu levels),Metabolite levels (cysteine-glutathione disulfide),Protein MENT levels (MENT.5744.12.3),Selenoprotein M levels,SELE protein levels,Selenocysteine lyase levels,Metabolite levels (tauro-beta-muricholate; tauro-alpha-muricholate/tauro-beta-muricholate),Metabolite levels (MHPG),Metabolite levels (S-methylcysteine; methylcysteine),15 kDa selenoprotein level in Chronic kidney disease with hypertension and no diabetes (20087_3),Serum nickel levels,Serum chromium levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Sulfatide (d18:1/24:0) levels,Metabolite levels (methionine sulfone),Selenocysteine lyase level in Chronic kidney disease with hypertension and no diabetes (21537_33),Semenogelin-2 levels (SEMG2.6373.54.3),"Selenide, water dikinase 1 levels",Metabolite levels (C18:3 CE; C18_3_CE),Sulfatide (d18:1/24:1) levels,Selenoprotein S levels,SELPLG protein levels,Change in serum metabolite levels
Maternal Plasma Sodium concentration (mg/L) at pregnancy week 26,Sodium levels,Urinary sodium levels,Gestational hypertension,Blood pressure measurement (high sodium intervention),Blood pressure measurement (low sodium intervention),General glucose level in pregnancy (gestational week 30-32),Sodium intake,Mercury levels in pregnancy,Blood pressure measurement (high sodium and potassium intervention),Mean platelet volume during first trimester of pregnancy,Urinary sodium excretion,Mean platelet volume during second trimester of pregnancy,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Systolic blood pressure x sodium interaction (1df test),Hypertension complicating pregnancy,Platelet count during  second trimester of pregnancy,Platelet count during  first trimester of pregnancy,Two-hour glucose in pregnancy (gestational week 30-32),Diastolic blood pressure x sodium interaction (1df test),Systolic blood pressure x sodium interaction (2df test),Early placenta insulin-like peptide levels,Systolic blood pressure in preeclampsia,Sodium levels in epilepsy,Urinary sodium to potassium ratio,Diastolic blood pressure x sodium interaction (2df test),Gestational insulin sensitivity,Fetal hemoglobin levels,Glycemic traits (pregnancy),Pregnancy zone protein levels,Blood osmolality (transformed sodium),Diastolic blood pressure in preeclampsia,Midgestational selenium levels,Mean platelet volume during third trimester of pregnancy,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Urinary sodium to creatinine ratio,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Fasting glucose in pregnancy (gestational week 14-16),Preeclampsia or other maternal hypertension (maternal genotype effect),Gestational diabetes mellitus,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Mean arterial pressure x sodium interaction (2df test),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",HCG level (plasma),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Platelet count during  third trimester of pregnancy,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 4 levels
Maternal Plasma Magnesium concentration (mg/L) at pregnancy week 26,Serum magnesium levels,Plasma magnesium levels,Magnesium levels,General glucose level in pregnancy (gestational week 30-32),Mercury levels in pregnancy,Urinary magnesium excretion,Urinary magnesium-to-creatinine ratio,Midgestational selenium levels,Gestational hypertension,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Membrane magnesium transporter 1 levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Urinary electrolytes (magnesium/calcium ratio),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Magnesium transporter NIPA4 levels,Two-hour glucose in pregnancy (gestational week 30-32),Gestational insulin sensitivity,Gestational diabetes mellitus,Magnesium-dependent phosphatase 1 level in Chronic kidney disease with hypertension and no diabetes (20923_10),Pregnancy zone protein levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Glycemic traits (pregnancy),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Metabolite levels (pregnanediol-3-glucuronide),Mean platelet volume during first trimester of pregnancy,HCG level (plasma),Serum levels of protein MGA,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Plasma manganese levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Lowest magnesium plasma levels after treatment with platinum based chemotherapy,Mean platelet volume during second trimester of pregnancy,Fetal hemoglobin levels,Pregnanediol-3-glucuronide levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Putative pregnancy-specific beta-1-glycoprotein 7 levels,Platelet count during  first trimester of pregnancy,Plasma metabolome feature (hilic_4394) (MG(18:00:00:0)),Gestational diabetes
Maternal Magnesium deficiency - Sufficient (≥ 20.68 mg/L); Marginally deficient (≥ 18.25 mg/L or < 20.68 mg/L); Deficient (< 18.25 mg/L) at pregnancy week 26,Magnesium levels,Serum magnesium levels,Plasma magnesium levels,Urinary magnesium-to-creatinine ratio,Membrane magnesium transporter 1 levels,Magnesium transporter NIPA4 levels,Urinary electrolytes (magnesium/calcium ratio),Urinary magnesium excretion,General glucose level in pregnancy (gestational week 30-32),Mercury levels in pregnancy,Sodium levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Manganese levels,Methylmalonate (mma) levels,Magnesium-dependent phosphatase 1 level in Chronic kidney disease with hypertension and no diabetes (20923_10),Serum manganese levels,MGLL/MPIG6B protein level ratio,Pregnanolone/allopregnanolone sulfate levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fetal hemoglobin levels,Midgestational selenium levels,Serum levels of protein MGA,Plasma manganese levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),MGLL/PDLIM7 protein level ratio,DAG1/MGLL protein level ratio,Pregnancy zone protein levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Lowest magnesium plasma levels after treatment with platinum based chemotherapy,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Zinc levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Gestational hypertension,Pregnenetriol sulfate levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Metabolite levels (pregnanediol-3-glucuronide),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Potassium levels,MGLL/SHMT1 protein level ratio,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Gestational diabetes mellitus,Serum levels of protein MGP,FADD/MGLL protein level ratio,Serum levels of protein MGAT4A,DKK1/MGLL protein level ratio,ENO2/MGLL protein level ratio
Maternal Plasma Phosphorus concentration (mg/L) at pregnancy week 26,Phosphorus levels,Serum phosphate levels,"Alkaline phosphatase, placental-like levels",Phosphate levels,Phosphorus intake,"Alkaline phosphatase, placental type levels",Pregnancy zone protein levels,Mean platelet volume during first trimester of pregnancy,Proteinuria in preeclampsia,"5alpha-pregnan-3beta,20alpha-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnanolone/allopregnanolone sulfate levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Mean platelet volume during second trimester of pregnancy,5alpha-pregnan-diol disulfate levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Platelet count during  first trimester of pregnancy,"Plasma 5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels in chronic kidney disease",Platelet count during  second trimester of pregnancy,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),"Plasma 5alpha-pregnan-3beta,20alpha-diol disulfate levels in chronic kidney disease",Systolic blood pressure in preeclampsia,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Mean platelet volume during third trimester of pregnancy,Diastolic blood pressure in preeclampsia,Phospholysine phosphohistidine inorganic pyrophosphate phosphatase levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Preeclampsia or other maternal hypertension (maternal genotype effect),Midgestational circulating levels of PCBs (fetal genetic effect),Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Midgestational circulating levels of PBDEs (fetal genetic effect),General glucose level in pregnancy (gestational week 30-32),Early placenta insulin-like peptide levels,Preeclampsia or small for gestational age infant (maternal genotype effect),Pregnancy-specific beta-1-glycoprotein 2 levels,Platelet count during  third trimester of pregnancy,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Pregnancy-specific beta-1-glycoprotein 1 levels,Adiponectin levels in pregnancy,Pregnancy-specific beta-1-glycoprotein 5 levels,Fetal hemoglobin levels,"Plasma 5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in chronic kidney disease"
Maternal Plasma Potassium concentration (mg/L) at pregnancy week 26,Potassium levels,Urinary potassium levels,Gestational hypertension,General glucose level in pregnancy (gestational week 30-32),Urinary sodium to potassium ratio,HCG level (plasma),Systolic blood pressure (dietary potassium intake interaction),Glycemic traits (pregnancy),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Blood pressure measurement (high sodium and potassium intervention),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Urinary potassium excretion,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Gestational insulin sensitivity,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Urinary potassium to creatinine ratio,Pregnancy-specific beta-1-glycoprotein 11 levels,Potassium chromate levels,Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Hypertension complicating pregnancy,Pregnancy-specific beta-1-glycoprotein 9 levels,Mercury levels in pregnancy,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy zone protein levels,Mean platelet volume during first trimester of pregnancy,Two-hour glucose in pregnancy (gestational week 30-32),Pregnancy-specific beta-1-glycoprotein 1 levels,Metabolite levels (pregnanediol-3-glucuronide),Early placenta insulin-like peptide levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,"Alkaline phosphatase, placental-like levels",Pregnancy-specific beta-1-glycoprotein 5 levels,Fetal hemoglobin levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Mean platelet volume during second trimester of pregnancy,Midgestational cytokine/chemokine levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 3 levels,Gestational diabetes mellitus,Midgestational selenium levels,Systolic blood pressure in preeclampsia,"Alkaline phosphatase, placental type levels",Platelet count during  first trimester of pregnancy,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Platelet count during  second trimester of pregnancy,Preeclampsia or other maternal hypertension (maternal genotype effect),Midgestational cytokine/chemokine levels (maternal genetic effect),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Placental weight (maternal genotype, adjusted for sex and gestational age)"
Maternal Plasma Calcium concentration (mg/L) at pregnancy week 26,Serum calcium levels,Plasma calcium levels,Calcium levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),General glucose level in pregnancy (gestational week 30-32),Calcium levels (UKB data field 30680),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Gestational hypertension,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Mercury levels in pregnancy,Two-hour glucose in pregnancy (gestational week 30-32),Gestational insulin sensitivity,Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Glycemic traits (pregnancy),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Metabolite levels (pregnanediol-3-glucuronide),HCG level (plasma),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,CA 15 3 plasma levels,Pregnancy-specific beta-1-glycoprotein 5 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy zone protein levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Neonatal total 25-hydroxyvitamin D levels (cord blood),Serum levels of protein CA6,Putative pregnancy-specific beta-1-glycoprotein 7 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Urinary calcium excretion,Fasting glucose in pregnancy (gestational week 14-16),Serum levels of protein CA2,Gestational diabetes mellitus,Early placenta insulin-like peptide levels,Serum levels of protein CA8,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Calcium-binding protein 2 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,"Placental weight (maternal genotype, adjusted for sex and gestational age)",Serum levels of protein CA1,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Hypertension complicating pregnancy
Maternal Plasma Iron concentration (ug/L) at pregnancy week 26,Serum iron levels,Plasma iron levels,Iron status biomarkers (iron levels),Iron levels,Iron status biomarkers (ferritin levels),Iron status biomarkers,Fetal hemoglobin levels,Iron status biomarkers (total iron binding capacity),Iron deficiency anemia,General glucose level in pregnancy (gestational week 30-32),Pregnancy zone protein levels,Iron deficiency anaemia,Liver iron content,Iron deficiency,Platelet count during  first trimester of pregnancy,Iron status biomarkers (transferrin levels),Platelet count during  second trimester of pregnancy,Glycemic traits (pregnancy),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Spleen iron concentration,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),HCG level (plasma),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Iron status biomarkers (transferrin saturation),Mean platelet volume during first trimester of pregnancy,Fetal hemoglobin levels in sickle cell anemia,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Mean platelet volume during second trimester of pregnancy,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pancreas iron content,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Platelet count during  third trimester of pregnancy,Pregnanediol-3-glucuronide levels,Midgestational selenium levels,Two-hour glucose in pregnancy (gestational week 30-32),Disorders of iron metabolism (PheCode 275.1),Pregnancy-specific beta-1-glycoprotein 3 levels,Type 2 diabetes (dietary heme iron intake interaction),Fetuin A plasma levels,Fasting glucose in pregnancy (gestational week 14-16),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Mean platelet volume during third trimester of pregnancy
Maternal Iron deficiency - Sufficient (≥ 558.8 ug/L); Deficient (< 558.6 ug/L) at pregnancy week 26,Iron deficiency anemia,Iron deficiency anaemia,Serum iron levels,Iron levels,Iron deficiency,Iron status biomarkers (iron levels),Plasma iron levels,Fetal hemoglobin levels,Iron status biomarkers (ferritin levels),Iron status biomarkers (total iron binding capacity),Iron status biomarkers,Disorders of iron metabolism (PheCode 275.1),Fetal hemoglobin levels in sickle cell anemia,Iron status biomarkers (transferrin saturation),Iron status biomarkers (transferrin levels),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Liver iron content,Type 2 diabetes (dietary heme iron intake interaction),Pregnancy zone protein levels,General glucose level in pregnancy (gestational week 30-32),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Disease topic 16 (Pregnancy complications-plus),Glycemic traits (pregnancy),High fetal hemoglobin in sickle cell disease,Pancreas iron content,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnanolone/allopregnanolone sulfate levels,Ferritin levels (FTH1.FTL.3031.66.1),Spleen iron concentration,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Preeclampsia or small for gestational age infant (maternal genotype effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Glycosuria in pregnancy (maternal genotype effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Diabetes (gestational),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnanediol-3-glucuronide levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fasting glucose in pregnancy (gestational week 14-16),Red blood cell folate levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 8 levels,Neonatal total 25-hydroxyvitamin D levels (cord blood),Severe gestational thrombocytopenia,Glycosuria in pregnancy (maternal and offspring genotype effect),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Platelet count during  second trimester of pregnancy,Platelet count during  third trimester of pregnancy,Platelet count during  first trimester of pregnancy
Maternal Plasma Ferritin concentration (ng/mL) at pregnancy week 26,Ferritin levels,Ferritin levels (FTH1.FTL.3031.66.1),Iron status biomarkers (ferritin levels),Fetuin A plasma levels,Ferritin level (brain),"Ferritin, mitochondrial levels",Fetuin-B levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Serum levels of protein FETUB,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Serum alpha-fetoprotein levels,Pregnancy zone protein levels,Serum iron levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Fetuin-B level in Chronic kidney disease with hypertension and no diabetes (3367_8),Platelet count during  first trimester of pregnancy,Pregnanediol-3-glucuronide levels,Follistatin-related protein 1 levels (FSTL1.13112.179.3),"Ferritin, mitochondrial level in Chronic kidney disease with hypertension and no diabetes (8048_9)","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",General glucose level in pregnancy (gestational week 30-32),Glycemic traits (pregnancy),Platelet count during  second trimester of pregnancy,Fetal hemoglobin levels,Plasma iron levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnenetriol sulfate levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Fasting glucose in pregnancy (gestational week 14-16),Adiponectin levels in pregnancy,Ferritin light chain levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Midgestational cytokine/chemokine levels (fetal genetic effect),Metabolite levels (pregnanediol-3-glucuronide),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels"
Maternal Ferritin deficiency - Sufficient (≥ 15 ng/mL); Deficient (< 15ng/mL) at pregnancy week 26,Ferritin levels,Ferritin levels (FTH1.FTL.3031.66.1),Iron status biomarkers (ferritin levels),"Ferritin, mitochondrial levels",Ferritin level (brain),Fetuin A plasma levels,Fetuin-B levels,Disease topic 16 (Pregnancy complications-plus),Serum levels of protein FETUB,Serum iron levels,Hepcidin/ferritin ratio,Pregnancy-specific beta-1-glycoprotein 11 levels,Follistatin-related protein 1 levels (FSTL1.13112.179.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 5 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),"Ferritin, mitochondrial level in Chronic kidney disease with hypertension and no diabetes (8048_9)",Pregnancy-specific beta-1-glycoprotein 4 levels,Glycosuria in pregnancy (maternal genotype effect),Fetal hemoglobin levels,Pregnancy zone protein levels,Pregnancy-specific beta-1-glycoprotein 9 levels,F9/FETUB protein level ratio,Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Glycemic traits (pregnancy),Glycosuria in pregnancy (maternal and offspring genotype effect),Iron deficiency,Pregnancy-specific beta-1-glycoprotein 1 levels,Iron deficiency anemia,Pregnancy-specific beta-1-glycoprotein 3 levels,Iron deficiency anaemia,Fetuin-B level in Chronic kidney disease with hypertension and no diabetes (3367_8),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnanolone/allopregnanolone sulfate levels,Iron levels,Follistatin levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Serum alpha-fetoprotein levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Ferritin light chain levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Iron status biomarkers (iron levels)
Maternal Plasma Copper concentration (µg/L) at pregnancy week 26,Serum copper levels,Plasma copper levels,Blood trace element (Cu levels),Copper levels,Mercury levels in pregnancy,Copper transport protein ATOX1 levels,Blood trace element (Se levels),Serum cadmium levels,Serum nickel levels,Copper homeostasis protein cutC homolog levels,Pregnanediol-3-glucuronide levels,Midgestational selenium levels,Midgestational circulating levels of PCBs (fetal genetic effect),Plasma lead levels,Blood trace element (Zn levels),Erythrocyte cadmium concentration,Midgestational circulating levels of PBDEs (fetal genetic effect),Plasma cadmium levels,Serum tin levels,Serum lead levels,Lead levels in blood,Plasma pregnanediol-3-glucuronide levels in chronic kidney disease,Superoxide dismutase [Cu-Zn] levels,Platelet count during  first trimester of pregnancy,Amiloride-sensitive amine oxidase [copper-containing] level in Chronic kidney disease with hypertension and no diabetes (15486_126),Amiloride-sensitive amine oxidase [copper-containing] level in Chronic kidney disease with hypertension and no diabetes (6209_2),Platelet count during  second trimester of pregnancy,Pregnancy zone protein levels,Serum cobalt levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),HCG level (plasma),Fetal hemoglobin levels,Metabolite levels (pregnanediol-3-glucuronide),Plasma iron levels,Urine pregnanediol-3-glucuronide levels in chronic kidney disease,Extracellular superoxide dismutase [Cu-Zn] levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Glycemic traits (pregnancy),Plasma tin levels,Plasma chromium levels,Mental development (prenatal lead exposure interaction),Pregnancy-specific beta-1-glycoprotein 8 levels,Mean platelet volume during first trimester of pregnancy,Serum iron levels,Plasma zinc levels,Platelet count during  third trimester of pregnancy,Mean platelet volume during second trimester of pregnancy,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Copper chaperone for superoxide dismutase levels
Maternal Copper deficiency - Sufficient (≥ 900 ug/L); Deficient (< 900 ug/L) at pregnancy week 26,Serum copper levels,Blood trace element (Cu levels),Plasma copper levels,Copper levels,Copper homeostasis protein cutC homolog levels,Mercury levels in pregnancy,Pregnanediol-3-glucuronide levels,Copper transport protein ATOX1 levels,Disease topic 16 (Pregnancy complications-plus),Blood trace element (Se levels),Glycosuria in pregnancy (maternal genotype effect),Fetal hemoglobin levels,Serum cadmium levels,Iron deficiency anemia,Plasma pregnanediol-3-glucuronide levels in chronic kidney disease,Glycosuria in pregnancy (maternal and offspring genotype effect),Metabolite levels (pregnanediol-3-glucuronide),Serum nickel levels,Midgestational selenium levels,Iron deficiency,Serum tin levels,Glycemic traits (pregnancy),Pregnancy zone protein levels,Iron deficiency anaemia,Serum iron levels,Diabetes (gestational),Preeclampsia or other maternal hypertension (maternal genotype effect),Glycosuria in pregnancy (offspring genotype effect),Blood trace element (Zn levels),Superoxide dismutase [Cu-Zn] levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnanolone/allopregnanolone sulfate levels,Urine pregnanediol-3-glucuronide levels in chronic kidney disease,Iron levels,Amiloride-sensitive amine oxidase [copper-containing] level in Chronic kidney disease with hypertension and no diabetes (15486_126),Gestational hypertension,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Fetal hemoglobin levels in sickle cell anemia,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Amiloride-sensitive amine oxidase [copper-containing] level in Chronic kidney disease with hypertension and no diabetes (6209_2),Preeclampsia (maternal genotype effect),Preeclampsia or small for gestational age infant (maternal genotype effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Midgestational circulating levels of PBDEs (fetal genetic effect),Erythrocyte cadmium concentration,Gestational insulin sensitivity,Plasma iron levels,Copper chaperone for superoxide dismutase levels,Pregnancy-specific beta-1-glycoprotein 8 levels
Maternal Plasma Zinc concentration (µg/L) at pregnancy week 26,Serum zinc levels,Plasma zinc levels,Zinc levels,Blood trace element (Zn levels),Zinc-alpha-2-glycoprotein levels (AZGP1.9312.8.3),Zinc intake,Zinc-alpha-2-glycoprotein levels,Zinc finger protein 18 levels (ZNF18.11372.2.3),Zinc finger protein 276 levels (ZNF276.14692.3.3),Mercury levels in pregnancy,Zinc finger protein 175 levels (ZNF175.12716.3.3),Zinc finger protein 276 level in Chronic kidney disease with hypertension and no diabetes (14692_3),Zinc fingers and homeoboxes protein 3 levels (ZHX3.10036.201.3),Zinc finger protein 18 levels,Plasma metabolome feature (hilic_2832) (Zinc lactate),Zinc fingers and homeoboxes protein 2 levels,Immunoglobulin measurement (zinc sulfate turbidity test),Zinc finger protein 275 levels,Zinc finger protein GLI2 levels,Zinc finger protein 134 levels,Zinc fingers and homeoboxes protein 1 levels,Zinc finger protein Helios levels,Myeloid zinc finger 1 levels,Zinc finger protein 276 levels,Zinc fingers and homeoboxes protein 3 levels,Zinc finger protein 180 levels,Zinc finger protein 10 levels,Zinc finger protein 23 levels,Zinc finger protein ZPR1 levels,Serum nickel levels,Zinc finger protein 175 levels,Zinc transporter 5 levels,Zinc finger protein 526 levels,Zinc finger protein 75D levels,Zinc finger protein 329 levels,Zinc finger protein 566 levels,AN1-type zinc finger protein 2B level in Chronic kidney disease with hypertension and no diabetes (23319_6),Pregnancy zone protein levels,AN1-type zinc finger protein 1 levels,Zinc finger protein 34 levels,Zinc finger protein 264 levels,Zinc finger protein 774 levels,Zinc finger protein 830 levels,Zinc finger protein 334 levels,Serum levels of protein ZNF276,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Blood trace element (Cu levels),Zinc transporter 3 levels,Serum levels of protein ZNF275,Serum copper levels
Maternal Zinc deficiency - Sufficient (≥700 ug/L); Deficient (< 700 ug/L) at pregnancy week 26,Serum zinc levels,Plasma zinc levels,Zinc levels,Zinc intake,Zinc finger protein 276 levels (ZNF276.14692.3.3),Blood trace element (Zn levels),Zinc finger protein 18 levels (ZNF18.11372.2.3),Zinc-alpha-2-glycoprotein levels (AZGP1.9312.8.3),Zinc finger protein 175 levels (ZNF175.12716.3.3),Mercury levels in pregnancy,Zinc-alpha-2-glycoprotein levels,Zinc fingers and homeoboxes protein 3 levels (ZHX3.10036.201.3),Zinc finger protein 276 level in Chronic kidney disease with hypertension and no diabetes (14692_3),Zinc finger protein 275 levels,Zinc fingers and homeoboxes protein 1 levels,Zinc fingers and homeoboxes protein 2 levels,Zinc finger protein GLI2 levels,Zinc fingers and homeoboxes protein 3 levels,Zinc finger protein 18 levels,Zinc finger protein 180 levels,Zinc finger protein 134 levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Myeloid zinc finger 1 levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Zinc finger protein 75D levels,Zinc finger protein 276 levels,Zinc finger protein 175 levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Zinc finger protein 10 levels,Zinc transporter 5 levels,Zinc finger protein 774 levels,AN1-type zinc finger protein 1 levels,Zinc finger protein 329 levels,Zinc finger protein 830 levels,Zinc finger protein 566 levels,Zinc finger protein Helios levels,Zinc finger protein 23 levels,Zinc finger protein 334 levels,Pregnancy zone protein levels,Zinc finger protein ZPR1 levels,Zinc finger protein 526 levels,Zinc finger protein 264 levels,AN1-type zinc finger protein 2B level in Chronic kidney disease with hypertension and no diabetes (23319_6),Zinc finger protein 34 levels,Zinc transporter 3 levels,AN1-type zinc finger protein 5 levels,Zinc finger protein 410 levels,Glycemic traits (pregnancy),Pregnanolone/allopregnanolone sulfate levels,Plasma metabolome feature (hilic_2832) (Zinc lactate)
Maternal Plasma Selenium concentration (ug/L) at pregnancy week 26,Midgestational selenium levels,Serum selenium levels,Plasma selenium levels,Plasma selenium concentration,Response to selenium supplementation (change in plasma selenium concentration),Blood and toenail selenium levels,Blood trace element (Se levels),Mercury levels in pregnancy,Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Toenail selenium levels,Metabolite levels (pregnanediol-3-glucuronide),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Selenoprotein S levels (VIMP.11286.78.3),Pregnancy-specific beta-1-glycoprotein 8 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy zone protein levels,Plasma pregnanediol-3-glucuronide levels in chronic kidney disease,Pregnancy-specific beta-1-glycoprotein 2 levels,15 kDa selenoprotein level in Chronic kidney disease with hypertension and no diabetes (20087_3),Pregnancy-specific beta-1-glycoprotein 1 levels,Urine pregnanediol-3-glucuronide levels in chronic kidney disease,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Selenoprotein S levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",General glucose level in pregnancy (gestational week 30-32),Pregnancy-specific beta-1-glycoprotein 4 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 5 levels,Selenoprotein P levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 3 levels,Serum levels of protein SELP,Selenoprotein H levels,Serum levels of protein SELPLG,Selenocysteine lyase level in Chronic kidney disease with hypertension and no diabetes (21537_33),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Selenium levels (reference vs low),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Selenoprotein W levels,Serum levels of protein SEL1L2
Maternal Plasma Folate (ng/ml) at pregnancy week 26,Serum folate levels,Folate pathway vitamin levels,Folate receptor beta levels,Folate receptor alpha levels,Red blood cell folate levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Folate receptor gamma levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels,General glucose level in pregnancy (gestational week 30-32),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 11 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 1 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Metabolite levels (pregnanediol-3-glucuronide),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Fasting glucose in pregnancy (gestational week 14-16),Pregnancy-specific beta-1-glycoprotein 2 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Folate receptor alpha level in Chronic kidney disease with hypertension and no diabetes (17455_42),Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Folate receptor gamma level in Chronic kidney disease with hypertension and no diabetes (15495_9),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Glycemic traits (pregnancy),Fetuin A plasma levels,Two-hour glucose in pregnancy (gestational week 30-32),HCG level (plasma),Gestational insulin sensitivity,Neonatal total 25-hydroxyvitamin D levels (cord blood),Early placenta insulin-like peptide levels,5alpha-pregnan-diol disulfate levels,Serum alpha-fetoprotein levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Lactotransferrin levels (LTF.2780.35.2),"Plasma 5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in chronic kidney disease"
Maternal Folate deficiency - Sufficient (> 6 ng/ml); Deficient (< 6 ng/mL) at pregnancy week 26,Serum folate levels,Folate pathway vitamin levels,Red blood cell folate levels,Folate receptor beta levels,Folate receptor alpha levels,Folate receptor gamma levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Folate receptor alpha level in Chronic kidney disease with hypertension and no diabetes (17455_42),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Folate receptor gamma level in Chronic kidney disease with hypertension and no diabetes (15495_9),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Embryonal Fyn-associated substrate levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Iron deficiency anemia,5alpha-pregnan-diol disulfate levels,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Iron deficiency anaemia,Follistatin-related protein 1 levels (FSTL1.13112.179.3),Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnanediol-3-glucuronide levels,Pregnanolone/allopregnanolone sulfate levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Neonatal total 25-hydroxyvitamin D levels (cord blood),Iron deficiency,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Pregnancy-specific beta-1-glycoprotein 11 levels,Glycolithocholate levels,Disease topic 16 (Pregnancy complications-plus),Lactotransferrin levels (LTF.2780.35.2),Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Follistatin-related protein 4 levels (FSTL4.9350.3.3)
Maternal Transferrin Receptor Levels - Transferrin Receptor Levels (nM/L) at pregnancy week 26,Transferrin receptor protein 1 levels (TFRC.8795.48.3),Transferrin receptor protein 1 levels,Transferrin receptor protein 2 levels,Transferrin N-glycan 14 levels,Transferrin N-glycan 21 levels,Transferrin N-glycan 26 levels,Transferrin N-glycan 19 levels,Transferrin N-glycan 17 levels,Transferrin N-glycan 22 levels,Transferrin N-glycan 11 levels,Transferrin N-glycan 23 levels,Transferrin N-glycan 29 levels,Transferrin N-glycan 31 levels,Transferrin N-glycan 25 levels,Transferrin N-glycan 20 levels,Platelet count during  first trimester of pregnancy,Midgestational cytokine/chemokine levels (fetal genetic effect),Transferrin N-glycan 34 levels,Transferrin N-glycan 24 levels,Transferrin N-glycan 28 levels,Transferrin N-glycan 27 levels,Midgestational cytokine/chemokine levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Platelet count during  second trimester of pregnancy,Transferrin N-glycan 30 levels,Transferrin N-glycan 3 levels,Transferrin N-glycan 9 levels,Transferrin N-glycan 33 levels,Transferrin N-glycan 35 levels,Iron status biomarkers (transferrin levels),Transferrin N-glycan 8 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Lactotransferrin levels (LTF.2780.35.2),Transferrin N-glycan 32 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Platelet count during  third trimester of pregnancy,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Netrin receptor UNC5C levels (UNC5C.5139.32.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 11 levels,Iron status biomarkers (transferrin saturation),Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Netrin receptor DCC levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Lactotransferrin levels,Pregnancy zone protein levels
Maternal Plasma Fatty Acids - Plasma_Myristic_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (14:0) levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Very long-chain saturated fatty acid levels (fatty acid 20:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Adiponectin levels in pregnancy,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Glycemic traits (pregnancy),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Total fatty acids levels (UKB data field 23442),Monounsaturated fatty acids levels (UKB data field 23447),Total fatty acid levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Circulating odd-numbered chain saturated fatty acid levels (C19:0),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Monounsaturated fatty acid levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Early placenta insulin-like peptide levels,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Fatty acid(20:3)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Serum linoleic acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C15:0),Fatty acids (20:3)W6 levels,Circulating odd-numbered chain saturated fatty acid levels (C23:0),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Gestational insulin sensitivity,Fatty acid desaturase activity (serum),Fatty acid(20:4)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_Myristic_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (15:0) levels,Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Adiponectin levels in pregnancy,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Glycemic traits (pregnancy),Fatty acids (14:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acid levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Monounsaturated fatty acids (16:1, 18:1) levels",Total fatty acids levels (UKB data field 23442),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Fatty acids (20:3)W6 levels,Monounsaturated fatty acids levels (UKB data field 23447),Trans fatty acid levels,Gestational insulin sensitivity,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Monounsaturated fatty acid levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Very long-chain saturated fatty acid levels (fatty acid 24:0),Early placenta insulin-like peptide levels,Serum linoleic acid concentration in metabolic syndrome,Fatty acid(20:3)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Fatty acid desaturase activity (serum),Polyunsaturated fatty acids levels (UKB data field 23446),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 22:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Polyunsaturated fatty acid levels,"Fatty acid-binding protein,intestinal levels","Fatty acid-binding protein, intestinal levels",Circulating odd-numbered chain saturated fatty acid levels (C19:0)
Maternal Plasma Fatty Acids - Plasma_Palmitic_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Fatty acids (14:0) levels,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 24:0),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Very long-chain saturated fatty acid levels (fatty acid 20:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acids levels (UKB data field 23442),Polyunsaturated fatty acids levels (UKB data field 23446),Circulating odd-numbered chain saturated fatty acid levels (C19:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Monounsaturated fatty acid levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acid(20:3)_[M-H]1- levels,Total fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C17:0),Glycemic traits (pregnancy),Fatty acid(18:4)_[M-H]1- levels,Fatty acid(20:4)_[M-H]1- levels,Polyunsaturated fatty acid levels,Palmitic acid (16:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Circulating odd-numbered chain saturated fatty acid levels (C15:0),Fatty acids (20:3)W6 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acid(22:5)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Fatty acid(22:6)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C23:0),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Fatty acid(16:1)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_Palmitic_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Fatty acids (20:5) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Total fatty acids levels (UKB data field 23442),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acid levels,Monounsaturated fatty acids levels (UKB data field 23447),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Postprandial monounsaturated fatty acids (16:1, 18:1)",Polyunsaturated fatty acids levels (UKB data field 23446),Glycemic traits (pregnancy),Palmitic acid (16:0) levels,Polyunsaturated fatty acid levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Monounsaturated fatty acid levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Fatty acids (20:3)W6 levels,Fatty acid(20:3)_[M-H]1- levels,Trans fatty acid levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acid(20:4)_[M-H]1- levels,Omega-3 fatty acids levels (UKB data field 23444),Very long-chain saturated fatty acid levels (fatty acid 20:0),Very long-chain saturated fatty acid levels (fatty acid 24:0),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Fatty acid(22:5)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Fatty acid(18:4)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Early placenta insulin-like peptide levels,"Fatty acid-binding protein, intestinal levels"
Maternal Plasma Fatty Acids - Plasma_Palmitoleic_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (15:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (20:5) levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acids (14:0) levels,Breast milk fatty acid composition (infant genotype effect),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Very long-chain saturated fatty acid levels (fatty acid 24:0),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),Monounsaturated fatty acids levels (UKB data field 23447),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Total fatty acids levels (UKB data field 23442),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Polyunsaturated fatty acids levels (UKB data field 23446),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Monounsaturated fatty acid levels,Serum linoleic acid concentration in metabolic syndrome,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Circulating odd-numbered chain saturated fatty acid levels (C15:0),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Total fatty acid levels,Fatty acid(20:3)_[M-H]1- levels,Glycemic traits (pregnancy),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Polyunsaturated fatty acid levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Fatty acids (20:3)W6 levels,Circulating odd-numbered chain saturated fatty acid levels (C23:0),Fatty acid(18:4)_[M-H]1- levels,Fatty acid(20:4)_[M-H]1- levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,"Fatty acid-binding protein, intestinal levels","Fatty acid-binding protein,intestinal levels",Fatty acid(22:5)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_Palmitoleic_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Fatty acids (20:5) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acids levels (UKB data field 23442),"Monounsaturated fatty acids (16:1, 18:1) levels",Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Total fatty acid levels,Polyunsaturated fatty acids levels (UKB data field 23446),Monounsaturated fatty acids levels (UKB data field 23447),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Glycemic traits (pregnancy),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Polyunsaturated fatty acid levels,Fatty acids (20:3)W6 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Monounsaturated fatty acid levels,Trans fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Serum linoleic acid concentration in metabolic syndrome,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Very long-chain saturated fatty acid levels (fatty acid 20:0),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Omega-3 fatty acids levels (UKB data field 23444),Very long-chain saturated fatty acid levels (fatty acid 24:0),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 22:0),Palmitoleic acid levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Palmitic acid (16:0) levels,Early placenta insulin-like peptide levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Fatty acid(20:3)_[M-H]1- levels,Adiponectin levels in pregnancy,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Circulating odd-numbered chain saturated fatty acid levels (C17:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Fatty acid-binding protein,intestinal levels","Fatty acid-binding protein, intestinal levels",Omega-6 fatty acids levels (UKB data field 23445)
Maternal Plasma Fatty Acids - Plasma_Stearic_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (infant genotype effect),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (20:5) levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 22:0),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Total fatty acids levels (UKB data field 23442),Very long-chain saturated fatty acid levels (fatty acid 20:0),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acid levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Polyunsaturated fatty acids levels (UKB data field 23446),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Monounsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Adiponectin levels in pregnancy,Fatty acid(20:3)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C17:0),Fatty acids (20:3)W6 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Glycemic traits (pregnancy),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Fatty acid(22:6)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Fatty acid(22:5)_[M-H]1- levels,Fatty acid(20:4)_[M-H]1- levels,Fatty acid(16:1)_[M-H]1- levels,Fatty acid desaturase activity (serum)
Maternal Plasma Fatty Acids - Plasma_Stearic_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Fatty acids (14:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Total fatty acid levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Total fatty acids levels (UKB data field 23442),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Adiponectin levels in pregnancy,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Glycemic traits (pregnancy),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Monounsaturated fatty acids levels (UKB data field 23447),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acids levels (UKB data field 23446),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Fatty acids (20:3)W6 levels,Trans fatty acid levels,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Very long-chain saturated fatty acid levels (fatty acid 24:0),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Omega-3 fatty acids levels (UKB data field 23444),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),Monounsaturated fatty acid levels,Fatty acid(20:3)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Polyunsaturated fatty acid levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Early placenta insulin-like peptide levels,Fatty acid desaturase activity (serum),"Fatty acid-binding protein, intestinal levels"
Maternal Plasma Fatty Acids - Plasma_Oleic_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Fatty acids (15:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acids (20:5) levels,Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 22:0),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Very long-chain saturated fatty acid levels (fatty acid 20:0),Fatty acids (14:0) levels,Polyunsaturated fatty acids levels (UKB data field 23446),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Monounsaturated fatty acid levels,Total fatty acids levels (UKB data field 23442),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Fatty acids (20:3)W6 levels,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,Serum linoleic acid concentration in metabolic syndrome,Total fatty acid levels,Fatty acid(20:3)_[M-H]1- levels,Polyunsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0),Glycemic traits (pregnancy),Omega-3 fatty acids levels (UKB data field 23444),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Fasting monounsaturated fatty acids (16:1, 18:1)"
Maternal Plasma Fatty Acids - Plasma_Oleic_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acids (14:0) levels,Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Polyunsaturated fatty acids levels (UKB data field 23446),"Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Total fatty acid levels,Fatty acids (20:3)W6 levels,Total fatty acids levels (UKB data field 23442),Glycemic traits (pregnancy),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Adiponectin levels in pregnancy,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acid levels,Monounsaturated fatty acid levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),Omega-3 fatty acids levels (UKB data field 23444),Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 22:0),Trans fatty acid levels,Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 20:0),Fatty acid(20:3)_[M-H]1- levels,Serum linoleic acid concentration in metabolic syndrome,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Omega-6 fatty acids levels (UKB data field 23445),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3)
Maternal Plasma Fatty Acids - Plasma_cis_Vaccenic_conc_mcg_ml at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,"Monounsaturated fatty acids (16:1, 18:1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Fatty acids (20:5) levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Breast milk fatty acid composition (infant genotype effect),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 22:0),Total fatty acids levels (UKB data field 23442),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Very long-chain saturated fatty acid levels (fatty acid 20:0),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Total fatty acid levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Polyunsaturated fatty acids levels (UKB data field 23446),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Circulating odd-numbered chain saturated fatty acid levels (C17:0),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Monounsaturated fatty acid levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Circulating odd-numbered chain saturated fatty acid levels (C15:0),Adiponectin levels in pregnancy,Circulating odd-numbered chain saturated fatty acid levels (C23:0),Polyunsaturated fatty acid levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Fatty acids (20:3)W6 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Serum linoleic acid concentration in metabolic syndrome,Trans fatty acid levels
Maternal Plasma Fatty Acids - Plasma_cis_Vaccenic_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (15:0) levels,Fatty acids (20:5) levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Total fatty acid levels,Fatty acids (14:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Total fatty acids levels (UKB data field 23442),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"5alpha-pregnan-3beta,20alpha-diol disulfate levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Adiponectin levels in pregnancy,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Monounsaturated fatty acids levels (UKB data field 23447),Polyunsaturated fatty acids levels (UKB data field 23446),Trans fatty acid levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acid levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),Monounsaturated fatty acid levels,Glycemic traits (pregnancy),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Fatty acids (20:3)W6 levels,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Very long-chain saturated fatty acid levels (fatty acid 20:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Saturated fatty acids levels (UKB data field 23448),Fatty acid desaturase activity (serum),Omega-3 fatty acids levels (UKB data field 23444),Serum docosahexaenoic fatty acid concentration in metabolic syndrome
Maternal Plasma Fatty Acids - Plasma_Linoleic_conc_mcg_ml at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Breast milk fatty acid composition (maternal genotype effect),Serum linoleic acid concentration in metabolic syndrome,Fatty acids (15:0) levels,Fatty acids (20:5) levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 20:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acids (14:0) levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Total fatty acids levels (UKB data field 23442),Total fatty acid levels,Monounsaturated fatty acids levels (UKB data field 23447),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Adiponectin levels in pregnancy,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acids (20:3)W6 levels,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Glycemic traits (pregnancy),Circulating odd-numbered chain saturated fatty acid levels (C17:0),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Polyunsaturated fatty acids levels (UKB data field 23446),Monounsaturated fatty acid levels,Fatty acid(20:3)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Fatty acid(18:4)_[M-H]1- levels,Fatty acid(20:4)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C23:0)
Maternal Plasma Fatty Acids - Plasma_Linoleic_percent at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Serum linoleic acid concentration in metabolic syndrome,Fatty acids (20:5) levels,Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acid levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Linoleic acid to total fatty acids percentage (UKB data field 23456),Adiponectin levels in pregnancy,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Fatty acids (14:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Glycemic traits (pregnancy),Total fatty acids levels (UKB data field 23442),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acids (20:3)W6 levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels","Postprandial monounsaturated fatty acids (16:1, 18:1)","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Monounsaturated fatty acids levels (UKB data field 23447),Polyunsaturated fatty acids levels (UKB data field 23446),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Very long-chain saturated fatty acid levels (fatty acid 24:0),Polyunsaturated fatty acid levels,Ratio of linoleic acid to total fatty acids,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Very long-chain saturated fatty acid levels (fatty acid 20:0),Trans fatty acid levels,"Fatty acid-binding protein, intestinal levels","Fatty acid-binding protein,intestinal levels",Monounsaturated fatty acid levels,Gestational insulin sensitivity,Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acid(20:3)_[M-H]1- levels,Early placenta insulin-like peptide levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3)
Maternal Plasma Fatty Acids - Plasma_Linolenic_n6_conc_mcg_ml at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Breast milk fatty acid composition (maternal genotype effect),"Monounsaturated fatty acids (16:1, 18:1) levels",Serum linoleic acid concentration in metabolic syndrome,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (15:0) levels,Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),Breast milk fatty acid composition (infant genotype effect),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Postprandial monounsaturated fatty acids (16:1, 18:1)","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Very long-chain saturated fatty acid levels (fatty acid 22:0),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Fatty acids (20:3)W6 levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 20:0),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Monounsaturated fatty acids levels (UKB data field 23447),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Total fatty acids levels (UKB data field 23442),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acid(18:4)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Monounsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C17:0),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acids levels (UKB data field 23446),Total fatty acid levels,Fatty acid(20:3)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels,Adiponectin levels in pregnancy,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C15:0),Omega-6 fatty acids levels (UKB data field 23445),Fatty acid(20:4)_[M-H]1- levels,"Fasting monounsaturated fatty acids (16:1, 18:1)"
Maternal Plasma Fatty Acids - Plasma_Linolenic_n6_percent at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Breast milk fatty acid composition (maternal genotype effect),"Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (20:5) levels,Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Serum linoleic acid concentration in metabolic syndrome,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (20:3)W6 levels,Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Total fatty acids levels (UKB data field 23442),Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Total fatty acid levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Adiponectin levels in pregnancy,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Very long-chain saturated fatty acid levels (fatty acid 24:0),Linoleic acid to total fatty acids percentage (UKB data field 23456),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Omega-6 fatty acids levels (UKB data field 23445),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acids levels (UKB data field 23446),Monounsaturated fatty acid levels,Fatty acid(18:4)_[M-H]1- levels,Glycemic traits (pregnancy),Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Fatty acid(22:6)_[M-H]1- levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Fatty acid(20:3)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acid levels,"Fatty acid-binding protein,intestinal levels","Fatty acid-binding protein, intestinal levels",Fatty acid(20:4)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_Linolenic_n3_conc_mcg_ml at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Breast milk fatty acid composition (maternal genotype effect),Serum linoleic acid concentration in metabolic syndrome,"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Breast milk fatty acid composition (infant genotype effect),Fatty acids (15:0) levels,Fatty acids (20:5) levels,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Very long-chain saturated fatty acid levels (fatty acid 24:0),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 22:0),Monounsaturated fatty acids levels (UKB data field 23447),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Very long-chain saturated fatty acid levels (fatty acid 20:0),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acids (14:0) levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Total fatty acids levels (UKB data field 23442),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acids (20:3)W6 levels,Fatty acid(20:3)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Monounsaturated fatty acid levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Polyunsaturated fatty acids levels (UKB data field 23446),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Fatty acid(18:4)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Total fatty acid levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Adiponectin levels in pregnancy,Circulating odd-numbered chain saturated fatty acid levels (C23:0),"Fasting monounsaturated fatty acids (16:1, 18:1)",Fatty acid(20:4)_[M-H]1- levels,"Fatty acid-binding protein, intestinal levels","Fatty acid-binding protein,intestinal levels"
Maternal Plasma Fatty Acids - Plasma_Linolenic_n3_percent at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Breast milk fatty acid composition (infant genotype effect),Serum linoleic acid concentration in metabolic syndrome,Fatty acids (20:5) levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (15:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Fatty acids (14:0) levels,"Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Fatty acids (20:3)W6 levels,Total fatty acids levels (UKB data field 23442),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Total fatty acid levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Adiponectin levels in pregnancy,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Polyunsaturated fatty acids levels (UKB data field 23446),Linoleic acid to total fatty acids percentage (UKB data field 23456),Fatty acid(20:3)_[M-H]1- levels,Monounsaturated fatty acid levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Glycemic traits (pregnancy),Omega-3 fatty acids levels (UKB data field 23444),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acid(18:4)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Polyunsaturated fatty acid levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,"Fatty acid-binding protein,intestinal levels","Fatty acid-binding protein, intestinal levels",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Fatty acid(20:4)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_20_0_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Very long-chain saturated fatty acid levels (fatty acid 20:0),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Fatty acids (14:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),"Postprandial monounsaturated fatty acids (16:1, 18:1)","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 22:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Fatty acid(20:3)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Fatty acid(20:4)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Total fatty acids levels (UKB data field 23442),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Monounsaturated fatty acids levels (UKB data field 23447),Total fatty acid levels,Fatty acids (20:3)W6 levels,Fatty acid(22:5)_[M-H]1- levels,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Fatty acid(22:6)_[M-H]1- levels,Fatty acid(18:4)_[M-H]1- levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Circulating odd-numbered chain saturated fatty acid levels (C19:0),Polyunsaturated fatty acids levels (UKB data field 23446),Fatty acid(22:4)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Monounsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C17:0),Glycemic traits (pregnancy),Serum linoleic acid concentration in metabolic syndrome,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C15:0),Early placenta insulin-like peptide levels
Maternal Plasma Fatty Acids - Plasma_20_0_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (14:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Total fatty acid levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Fatty acid(20:3)_[M-H]1- levels,Total fatty acids levels (UKB data field 23442),"Postprandial monounsaturated fatty acids (16:1, 18:1)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acid(20:4)_[M-H]1- levels,Fatty acids (20:3)W6 levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Very long-chain saturated fatty acid levels (fatty acid 20:0),Very long-chain saturated fatty acid levels (fatty acid 24:0),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(22:5)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Glycemic traits (pregnancy),Adiponectin levels in pregnancy,Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acid(22:6)_[M-H]1- levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Polyunsaturated fatty acids levels (UKB data field 23446),Fatty acid(18:4)_[M-H]1- levels,Fatty acid(22:4)_[M-H]1- levels,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Trans fatty acid levels,Polyunsaturated fatty acid levels,Monounsaturated fatty acid levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Early placenta insulin-like peptide levels,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(16:1)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_20_1_n9_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Fatty acids (15:0) levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Postprandial monounsaturated fatty acids (16:1, 18:1)","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Fatty acids (14:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Very long-chain saturated fatty acid levels (fatty acid 24:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acid(20:3)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Fatty acid(20:4)_[M-H]1- levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Monounsaturated fatty acids levels (UKB data field 23447),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Total fatty acids levels (UKB data field 23442),Fatty acid(18:4)_[M-H]1- levels,Fatty acid(22:5)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels,Fatty acids (20:3)W6 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Fatty acid(22:4)_[M-H]1- levels,Total fatty acid levels,Polyunsaturated fatty acids levels (UKB data field 23446),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Glycemic traits (pregnancy),Monounsaturated fatty acid levels,Adiponectin levels in pregnancy,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Fatty acid(16:1)_[M-H]1- levels,Early placenta insulin-like peptide levels
Maternal Plasma Fatty Acids - Plasma_20_1_n9_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (14:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Fatty acid(20:3)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acids levels (UKB data field 23442),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Total fatty acid levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acid(20:4)_[M-H]1- levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (20:3)W6 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Monounsaturated fatty acids levels (UKB data field 23447),Fatty acid(22:6)_[M-H]1- levels,Fatty acid(22:5)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Glycemic traits (pregnancy),Adiponectin levels in pregnancy,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 24:0),Polyunsaturated fatty acids levels (UKB data field 23446),Fatty acid(18:4)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Very long-chain saturated fatty acid levels (fatty acid 20:0),Fatty acid(22:4)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 22:0),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Fatty acid(16:1)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Monounsaturated fatty acid levels,Polyunsaturated fatty acid levels,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome
Maternal Plasma Fatty Acids - Plasma_20_2_n6_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Breast milk fatty acid composition (infant genotype effect),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Very long-chain saturated fatty acid levels (fatty acid 20:0),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Fatty acids (20:3)W6 levels,Fatty acid(20:3)_[M-H]1- levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acid(20:4)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Monounsaturated fatty acids levels (UKB data field 23447),Fatty acid(22:6)_[M-H]1- levels,Fatty acid(18:4)_[M-H]1- levels,Fatty acid(22:5)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Total fatty acids levels (UKB data field 23442),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Total fatty acid levels,Fatty acid(22:4)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Monounsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C17:0),Polyunsaturated fatty acids levels (UKB data field 23446),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C15:0),Adiponectin levels in pregnancy,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3)
Maternal Plasma Fatty Acids - Plasma_20_2_n6_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fatty acids (14:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (20:3)W6 levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Fatty acid(20:3)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acid levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Total fatty acids levels (UKB data field 23442),Fatty acid(22:6)_[M-H]1- levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acid(20:4)_[M-H]1- levels,Fatty acid(22:5)_[M-H]1- levels,Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 24:0),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(18:4)_[M-H]1- levels,Adiponectin levels in pregnancy,Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Fatty acid(22:4)_[M-H]1- levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acids levels (UKB data field 23446),Glycemic traits (pregnancy),Monounsaturated fatty acid levels,Omega-6 fatty acids levels (UKB data field 23445),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Fatty acid(16:1)_[M-H]1- levels,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acid levels
Maternal Plasma Fatty Acids - Plasma_20_3_n6_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Very long-chain saturated fatty acid levels (fatty acid 24:0),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acids (14:0) levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acid(20:3)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Fatty acids (20:3)W6 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acid(20:4)_[M-H]1- levels,Monounsaturated fatty acids levels (UKB data field 23447),Fatty acid(22:6)_[M-H]1- levels,Fatty acid(18:4)_[M-H]1- levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Total fatty acids levels (UKB data field 23442),Fatty acid(22:5)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Total fatty acid levels,Fatty acid(22:4)_[M-H]1- levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Polyunsaturated fatty acids levels (UKB data field 23446),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Monounsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Early placenta insulin-like peptide levels,Adiponectin levels in pregnancy
Maternal Plasma Fatty Acids - Plasma_20_3_n6_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Fatty acids (20:3)W6 levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Fatty acid(20:3)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Total fatty acid levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Total fatty acids levels (UKB data field 23442),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acid(22:6)_[M-H]1- levels,Fatty acid(20:4)_[M-H]1- levels,Fatty acid(22:5)_[M-H]1- levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Monounsaturated fatty acids levels (UKB data field 23447),Fatty acid(18:4)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Adiponectin levels in pregnancy,Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acid(22:4)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acids levels (UKB data field 23446),Glycemic traits (pregnancy),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Monounsaturated fatty acid levels,Omega-6 fatty acids levels (UKB data field 23445),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(16:1)_[M-H]1- levels,Omega-3 fatty acids levels (UKB data field 23444),Polyunsaturated fatty acid levels
Maternal Plasma Fatty Acids - Plasma_Arachidonic_n6_conc_mcg_ml at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fatty acids (20:5) levels,Breast milk fatty acid composition (infant genotype effect),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Fatty acids (14:0) levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),Fatty acids (20:3)W6 levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Monounsaturated fatty acids levels (UKB data field 23447),Fatty acid(18:4)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels,Total fatty acids levels (UKB data field 23442),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Adiponectin levels in pregnancy,Fatty acid(20:3)_[M-H]1- levels,Fatty acid(22:5)_[M-H]1- levels,Total fatty acid levels,Fatty acid(20:4)_[M-H]1- levels,Fatty acid(22:4)_[M-H]1- levels,Monounsaturated fatty acid levels,Omega-6 fatty acids levels (UKB data field 23445),Polyunsaturated fatty acids levels (UKB data field 23446),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Glycemic traits (pregnancy),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Circulating odd-numbered chain saturated fatty acid levels (C19:0),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome
Maternal Plasma Fatty Acids - Plasma_Arachidonic_n6_percent at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (20:5) levels,Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (14:0) levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Fatty acids (20:3)W6 levels,"Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Adiponectin levels in pregnancy,Total fatty acids levels (UKB data field 23442),Total fatty acid levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Omega-6 fatty acids levels (UKB data field 23445),Fatty acid(22:6)_[M-H]1- levels,Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 24:0),Fatty acid(20:3)_[M-H]1- levels,Fatty acid(18:4)_[M-H]1- levels,Glycemic traits (pregnancy),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Fatty acid(22:5)_[M-H]1- levels,Polyunsaturated fatty acids levels (UKB data field 23446),Fatty acid(20:4)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 22:0),Monounsaturated fatty acid levels,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(22:4)_[M-H]1- levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Very long-chain saturated fatty acid levels (fatty acid 20:0),Omega-3 fatty acids levels (UKB data field 23444),Fatty acid(16:1)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_22_0_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (14:0) levels,Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 24:0),"Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Very long-chain saturated fatty acid levels (fatty acid 20:0),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Fatty acid(22:5)_[M-H]1- levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acid(22:6)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Fatty acid(20:3)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acid(22:4)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acid(20:4)_[M-H]1- levels,Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Total fatty acids levels (UKB data field 23442),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acid(18:4)_[M-H]1- levels,Fatty acids (20:3)W6 levels,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Total fatty acid levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C17:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Polyunsaturated fatty acids levels (UKB data field 23446),Early placenta insulin-like peptide levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Monounsaturated fatty acid levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Fatty acid(16:1)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0),Glycemic traits (pregnancy),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3)
Maternal Plasma Fatty Acids - Plasma_22_0_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Fatty acids (20:5) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (14:0) levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Total fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acids levels (UKB data field 23442),"Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Fatty acid(22:5)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels,Fatty acid(20:3)_[M-H]1- levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (20:3)W6 levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acid(22:4)_[M-H]1- levels,Fatty acid(20:4)_[M-H]1- levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Very long-chain saturated fatty acid levels (fatty acid 22:0),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Glycemic traits (pregnancy),Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 24:0),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Polyunsaturated fatty acids levels (UKB data field 23446),Fatty acid(18:4)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Adiponectin levels in pregnancy,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Fatty acid(16:1)_[M-H]1- levels,Trans fatty acid levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Monounsaturated fatty acid levels,Early placenta insulin-like peptide levels,Polyunsaturated fatty acid levels,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Omega-3 fatty acids levels (UKB data field 23444)
Maternal Plasma Fatty Acids - Plasma_20_4_n3_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Fatty acids (14:0) levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Very long-chain saturated fatty acid levels (fatty acid 20:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Fatty acid(20:3)_[M-H]1- levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Very long-chain saturated fatty acid levels (fatty acid 22:0),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acid(20:4)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acid(18:4)_[M-H]1- levels,Monounsaturated fatty acids levels (UKB data field 23447),Fatty acids (20:3)W6 levels,Total fatty acids levels (UKB data field 23442),Fatty acid(22:5)_[M-H]1- levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Fatty acid(22:6)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Fatty acid(22:4)_[M-H]1- levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Total fatty acid levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Polyunsaturated fatty acids levels (UKB data field 23446),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Monounsaturated fatty acid levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Early placenta insulin-like peptide levels,Circulating odd-numbered chain saturated fatty acid levels (C17:0),Glycemic traits (pregnancy),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Serum docosahexaenoic fatty acid concentration in metabolic syndrome
Maternal Plasma Fatty Acids - Plasma_20_4_n3_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Fatty acid(20:3)_[M-H]1- levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Postprandial monounsaturated fatty acids (16:1, 18:1)",Fatty acid(20:4)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acids (20:3)W6 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Total fatty acid levels,Total fatty acids levels (UKB data field 23442),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Fatty acid(22:5)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels,Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Fatty acid(18:4)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),Adiponectin levels in pregnancy,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Fatty acid(22:4)_[M-H]1- levels,Glycemic traits (pregnancy),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 20:0),Polyunsaturated fatty acids levels (UKB data field 23446),Very long-chain saturated fatty acid levels (fatty acid 22:0),Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Monounsaturated fatty acid levels,Polyunsaturated fatty acid levels,Early placenta insulin-like peptide levels,Omega-3 fatty acids levels (UKB data field 23444),Fatty acid(16:1)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3)
Maternal Plasma Fatty Acids - Plasma_EPA_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acids (15:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Fatty acids (14:0) levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Monounsaturated fatty acids levels (UKB data field 23447),Total fatty acids levels (UKB data field 23442),Very long-chain saturated fatty acid levels (fatty acid 24:0),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Polyunsaturated fatty acids levels (UKB data field 23446),Total fatty acid levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Adiponectin levels in pregnancy,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Monounsaturated fatty acid levels,Fatty acids (20:3)W6 levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Omega-3 fatty acids levels (UKB data field 23444),Polyunsaturated fatty acid levels,Glycemic traits (pregnancy),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Fatty acid(20:3)_[M-H]1- levels,Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,Early placenta insulin-like peptide levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Serum linoleic acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3)
Maternal Plasma Fatty Acids - Plasma_EPA_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,Fatty acids (20:5) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Total fatty acid levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acids levels (UKB data field 23442),"Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (14:0) levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Polyunsaturated fatty acids levels (UKB data field 23446),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Adiponectin levels in pregnancy,"5alpha-pregnan-3beta,20alpha-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (20:3)W6 levels,Omega-3 fatty acids levels (UKB data field 23444),Polyunsaturated fatty acid levels,Glycemic traits (pregnancy),Trans fatty acid levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,"Fatty acid-binding protein,intestinal levels","Fatty acid-binding protein, intestinal levels",Monounsaturated fatty acid levels,Early placenta insulin-like peptide levels,Omega-6 fatty acids levels (UKB data field 23445),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 24:0),Saturated fatty acids levels (UKB data field 23448),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Serum linoleic acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3)
Maternal Plasma Fatty Acids - Plasma_22_4_n6_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (20:5) levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Very long-chain saturated fatty acid levels (fatty acid 24:0),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Fatty acids (14:0) levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Very long-chain saturated fatty acid levels (fatty acid 22:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Fatty acid(22:6)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acid(22:5)_[M-H]1- levels,Fatty acids (20:3)W6 levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Fatty acid(18:4)_[M-H]1- levels,Fatty acid(22:4)_[M-H]1- levels,Fatty acid(20:3)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Monounsaturated fatty acids levels (UKB data field 23447),Fatty acid(20:4)_[M-H]1- levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Total fatty acids levels (UKB data field 23442),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Circulating odd-numbered chain saturated fatty acid levels (C19:0),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Circulating odd-numbered chain saturated fatty acid levels (C17:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Total fatty acid levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Fatty acid(16:1)_[M-H]1- levels,Polyunsaturated fatty acids levels (UKB data field 23446),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Early placenta insulin-like peptide levels,Monounsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0)
Maternal Plasma Fatty Acids - Plasma_22_4_n6_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (20:5) levels,Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Fatty acids (14:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Fatty acids (20:3)W6 levels,Fatty acid(22:6)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Fatty acid(22:5)_[M-H]1- levels,Total fatty acids levels (UKB data field 23442),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Total fatty acid levels,Fatty acid(20:3)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acid(22:4)_[M-H]1- levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acid(20:4)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Monounsaturated fatty acids levels (UKB data field 23447),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Fatty acid(18:4)_[M-H]1- levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Glycemic traits (pregnancy),Polyunsaturated fatty acids levels (UKB data field 23446),Adiponectin levels in pregnancy,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Fatty acid(16:1)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Omega-6 fatty acids levels (UKB data field 23445),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 20:0),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Monounsaturated fatty acid levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Polyunsaturated fatty acid levels,Early placenta insulin-like peptide levels
Maternal Plasma Fatty Acids - Plasma_DPA_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Breast milk fatty acid composition (infant genotype effect),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (15:0) levels,Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Postprandial monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Very long-chain saturated fatty acid levels (fatty acid 24:0),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Fatty acids (14:0) levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 22:0),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Total fatty acids levels (UKB data field 23442),Total fatty acid levels,Monounsaturated fatty acids levels (UKB data field 23447),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Polyunsaturated fatty acids levels (UKB data field 23446),5alpha-pregnan-diol disulfate levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Adiponectin levels in pregnancy,Early placenta insulin-like peptide levels,Fatty acid desaturase activity (serum),"Fatty acid-binding protein,intestinal levels","Fatty acid-binding protein, intestinal levels",Circulating odd-numbered chain saturated fatty acid levels (C19:0),Monounsaturated fatty acid levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Polyunsaturated fatty acid levels,Fatty acid(20:3)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome
Maternal Plasma Fatty Acids - Plasma_DPA_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),5alpha-pregnan-diol disulfate levels,Fatty acids (20:5) levels,Fatty acids (15:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Adiponectin levels in pregnancy,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Early placenta insulin-like peptide levels,Total fatty acid levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acids (14:0) levels,Total fatty acids levels (UKB data field 23442),"Monounsaturated fatty acids (16:1, 18:1) levels","Postprandial monounsaturated fatty acids (16:1, 18:1)",Glycemic traits (pregnancy),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acids levels (UKB data field 23446),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Gestational insulin sensitivity,"Fatty acid-binding protein, liver levels","Fatty acid-binding protein, liver levels (FABP1.11516.7.3)","Fatty acid-binding protein,intestinal levels","Fatty acid-binding protein, intestinal levels",Polyunsaturated fatty acid levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Fatty acid desaturase activity (serum),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 24:0),Fatty acids (20:3)W6 levels
Maternal Plasma Fatty Acids - Plasma_DHA_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (15:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (20:5) levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Adiponectin levels in pregnancy,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Postprandial monounsaturated fatty acids (16:1, 18:1)",Fatty acids (14:0) levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Very long-chain saturated fatty acid levels (fatty acid 22:0),Glycemic traits (pregnancy),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Monounsaturated fatty acids levels (UKB data field 23447),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Very long-chain saturated fatty acid levels (fatty acid 20:0),Total fatty acids levels (UKB data field 23442),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Omega-3 fatty acids levels (UKB data field 23444),Total fatty acid levels,Early placenta insulin-like peptide levels,Monounsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Fatty acid(20:3)_[M-H]1- levels,Polyunsaturated fatty acids levels (UKB data field 23446),Fatty acid(22:6)_[M-H]1- levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(22:5)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_DHA_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (15:0) levels,Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Adiponectin levels in pregnancy,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Glycemic traits (pregnancy),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Fatty acids (14:0) levels,Total fatty acid levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Total fatty acids levels (UKB data field 23442),Early placenta insulin-like peptide levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),5alpha-pregnan-diol disulfate levels,Omega-3 fatty acids levels (UKB data field 23444),Gestational insulin sensitivity,Monounsaturated fatty acids levels (UKB data field 23447),Fatty acids (20:3)W6 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Docosahexaenoic acid to total fatty acids percentage (UKB data field 23457),Omega-6 fatty acids levels (UKB data field 23445),Monounsaturated fatty acid levels,Polyunsaturated fatty acids levels (UKB data field 23446),Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Serum total polyunsaturated fatty acid concentration in metabolic syndrome
Maternal Plasma Fatty Acids - Plasma_Total_FA_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (20:5) levels,Total fatty acids levels (UKB data field 23442),Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Total fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 24:0),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Polyunsaturated fatty acids levels (UKB data field 23446),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Very long-chain saturated fatty acid levels (fatty acid 20:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acids (20:3)W6 levels,Omega-3 fatty acids levels (UKB data field 23444),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Monounsaturated fatty acid levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acid(20:3)_[M-H]1- levels,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Saturated fatty acids levels (UKB data field 23448),Omega-6 fatty acids levels (UKB data field 23445),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acid levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Circulating odd-numbered chain saturated fatty acid levels (C17:0),Glycemic traits (pregnancy),Fatty acid(20:4)_[M-H]1- levels,Fatty acid(18:4)_[M-H]1- levels,Trans fatty acid levels
Maternal Plasma Fatty Acids - Plasma_Total FA_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (20:5) levels,Total fatty acid levels,Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Total fatty acids levels (UKB data field 23442),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Fatty acids (14:0) levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Monounsaturated fatty acids levels (UKB data field 23447),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Polyunsaturated fatty acids levels (UKB data field 23446),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Trans fatty acid levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Glycemic traits (pregnancy),Fatty acids (20:3)W6 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20alpha-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Omega-3 fatty acids levels (UKB data field 23444),Polyunsaturated fatty acid levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Omega-6 fatty acids levels (UKB data field 23445),Monounsaturated fatty acid levels,"Fatty acid-binding protein, intestinal levels","Fatty acid-binding protein,intestinal levels",Saturated fatty acids levels (UKB data field 23448),Linoleic acid to total fatty acids percentage (UKB data field 23456),Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Adiponectin levels in pregnancy,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,Omega-3 fatty acids to total fatty acids percentage (UKB data field 23451),Very long-chain saturated fatty acid levels (fatty acid 24:0),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 20:0)
Maternal Plasma Fatty Acids - Plasma_Total_n3_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Fatty acids (20:5) levels,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Total fatty acids levels (UKB data field 23442),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Monounsaturated fatty acids levels (UKB data field 23447),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Total fatty acid levels,Fatty acids (14:0) levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Omega-3 fatty acids levels (UKB data field 23444),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Polyunsaturated fatty acids levels (UKB data field 23446),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 22:0),Monounsaturated fatty acid levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Fatty acids (20:3)W6 levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Fatty acid(20:3)_[M-H]1- levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Circulating odd-numbered chain saturated fatty acid levels (C19:0),"Fasting monounsaturated fatty acids (16:1, 18:1)",Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(18:4)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Circulating odd-numbered chain saturated fatty acid levels (C17:0),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Circulating odd-numbered chain saturated fatty acid levels (C23:0),Saturated fatty acids levels (UKB data field 23448),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Omega-6 fatty acids levels (UKB data field 23445),Polyunsaturated fatty acid levels,Fatty acid(22:6)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_Total_n3_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (infant genotype effect),Total fatty acids levels (UKB data field 23442),Total fatty acid levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acids (14:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Omega-3 fatty acids levels (UKB data field 23444),Monounsaturated fatty acids levels (UKB data field 23447),Fatty acids (20:3)W6 levels,"Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Polyunsaturated fatty acids levels (UKB data field 23446),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Fatty acid(20:3)_[M-H]1- levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Monounsaturated fatty acid levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Omega-6 fatty acids levels (UKB data field 23445),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Polyunsaturated fatty acid levels,Omega-3 fatty acids to total fatty acids percentage (UKB data field 23451),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Very long-chain saturated fatty acid levels (fatty acid 24:0),Saturated fatty acids levels (UKB data field 23448),Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Glycemic traits (pregnancy),Trans fatty acid levels,Fatty acid(22:6)_[M-H]1- levels,Adiponectin levels in pregnancy,Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acid(18:4)_[M-H]1- levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Fatty acid(20:4)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_Total_n6_conc_mcg_ml at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (20:5) levels,Breast milk fatty acid composition (infant genotype effect),Total fatty acids levels (UKB data field 23442),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Monounsaturated fatty acids levels (UKB data field 23447),Fatty acids (20:3)W6 levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Fatty acids (14:0) levels,Very long-chain saturated fatty acid levels (fatty acid 24:0),Total fatty acid levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Omega-6 fatty acids levels (UKB data field 23445),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),Polyunsaturated fatty acids levels (UKB data field 23446),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Monounsaturated fatty acid levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Circulating odd-numbered chain saturated fatty acid levels (C19:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Fatty acid(18:4)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C17:0),Omega-3 fatty acids levels (UKB data field 23444),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Fatty acid(20:3)_[M-H]1- levels,Saturated fatty acids levels (UKB data field 23448),Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Adiponectin levels in pregnancy,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","Fasting monounsaturated fatty acids (16:1, 18:1)","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3)
Maternal Plasma Fatty Acids - Plasma_Total_n6_percent at pregnancy week 26,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Total fatty acid levels,Total fatty acids levels (UKB data field 23442),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (20:3)W6 levels,Fatty acids (14:0) levels,Omega-6 fatty acids levels (UKB data field 23445),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Monounsaturated fatty acids levels (UKB data field 23447),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452),Polyunsaturated fatty acids levels (UKB data field 23446),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Omega-3 fatty acids levels (UKB data field 23444),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Monounsaturated fatty acid levels,Total omega-6 fatty acid levels,Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(22:6)_[M-H]1- levels,Omega-6 fatty acids levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Very long-chain saturated fatty acid levels (fatty acid 24:0),Omega-6 fatty acid levels,Adiponectin levels in pregnancy,Saturated fatty acids levels (UKB data field 23448),Fatty acid(20:3)_[M-H]1- levels,Fatty acid(18:4)_[M-H]1- levels,Trans fatty acid levels,Polyunsaturated fatty acid levels,Very long-chain saturated fatty acid levels (fatty acid 22:0),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Glycemic traits (pregnancy),"5alpha-pregnan-3beta,20alpha-diol disulfate levels"
Maternal Plasma Fatty Acids - Plasma_SFA_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Monounsaturated fatty acids (16:1, 18:1) levels",Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fatty acids (20:5) levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Very long-chain saturated fatty acid levels (fatty acid 22:0),Total fatty acids levels (UKB data field 23442),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Very long-chain saturated fatty acid levels (fatty acid 20:0),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Total fatty acid levels,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acids levels (UKB data field 23446),Monounsaturated fatty acid levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Circulating odd-numbered chain saturated fatty acid levels (C19:0),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Glycemic traits (pregnancy),Circulating odd-numbered chain saturated fatty acid levels (C17:0),Fatty acids (20:3)W6 levels,Fatty acid(20:3)_[M-H]1- levels,Fatty acid desaturase activity (serum),Polyunsaturated fatty acid levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Fatty acid(22:6)_[M-H]1- levels,Fatty acid(22:5)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_Total_SFA_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Fatty acids (20:5) levels,Breast milk fatty acid composition (infant genotype effect),Total fatty acid levels,Total fatty acids levels (UKB data field 23442),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Fatty acids (14:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Polyunsaturated fatty acids levels (UKB data field 23446),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","Postprandial monounsaturated fatty acids (16:1, 18:1)",Serum docosahexaenoic fatty acid concentration in metabolic syndrome,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Monounsaturated fatty acid levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Polyunsaturated fatty acid levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Trans fatty acid levels,Glycemic traits (pregnancy),Fatty acids (20:3)W6 levels,Omega-6 fatty acids levels (UKB data field 23445),Omega-3 fatty acids levels (UKB data field 23444),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 24:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Very long-chain saturated fatty acid levels (fatty acid 20:0),Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Saturated fatty acids levels (UKB data field 23448),Fatty acid desaturase activity (serum),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,Adiponectin levels in pregnancy,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Fatty acid(20:3)_[M-H]1- levels
Maternal Plasma Fatty Acids - Plasma_MUFA_conc_mcg_ml at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),"Monounsaturated fatty acids (16:1, 18:1) levels",Monounsaturated fatty acids levels (UKB data field 23447),Breast milk fatty acid composition (infant genotype effect),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Monounsaturated fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Fatty acids (15:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (20:5) levels,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Total fatty acids levels (UKB data field 23442),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Fatty acids (14:0) levels,Polyunsaturated fatty acids levels (UKB data field 23446),Total fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 20:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Fatty acid(20:3)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Circulating odd-numbered chain saturated fatty acid levels (C19:0),Fatty acid(20:4)_[M-H]1- levels,"Fasting monounsaturated fatty acids (16:1, 18:1)",Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Fatty acid(18:4)_[M-H]1- levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Circulating odd-numbered chain saturated fatty acid levels (C17:0),Polyunsaturated fatty acid levels,Fatty acid(22:6)_[M-H]1- levels,Fatty acid(22:5)_[M-H]1- levels,Fatty acid(16:1)_[M-H]1- levels,Saturated fatty acids levels (UKB data field 23448),Omega-3 fatty acids levels (UKB data field 23444),Circulating odd-numbered chain saturated fatty acid levels (C15:0),Fatty acid desaturase activity (serum),Fatty acid(22:4)_[M-H]1- levels,Fatty acids (20:3)W6 levels,Circulating odd-numbered chain saturated fatty acid levels (C23:0)
Maternal Plasma Fatty Acids - Plasma_Total_MUFA_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),"Monounsaturated fatty acids (16:1, 18:1) levels",Total fatty acid levels,Monounsaturated fatty acids levels (UKB data field 23447),Total fatty acids levels (UKB data field 23442),Fatty acids (15:0) levels,Fatty acids (20:5) levels,Breast milk fatty acid composition (infant genotype effect),Monounsaturated fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Polyunsaturated fatty acids levels (UKB data field 23446),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fatty acids (14:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acid levels,Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),Omega-3 fatty acids levels (UKB data field 23444),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Fatty acid(20:3)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Saturated fatty acids levels (UKB data field 23448),Very long-chain saturated fatty acid levels (fatty acid 24:0),Omega-6 fatty acids levels (UKB data field 23445),Fatty acids (20:3)W6 levels,Trans fatty acid levels,Fatty acid(20:4)_[M-H]1- levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Very long-chain saturated fatty acid levels (fatty acid 20:0),Fatty acid(16:1)_[M-H]1- levels,Fatty acid(18:4)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels,Fatty acid desaturase activity (serum),Fatty acid(22:5)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 22:0),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),"Fasting monounsaturated fatty acids (16:1, 18:1)","5alpha-pregnan-3beta,20alpha-diol disulfate levels"
Maternal Plasma Fatty Acids - Plasma_PUFA_conc at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Breast milk fatty acid composition (infant genotype effect),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Polyunsaturated fatty acids levels (UKB data field 23446),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Monounsaturated fatty acids levels (UKB data field 23447),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Fatty acids (15:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Polyunsaturated fatty acid levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Adiponectin levels in pregnancy,"Monounsaturated fatty acids (16:1, 18:1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Early placenta insulin-like peptide levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Total fatty acids levels (UKB data field 23442),Very long-chain saturated fatty acid levels (fatty acid 24:0),Fatty acids (20:5) levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Monounsaturated fatty acid levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Glycemic traits (pregnancy),Fatty acids (14:0) levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Very long-chain saturated fatty acid levels (fatty acid 22:0),Total fatty acid levels,Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,"5alpha-pregnan-3beta,20alpha-diol disulfate levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Fatty acid desaturase activity (serum),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Postprandial saturated fatty acids,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Postprandial total fatty acids,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 11 levels,"Fatty acid-binding protein, intestinal levels"
Maternal Plasma Fatty Acids - Plasma_Total_PUFA_percent at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Polyunsaturated fatty acids levels (UKB data field 23446),Fatty acids (15:0) levels,Total fatty acids levels (UKB data field 23442),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Monounsaturated fatty acids levels (UKB data field 23447),Polyunsaturated fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acids (20:5) levels,Total fatty acid levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fatty acids (14:0) levels,Monounsaturated fatty acid levels,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Polyunsaturated fatty acids to total fatty acids percentage (UKB data field 23453),Omega-3 fatty acids levels (UKB data field 23444),Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Saturated fatty acids levels (UKB data field 23448),Very long-chain saturated fatty acid levels (fatty acid 24:0),Postprandial total fatty acids,Trans fatty acid levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Other polyunsaturated fatty acid levels than 18:2,Very long-chain saturated fatty acid levels (fatty acid 22:0),Adiponectin levels in pregnancy,Docosahexaenoic acid to total fatty acids percentage (UKB data field 23457),Fatty acid desaturase activity (serum),Omega-6 fatty acids levels (UKB data field 23445),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Circulating odd-numbered chain saturated fatty acid levels (C19:0),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome
Maternal Plasma Fatty Acids - Ratio_Plasma_n3_to_n6 at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fatty acids (20:5) levels,Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Fatty acids (20:3)W6 levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Fatty acids (14:0) levels,Omega-6 fatty acids to omega-3 fatty acids ratio (UKB data field 23459),Monounsaturated fatty acids levels (UKB data field 23447),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Very long-chain saturated fatty acid levels (fatty acid 24:0),Total fatty acids levels (UKB data field 23442),Omega-6 fatty acids levels (UKB data field 23445),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Ratio of omega-6 fatty acids to total fatty acids,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Very long-chain saturated fatty acid levels (fatty acid 22:0),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Monounsaturated fatty acid levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Polyunsaturated fatty acids levels (UKB data field 23446),"Fasting monounsaturated fatty acids (16:1, 18:1)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Omega-3 fatty acids levels (UKB data field 23444),Fatty acid(22:6)_[M-H]1- levels,Total fatty acid levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fatty acid(20:3)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acid(18:4)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Circulating odd-numbered chain saturated fatty acid levels (C17:0),Circulating odd-numbered chain saturated fatty acid levels (C19:0),Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Fatty acid(16:1)_[M-H]1- levels,Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Serum total polyunsaturated fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Ratio of omega-3 fatty acids to total fatty acids
Maternal Plasma Fatty Acids - Ratio_Plasma_n6_to_n3 at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Fatty acids (20:3)W6 levels,Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Omega-6 fatty acids to omega-3 fatty acids ratio (UKB data field 23459),Fatty acids (14:0) levels,Monounsaturated fatty acids levels (UKB data field 23447),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Omega-6 fatty acids levels (UKB data field 23445),Very long-chain saturated fatty acid levels (fatty acid 24:0),Total fatty acids levels (UKB data field 23442),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Ratio of omega-6 fatty acids to total fatty acids,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Monounsaturated fatty acid levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Very long-chain saturated fatty acid levels (fatty acid 22:0),"Fasting monounsaturated fatty acids (16:1, 18:1)",Polyunsaturated fatty acids levels (UKB data field 23446),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Omega-3 fatty acids levels (UKB data field 23444),Fatty acid(22:6)_[M-H]1- levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Total fatty acid levels,Fatty acid(20:3)_[M-H]1- levels,Fatty acid(18:4)_[M-H]1- levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Very long-chain saturated fatty acid levels (fatty acid 20:0),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Circulating odd-numbered chain saturated fatty acid levels (C17:0),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Circulating odd-numbered chain saturated fatty acid levels (C19:0),Fatty acid(16:1)_[M-H]1- levels,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Ratio of omega-3 fatty acids to total fatty acids
Maternal Plasma Fatty Acids - Ratio_Plasma_AA_to_DHA at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Ratio of docosahexaenoic acid to total fatty acid levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Postprandial monounsaturated fatty acids (16:1, 18:1)",Very long-chain saturated fatty acid levels (fatty acid 24:0),Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 22:0),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Adiponectin levels in pregnancy,Total fatty acid levels,Total fatty acids levels (UKB data field 23442),Monounsaturated fatty acid levels,Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Fatty acids (20:3)W6 levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Polyunsaturated fatty acids levels (UKB data field 23446),Fatty acid(20:3)_[M-H]1- levels,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Omega-3 fatty acids levels (UKB data field 23444),Trans fatty acid levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Glycemic traits (pregnancy),Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome,Polyunsaturated fatty acid levels,Circulating odd-numbered chain saturated fatty acid levels (C19:0)
Maternal Plasma Fatty Acids - Ratio_Plasma_AA_to_EPA at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Fatty acids (15:0) levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Fatty acids (20:5) levels,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Fatty acids (14:0) levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Postprandial monounsaturated fatty acids (16:1, 18:1)",Monounsaturated fatty acids levels (UKB data field 23447),Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Polyunsaturated fatty acids levels (UKB data field 23446),Total fatty acids levels (UKB data field 23442),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Very long-chain saturated fatty acid levels (fatty acid 24:0),Total fatty acid levels,Adiponectin levels in pregnancy,Fatty acids (20:3)W6 levels,Very long-chain saturated fatty acid levels (fatty acid 22:0),Polyunsaturated fatty acid levels,Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Omega-3 fatty acids levels (UKB data field 23444),Very long-chain saturated fatty acid levels (fatty acid 20:0),Monounsaturated fatty acid levels,Trans fatty acid levels,Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome,Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Early placenta insulin-like peptide levels,Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome,"Fatty acid-binding protein, intestinal levels","Fatty acid-binding protein,intestinal levels",Glycemic traits (pregnancy),Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Fatty acid(20:3)_[M-H]1- levels
Maternal Plasma Fatty Acids - Ratio_Plasma_DHA_to_DPA at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Breast milk fatty acid composition (infant genotype effect),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"5alpha-pregnan-3beta,20alpha-diol disulfate levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Fatty acids (15:0) levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"Monounsaturated fatty acids (16:1, 18:1) levels",5alpha-pregnan-diol disulfate levels,Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Fatty acids (20:5) levels,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Early placenta insulin-like peptide levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Fatty acids (14:0) levels,Adiponectin levels in pregnancy,Ratio of docosahexaenoic acid to total fatty acid levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Very long-chain saturated fatty acid levels (fatty acid 24:0),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Glycemic traits (pregnancy),Gestational insulin sensitivity,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Very long-chain saturated fatty acid levels (fatty acid 22:0),Monounsaturated fatty acids levels (UKB data field 23447),Very long-chain saturated fatty acid levels (fatty acid 20:0),Polyunsaturated fatty acids levels (UKB data field 23446),Neonatal total 25-hydroxyvitamin D levels (cord blood),Total fatty acids levels (UKB data field 23442),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Serum total polyunsaturated fatty acid concentration in metabolic syndrome,Fatty acids (20:3)W6 levels,Total fatty acid levels
Maternal Plasma fatty acids-Ratio_Plasma_AA_to_DHAEPA at pregnancy week 26,Breast milk fatty acid composition (maternal genotype effect),Breast milk fatty acid composition (infant genotype effect),Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acids (15:0) levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Fatty acids (20:5) levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),"Monounsaturated fatty acids (16:1, 18:1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Fatty acids (14:0) levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Serum docosahexaenoic fatty acid concentration in metabolic syndrome,Ratio of docosahexaenoic acid to total fatty acid levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),"Postprandial monounsaturated fatty acids (16:1, 18:1)",Very long-chain saturated fatty acid levels (fatty acid 24:0),Very long-chain saturated fatty acid levels (fatty acid 22:0),Fatty acid(20:3)_[M-H]1- levels,Fatty acid(22:6)_[M-H]1- levels,Fatty acid(22:5)_[M-H]1- levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Fatty acids (20:3)W6 levels,5alpha-pregnan-diol disulfate levels,Fatty acid(20:4)_[M-H]1- levels,Fatty acid(18:4)_[M-H]1- levels,Early placenta insulin-like peptide levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Total fatty acids levels (UKB data field 23442),Fatty acid(22:4)_[M-H]1- levels,Fatty acid(16:1)_[M-H]1- levels,Total fatty acid levels,Monounsaturated fatty acids levels (UKB data field 23447),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Glycemic traits (pregnancy),Ratio of 22:6 docosahexaenoic acid to total fatty acids,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Adiponectin levels in pregnancy
Maternal Plasma Vitamin B2 - Flavin Mononucleotide (nmol/L)- Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 1 levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),Vitamin levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Orofacial cleft x maternal vitamin supplementation interaction (2df),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Folate pathway vitamin levels,Midgestational cytokine/chemokine levels (fetal genetic effect),Midgestational cytokine/chemokine levels (maternal genetic effect),Vitamin B12 levels,Vitamin B2 intake,Serum folate levels,Vitamin B1 intake,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Midgestational circulating levels of PCBs (fetal genetic effect),Midgestational circulating levels of PBDEs (fetal genetic effect),Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),Glycemic traits (pregnancy),Adiponectin levels in pregnancy,Serum 25-Hydroxyvitamin D levels,5alpha-pregnan-diol disulfate levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Pregnanediol-3-glucuronide levels,Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect)
Maternal Plasma Vitamin B2 - Neopterin (nmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 8 levels,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 3 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),Adiponectin levels in pregnancy,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Vitamin levels,Midgestational cytokine/chemokine levels (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Pregnanediol-3-glucuronide levels,Early placenta insulin-like peptide levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Midgestational cytokine/chemokine levels (maternal genetic effect),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Metabolite levels (pregnanediol-3-glucuronide),5alpha-pregnan-diol disulfate levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Orofacial cleft x maternal vitamin supplementation interaction (2df),Serum levels of protein NAB1,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),Serum levels of protein NEO1,Serum levels of protein NAB2,Midgestational circulating levels of PCBs (fetal genetic effect),General glucose level in pregnancy (gestational week 30-32),Serum levels of protein NMRAL1,Folate pathway vitamin levels,Glycemic traits (pregnancy)
Maternal Plasma Vitamin B2 - Riboflavin (nmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Pregnancy-specific beta-1-glycoprotein 3 levels,Vitamin levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnanediol-3-glucuronide levels,Orofacial cleft x maternal vitamin supplementation interaction (2df),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Folate pathway vitamin levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Midgestational circulating levels of PCBs (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Adiponectin levels in pregnancy,Riboflavin kinase levels (RFK.13059.33.3),Glycemic traits (pregnancy),5alpha-pregnan-diol disulfate levels,Serum folate levels,Vitamin B12 levels,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),Vitamin B2 intake,Midgestational circulating levels of PBDEs (fetal genetic effect),Retinol (Vitamin A) levels,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Midgestational cytokine/chemokine levels (fetal genetic effect),Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect)
Maternal Plasma Vitamin B3 - N1-methylnicotinamide (nmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Vitamin levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 1 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Metabolite levels (pregnanediol-3-glucuronide),Pregnanediol-3-glucuronide levels,Orofacial cleft x maternal vitamin supplementation interaction (2df),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Folate pathway vitamin levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Vitamin B1 intake,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",N6-methyllysine levels (elderly offspring),5alpha-pregnan-diol disulfate levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Midgestational circulating levels of PCBs (fetal genetic effect),Midgestational cytokine/chemokine levels (fetal genetic effect),Serum 25-Hydroxyvitamin D levels,Vitamin B12 levels,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),Midgestational cytokine/chemokine levels (maternal genetic effect),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),Adiponectin levels in pregnancy,Retinol (Vitamin A) levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect)
Maternal Plasma Vitamin B3 - Nicotinamide (nmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Vitamin levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnanediol-3-glucuronide levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Pregnancy-specific beta-1-glycoprotein 11 levels,Metabolite levels (pregnanediol-3-glucuronide),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Nicotinamide levels,Orofacial cleft x maternal vitamin supplementation interaction (2df),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Midgestational cytokine/chemokine levels (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Folate pathway vitamin levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Midgestational circulating levels of PCBs (fetal genetic effect),Midgestational cytokine/chemokine levels (maternal genetic effect),Serum 25-Hydroxyvitamin D levels,Retinol (Vitamin A) levels,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),Nicotinamide phosphoribosyltransferase levels (NAMPT.5011.11.1),N6-methyllysine levels (elderly offspring),5alpha-pregnan-diol disulfate levels,Vitamin B1 intake,Vitamin B12 levels,Nicotinamide N-methyltransferase levels,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),Glycemic traits (pregnancy)
Maternal Plasma Vitamin B3 - Nicotinic acid (nmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 2 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Plasma metabolome feature (hilic_4134) (Nicotinic acid mononucleotide),Pregnancy-specific beta-1-glycoprotein 1 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 11 levels,Metabolite levels (pregnanediol-3-glucuronide),Vitamin levels,Pregnanediol-3-glucuronide levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Midgestational circulating levels of PCBs (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Nicotinamide levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Retinol (Vitamin A) levels,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),Folate pathway vitamin levels,Nicotinamide phosphoribosyltransferase levels (NAMPT.5011.11.1),Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),N6-methyllysine levels (elderly offspring),Midgestational cytokine/chemokine levels (fetal genetic effect),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Orofacial cleft x maternal vitamin supplementation interaction (2df),5alpha-pregnan-diol disulfate levels,Serum folate levels,Vitamin B12 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes","N2-acetyl,N6,N6-dimethyllysine levels (elderly offspring)"
Maternal Plasma Vitamin B3 - Trigonelline (µmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 3 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Vitamin levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 2 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnanediol-3-glucuronide levels,Metabolite levels (pregnanediol-3-glucuronide),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Glycemic traits (pregnancy),Midgestational cytokine/chemokine levels (fetal genetic effect),Adiponectin levels in pregnancy,Vitamin B1 intake,5alpha-pregnan-diol disulfate levels,Midgestational cytokine/chemokine levels (maternal genetic effect),Transcobalamin-1 levels (TCN1.11232.46.3),Vitamin B12 levels,Folate pathway vitamin levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Orofacial cleft x maternal vitamin supplementation interaction (2df),Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),Retinol (Vitamin A) levels,Early placenta insulin-like peptide levels,Serum 25-Hydroxyvitamin D levels,Pregnanolone/allopregnanolone sulfate levels
Maternal Plasma Vitamin B6 - Pyridoxal (nmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 8 levels,Vitamin levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 11 levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 3 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Orofacial cleft x maternal vitamin supplementation interaction (2df),Midgestational cytokine/chemokine levels (fetal genetic effect),Folate pathway vitamin levels,5alpha-pregnan-diol disulfate levels,Midgestational cytokine/chemokine levels (maternal genetic effect),Retinol (Vitamin A) levels,Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),Pregnanediol-3-glucuronide levels,Midgestational circulating levels of PCBs (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Midgestational circulating levels of PBDEs (fetal genetic effect),Glycemic traits (pregnancy),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect),Serum 25-Hydroxyvitamin D levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Adiponectin levels in pregnancy,Vitamin C levels,Serum folate levels,"N6,N6-dimethyllysine levels (elderly offspring)"
Maternal Plasma Vitamin B6 - Pyridoxal 5-phosphate (nmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Vitamin levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),Pregnancy-specific beta-1-glycoprotein 4 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",5alpha-pregnan-diol disulfate levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Orofacial cleft x maternal vitamin supplementation interaction (2df),Pregnancy-specific beta-1-glycoprotein 3 levels,Folate pathway vitamin levels,Serum 25-Hydroxyvitamin D levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),Midgestational circulating levels of PCBs (fetal genetic effect),Midgestational cytokine/chemokine levels (fetal genetic effect),Retinol (Vitamin A) levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Midgestational cytokine/chemokine levels (maternal genetic effect),Midgestational circulating levels of PBDEs (fetal genetic effect),Plasma pyridoxal phosphate levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Vitamin C levels,Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect),Metabolite levels (pregnanediol-3-glucuronide),Serum 25-Hydroxyvitamin D level variance,Pregnanolone/allopregnanolone sulfate levels,Pregnanediol-3-glucuronide levels,25-hydroxyvitamin D levels (skin colour stratified)
Maternal Plasma vitamin B6 - PLP (nmoles/L) at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Neonatal total 25-hydroxyvitamin D levels (cord blood),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Early placenta insulin-like peptide levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels,Serum levels of protein MPP6,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Midgestational circulating levels of PCBs (fetal genetic effect),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Vitamin levels,5alpha-pregnan-diol disulfate levels,Pregnancy-specific beta-1-glycoprotein 1 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 9 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Midgestational circulating levels of PBDEs (fetal genetic effect),Platelet count during  first trimester of pregnancy,Adiponectin levels in pregnancy,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Midgestational cytokine/chemokine levels (fetal genetic effect),Midgestational cytokine/chemokine levels (maternal genetic effect),Pregnancy zone protein levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Mean platelet volume during first trimester of pregnancy,Platelet count during  second trimester of pregnancy,Metabolite levels (pregnanediol-3-glucuronide),Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Serum levels of protein NPPB,Phosphatidylinositol (18:0_22:5) (n6) levels,Serum levels of protein DPP7,Pregnanediol-3-glucuronide levels,Serum levels of protein PRELP,"Alkaline phosphatase, placental type levels"
Maternal Plasma vitamin B6 - PLP categories - Sufficient (≥ 20 nmol/L); Deficient (< 20 nmol/L) at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Vitamin levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Early placenta insulin-like peptide levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 5 levels,Serum levels of protein MPP6,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Midgestational circulating levels of PCBs (fetal genetic effect),Serum levels of protein DPP7,Pregnancy-specific beta-1-glycoprotein 4 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy zone protein levels,Midgestational circulating levels of PBDEs (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 9 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 11 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,"Alkaline phosphatase, placental type levels",Protein amnionless [Cleaved into: Soluble protein amnionless] levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Vitamin D-binding protein levels (GC.6581.50.3),Pregnancy-specific beta-1-glycoprotein 2 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",5alpha-pregnan-diol disulfate levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Serum levels of protein H6PD,Serum phosphate levels,"Alkaline phosphatase, placental-like levels",Serum levels of protein PRELP,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Adiponectin levels in pregnancy,Pregnanolone/allopregnanolone sulfate levels,Serum levels of protein PNP,Serum levels of protein PPBP,Serum levels of protein INPP5B,Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Platelet count during  first trimester of pregnancy,DPP6/NELL2 protein level ratio,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))"
Maternal Plasma Vitamin B6 - Pyridoxic acid (nmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 8 levels,Vitamin levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 3 levels,Midgestational cytokine/chemokine levels (fetal genetic effect),Midgestational cytokine/chemokine levels (maternal genetic effect),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Orofacial cleft x maternal vitamin supplementation interaction (2df),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Midgestational circulating levels of PCBs (fetal genetic effect),Midgestational circulating levels of PBDEs (fetal genetic effect),Plasma pyridoxal phosphate levels,Folate pathway vitamin levels,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),Glycemic traits (pregnancy),Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnanediol-3-glucuronide levels,Neonatal cytokine/chemokine levels (maternal genetic effect),Retinol (Vitamin A) levels,Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect),5alpha-pregnan-diol disulfate levels,Neonatal cytokine/chemokine levels (fetal genetic effect),"N6,N6-dimethyllysine levels (elderly offspring)",Vitamin C levels,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),N6-methyllysine levels (elderly offspring),Plasma pyridoxic acid to pyridoxal phosphate ratio,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels"
Maternal Plasma Vitamin B6 - Pyridoxic acid (nmol/L) at pregnancy week 26. Low detection values indicated by 8888,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Plasma pyridoxal phosphate levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Vitamin levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Plasma pyridoxic acid to pyridoxal phosphate ratio,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 4 levels,Pyridoxal levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 11 levels,Midgestational circulating levels of PBDEs (fetal genetic effect),Midgestational cytokine/chemokine levels (fetal genetic effect),Metabolite levels (pregnanediol-3-glucuronide),"N6,N6-dimethyllysine levels (elderly offspring)",Pregnancy-specific beta-1-glycoprotein 1 levels,RBC levels of Pyridoxal,Pyridoxal phosphate homeostasis protein levels,Pregnancy-specific beta-1-glycoprotein 3 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma metabolome feature (c18_20) (Pyruvic acid),Midgestational circulating levels of PCBs (fetal genetic effect),Midgestational cytokine/chemokine levels (maternal genetic effect),Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Plasma metabolome feature (c18_343) (Pyrrolidonecarboxylic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Folate pathway vitamin levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Neonatal cytokine/chemokine levels (maternal genetic effect),Retinol (Vitamin A) levels,Neonatal cytokine/chemokine levels (fetal genetic effect),N6-methyllysine levels (elderly offspring),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Vitamin D-binding protein levels (GC.6581.50.3)
Maternal Plasma Vitamin B6 - Pyridoxine (nmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Vitamin levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Pregnancy-specific beta-1-glycoprotein 5 levels,Orofacial cleft x maternal periconceptional multivitamin use interaction (2df),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Midgestational cytokine/chemokine levels (maternal genetic effect),Midgestational cytokine/chemokine levels (fetal genetic effect),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Glycemic traits (pregnancy),Adiponectin levels in pregnancy,Orofacial cleft x maternal vitamin supplementation interaction (2df),Pregnanediol-3-glucuronide levels,Metabolite levels (pregnanediol-3-glucuronide),"N6,N6-dimethyllysine levels (elderly offspring)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Folate pathway vitamin levels,Midgestational circulating levels of PBDEs (fetal genetic effect),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),N6-methyllysine levels (elderly offspring),Neonatal cytokine/chemokine levels (maternal genetic effect),Early placenta insulin-like peptide levels,Midgestational circulating levels of PCBs (fetal genetic effect),5alpha-pregnan-diol disulfate levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Neonatal cytokine/chemokine levels (fetal genetic effect),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes"
Maternal Plasma Vitamin B12 - Plasma Vitamin B12 (pg/ml) at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Vitamin B12 levels,Vitamin B1 intake,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Neonatal total 25-hydroxyvitamin D levels (cord blood),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Vitamin levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Midgestational circulating levels of PCBs (fetal genetic effect),Metabolite levels (pregnanediol-3-glucuronide),Pregnanediol-3-glucuronide levels,Fetal hemoglobin levels,Transcobalamin-1 levels,Transcobalamin-1 levels (TCN1.11232.46.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Transcobalamin-2 levels,Vitamin B2 intake,Midgestational circulating levels of PBDEs (fetal genetic effect),Holo-Transcobalamin-2 levels,Early placenta insulin-like peptide levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Transcobalamin-2 levels (TCN2.5584.21.3),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Adiponectin levels in pregnancy,General glucose level in pregnancy (gestational week 30-32),Gestational insulin sensitivity,Pregnancy zone protein levels,HCG level (plasma),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Midgestational cytokine/chemokine levels (fetal genetic effect),Beta-crystallin B1 levels,Neonatal jaundice (maternal effect)
Maternal Three categories by clinical cut-offs - Sufficient (≥ 300 pg/ml); Marginally deficient (200-299 pg/ml); Deficient (< 200 pg/ml) at pregnancy week 26,Pregnanolone/allopregnanolone sulfate levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 3 levels,5alpha-pregnan-diol disulfate levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 5 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 8 levels,Fetal hemoglobin levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Pregnancy-specific beta-1-glycoprotein 9 levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 1 levels,Human Chorionic Gonadotropin levels (CGA.CGB.4914.10.1),Pregnancy zone protein levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Glycemic traits (pregnancy),General glucose level in pregnancy (gestational week 30-32),Human Chorionic Gonadotropin levels,Early placenta insulin-like peptide levels,Neonatal total 25-hydroxyvitamin D levels (cord blood),"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes","Placental weight (paternal genotype, adjusted for sex and gestational age)","Placental weight (fetal genotype, adjusted for sex and gestational age)",Disease topic 16 (Pregnancy complications-plus),"Placental weight (maternal genotype, adjusted for sex and gestational age)",Pregnanolone/allopregnanolone sulfate levels in elite athletes,Glycosuria in pregnancy (maternal genotype effect),"Alkaline phosphatase, placental type levels",Glycosuria in pregnancy (maternal and offspring genotype effect),Adiponectin levels in pregnancy,"Placental weight (fetal genotype, adjusted for sex)"
Maternal Two categories - Sufficient (≥ 300 pg/ml); Deficient (< 300 pg/ml) at pregnancy week 26,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnanolone/allopregnanolone sulfate levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Fetal hemoglobin levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnanediol-3-glucuronide levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 1 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 8 levels,Glycemic traits (pregnancy),5alpha-pregnan-diol disulfate levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Pregnancy-specific beta-1-glycoprotein 9 levels,General glucose level in pregnancy (gestational week 30-32),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Metabolite levels (pregnanediol-3-glucuronide),"Alkaline phosphatase, placental type levels",Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy zone protein levels,Pregnancy-specific beta-1-glycoprotein 11 levels,"Placental weight (fetal genotype, adjusted for sex and gestational age)",Early placenta insulin-like peptide levels,"Alkaline phosphatase, placental-like levels",Human Chorionic Gonadotropin levels (CGA.CGB.4914.10.1),"Placental weight (maternal genotype, adjusted for sex and gestational age)",Glycosuria in pregnancy (maternal genotype effect),"Placental weight (paternal genotype, adjusted for sex and gestational age)",Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Glycosuria in pregnancy (maternal and offspring genotype effect),Two-hour glucose in pregnancy (gestational week 30-32),"Placental weight (fetal genotype, adjusted for sex)",Disease topic 16 (Pregnancy complications-plus),"Placental weight (maternal genotype, adjusted for sex)",Diabetes (gestational),Preeclampsia or small for gestational age infant (maternal genotype effect),"Placental weight (paternal genotype, adjusted for sex)",Glycosuria in pregnancy (offspring genotype effect)
Maternal Plasma Vitamin D3 - Plasma Vitamin D (nmol/L) at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Serum 25-Hydroxyvitamin D levels,Vitamin D levels,Vitamin D levels (dietary vitamin D intake interaction),25-Hydroxyvitamin D levels,Serum vitamin D-binding protein levels,Vitamin D3 levels,Serum 25-Hydroxyvitamin D level variance,Vitamin D-binding protein levels (GC.6581.50.3),25-hydroxyvitamin D levels (skin colour stratified),Vitamin D-binding protein levels (adjusted for GC haplotype),Serum 25-Hydroxyvitamin D levels x season interaction,Vitamin D3 receptor levels,Vitamin D-binding protein levels,Vitamin D levels or COVID-19 (MTAG),Vitamin D insufficiency,Bioavailable vitamin D levels in type 2 diabetes,25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Vitamin levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Serum vitamin D-binding protein levels in type 2 diabetes,Vitamin D levels x vegetarianism interaction,25-hydroxyvitamin D levels x skin colour (very fair vs. fair) interaction,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),5alpha-pregnan-diol disulfate levels,Apolipoprotein D levels (APOD.4712.28.2),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnanediol-3-glucuronide levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 3 levels,Depression score x vitamin D interaction,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),"5alpha-pregnan-3beta,20alpha-diol disulfate levels","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Midgestational cytokine/chemokine levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 8 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)"
Maternal Plasma Vitamin D3 - 3 categories (nmol/L) - Sufficient (>= 50 nmol/L); Marginally Deficient (30-49 nmol/L); Deficient (< 30 nmol/L)  (Reference:IOM) at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Vitamin D3 levels,Vitamin D levels,Vitamin D3 receptor levels,Vitamin D-binding protein levels (GC.6581.50.3),Vitamin D levels (dietary vitamin D intake interaction),Vitamin D-binding protein levels (adjusted for GC haplotype),25-hydroxyvitamin D levels (skin colour stratified),Serum vitamin D-binding protein levels,25-Hydroxyvitamin D levels,Serum 25-Hydroxyvitamin D levels,Vitamin levels,Vitamin D-binding protein levels,Vitamin D insufficiency,Vitamin D levels or COVID-19 (MTAG),Serum 25-Hydroxyvitamin D level variance,Bioavailable vitamin D levels in type 2 diabetes,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Serum vitamin D-binding protein levels in type 2 diabetes,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Vitamin D levels x vegetarianism interaction,Retinol (Vitamin A) levels,Serum 25-Hydroxyvitamin D levels x season interaction,25-hydroxyvitamin D levels x skin colour (very fair vs. fair) interaction,"5alpha-pregnan-3beta,20alpha-diol disulfate levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Metabolite levels (pregnanediol-3-glucuronide),Folate pathway vitamin levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),5alpha-pregnan-diol disulfate levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Gamma-crystallin D levels,Vitamin D levels (adjusted for BMI) x vegetarianism interaction,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Orofacial cleft x maternal periconceptional multivitamin use interaction (1df),Apolipoprotein D levels (APOD.4712.28.2)
Maternal Plasma Vitamin D3 - 3 categories (nmol/L) - Sufficient (> 75 nmol/L); Insufficient (50-75 nmol/L); Deficient (< 50 nmol/L) (Reference: Endocrine Society ) at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Vitamin D3 levels,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Vitamin D levels,Vitamin D3 receptor levels,Vitamin D-binding protein levels (GC.6581.50.3),Vitamin levels,Vitamin D levels (dietary vitamin D intake interaction),25-Hydroxyvitamin D levels,Serum vitamin D-binding protein levels,Vitamin D-binding protein levels (adjusted for GC haplotype),25-hydroxyvitamin D levels (skin colour stratified),Vitamin D-binding protein levels,Serum 25-Hydroxyvitamin D levels,Vitamin D insufficiency,Vitamin D levels or COVID-19 (MTAG),Serum 25-Hydroxyvitamin D level variance,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Bioavailable vitamin D levels in type 2 diabetes,Pregnanediol-3-glucuronide levels,Retinol (Vitamin A) levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Serum vitamin D-binding protein levels in type 2 diabetes,Metabolite levels (pregnanediol-3-glucuronide),25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 3 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Folate pathway vitamin levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Vitamin D levels x vegetarianism interaction,Serum 25-Hydroxyvitamin D levels x season interaction,5alpha-pregnan-diol disulfate levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Gamma-crystallin D levels,25-hydroxyvitamin D levels x skin colour (very fair vs. fair) interaction,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Vitamin C levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels
Maternal Amino Acid & Intermediates: Arginine & Metabolites  - Arginine (µmol/L) -Bevital panel at pregnancy week 26,Arginine levels (Metabolon platform),L-arginine levels,Arginine levels (Biocrates platform),Plasma metabolome feature (c18_789) (Arginine),Metabolite levels (arginine),Arginine levels,Arginine/serine-rich protein 1 levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Plasma arginine levels in chronic kidney disease,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 4 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Arginine levels in elite athletes,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnanediol-3-glucuronide levels,Protein arginine N-methyltransferase 3 levels,Metabolite levels (homoarginine),Adiponectin levels in pregnancy,Early placenta insulin-like peptide levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Homoarginine levels,Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Protein amnionless [Cleaved into: Soluble protein amnionless] levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Metabolite levels (arginylphenylalanine),Argininosuccinate synthase levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational cytokine/chemokine levels (fetal genetic effect),Plasma homoarginine levels in chronic kidney disease,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Glycemic traits (pregnancy),Vaginal microbiome MetaCyc pathway (ARG+POLYAMINE-SYN|superpathway of arginine and polyamine biosynthesis),Metabolite levels (N-acetylasparagine),Pregnanolone/allopregnanolone sulfate levels,Plasma argininate* levels in chronic kidney disease
Maternal Amino Acid & Intermediates: Arginine & Metabolites  - Asymmetric dimethylarginine (µmol/L) -Bevital panel at pregnancy week 26,Arginine levels (Metabolon platform),L-arginine levels,Plasma metabolome feature (c18_789) (Arginine),Arginine levels (Biocrates platform),Metabolite levels (arginine),Arginine levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 4 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 9 levels,Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Plasma arginine levels in chronic kidney disease,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Arginine/serine-rich protein 1 levels,Arginine levels in elite athletes,Pregnancy-specific beta-1-glycoprotein 3 levels,Metabolite levels (homoarginine),Pregnancy-specific beta-1-glycoprotein 1 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnanediol-3-glucuronide levels,Asymmetrical dimethylarginine levels,Serum dimethylarginine levels (asymmetric/symetric ratio),Homoarginine levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Protein arginine N-methyltransferase 3 levels,Adiponectin levels in pregnancy,Symmetric dimethylarginine levels in chronic kidney disease,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Midgestational total 25-hydroxyvitamin D levels (antenatal blood),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Early placenta insulin-like peptide levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Plasma homoarginine levels in chronic kidney disease,Metabolite levels (arginylphenylalanine),Glycemic traits (pregnancy),Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Metabolite levels (N-acetylasparagine),Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA)
Maternal Amino Acid & Intermediates: Arginine & Metabolites  - Creatine (µmol/L) -Bevital panel at pregnancy week 26,Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 9 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 8 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Metabolite levels (arginine),Pregnancy-specific beta-1-glycoprotein 4 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnanediol-3-glucuronide levels in elite athletes,Plasma metabolome feature (c18_789) (Arginine),Pregnancy-specific beta-1-glycoprotein 2 levels,Arginine levels (Metabolon platform),Pregnancy-specific beta-1-glycoprotein 11 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 1 levels,Early placenta insulin-like peptide levels,Pregnancy-specific beta-1-glycoprotein 3 levels,L-arginine levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Plasma pregnanediol-3-glucuronide levels in chronic kidney disease,Arginine levels (Biocrates platform),Adiponectin levels in pregnancy,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Arginine levels in elite athletes,Urine pregnanediol-3-glucuronide levels in chronic kidney disease,Arginine levels,Metabolite levels (creatine),Pregnancy zone protein levels,Plasma arginine levels in chronic kidney disease,Glycemic traits (pregnancy),Arginine/serine-rich protein 1 levels,Alanine aminotransferase levels (adjusted for BMI) x vegetarianism interaction,Pregnanolone/allopregnanolone sulfate levels in elite athletes,"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Metabolite levels (homoarginine),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Alanine aminotransferase levels x BMI interaction,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Metabolite levels (glycine),Plasma free amino acid levels
Maternal Amino Acid & Intermediates: Arginine & Metabolites  - Creatinine (µmol/L) -Bevital panel at pregnancy week 26,Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Metabolite levels (arginine),Arginine levels (Biocrates platform),Arginine levels (Metabolon platform),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",L-arginine levels,Plasma pregnanediol-3-glucuronide levels in chronic kidney disease,Plasma metabolome feature (c18_789) (Arginine),Early placenta insulin-like peptide levels,Arginine levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Plasma arginine levels in chronic kidney disease,Urine pregnanediol-3-glucuronide levels in chronic kidney disease,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Arginine/serine-rich protein 1 levels,Adiponectin levels in pregnancy,Pregnanediol-3-glucuronide levels in elite athletes,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Pregnancy zone protein levels,Glycemic traits (pregnancy),Midgestational cytokine/chemokine levels (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 4 level in Chronic kidney disease with hypertension and no diabetes (5649_83),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Arginine levels in elite athletes,Proteinuria in preeclampsia,Metabolite levels (homoarginine),Serum creatinine levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 3 level in Chronic kidney disease with hypertension and no diabetes (6444_15),Pregnancy-specific beta-1-glycoprotein 1 level in Chronic kidney disease with hypertension and no diabetes (15631_18)
Maternal Amino Acid & Intermediates: Arginine & Metabolites  - Homoarginine (µmol/L) -Bevital panel at pregnancy week 26,L-arginine levels,Arginine levels (Biocrates platform),Arginine levels (Metabolon platform),Homoarginine levels,Plasma metabolome feature (c18_789) (Arginine),Metabolite levels (arginine),Metabolite levels (homoarginine),Arginine levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Plasma homoarginine levels in chronic kidney disease,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Arginine/serine-rich protein 1 levels,Metabolite levels (pregnanediol-3-glucuronide),Plasma arginine levels in chronic kidney disease,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Arginine levels in elite athletes,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Urine homoarginine levels in chronic kidney disease,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Homoarginine levels in elite athletes,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Protein arginine N-methyltransferase 3 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Early placenta insulin-like peptide levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Adiponectin levels in pregnancy,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Metabolite levels (arginylphenylalanine),Glycemic traits (pregnancy),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Protein amnionless [Cleaved into: Soluble protein amnionless] levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnanediol-3-glucuronide levels in elite athletes,Midgestational cytokine/chemokine levels (fetal genetic effect),Plasma pregnanediol-3-glucuronide levels in chronic kidney disease
Maternal Amino Acid & Intermediates: Arginine & Metabolites  - Symmetric dimethylarginine (µmol/L) -Bevital panel at pregnancy week 26,Arginine levels (Metabolon platform),L-arginine levels,Plasma metabolome feature (c18_789) (Arginine),Arginine levels (Biocrates platform),Metabolite levels (arginine),Arginine levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 4 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Arginine/serine-rich protein 1 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Plasma arginine levels in chronic kidney disease,Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Arginine levels in elite athletes,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Metabolite levels (homoarginine),Pregnancy-specific beta-1-glycoprotein 1 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Protein arginine N-methyltransferase 3 levels,Pregnanediol-3-glucuronide levels,Homoarginine levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Adiponectin levels in pregnancy,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Asymmetrical dimethylarginine levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Early placenta insulin-like peptide levels,Serum dimethylarginine levels (asymmetric/symetric ratio),Symmetric dimethylarginine levels in chronic kidney disease,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Metabolite levels (arginylphenylalanine),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Plasma homoarginine levels in chronic kidney disease,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Midgestational cytokine/chemokine levels (fetal genetic effect)
Maternal Amino Acid & Intermediates: Arginine & Metabolites  - Trimethyllysine (µmol/L) -Bevital panel at pregnancy week 26,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Plasma metabolome feature (c18_789) (Arginine),Pregnancy-specific beta-1-glycoprotein 5 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Arginine levels (Metabolon platform),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Metabolite levels (arginine),Adiponectin levels in pregnancy,Arginine levels (Biocrates platform),Pregnanediol-3-glucuronide levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Early placenta insulin-like peptide levels,L-arginine levels,Glycemic traits (pregnancy),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Arginine levels,Midgestational cytokine/chemokine levels (fetal genetic effect),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnanolone/allopregnanolone sulfate levels,Arginine/serine-rich protein 1 levels,Midgestational cytokine/chemokine levels (maternal genetic effect),"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Metabolite levels (homoarginine),General glucose level in pregnancy (gestational week 30-32),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes",Glycosuria in pregnancy (maternal genotype effect),Plasma arginine levels in chronic kidney disease,Glycosuria in pregnancy (maternal and offspring genotype effect),5alpha-pregnan-diol disulfate levels
Maternal Amino Acid & Intermediates: Cysteine & Metabolites  - Cystathionine (µmol/L) -Bevital panel at pregnancy week 26,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Midgestational cytokine/chemokine levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 8 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 2 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Putative pregnancy-specific beta-1-glycoprotein 7 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 4 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Metabolite levels (cysteinylglycine),Pregnancy-specific beta-1-glycoprotein 1 levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 3 levels,Cysteine levels,Midgestational cytokine/chemokine levels (maternal genetic effect),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Cysteine and glycine-rich protein 1 levels,Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 5 levels,Neonatal cytokine/chemokine levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Cystathionine levels,Cysteinylglycine levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Metabolite levels (cysteinylglycine disulfide),Neonatal cytokine/chemokine levels (maternal genetic effect),Metabolite levels (cysteine-glutathione disulfide),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Cysteine and glycine-rich protein 2 levels,Plasma cystathionine levels in chronic kidney disease,Plasma metabolome feature (hilic_5137) (Cysteineglutathione disulfide),Pregnanediol-3-glucuronide levels,Plasma cysteinylglycine levels in chronic kidney disease,Metabolite levels (cystathionine; cmh_cystathionine),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes",Cysteine and glycine-rich protein 3 levels,Urine cysteinylglycine levels in chronic kidney disease,"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes"
Maternal Amino Acid & Intermediates: Cysteine & Metabolites  - Total Homocysteine (µmol/L) - Bevital panel at pregnancy week 26,Plasma homocysteine levels,Homocysteine levels,Plasma homocysteine levels (post-methionine load test),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 8 levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 4 levels,Cysteine and glycine-rich protein 1 levels,Cysteine levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Putative pregnancy-specific beta-1-glycoprotein 7 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Metabolite levels (cysteinylglycine),Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Cysteinylglycine levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Cysteine and glycine-rich protein 2 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Metabolite levels (pregnanediol-3-glucuronide),Midgestational cytokine/chemokine levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 9 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Cysteine and glycine-rich protein 3 levels,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Plasma cysteinylglycine levels in chronic kidney disease,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Pregnanediol-3-glucuronide levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Midgestational cytokine/chemokine levels (maternal genetic effect),RBC levels of S-Adenosyl-L-homocysteine,Cysteine-rich protein 1 levels,Urine cysteinylglycine levels in chronic kidney disease,Glycemic traits (pregnancy),Neonatal total 25-hydroxyvitamin D levels (cord blood),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Metabolite levels (S-methylcysteine; methylcysteine),Plasma metabolome feature (hilic_5137) (Cysteineglutathione disulfide)
Maternal Amino Acid & Intermediates: Cysteine & Metabolites  - Total cysteine (µmol/L) - Bevital panel at pregnancy week 26,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Cysteine and glycine-rich protein 1 levels,Cysteine levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 4 levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 11 levels,Metabolite levels (cysteinylglycine),Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Cysteine and glycine-rich protein 2 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Metabolite levels (pregnanediol-3-glucuronide),Cysteinylglycine levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Cysteine and glycine-rich protein 3 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Midgestational cytokine/chemokine levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnanediol-3-glucuronide levels,Plasma cysteinylglycine levels in chronic kidney disease,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Plasma homocysteine levels (post-methionine load test),Plasma homocysteine levels,Cysteine-rich protein 1 levels,Urine cysteinylglycine levels in chronic kidney disease,Midgestational cytokine/chemokine levels (maternal genetic effect),Urine cysteine levels in chronic kidney disease,Homocysteine levels,"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Glycemic traits (pregnancy),Metabolite levels (cysteinylglycine disulfide),Neonatal total 25-hydroxyvitamin D levels (cord blood)
Maternal Amino Acid & Intermediates: Histidine & Metabolites  - 1-Methylhistidine (1-MH) (µmol/L) - Bevital panel at pregnancy week 26,Metabolite levels (1-methylhistidine),1-methylhistidine levels,Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Metabolite levels (N-acetyl-1-methylhistidine),Metabolite levels (N-acetylhistidine),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Histidine levels (Metabolon platform),Metabolite levels (N-acetyl-3-methylhistidine),N-acetyl-1-methylhistidine levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",1-methylhistidine levels in elite athletes,Metabolite levels (pregnanediol-3-glucuronide),Histidine levels,Histidine-rich glycoprotein levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Histidine levels (Biocrates platform),N-acetyl-3-methylhistidine levels,N-acetylhistidine levels,Urine 1-methylhistidine levels in chronic kidney disease,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,3-methylhistidine levels in elite athletes,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels,Histidine levels (UKB data field 23463),Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Histidine betaine (hercynine) levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 2 levels,Gamma-glutamylhistidine levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Plasma metabolome feature (hilic_1928) ((3S)-3-Hydroxy-L-enduracididine),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Histidine meal response (LMM),Metabolite levels (histidylphenylalanine),N-acetyl-1-methylhistidine levels in elite athletes,Plasma N-acetyl-1-methylhistidine* levels in chronic kidney disease,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Histidine triad nucleotide-binding protein 1 levels (HINT1.5900.11.2),Pregnanediol-3-glucuronide levels,Metabolite levels (glycine),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine)
Maternal Amino Acid & Intermediates: Histidine & Metabolites  - 3-Methylhistidine (3-MH) (µmol/L) - Bevital panel at pregnancy week 26,Metabolite levels (1-methylhistidine),1-methylhistidine levels,Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Metabolite levels (N-acetylhistidine),Metabolite levels (N-acetyl-1-methylhistidine),Metabolite levels (N-acetyl-3-methylhistidine),Histidine levels (Metabolon platform),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",N-acetyl-3-methylhistidine levels,Histidine levels,N-acetyl-1-methylhistidine levels,3-methylhistidine levels in elite athletes,Histidine-rich glycoprotein levels,1-methylhistidine levels in elite athletes,Histidine levels (Biocrates platform),Histidine levels (UKB data field 23463),N-acetylhistidine levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Histidine betaine (hercynine) levels,Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Plasma metabolome feature (hilic_1928) ((3S)-3-Hydroxy-L-enduracididine),Pregnancy-specific beta-1-glycoprotein 9 levels,Urine 1-methylhistidine levels in chronic kidney disease,Pregnancy-specific beta-1-glycoprotein 8 levels,Histidine meal response (LMM),Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Metabolite levels (histidylphenylalanine),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Gamma-glutamylhistidine levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Plasma N-acetyl-3-methylhistidine* levels in chronic kidney disease,N-acetyl-3-methylhistidine levels in elite athletes,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Metabolite levels (histidylleucine),Glutamine-to-histidine ratio,Metabolite levels (glycine),Pregnancy-specific beta-1-glycoprotein 2 levels,N-acetyl-1-methylhistidine levels in elite athletes,Metabolite levels (hexanoylglycine),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Histidine triad nucleotide-binding protein 1 levels (HINT1.5900.11.2),Plasma N-acetyl-1-methylhistidine* levels in chronic kidney disease
Maternal Amino Acid & Intermediates: Histidine & Metabolites  - Histidine (µmol/L) - Bevital panel at pregnancy week 26,Histidine levels (Metabolon platform),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Histidine-rich glycoprotein levels,Histidine levels,Metabolite levels (pregnanediol-3-glucuronide),Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Histidine levels (Biocrates platform),Metabolite levels (N-acetylhistidine),Metabolite levels (1-methylhistidine),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Histidine betaine (hercynine) levels,Histidine levels (UKB data field 23463),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Metabolite levels (N-acetyl-1-methylhistidine),Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,1-methylhistidine levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Glutamine-to-histidine ratio,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Metabolite levels (N-acetyl-3-methylhistidine),Histidine meal response (LMM),Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnanediol-3-glucuronide levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Metabolite levels (histidylphenylalanine),Histidine triad nucleotide-binding protein 1 levels (HINT1.5900.11.2),Metabolite levels (histidylleucine),Metabolite levels (glycine),Early placenta insulin-like peptide levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Metabolite levels (hexanoylglycine),Histidine levels in elite athletes,Plasma free amino acid levels,N-acetylhistidine levels,Plasma metabolome feature (hilic_1928) ((3S)-3-Hydroxy-L-enduracididine),Histidine meal response (OrNLSr),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Metabolite levels (cytidine)
Maternal Amino Acid & Intermediates: Methionine & Metabolites  - Methionine (µmol/L) - Bevital panel at pregnancy week 26,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Methionine levels,Methionine levels (Biocrates platform),Methionine levels (Metabolon platform),Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",RBC levels of Methionine,Plasma homocysteine levels (post-methionine load test),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Methionine synthase levels,Methionine aminopeptidase 2 levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnanediol-3-glucuronide levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 1 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 3 levels,"Methionine aminopeptidase 1D, mitochondrial levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Pregnancy-specific beta-1-glycoprotein 11 levels,Early placenta insulin-like peptide levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Metabolite levels (methionine sulfone),Methionine levels in elite athletes,Methionine adenosyltransferase 2 subunit beta levels,5alpha-pregnan-diol disulfate levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes",Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Adiponectin levels in pregnancy,Midgestational cytokine/chemokine levels (fetal genetic effect),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Plasma methionine sulfone levels in chronic kidney disease,Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect)
Maternal Amino Acid & Intermediates: Methionine & Metabolites  - Methionine sulfoxide (µmol/L) - Bevital panel at pregnancy week 26,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Metabolite levels (methionine sulfone),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Methionine levels (Metabolon platform),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Methionine levels,Methionine levels (Biocrates platform),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 8 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 9 levels,RBC levels of Methionine,Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnanediol-3-glucuronide levels,Plasma homocysteine levels (post-methionine load test),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Plasma methionine sulfone levels in chronic kidney disease,Methionine-R-sulfoxide reductase B3 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Methionine synthase levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Methionine aminopeptidase 2 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 3 levels,Methionine sulfone levels,Urine methionine sulfone levels in chronic kidney disease,"Methionine-R-sulfoxide reductase B2, mitochondrial levels",5alpha-pregnan-diol disulfate levels,Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine),"Methionine aminopeptidase 1D, mitochondrial levels",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 11 levels,"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Pregnanolone/allopregnanolone sulfate levels,Urine methionine sulfoxide levels in chronic kidney disease,Methioninesulfoxide levels,Early placenta insulin-like peptide levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood)
Maternal Amino Acid & Intermediates: Tryptophan & Metabolites  - 3-Hydroxyanthranilic acid (nmol/L) - Bevital panel at pregnancy week 26,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma metabolome feature (hilic_2249) (L-Tryptophan),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Metabolite levels (tryptophan),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 9 levels,Metabolite levels (pregnanediol-3-glucuronide),Metabolite levels (tryptophan betaine),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 3 levels,Tryptophan levels,Pregnancy-specific beta-1-glycoprotein 4 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Pregnancy-specific beta-1-glycoprotein 5 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Putative pregnancy-specific beta-1-glycoprotein 7 levels,Early placenta insulin-like peptide levels,Tryptophan levels (Metabolon platform),Tryptophan levels (Biocrates platform),Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",N-acetyl-d-tryptophan levels,Tryptophan betaine  levels,Tryptophan betaine levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Glycemic traits (pregnancy),"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Urine tryptophan levels in chronic kidney disease,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels in elite athletes","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Adiponectin levels in pregnancy,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Tryptophan levels in elite athletes,Breast milk fatty acid composition (maternal genotype effect),Gut bacterial pathway abundance (TRPSYN.PWY..L.tryptophan.biosynthesis),Plasma metabolome feature (hilic_1399) (Indole ethanol (Tryptophanol))
Maternal Amino Acid & Intermediates: Tryptophan & Metabolites  - 3-Hydroxykynurenine (nmol/L) - Bevital panel at pregnancy week 26,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 9 levels,Plasma metabolome feature (hilic_2249) (L-Tryptophan),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Metabolite levels (tryptophan betaine),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Metabolite levels (tryptophan),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 3 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Tryptophan levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Tryptophan betaine  levels,Tryptophan betaine levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Early placenta insulin-like peptide levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 1 levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Pregnancy-specific beta-1-glycoprotein 11 levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),N-acetyl-d-tryptophan levels,Pregnanediol-3-glucuronide levels in elite athletes,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Tryptophan levels (Biocrates platform),Glycemic traits (pregnancy),Tryptophan levels (Metabolon platform),Adiponectin levels in pregnancy,Plasma tryptophan betaine levels in chronic kidney disease,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Tryptophan betaine levels in elite athletes,Urine tryptophan levels in chronic kidney disease,"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Tryptophan levels in elite athletes,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels in elite athletes","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels"
Maternal Amino Acid & Intermediates: Tryptophan & Metabolites  - Anthranilic acid (nmol/L) - Bevital panel at pregnancy week 26,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma metabolome feature (hilic_2249) (L-Tryptophan),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Metabolite levels (tryptophan),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Metabolite levels (tryptophan betaine),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Tryptophan levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Tryptophan levels (Metabolon platform),Pregnancy-specific beta-1-glycoprotein 9 levels,Early placenta insulin-like peptide levels,Metabolite levels (pregnanediol-3-glucuronide),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Pregnancy-specific beta-1-glycoprotein 4 levels,Tryptophan levels (Biocrates platform),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Adiponectin levels in pregnancy,N-acetyl-d-tryptophan levels,Tryptophan betaine levels,Tryptophan betaine  levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Glycemic traits (pregnancy),Pregnanediol-3-glucuronide levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Urine tryptophan levels in chronic kidney disease,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes",Gut bacterial pathway abundance (TRPSYN.PWY..L.tryptophan.biosynthesis),Tryptophan levels in elite athletes,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels in elite athletes",Metabolite levels (N-acetyl-aspartyl-glutamate (NAAG)),Metabolite levels (aspartylphenylalanine),5alpha-pregnan-diol disulfate levels,Metabolite levels (N-acetyltryptophan)
Maternal Amino Acid & Intermediates: Tryptophan & Metabolites  - Kynurenic acid (nmol/L) - Bevital panel at pregnancy week 26,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Plasma metabolome feature (hilic_2249) (L-Tryptophan),Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Early placenta insulin-like peptide levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Metabolite levels (tryptophan),Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 8 levels,Tryptophan levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Metabolite levels (tryptophan betaine),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",N-acetyl-d-tryptophan levels,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Glycemic traits (pregnancy),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Tryptophan levels (Biocrates platform),Tryptophan levels (Metabolon platform),Adiponectin levels in pregnancy,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Tryptophan betaine  levels,Tryptophan betaine levels,Plasma metabolome feature (hilic_2278) (Kynurenine),Plasma kynurenine to tryptophan ratio in major depressive disorder,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnanediol-3-glucuronide levels in elite athletes,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Urine tryptophan levels in chronic kidney disease,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),5alpha-pregnan-diol disulfate levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes",Pregnancy zone protein levels,Plasma free amino acid levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes"
Maternal Amino Acid & Intermediates: Tryptophan & Metabolites  - Kynurenine (µmol/L) - Bevital panel at pregnancy week 26,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 9 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma metabolome feature (hilic_2249) (L-Tryptophan),Metabolite levels (tryptophan betaine),Metabolite levels (pregnanediol-3-glucuronide),Metabolite levels (tryptophan),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Early placenta insulin-like peptide levels,Tryptophan levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Tryptophan betaine levels,Tryptophan betaine  levels,Plasma kynurenine to tryptophan ratio in major depressive disorder,Putative pregnancy-specific beta-1-glycoprotein 7 levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnanediol-3-glucuronide levels,Plasma metabolome feature (hilic_2278) (Kynurenine),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,N-acetyl-d-tryptophan levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Tryptophan levels (Biocrates platform),Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Adiponectin levels in pregnancy,Pregnancy-specific beta-1-glycoprotein 3 levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Plasma tryptophan betaine levels in chronic kidney disease,Tryptophan levels (Metabolon platform),Glycemic traits (pregnancy),Urine tryptophan levels in chronic kidney disease,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Tryptophan betaine levels in elite athletes,"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Tryptophan levels in elite athletes,Kynurenine levels,Tryptase alpha/beta-1 levels,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Tryptase beta-1 levels,ADH4/KYNU protein level ratio,Pregnanediol-3-glucuronide levels in elite athletes,Metabolite levels (phenylalanine),"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels"
Maternal Amino Acid & Intermediates: Tryptophan & Metabolites  - Quinolinic acid (nmol/L) - Bevital panel at pregnancy week 26,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Plasma metabolome feature (hilic_2249) (L-Tryptophan),Plasma metabolome feature (c18_713) (Quinolinic acid),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnanediol-3-glucuronide levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Early placenta insulin-like peptide levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Metabolite levels (tryptophan),Pregnancy-specific beta-1-glycoprotein 9 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 5 levels,Glycemic traits (pregnancy),Tryptophan levels,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Pregnancy-specific beta-1-glycoprotein 8 levels,Metabolite levels (tryptophan betaine),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnancy-specific beta-1-glycoprotein 3 levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Tryptophan levels (Biocrates platform),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Pregnancy-specific beta-1-glycoprotein 11 levels,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Pregnanediol-3-glucuronide levels in elite athletes,N-acetyl-d-tryptophan levels,Tryptophan levels (Metabolon platform),"5alpha-pregnan-3beta,20alpha-diol disulfate levels","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Plasma free amino acid levels (adjusted for twenty other PFAAs),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),5alpha-pregnan-diol disulfate levels,Urine tryptophan levels in chronic kidney disease,Breast milk fatty acid composition (maternal genotype effect),Pregnancy zone protein levels,Adiponectin levels in pregnancy,Metabolite levels (phenylalanine),"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Tryptophan betaine  levels
Maternal Amino Acid & Intermediates: Tryptophan & Metabolites  - Tryptophan (µmol/L) - Bevital panel at pregnancy week 26,Tryptophan levels,Plasma metabolome feature (hilic_2249) (L-Tryptophan),Metabolite levels (tryptophan),Metabolite levels (tryptophan betaine),Tryptophan levels (Biocrates platform),Tryptophan betaine  levels,Tryptophan betaine levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Tryptophan levels (Metabolon platform),Pregnancy-specific beta-1-glycoprotein 9 levels,Early placenta insulin-like peptide levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,N-acetyl-d-tryptophan levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Tryptophan levels in elite athletes,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Urine tryptophan levels in chronic kidney disease,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 3 levels,Plasma tryptophan betaine levels in chronic kidney disease,Gut bacterial pathway abundance (TRPSYN.PWY..L.tryptophan.biosynthesis),Tryptophan betaine levels in elite athletes,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Metabolite levels (pregnanediol-3-glucuronide),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Adiponectin levels in pregnancy,"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Glycemic traits (pregnancy),Metabolite levels (N-acetyltryptophan),Tryptase alpha/beta-1 levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels","Tryptophan 2,3-dioxygenase levels",Pregnanediol-3-glucuronide levels,Tryptase beta-1 levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Pregnancy zone protein levels,Gamma-glutamyltryptophan levels
Maternal Amino Acid & Intermediates: Tryptophan & Metabolites  - Xanthurenic acid (nmol/L) - Bevital panel at pregnancy week 26,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 9 levels,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Plasma metabolome feature (hilic_2249) (L-Tryptophan),"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Metabolite levels (pregnanediol-3-glucuronide),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Metabolite levels (tryptophan),Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 11 levels,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Tryptophan levels,Metabolite levels (tryptophan betaine),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnanediol-3-glucuronide levels,Early placenta insulin-like peptide levels,Tryptophan levels (Biocrates platform),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Glycemic traits (pregnancy),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Tryptophan levels (Metabolon platform),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",N-acetyl-d-tryptophan levels,Tryptophan betaine levels,Tryptophan betaine  levels,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Adiponectin levels in pregnancy,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Breast milk fatty acid composition (maternal genotype effect),Urine tryptophan levels in chronic kidney disease,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",Gut bacterial pathway abundance (TRPSYN.PWY..L.tryptophan.biosynthesis),Pregnanediol-3-glucuronide levels in elite athletes,Protein amnionless [Cleaved into: Soluble protein amnionless] levels,Tryptophan levels in elite athletes,Tryptase alpha/beta-1 levels,Metabolite levels (17alpha-hydroxypregnanolone glucuronide),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Metabolite levels (N-acetyl-aspartyl-glutamate (NAAG)),5alpha-pregnan-diol disulfate levels
Maternal Choline Metabolism: Choline & Metabolites  - Betaine (µmol/L) - Bevital panel at pregnancy week 26,Choline levels (elderly offspring),RBC levels of Choline,Plasma choline levels in chronic kidney disease,Urine choline levels in chronic kidney disease,Metabolite levels (pregnanediol-3-glucuronide),Choline levels,Plasma metabolome feature (hilic_1031) (Proline betaine),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Choline phosphate levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Pregnancy-specific beta-1-glycoprotein 8 levels,Intrahepatic cholestasis of pregnancy,Choline/ethanolamine kinase levels (CHKB.13117.232.3),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 9 levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Choline levels (advanced age),Pregnancy-specific beta-1-glycoprotein 1 levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Phosphatidylcholine and other choline levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Pregnancy-specific beta-1-glycoprotein 4 levels,Choline levels in elite athletes,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Pregnancy-specific beta-1-glycoprotein 11 levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Pregnanediol-3-glucuronide levels,Metabolite levels (3beta-hydroxy-5-cholestenoate),Putative pregnancy-specific beta-1-glycoprotein 7 levels,Choline/ethanolamine kinase levels,Total cholines levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Cholesteryl ester (24:1) levels,Metabolite levels (proline),Cholesteryl ester (22:1) levels,Cholesteryl ester (24:0) levels,Cholesteryl ester (22:5) (n6) levels,Cholesteryl ester (22:0) levels,Cholesteryl ester (20:1) levels,Fasting phosphatidylcholine and other cholines,Glycemic traits (pregnancy),Metabolite levels (asparagylvaline),Cholesteryl ester (20:2) levels,Cholesteryl ester (20:0) levels,Cholesteryl ester (24:6) levels,Cholesteryl ester (24:5) levels
Maternal Choline Metabolism: Choline & Metabolites  - Choline (µmol/L) - Bevital panel at pregnancy week 26,Choline levels (elderly offspring),RBC levels of Choline,Plasma choline levels in chronic kidney disease,Choline levels,Choline phosphate levels,Urine choline levels in chronic kidney disease,Choline/ethanolamine kinase levels (CHKB.13117.232.3),Phosphatidylcholine and other choline levels,Choline levels (advanced age),Metabolite levels (pregnanediol-3-glucuronide),Intrahepatic cholestasis of pregnancy,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Choline levels in elite athletes,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Total cholines levels,Cholesteryl ester (22:0) levels,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Choline/ethanolamine kinase levels,Cholesteryl ester (22:1) levels,Cholesteryl ester (22:5) (n6) levels,Plasma metabolome feature (hilic_1031) (Proline betaine),Cholesteryl ester (24:1) levels,Cholesteryl ester (20:1) levels,Cholesteryl ester (18:2) levels,Cholesteryl ester (18:0) levels,Cholesteryl ester (24:0) levels,Cholesteryl ester (20:2) levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Cholesteryl ester (20:0) levels,Cholesteryl ester (22:6) levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Metabolite levels (3beta-hydroxy-5-cholestenoate),Fasting phosphatidylcholine and other cholines,Cholesteryl ester (22:4) levels,Cholesteryl ester (18:3) levels,Cholesteryl ester (22:5) (n3) levels,Cholesteryl ester (24:6) levels,Cholesteryl ester (20:3) levels,Cholesteryl ester_18:0_[M+NH4]1+ levels,Pregnancy-specific beta-1-glycoprotein 8 levels,Cholesteryl ester (24:5) levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Cholesteryl ester (16:1) levels,Cholesteryl esters in LDL (UKB data field 23417),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Cholesteryl ester (20:4) levels,Cholesteryl ester (24:4) levels,Cholesteryl ester (20:5) levels,Pregnanediol-3-glucuronide levels
Maternal Choline Metabolism: Choline & Metabolites  - Dimethylglycine (µmol/L) - Bevital panel at pregnancy week 26,Choline levels (elderly offspring),RBC levels of Choline,Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Plasma choline levels in chronic kidney disease,Choline levels,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Choline/ethanolamine kinase levels (CHKB.13117.232.3),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Choline phosphate levels,Urine choline levels in chronic kidney disease,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Intrahepatic cholestasis of pregnancy,Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Phosphatidylcholine and other choline levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Pregnancy-specific beta-1-glycoprotein 8 levels,Choline levels (advanced age),Pregnanediol-3-glucuronide levels,Choline/ethanolamine kinase levels,Glycemic traits (pregnancy),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Pregnancy-specific beta-1-glycoprotein 9 levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 11 levels,Choline levels in elite athletes,Pregnancy-specific beta-1-glycoprotein 1 levels,Plasma metabolome feature (hilic_1031) (Proline betaine),Pregnancy-specific beta-1-glycoprotein 2 levels,Total cholines levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Fasting phosphatidylcholine and other cholines,Plasma metabolome feature (c18_357) (N-Acryloylglycine),Metabolite levels (cysteinylglycine),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Metabolite levels (N-acetylglycine; acetylglycine),"5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels",Cholesteryl ester (22:5) (n6) levels,Metabolite levels (3beta-hydroxy-5-cholestenoate),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Plasma metabolome feature (c18_2759) (24-Dihydroxy-46-dimethoxy-3-prenylchalcone),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Metabolite levels (adipoylcarnitine (C6-DC)),Pregnancy-specific beta-1-glycoprotein 5 levels,Cholesteryl ester (22:0) levels
Maternal Choline Metabolism: Choline & Metabolites  - Trimethylamineoxide (µmol/L) - Bevital panel at pregnancy week 26,Choline levels (elderly offspring),RBC levels of Choline,"Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Metabolite levels (pregnanediol-3-glucuronide),Plasma choline levels in chronic kidney disease,Choline/ethanolamine kinase levels (CHKB.13117.232.3),"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)",Choline levels,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Choline phosphate levels,Urine choline levels in chronic kidney disease,Intrahepatic cholestasis of pregnancy,"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)",Plasma metabolome feature (hilic_1031) (Proline betaine),Choline/ethanolamine kinase levels,Choline levels (advanced age),Metabolite levels (3beta-hydroxy-5-cholestenoate),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Plasma metabolome feature (hilic_3392) (4-Hydroxyphenylacetylglutamine),Choline levels in elite athletes,Cholesteryl ester (22:0) levels,Phosphatidylcholine and other choline levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Cholesteryl ester (22:5) (n6) levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Cholesteryl ester (22:1) levels,Plasma metabolome feature (c18_1322) (2-Chloro-45-xylyl N-hydroxy-N-methylcarbamate),Plasma metabolome feature (hilic_2662) (Butyrylcarnitine),Pregnanediol-3-glucuronide levels,Cholesteryl ester (20:2) levels,Cholesteryl ester (20:0) levels,Cholesteryl ester (20:1) levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Cholesteryl ester_18:0_[M+NH4]1+ levels,Cholesteryl ester (22:5) (n3) levels,Cholesteryl ester (22:6) levels,Cholesteryl ester (22:4) levels,Metabolite levels (3b-hydroxy-5-cholenoic acid),Cholesteryl ester (24:1) levels,Cholesteryl ester (24:0) levels,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Plasma metabolome feature (c18_2759) (24-Dihydroxy-46-dimethoxy-3-prenylchalcone),Cholesteryl ester (18:2) levels,Cholesteryl ester_18:2_[M+NH4]1+ levels,NH4_C22:4 Cholesteryl ester levels in chronic kidney disease,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Cholesteryl ester (18:0) levels,Cholesteryl esters in LDL (UKB data field 23417),Plasma metabolome feature (c18_2790) (Chlorophacinone)
Maternal Cotinine: Cotinine & Metabolite  - Cotinine (nmol/L) - Bevital panel at pregnancy week 26,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))",Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels","X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Pregnanolone/allopregnanolone sulfate levels,Cotinine levels in current smokers,"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels","5alpha-pregnan-3beta,20alpha-diol disulfate levels",Pregnanediol-3-glucuronide levels,Serum levels of protein COTL1,5alpha-pregnan-diol disulfate levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Cotinine and 3'-hydroxycotinine levels in current smokers,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Cotinine levels in smokers with chronic obstructive pulmonary disease,Adiponectin levels in pregnancy,Midgestational cytokine/chemokine levels (fetal genetic effect),Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnanolone/allopregnanolone sulfate levels in elite athletes,Midgestational cytokine/chemokine levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Midgestational selenium levels,Metabolite levels (pregnenetriol disulfate),Pregnenetriol disulfate levels,Gestational diabetes mellitus,Pregnancy-specific beta-1-glycoprotein 8 levels,Midgestational circulating levels of PCBs (fetal genetic effect),Metabolite levels (pregnenetriol sulfate),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Pregnenediol sulfate (C21H34O5S) levels,Pregnancy-specific beta-1-glycoprotein 2 levels,Cotinine glucuronidation,General glucose level in pregnancy (gestational week 30-32),"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes",Pregnenetriol sulfate levels,Pregnancy-specific beta-1-glycoprotein 5 levels,Serum metabolite levels (CMS),"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Pregnancy-specific beta-1-glycoprotein 9 levels,Glycemic traits (pregnancy),Putative pregnancy-specific beta-1-glycoprotein 7 levels
Maternal Cotinine: Cotinine & Metabolite  - Trans-3-Hydroxy Cotinine (nmol/L) - Bevital panel at pregnancy week 26,"Metabolite levels (5alpha-pregnan-3(alpha or beta),20beta-diol disulfate; 5alpha-pregnan-diol disulfate)","Metabolite levels (5alpha-pregnan-3beta,20beta-diol monosulfate (1))",Metabolite levels (pregnanediol-3-glucuronide),"Metabolite levels (5alpha-pregnan-3beta,20alpha-diol monosulfate (2))","Metabolite levels (5alpha-pregnan-3beta,20alpha-diol disulfate)","5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels","5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels",Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Pregnanediol-3-glucuronide levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Serum levels of protein COTL1,Cotinine levels in current smokers,Cotinine and 3'-hydroxycotinine levels in current smokers,"X-11445--5-alpha-pregnan-3beta,20alpha-disulfate levels","5alpha-pregnan-3beta,20alpha-diol monosulfate (1) levels",Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),"5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels",Pregnanolone/allopregnanolone sulfate levels,"5alpha-pregnan-3beta,20alpha-diol disulfate levels",5alpha-pregnan-diol disulfate levels,Pregnancy-specific beta-1-glycoprotein 4 levels (PSG4.5649.83.3),Cotinine levels in smokers with chronic obstructive pulmonary disease,Midgestational cytokine/chemokine levels (fetal genetic effect),Adiponectin levels in pregnancy,Pregnancy-specific beta-1-glycoprotein 3 levels (PSG3.6444.15.3),Midgestational cytokine/chemokine levels (maternal genetic effect),Pregnancy-specific beta-1-glycoprotein 4 levels,Pregnanolone/allopregnanolone sulfate levels in elite athletes,Pregnancy-specific beta-1-glycoprotein 5 levels (PSG5.9314.9.3),Pregnancy-specific beta-1-glycoprotein 9 levels (PSG9.9335.28.3),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (cord blood),"5alpha-pregnan-3(alpha or beta),20beta-diol disulfate levels in elite athletes",Pregnancy-specific beta-1-glycoprotein 8 levels,Pregnancy-specific beta-1-glycoprotein 3 levels,Midgestational selenium levels,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Cotinine glucuronidation,"5alpha-pregnan-3beta,20beta-diol monosulfate (1) levels in elite athletes",Pregnancy-specific beta-1-glycoprotein 2 levels,"5alpha-pregnan-3beta-ol,20-one sulfate levels in elite athletes",Gestational diabetes mellitus,Pregnancy-specific beta-1-glycoprotein 5 levels,Midgestational circulating levels of PCBs (fetal genetic effect),Pregnenetriol disulfate levels,Pregnancy-specific beta-1-glycoprotein 9 levels,Plasma pregnanediol-3-glucuronide levels in chronic kidney disease,Urine pregnanediol-3-glucuronide levels in chronic kidney disease,Putative pregnancy-specific beta-1-glycoprotein 7 levels,Metabolite levels (pregnenetriol disulfate)
Hemolysis,Hematuria,hemolysis of donated blood (osmotic),hemolysis of donated blood (oxidative),Sickle cell anemia (haemolysis),Hematocrit,Hemoglobin,hemolysis of donated blood (cold-storage),End-stage coagulation,Osmotic hemolysis of cold stored red blood cells,Hematuria (moderate to severe),Fibrinogen,Hematocrit levels,ICD10 R31: Hematuria,Hematological parameters,Hematuria (mild),Thrombosis,Hemorrhoids,Hemostatic factors and hematological phenotypes,Hemorrhagic stroke,Acute kidney injury,HEMK2 level (plasma),Albuminuria,Renal function,Hematological and biochemical traits,Aplastic anemia,Hemopexin level (plasma),Heme oxygenase 2 levels (HMOX2.2622.18.1),Heme oxygenase 2 levels,Severe aplastic anemia,Hemojuvelin levels (HFE2.3332.57.1),Chronic renal failure,Acute kidney injury (model 2),Hemoglobin concentration,Acute kidney injury (model 3),Blood osmolality (transformed sodium),Acute kidney injury (model 1),Cytochrome c-type heme lyase level in Chronic kidney disease with hypertension and no diabetes (24453_75),Hemojuvelin levels,RBC levels of ATP (consider breakdown) (uM),Hemicentin-2 levels,Declining hemoglobin trajectory in blood donors,Blood pressure,Hemopexin level (CSF),Reticulocyte haemoglobin equivalent,Hemoglobin levels,Hematology traits,Red blood cell haemoglobin equivalent,Nephropathy,Proteinuria,Hereditary hemolytic anemias (PheCode 282)
Homocysteine (Reported Values: 6-20 µmol/L),Homocysteine levels,Plasma homocysteine levels,Plasma homocysteine levels (post-methionine load test),Cysteine levels,X-11786--methylcysteine levels,RBC levels of S-Adenosyl-L-homocysteine,Metabolite levels (S-methylcysteine; methylcysteine),Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine),S-methylcysteine levels,Metabolite levels (HVA/5-HIAA ratio),Cysteinylglycine levels,Metabolite levels (cysteinylglycine),Plasma metabolome feature (hilic_5137) (Cysteineglutathione disulfide),Cysteine sulfinic acid levels,Metabolite levels (5-HIAA),4-hydroxyphenylacetoylcarnitine levels,Hydantoin-5-propionic acid levels,Serum levels of protein HDAC8,Cysteine levels in elite athletes,Phosphopantothenoylcysteine decarboxylase levels,AHCY/HSPA1A protein level ratio,AHCY/FADD protein level ratio,Metabolite levels (homoarginine),7-alpha-hydroxy-3-oxo-4-cholestenoate (7-hoca) levels,N-acetylthreonine levels,Metabolite levels (12-HETE),AHCY/SNAP23 protein level ratio,RBC levels of [Similar to: gamma-Glutamylcysteine; deltaMass: -146.3080 Da],Metabolite levels (N-acetylthreonine),Cysteine-glutathione disulfide levels,S-methylcysteine sulfoxide levels,Metabolite levels (cysteine-glutathione disulfide),Metabolite levels (cysteinylglycine disulfide),Serum levels of protein HNF4A,Metabolite levels (glycylphenylalanine),Homocitrulline levels,S-methylmethionine--homocysteine S-methyltransferase BHMT2 levels,Haptoglobin levels (HP.3054.3.2),AHCY/KYAT1 protein level ratio,HAGH/HMBS protein level ratio,Metabolite levels (5-HIAA/ MHPG Ratio),Metabolite levels (HVA-5-HIAA Factor score),Plasma metabolome feature (hilic_39) (Ethyl thiocyanate),Cyclin-H levels (CCNH.9848.22.3),Protein MENT levels (MENT.5744.12.3),Histidine betaine (hercynine) levels,RBC levels of 14-HDoHE.1,Cysteinylglycine disulfide levels,3-hydroxybutyroylglycine levels,Cysteine-rich protein 1 levels
Choline (Reported Values: 5-15 µmol/L),Choline levels,Total cholines levels,Choline phosphate levels,Cholate levels,Choline levels (advanced age),RBC levels of Choline,3-hydroxy-5-cholestenoic acid levels,Choline levels in elite athletes,Total cholines levels (UKB data field 23436),Cholesteryl ester (22:5) (n3) levels,Cholesteryl ester (20:0) levels,Cholesteryl ester (22:5) (n6) levels,Choline levels (elderly offspring),Cholesteryl ester (20:3) levels,Cholesteryl ester (20:5) levels,Cholesteryl ester (22:0) levels,Cholesteryl ester (22:6) levels,Cholesteryl ester (18:3) levels,Cholesteryl ester (18:0) levels,Cholesteryl ester (24:0) levels,Cholesteryl ester (22:4) levels,Cholesteryl ester (20:4) levels,Cholesteryl ester (24:5) levels,Cholic acid glucuronide levels,Metabolite levels (3b-hydroxy-5-cholenoic acid),Cholesteryl ester (20:2) levels,Cholesteryl ester (15:0) levels,Cholesteryl ester (24:6) levels,Cholesteryl ester (16:0) levels,Cholesteryl ester (18:2) levels,Cholesteryl ester(18:0)_[M+NH4]1+ levels,Cholesteryl ester (20:1) levels,Cholesteryl ester (24:4) levels,Cholesteryl ester (22:1) levels,4-cholesten-3-one levels,Cholesteryl ester (24:1) levels,3b-hydroxy-5-cholenoic acid levels,Cholesteryl ester (17:0) levels,Cholesteryl ester (14:0) levels,Cholesteryl ester (16:2) levels,Cholesteryl ester(16:0)_[M+NH4]1+ levels,Cholesteryl ester(20:5)_[M+NH4]1+ levels,Cholesteryl ester (16:1) levels,Cholesteryl ester_18:0_[M+NH4]1+ levels,Cholesteryl ester_20:5_[M+NH4]1+ levels,Cholesteryl ester (17:1) levels,Cholesteryl ester_17:0_[M+NH4]1+ levels,Cholesteryl ester_22:6_[M+NH4]1+ levels,Cholesteryl ester_22:5_[M+NH4]1+ levels,Cholesteryl ester_18:3_[M+NH4]1+ levels
Betaine (Reported Values: 20-60 µmol/L),Betaine levels,Metabolite levels (betaine),Betaine-to-pyroglutamine ratio,Metabolite levels (beta-alanine; beta_alanine),Beta-alanine levels,Valine levels (Biocrates platform),Betaine levels in elite athletes,Betaine levels in individuals undergoing cardiac evaluation,Metabolite levels (valine),Beta-aminoisobutyric acid levels,Valine levels,Valine-to-proline ratio,Metabolite levels (tryptophan betaine),Valine levels (Metabolon platform),Metabolite levels (N-acetyl-beta-alanine),N-acetyl-beta-alanine levels,Plasma betaine levels in chronic kidney disease,Urine betaine levels in chronic kidney disease,N-carbamoyl-beta-alanine levels,Metabolite levels (beta-hydroxyisovalerate),Beta-trace protein levels,Beta-hydroxyisovaleroylcarnitine levels,Tryptophan betaine levels,Tryptophan betaine  levels,Valine-to-isovalerylcarnitine ratio,Beta-hydroxyisovalerate levels,Metabolite levels (beta-hydroxyisovaleroylcarnitine),Metabolite levels (beta-citrylglutamate),Lithostathine-1-beta levels,Beta-defensin 110 levels,N-lactoyl valine levels,Branched-chain amino acid levels (Valine),Metabolite levels (C18:3 CE; C18_3_CE),Metabolite levels (lysine),Beta-citrylglutamate levels,Metabolite levels (alanine),Beta-defensin 128 levels,Beta-crystallin B2 levels (CRYBB2.10000.28.3),Metabolite levels (serine),Metabolite levels (adrenate (22:4n6); adrenate),"Metabolite levels (ceramide (d18:1/20:0, d16:1/22:0, d20:1/18:0))","Metabolite levels (ceramide (d16:1/24:1, d18:1/22:1))",1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Metabolite levels (glyco-beta-muricholate),Lithostathine-1-alpha levels,Histidine betaine (hercynine) levels,Metabolite levels (orotate; cmh_orotate; Orotate),Beta-defensin 104 levels (DEFB104A.5763.67.3),Metabolite levels (isobutyrylglycine),"3-bromo-5-chloro-2,6-dihydroxybenzoic acid levels"
Dimethylglycine (Reported Values: 1.5–5 µmol/L),Dimethylglycine levels,Metabolite levels (dimethylglycine),Isovalerylglycine levels,Glycine levels (Biocrates platform),Picolinoylglycine (X-12170) levels,Metabolite levels (isovalerylglycine),Isobutyrylglycine levels,"N,n-dimethylalanine (X-23585) levels",Metabolite levels (isobutyrylglycine),Hexanoylglycine levels,Dimethylglycine levels in elite athletes,Isoleucylglycine levels,Metabolite levels (N-acetylglycine; acetylglycine),"X-12442--5,8-tetradecadienoate levels","Cis-3,4-methyleneheptanoylglycine levels",Propionylglycine levels,Metabolite levels (hexanoylglycine),Metabolite levels (isoleucylglycine),Metabolite levels (glycine),Glycine levels,Metabolite levels (propionylglycine),Metabolite levels (3-hydroxybutyroylglycine),1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels,N-acetylglycine levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Glycine levels (Metabolon platform),1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels,Dimethylglycine levels in chronic kidney disease,1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6) levels,"N,N-dimethylalanine levels",1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) levels,Metabolite levels (trans-2-hexenoylglycine),Cysteinylglycine disulfide levels,Diacylglycerol(36:3)_[M+NH4]1+ levels,Docosapentaenoate (n6 DPA; 22:5n6) levels,Metabolite levels (cysteinylglycine disulfide),Plasma dimethylglycine levels in chronic kidney disease,Metabolite levels (tigloylglycine),Dihydroceramide (d18:0/20:0) levels,1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels,Metabolite levels (docosapentaenoate (n6 DPA; 22:5n6); docosapentaenoate),3-hydroxybutyroylglycine levels,Metabolite levels (gamma-glutamylglycine),1-docosahexaenoyl-GPC (22:6) levels,Metabolite levels (2-butenoylglycine),Dihydroceramide (d18:0/24:0) levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Dihydroceramide (d18:0/22:0) levels,Diacylglycerol(36:4)_[M+NH4]1+ levels,Dihydroceramide (d18:0/24:1) levels
Creatinine (Reported Values: 50-100 µmol/L),Creatinine levels,Serum creatinine levels,Urinary creatinine levels,Creatinine levels (UKB data field 23478),Creatinine levels (UKB data field 30700),Creatinine levels in elite athletes,Urinary sodium to creatinine ratio,Creatine levels,Urinary potassium to creatinine ratio,Urinary albumin-to-creatinine ratio,Glomerular filtration rate (creatinine),Urinary uromodulin levels (indexed to creatinine),Urinary magnesium-to-creatinine ratio,Metabolite levels (creatine),Estimated glomerular filtration rate (creatinine),Creatine kinase M-type levels (CKM.2670.67.4),Creatinine clearance,Chronic kidney disease and serum creatinine levels,"Estimated glomerular filtration rate (creatinine, Rapid3)","Estimated glomerular filtration rate (creatinine, CKDi25)",Urine 6-hydroxymelatonin sulfate-to-creatinine ratio,Plasma metabolome feature (hilic_502) (Creatinine),Urinary albumin-to-creatinine ratio in non-diabetics,Cripto levels (serum),Urinary uric acid to urinary creatinine ratio,Peak creatinine levels in vancomycin therapy,Glomerular filtration rate in non diabetics (creatinine),Serum urea levels,Ketonuria (moderate to severe),Calnexin levels (CANX.8834.58.3),Serum levels of protein CROT,Creatine levels in elite athletes,Glucagon levels (GCG.4891.50.1),Endostatin levels (COL18A1.2201.17.6),Serum levels of protein CRTAM,Creatine kinase levels,calreticulin level (plasma),Serum levels of protein CRAT,Creatinine levels (adjusted for BMI) x vegetarianism interaction,Glomerular filtration rate in diabetics (creatinine),Nephronectin levels,Serum urate levels,Urea levels,Calpastatin levels (CAST.3026.5.2),Protein MENT levels (MENT.5744.12.3),Bipolar disorder or glomerular filtration rate estimated from creatine (MTAG),Blood urea nitrogen levels,Haptoglobin levels (HP.3054.3.2),Proteinuria (moderate to severe),Creatinine levels in ischemic stroke
Methionine (Reported Values: 18-50 µmol/L),Methionine levels (Biocrates platform),Methionine levels,Methionine levels (Metabolon platform),Methioninesulfoxide levels,Methionine sulfone levels,Methionine synthase levels,Methionine sulfoxide levels,Metabolite levels (methionine sulfone),RBC levels of Methionine,Methionine levels in elite athletes,Methoxychlor levels,"N,n-dimethylalanine (X-23585) levels",Metabolite levels (myristoleate (14:1n5); myristoleic acid),Metabolite levels (3-methoxytyrosine),Metabolite levels (hypotaurine),Metabolite levels (N-acetylthreonine),Plasma metabolome feature (hilic_977) (Metenamine),Methionine sulfone levels in elite athletes,3-methoxytyrosine levels,Methionine sulfoxide levels in elite athletes,N-formylmethionine levels,Threonine levels (Biocrates platform),5-acetylamino-6-amino-3-methyluracil levels,Metabolite levels  (X-11787),Methionine aminopeptidase 2 levels,N-acetylthreonine levels,Metabolite levels (threonine),Metabolite levels (C18:3 CE; C18_3_CE),Metabolite levels (isoleucylthreonine),Metabolite levels (N-formylmethionine; formylmethionine),"3,4-methyleneheptanoate levels",Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Metabolite levels (dimethylglycine),Plasma homocysteine levels (post-methionine load test),Methylmalonate (mma) levels,Metabolite levels (12-HETE),"Metabolite levels (N6,N6-dimethyllysine; N6.N6-dimethyllysine)",5-acetylamino-6-formylamino-3-methyluracil levels,Metabolite levels (3-methoxytyramine sulfate),"5,6-dihydrouridine (X-11429) levels",Metabolite levels (5-HIAA),Metabolite levels (C20:5 CE; C20_5_CE),5-methyluridine (ribothymidine) levels,Metabolite levels (1-methylhistidine),1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Hypotaurine levels,"N,N-dimethylalanine levels",Metabolite levels (5-acetylamino-6-amino-3-methyluracil),X-12510--2-aminooctanoic acid levels,Alkylphosphatidylethanolamine (O-16:0/20:3) levels
Methioninesulfate (Reported Values: 0.5-5 µmol/L),Methioninesulfoxide levels,Methionine sulfone levels,Methionine sulfoxide levels,Metabolite levels (methionine sulfone),Sulfatide (d18:1/16:0(OH) levels) levels,Sulfatide (d18:1/24:0(OH) levels) levels,Methionine levels (Biocrates platform),Sulfatide (d18:1/24:1(OH) levels) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Dimethyl sulfone levels,Sulfatide (d18:1/16:0) levels,Sulfatide (d18:1/24:0) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,3-methoxytyramine sulfate levels,Sulfatide (d18:1/24:1) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,"N,n-dimethylalanine (X-23585) levels",Metabolite levels (myristoleate (14:1n5); myristoleic acid),Lithocholate sulfate (1) (X-17469) levels,"5alpha-androstan-3alpha,17beta-diol monosulfate (2) levels",2-methoxyacetaminophen sulfate levels,Pregnenediol disulfate (C21H34O8S2) levels,Methionine levels,4-ethylphenylsulfate levels,X-11593--O-methylascorbate levels,Metabolite levels (3-methoxytyramine sulfate),Plasma metabolome feature (c18_1550) (Bis(methylsulfonylmethyl) disulfide),"5alpha-androstan-3alpha,17beta-diol monosulfate (1) levels",1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Methoxychlor levels,Endosulfan levels,1-palmitoyl-2-dihomo-linolenoyl-GPE (16:0/20:3) levels,"5alpha-androstan-3beta,17beta-diol monosulfate (2) levels",Metabolite levels (lithocholate sulfate (1)),Methionine levels (Metabolon platform),Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),N-stearoyl-sphingadienine (d18:2/18:0) levels,Pregnenetriol disulfate (X-11440) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Total Sulfatide levels,"X-12442--5,8-tetradecadienoate levels",1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,Metabolite levels (pregnen-diol disulfate; pregnenediol disulfate (C21H34O8S2); pregnen-diol disulfate C21H34O8S2),"N6,n6,n6-trimethyllysine levels","5alpha-androstan-3beta,17beta-diol monosulfate (1) levels",1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,"4-androsten-3beta,17beta-diol monosulfate (2) levels",1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Metabolite levels (3-methoxytyrosine)
Arginine (Reported Values: 40-100 µmol/L),Arginine levels (Biocrates platform),Arginine levels,L-arginine levels,Metabolite levels (arginine),Arginine levels (Metabolon platform),Plasma metabolome feature (c18_789) (Arginine),Arginine levels in elite athletes,N-acetylarginine levels,Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Metabolite levels (homoarginine),Homoarginine levels,Argininosuccinate synthase levels,Margaroylcarnitine (C17) levels,N-alpha-acetylarginine levels,Piperine levels,Acylcarnitine (14:0) levels,Acylcarnitine (10:0) levels,Plasma arginine levels in chronic kidney disease,Alanine levels,N-acetylmethionine levels,Metabolite levels (alanine),Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Acylcarnitine (15:0) (a) levels,Acylcarnitine (12:0) levels,Valine levels,Stearidonate (18:4n3) levels,Metabolite levels (adrenate (22:4n6); adrenate),Acylcarnitine (17:0) (a) levels,Acylcarnitine (10:1) levels,Acylcarnitine (14:1) levels,Serine levels,Metabolite levels (serine),Valine-to-proline ratio,Acylcarnitine (13:0) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Acylcarnitine (18:0) levels,Arginase-1 levels,Alanine levels (UKB data field 23460),Acylcarnitine (16:0) levels,Stearidonate 18:4n3 levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Dimethylarginine (sdma + adma) levels,Arginine/serine-rich protein 1 levels,Argininate levels,Octadecadienylcarnitine levels,Metabolite levels (N-acetylasparagine),Levulinoylcarnitine levels,Metabolite levels (arginylphenylalanine),"N,N,N-trimethyl-5-aminovalerate levels"
ADMA (Reported Values: 0.4-0.8 µmol/L),ADMA levels,Dimethylarginine (sdma + adma) levels,NMMA levels,Adseverin levels (SCIN.12684.5.3),Adseverin levels,Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),ADM/CLMP protein level ratio,ADA protein levels,ADM levels,ADM2 levels,Serum levels of protein ADM,ADGRE5/SEMA7A protein level ratio,ADH4/CA5A protein level ratio,ADpSGEGDFXAEGGGVR levels,Adrenomedullin levels (ADM.14115.34.3),FFA Adrenic Acid a levels,ADA2/COMP protein level ratio,ASAHL level (plasma),Serum levels of protein ADRM1,Adrenate (22:4n6) levels,Metabolite levels (SDMA),ADA2/VCAM1 protein level ratio,Methylmalonate (mma) levels,Adrenomedullin levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Augurin levels (C2orf40.6362.6.3),AXL/MCAM protein level ratio,ADGRE2/ADGRE5 protein level ratio,aparc-a2009s lh volume G-parietal-sup,APOM/MCAM protein level ratio,Vanillylmandelate (VMA) levels,Metabolite levels (adrenate (22:4n6); adrenate),MICA level (plasma),RBC levels of ADP,Decadienedioic acid (C10:2-DC) levels,SEM5A level (plasma),Semaphorin-5A levels (SEMA5A.13132.14.3),ADH4/C19orf12 protein level ratio,ASAH2 level (plasma),ADGRG2/NRCAM protein level ratio,Apo-CIII0c levels,ADH4/KYNU protein level ratio,Semaphorin-3G levels (SEMA3G.5628.21.3),FFA Adrenic Acid b levels,Semaphorin-6A levels (SEMA6A.7945.10.3),AK1A1 level (plasma),Protein FAM163A levels (FAM163A.6260.14.3),ACY1/ADH4 protein level ratio,ADH4/GSTA1 protein level ratio,ADGRE5/VCAM1 protein level ratio
SDMA (Reported Values: 0.4-0.9 µmol/L),Dimethylarginine (sdma + adma) levels,NMMA levels,ADMA levels,Metabolite levels (SDMA),Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),PSMA level (CSF),SDC4/SEMA4D protein level ratio,MICA level (plasma),Vanillylmandelate (VMA) levels,Semaphorin-3G levels (SEMA3G.5628.21.3),BCMA level (brain),Semaphorin-6A levels (SEMA6A.7945.10.3),SEM5A level (plasma),SDC4/SMAD1 protein level ratio,Metabolite levels (NMMA),Semaphorin 3A level (plasma),Methylmalonate (mma) levels,Semaphorin-5A levels (SEMA5A.13132.14.3),3-methoxytyramine sulfate levels,SAA plasma levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Semaphorin-3A levels (SEMA3A.3222.11.2),Protein Mdm4 levels,Semaphorin-3E levels (SEMA3E.5363.51.3),DRG2/SEMA4D protein level ratio,MIA level (plasma),DERM level (plasma),Semaphorin-3C levels (SEMA3C.6448.36.3),Urine dimethylarginine (SDMA + ADMA) levels in chronic kidney disease,Siglec-6 level (plasma),Dimethyl sulfone levels,Semaphorin-4D levels (SEMA4D.5737.61.3),BCAM/SEMA7A protein level ratio,Semaphorin 3E level (plasma),Decadienedioic acid (C10:2-DC) levels,Semaphorin-3G levels,SDC4/SELP protein level ratio,Metabolite levels (vanillylmandelate (VMA)),Semaphorin-3B levels (SEMA3B.5667.3.3),ASAHL level (plasma),CA13/SMARCA2 protein level ratio,ADGRE5/SEMA7A protein level ratio,MIC-1 level (plasma),SMAD5 protein levels,Metabolite levels (3-methoxytyramine sulfate),S100A12 level (plasma),Plasma dimethylarginine (SDMA + ADMA) levels in chronic kidney disease,LDLR chaperone MESD levels,"3,5-dichloro-2,6-dihydroxybenzoic acid levels",sICAM-1 level (plasma)
Homoarginine (Reported Values: 1-6 µmol/L),Homoarginine levels,Metabolite levels (homoarginine),Arginine levels (Biocrates platform),L-arginine levels,Homoarginine levels in elite athletes,Arginine levels,Metabolite levels (arginine),Plasma homoarginine levels in chronic kidney disease,Urine homoarginine levels in chronic kidney disease,Arginine levels (Metabolon platform),Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),4-hydroxyphenylacetoylcarnitine levels,N-acetylarginine levels,Margaroylcarnitine (C17) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,"N,n-dimethylalanine (X-23585) levels",1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-methylguanosine levels,Metabolite levels (homostachydrine),1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,N-alpha-acetylarginine levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,"3,4-methyleneheptanoate levels",Plasma metabolome feature (c18_789) (Arginine),Metabolite levels (adrenate (22:4n6); adrenate),Linoleoylcarnitine (C18:2) levels,"N2,n2-dimethylguanosine levels",N-trimethyl 5-aminovalerate (X-21365) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),Serine levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Semaphorin-4F levels,Metabolite levels (serine),1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Serine levels (Biocrates platform),"Indoleacetate-to-N2,N2-dimethylguanosine ratio",Semaphorin-5A levels (SEMA5A.13132.14.3),Stearidonate 18:4n3 levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,1-palmitoyl-2-dihomo-linolenoyl-GPE (16:0/20:3) levels,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels,Stearidonate (18:4n3) levels,Metabolite levels (dihomo-linoleoylcarnitine (C20:2)),3-hydroxyoleoylcarnitine levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels
Trimethyllysine (Reported Values: 0.3-2 µmol/L),"N6,n6,n6-trimethyllysine levels",Plasma trimethyllysine levels,"Hydroxy-N6,N6,N6-trimethyllysine levels","1,3,7-trimethylurate levels","Metabolite levels (N-6-trimethyllysine; N6,N6,N6-trimethyllysine; N6.N6.N6-trimethyllysine)",Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-stearoyl-2-oleoyl-GPE (18:0/18:1) levels,Sterol ester (27:1/20:4) levels,Sterol ester (27:1/20:5) levels,Sulfatide (d18:1/16:0(OH) levels) levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,Sterol ester (27:1/20:3) levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Sulfatide (d18:1/24:0(OH) levels) levels,Sterol ester (27:1/22:6) levels,Sterol ester (27:1/20:2) levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels,1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) levels,Sulfatide (d18:1/24:1(OH) levels) levels,Sterol ester (27:1/18:3) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,Sterol ester (27:1/16:0) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Sterol ester (27:1/16:1) levels,Sterol ester (27:1/18:2) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,"5alpha-androstan-3alpha,17beta-diol monosulfate (2) levels","4-androsten-3beta,17beta-diol monosulfate (2) levels",1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels,1-stearoyl-2-oleoyl-GPI (18:0/18:1) levels,Sterol ester (27:1/14:0) levels,4-ethylphenylsulfate levels,"5alpha-androstan-3beta,17beta-diol monosulfate (2) levels",Sterol ester (27:1/17:0) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,Sterol ester (27:1/18:0) levels,"DHEA-S-to-4-androsten-3beta,17beta-diol disulfate 2 ratio",1-oleoyl-GPE (18:1) levels,Metabolite levels (N6-methyllysine),Isoeugenol sulfate levels,Sterol ester (27:1/18:1) levels,1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) levels,Sterol ester (27:1/17:1) levels,1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) levels
Cysteine (Reported Values: 150-400 µmol/L),Cysteine levels,Cysteine sulfinic acid levels,Cysteine s-sulfate levels,Metabolite levels (cysteinylglycine),Cysteine levels in elite athletes,Metabolite levels (cysteinylglycine disulfide),Cysteinylglycine levels,Cysteinylglycine disulfide levels,X-11786--methylcysteine levels,Cysteine-glutathione disulfide levels,Metabolite levels (cysteine-glutathione disulfide),Metabolite levels (S-methylcysteine; methylcysteine),Homocysteine levels,Cystine levels,Urine cysteine levels in chronic kidney disease,Cysteine-rich protein 1 levels,Plasma metabolome feature (hilic_5137) (Cysteineglutathione disulfide),Cysteine-rich protein 2 levels,Phosphopantothenate--cysteine ligase levels,S-methylcysteine levels,Cysteine sulfinic acid levels in elite athletes,Cysteine s-sulfate levels in elite athletes,Cysteine protease ATG4A levels,S-methylcysteine sulfoxide levels,Cystatin-8 levels (CST8.10572.65.3),Cyclin-C levels (CCNC.7817.36.3),Cyclin-H levels (CCNH.9848.22.3),Cystatin-F levels (CST7.3302.58.1),Metabolite levels (C38_5_PC),Metabolite levels (cytidine),Urine 3-S-cysteinyl-2-methylpropanoate* levels in chronic kidney disease,Metabolite levels (cystathionine; cmh_cystathionine),(S)-a-amino-omega-caprolactam levels,Urine cysteinylglycine disulfide* levels in chronic kidney disease,3-(cystein-S-yl)acetaminophen levels,Plasma homocysteine levels,Plasma cysteinylglycine disulfide* levels in chronic kidney disease,Phosphopantothenoylcysteine decarboxylase levels,Cytohesin-2 levels (CYTH2.12533.135.3),Cystatin M level (CSF),Metabolite levels (C18:3 CE; C18_3_CE),Metabolite levels (C38:2 PC; C38_2_PC),CCDC80/CCL27 protein level ratio,Plasma homocysteine levels (post-methionine load test),Metabolite levels  (X-11787),Cystatin-M levels (CST6.3303.23.2),Cysteine-glutathione disulfide levels in elite athletes,Plasma cysteinylglycine levels in chronic kidney disease,Urine cysteinylglycine levels in chronic kidney disease,Cytidine levels
Histidine (Reported Values: 50-100 µmol/L),Histidine levels,Histidine levels (Biocrates platform),Histidine levels (UKB data field 23463),Histidine levels (Metabolon platform),Histidine betaine (hercynine) levels,Urate-to-histidine ratio,Glutamine-to-histidine ratio,Metabolite levels (histidylvaline),Metabolite levels (1-methylhistidine),Histidine levels in elite athletes,1-methylhistidine levels,Histidine meal response (LMM),Metabolite levels (histidylleucine),Metabolite levels (N-acetylhistidine),Metabolite levels (N-acetyl-1-methylhistidine),N-acetyl-1-methylhistidine levels,Metabolite levels (N-acetyl-3-methylhistidine),N-acetyl-3-methylhistidine levels,N-acetylhistidine levels,"5,6-dihydrouridine (X-11429) levels",Histidine-rich glycoprotein levels,Metabolite levels (histidylphenylalanine),Gamma-glutamylhistidine levels,Orotidine levels,Myristoylcarnitine levels,Metabolite levels (orotidine),Fasting histidine,Histidine meal response (OrNLSr),Urine histidine levels in chronic kidney disease,L-Histidine to Uric acid ratio in coronary artery disease,Myristoylcarnitine (C14) levels,Myristoleoylcarnitine levels,Myristoleoylcarnitine (C14:1) levels,Plasma metabolome feature (c18_1013) (N-Acetylhistidine),"5,6-dihydrouridine levels",Pseudouridine levels,Histatin-3 levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),Metabolite levels (cytidine),5-methyluridine (ribothymidine) levels,Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),Monohexosylceramide (d16:1/20:0) levels,Cytidine levels,Histatin-1 levels (HTN1.10608.9.3),Histatin-1 levels,Dihydroceramide (d18:0/20:0) levels,Octadecadienylcarnitine levels,Monohexosylceramide (d16:1/24:0) levels,Metabolite levels (uracil; Uracil),Metabolite levels (2'-O-methylcytidine)
Trimethylamine N oxide (Reported Values: 0.5-60 µmol/L),Trimethylamine n-oxide levels,Plasma trimethylamine N-oxide levels,Trimethylamine N-oxide levels in elite athletes,Trimethylamine levels,"N6,n6,n6-trimethyllysine levels","Hydroxy-N6,N6,N6-trimethyllysine levels","1,3,7-trimethylurate levels","N,n-dimethylalanine (X-23585) levels",N-trimethyl 5-aminovalerate (X-21365) levels,"N,N,N-trimethyl-5-aminovalerate levels","Metabolite levels (N-6-trimethyllysine; N6,N6,N6-trimethyllysine; N6.N6.N6-trimethyllysine)",Docosatrienoate (22:3n3) levels,"Metabolite levels (N,N,N-trimethyl-5-aminovalerate; N-trimethyl 5-aminovalerate)",Nisinate (24:6n3) levels,N-oleoyltaurine levels,Stearidonate 18:4n3 levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,Docosapentaenoate n3 DPA; 22:5n3 levels,Docosatrienoate (22:3n6) levels,Docosapentaenoate n3 DPA; 22:5n3-to-X-12627 ratio,Stearidonate (18:4n3) levels,Sulfatide (d18:1/16:0(OH) levels) levels,3-methoxytyramine sulfate levels,Sulfatide (d18:1/24:0(OH) levels) levels,Metabolite levels (10-undecenoate (11:1n1)),Tyramine O-sulfate levels,Docosapentaenoate (n3 DPA; 22:5n3) levels,X-11593--O-methylascorbate levels,"X-12442--5,8-tetradecadienoate levels",2-hydroxy-4-(methylthio)butanoic acid levels,Eicosapentaenoate EPA; 20:5n3 levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,Sulfatide (d18:1/24:1(OH) levels) levels,X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n3) levels,1-stearoyl-2-meadoyl-GPC (18:0/20:3n9) levels,3-Indolepropionic acid to Trimethylamine N-oxide ratio in coronary artery disease,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Metabolite levels (adrenate (22:4n6); adrenate),N-formylanthranilic acid levels,1-arachidonoyl-GPE (20:4n6) levels,Metabolite levels (stearidonate (18:4n3)),Metabolite levels (5-dodecenoate (12:1n7); 5-dodecenoate),N-acetylmethionine levels,Metabolite levels (docosapentaenoate (n3 DPA; 22:5n3)),Metabolite levels (N-oleoyltaurine),Methionine sulfoxide levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels
Creatine (Reported Values: 10-100 µmol/L),Creatine levels,Metabolite levels (creatine),Creatine levels in elite athletes,Creatine kinase M-type levels (CKM.2670.67.4),Carnitine levels in elite athletes,Creatinine levels in elite athletes,Myristoylcarnitine (C14) levels in elite athletes,Creatine kinase levels,Eicosenoylcarnitine (C20:1) levels in elite athletes,Margaroylcarnitine levels in elite athletes,Glutarylcarnitine (C5-DC) levels in elite athletes,Myristoleoylcarnitine (C14:1) levels in elite athletes,Linoleoylcarnitine (C18:2) levels in elite athletes,Ximenoylcarnitine (C26:1) levels in elite athletes,Laurylcarnitine (C12) levels in elite athletes,Decanoylcarnitine (C10) levels in elite athletes,Isovalerylcarnitine (C5) levels in elite athletes,Creatinine levels,Cerotoylcarnitine (C26) levels in elite athletes,Linolenoylcarnitine (C18:3) levels in elite athletes,Dihomo-linolenoylcarnitine (20:3n3 or 6) levels in elite athletes,Deoxycarnitine levels in elite athletes,CRTAM/LY9 protein level ratio,Metabolite levels (carnitine),Propionylcarnitine (C3) levels in elite athletes,Dihomo-linoleoylcarnitine (C20:2) levels in elite athletes,Arachidonoylcarnitine (C20:4) levels in elite athletes,Serum creatinine levels,Oleoylcarnitine (C18:1) levels in elite athletes,Lignoceroylcarnitine (C24) levels in elite athletes,Creatine kinase B-type levels,Octanoylcarnitine (C8) levels in elite athletes,Acetylcarnitine (C2) levels in elite athletes,Citrate levels in elite athletes,Carnitine levels,Creatine kinase M-type:Creatine kinase B-type heterodimer levels,Stearoylcarnitine (C18) levels in elite athletes,Creatinine levels (UKB data field 23478),Hexanoylcarnitine (C6) levels in elite athletes,Nervonoylcarnitine (C24:1) levels in elite athletes,Cis-4-decenoylcarnitine (C10:1) levels in elite athletes,Glucuronate levels in elite athletes,Cripto levels (serum),Urinary magnesium-to-creatinine ratio,Creatinine levels (UKB data field 30700),Myristoylcarnitine levels,Protein MENT levels (MENT.5744.12.3),Adipoylcarnitine (C6-DC) levels in elite athletes,Trans-urocanate levels in elite athletes,Leucine levels in elite athletes
m1Histidine (Reported Values: 0.5-15 µmol/L),1-methylhistidine levels,Metabolite levels (1-methylhistidine),N-acetyl-1-methylhistidine levels,Metabolite levels (N-acetylhistidine),Histidine levels (Biocrates platform),N-acetyl-3-methylhistidine levels,Metabolite levels (N-acetyl-1-methylhistidine),N-acetylhistidine levels,Metabolite levels (N-acetyl-3-methylhistidine),Histidine levels,Histidine levels (UKB data field 23463),"5,6-dihydrouridine (X-11429) levels",Histidine levels (Metabolon platform),Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Gamma-glutamylhistidine levels,Metabolite levels (orotidine),"5,6-dihydrouridine levels",Metabolite levels (1-methylhistamine; _1_methylhistamine),Metabolite levels (2-aminoadipate; cmh_aminoadipate),Metabolite levels (histidylvaline),Urate-to-histidine ratio,Pseudouridine levels,Metabolite levels (3-methylcytidine),Metabolite levels ((N(1) + N(8))-acetylspermidine),Metabolite levels (cytidine),Metabolite levels (hypotaurine),Orotidine levels,Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),Metabolite levels  (X-11787),Monohexosylceramide (d16:1/24:0) levels,(N(1) + N(8))-acetylspermidine levels,Metabolite levels (ethylmalonate),5-methyluridine (ribothymidine) levels,Monohexosylceramide (d16:1/22:0) levels,1-methylhistidine levels in elite athletes,Monohexosylceramide (d16:1/20:0) levels,Histidine betaine (hercynine) levels,Tartronate (hydroxymalonate) levels,Monohexosylceramide (d16:1/18:0) levels,Margaroylcarnitine (C17) levels,Glutamine-to-histidine ratio,Metabolite levels (2'-O-methylcytidine),Histidine meal response (LMM),Metabolite levels (myristoleate (14:1n5); myristoleic acid),Metabolite levels (histidylleucine),Metabolite levels (histidylphenylalanine),Octadecadienylcarnitine levels,Metabolite levels (2'-O-methyluridine),Metabolite levels (N('1)-acetylspermidine; N1-acetylspermidine),Monohexosylceramide (d18:1/16:0) levels
m3Histidine (Reported Values: 2.7-10 µmol/L),1-methylhistidine levels,Metabolite levels (1-methylhistidine),N-acetyl-3-methylhistidine levels,Histidine levels (Biocrates platform),N-acetyl-1-methylhistidine levels,Metabolite levels (N-acetyl-3-methylhistidine),Metabolite levels (N-acetylhistidine),Metabolite levels (N-acetyl-1-methylhistidine),Histidine levels,Histidine levels (UKB data field 23463),N-acetylhistidine levels,"5,6-dihydrouridine (X-11429) levels",Histidine levels (Metabolon platform),Gamma-glutamylhistidine levels,"5,6-dihydrouridine levels",Urate-to-histidine ratio,Metabolite levels (orotidine),Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Metabolite levels (histidylvaline),Metabolite levels (2-aminoadipate; cmh_aminoadipate),Metabolite levels (1-methylhistamine; _1_methylhistamine),5-methyluridine (ribothymidine) levels,Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),Tartronate (hydroxymalonate) levels,1-methylhistidine levels in elite athletes,3-methylhistidine levels in elite athletes,Pseudouridine levels,Metabolite levels (3-methylcytidine),Metabolite levels (hypotaurine),Metabolite levels (ethylmalonate),Metabolite levels (2'-O-methyluridine),Orotidine levels,Margaroylcarnitine (C17) levels,Metabolite levels (histidylleucine),Octadecadienylcarnitine levels,Metabolite levels  (X-11787),Metabolite levels (cytidine),Metabolite levels (myristoleate (14:1n5); myristoleic acid),Myristoylcarnitine (C14) levels,2'-o-methyluridine levels,Glutamine-to-histidine ratio,Metabolite levels (histidylphenylalanine),Monohexosylceramide (d16:1/24:0) levels,Myristoleoylcarnitine (C14:1) levels,Metabolite levels ((N(1) + N(8))-acetylspermidine),Monohexosylceramide (d16:1/22:0) levels,Metabolite levels (uridine; cmh_uridine; Uridine),Histidine betaine (hercynine) levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Monohexosylceramide (d16:1/20:0) levels
Pyridoxal phosphate (Reported Values: 15–150 nmol//L),Pyridoxal 5'-phosphate levels,Plasma pyridoxal phosphate to pyridoxal ratio,Plasma pyridoxal phosphate levels,Plasma pyridoxic acid to pyridoxal phosphate ratio,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,Pyridoxal phosphate phosphatase levels,Phosphate-to-erythronate ratio,Pyridoxate levels,Phosphate levels,Cerebrospinal fluid pyridoxal phosphate levels,Pyridoxal phosphate homeostasis protein levels,Pyridoxal levels,Serum phosphate levels,Phosphorus levels,Phosphatidylinositol (18:0_22:5) (n6) levels,Phosphatidylinositol (18:0_22:5) (n3) levels,Phosphatidylinositol (16:0_20:3) (a) levels,Phosphatidylinositol (18:0_20:3) (a) levels,RBC levels of Pyridoxamine 5'-phosphate,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,Phosphatidylinositol (18:0_22:6) levels,Phosphatidylinositol (18:0_22:4) levels,Pyridoxine-5-phosphate oxidase levels,Inorganic pyrophosphatase levels,Phosphatidylinositol (18:0_20:3) levels,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels,Phospholysine phosphohistidine inorganic pyrophosphate phosphatase levels,Phosphatidylinositol (16:0_20:4) levels,Phosphatidylinositol (20:0_20:4) levels,Phosphatidylinositol (18:0_20:4) levels,1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels,Phosphatidylinositol (18:0_20:2) levels,Phosphatidylinositol (16:0_18:2) levels,Phosphatidylinositol-O(33:0)_[M-H]1- levels,Phosphatidylinositol (16:0_16:1) levels,Phosphatidylinositol (18:0_18:2) levels,Choline phosphate levels,Phosphatidylinositol (16:0/16:0) levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels,Phosphatidylinositol (16:0_18:1) levels,Phosphatidylinositol (18:1_20:4) levels,Phosphatidylinositol (18:0_18:1) levels,1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (p-16:0/22:6) levels,Phosphatidylinositol (38:5) (a) levels,Pyridoxate levels in elite athletes,Glycerol 3-phosphate levels,Phosphatidylinositol (18:1_18:2) levels,Pyridoxamine levels,1-(1-enyl-stearoyl)-2-oleoyl-GPC (p-18:0/18:1) levels,1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levels
Pyridoxal (Reported Values: 5–150 nmol/L),Pyridoxal levels,Pyridoxate levels,RBC levels of Pyridoxal,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Pyridoxal 5'-phosphate levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,Pyridoxamine levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels,Plasma pyridoxal phosphate to pyridoxal ratio,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Plasma pyridoxal phosphate levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Plasma pyridoxic acid to pyridoxal phosphate ratio,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,1-(1-enyl-stearoyl)-2-linoleoyl-GPC (p-18:0/18:2) levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels (advanced age),Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) levels,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,X-11315-to-pyroglutamine ratio,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels
Pyridoxic acid (Reported Values: 10–200 nmol/L),Plasma pyridoxic acid to pyridoxal phosphate ratio,Pyridoxate levels,Pyroglutamic acid levels,Pyridoxal levels,Pyridoxal 5'-phosphate levels,Pyridoxamine levels,Butyric acid levels,Plasma pyridoxal phosphate levels,Plasma metabolome feature (c18_20) (Pyruvic acid),X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Plasma metabolome feature (c18_343) (Pyrrolidonecarboxylic acid),Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,Plasma pyridoxal phosphate to pyridoxal ratio,X-11315-to-pyroglutamine ratio,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Metabolite levels (5-oxoproline; pyroglutamic_acid),RBC levels of Pyridoxal,Pyridoxine-5-phosphate oxidase levels,Palmitic acid (16:0) levels,Pyridoxate levels in elite athletes,Cerebrospinal fluid pyridoxal phosphate levels,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,3-Indolepropionic acid to 4-Pyridoxic acid ratio in coronary artery disease,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Oxaloacetic acid levels,Gondoic acid (20:1n-9) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,RBC levels of Pyridoxamine,Metabolite levels (Pyroglutamine),2-o-methylascorbic acid levels,Pyruvate levels (UKB data field 23472),X-12510--2-aminooctanoic acid levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,N-acetyl neuraminic acid levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Pyruvate levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,N-acetylaspartic acid levels,Plasma metabolome feature (hilic_1348) (3-Pyridylacetic acid),1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,X-12244--N-acetylcarnosine levels,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels,dihydroferulic acid levels,Metabolite levels (S-1-pyrroline-5-carboxylate),6-oxopiperidine-2-carboxylic acid levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels
Pyridoxine (Reported Values: NA),Pyridoxate levels,Pyridoxamine levels,Pyridoxine-5-phosphate oxidase levels,Pyridoxal levels,Pyridoxate levels in elite athletes,Plasma pyridoxic acid to pyridoxal phosphate ratio,Calnexin levels (CANX.8834.58.3),RBC levels of Pyridoxamine,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,RBC levels of Pyridoxal,Radixin levels,Plasma pyridoxal phosphate levels,N1-methyl-2-pyridone-5-carboxamide levels,Sulfiredoxin-1 levels,Pyruvate levels (UKB data field 23472),Pyridoxal levels in elite athletes,Pyridoxal 5'-phosphate levels,Aprataxin levels,Metabolite levels (Pyroglutamine),Pyrraline levels in elite athletes,Cerebrospinal fluid pyridoxal phosphate levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,X-11315-to-pyroglutamine ratio,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,Pyroglutamine levels,Plasma pyridoxal phosphate to pyridoxal ratio,Metabolite levels (S-1-pyrroline-5-carboxylate),Plasma metabolome feature (c18_343) (Pyrrolidonecarboxylic acid),RBC levels of Pyridoxamine 5'-phosphate,Sulfiredoxin-1 levels (SRXN1.14268.4.3),Eotaxin levels (CCL11.5301.7.3),Calnexin levels,Pyroglutamic acid levels,Plasma metabolome feature (c18_20) (Pyruvic acid),tricyclic pyrone compound response (IC50),S-1-pyrroline-5-carboxylate levels,2-pyrrolidinone levels in elite athletes,Pyruvate levels,Neurexin-3 levels,Dixin levels,Neuronal pentraxin-2 levels (NPTX2.6521.35.3),Eotaxin levels,Peroxisomal NADH pyrophosphatase NUDT12 levels (NUDT12.13947.371.3),X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,Neurexin-1 levels (NRXN1.8971.9.3),Metabolite levels (pyruvate; cmh_pyruvate; Pyruvate),Thioredoxin levels,Ataxin-10 levels,Phosphatidylcholine (18:0_22:5) (n3) levels/Phosphatidylcholine (20:1_20:4) levels,Nucleolin levels (NCL.13655.34.3)
Thiamine (Reported Values: 2–50 nmol/L),Thiamine-triphosphatase levels,Thioproline levels,Threonate levels,Metabolite levels (threonylphenylalanine),Thiamin pyrophosphokinase 1 levels,Vitamin levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),Metabolite levels (threonine),Myristoleoylcarnitine levels,Metabolite levels (ethylmalonate),Metabolite levels (erythronate; erythronate/threonate),Myristoylcarnitine levels,Triiodothyronine levels,Metabolite levels (ergothioneine),Thioredoxin levels,Threonine levels (Biocrates platform),Methylmalonate (mma) levels,Ethylmalonate levels,Metabolite levels (hypotaurine),Ergothioneine levels,Protein MENT levels (MENT.5744.12.3),Sodium levels,Metabolite levels  (X-11787),Threonylphenylalanine levels,Gamma-glutamylhistidine levels,Metabolite levels (NMMA),MME/NT5E protein level ratio,Mannonate levels,(S)-a-amino-omega-caprolactam levels,Trigonelline (n'-methylnicotinate) levels,Metabolite levels (1-methylhistidine),Urate-to-histidine ratio,Free triiodothyronine (T3) levels,1-methylhistidine levels,Metabolite levels (thyroxine),Serum manganese levels,Metabolite levels (serine),"5,6-dihydrouridine (X-11429) levels",Magnesium levels,Metabolite levels (malate; cmh_malate; Malate),Threonine levels,Urinary electrolytes (magnesium/calcium ratio),Metabolite levels (2-aminoadipate; cmh_aminoadipate),Metabolite levels (lysine),Metabolite levels (valine),Hypotaurine levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,HNMT/SETMAR protein level ratio,Histidine levels,Metabolite levels (arginine)
Thiamine monophosphate (Reported Values: 2–15 nmol/L),Thiamine-triphosphatase levels,Thiamin pyrophosphokinase 1 levels,Phosphate levels,Serum phosphate levels,Phosphorus levels,Phosphate-to-erythronate ratio,THPO protein levels,Protein MENT levels (MENT.5744.12.3),Metabolite levels (myristoleate (14:1n5); myristoleic acid),ESAM/THPO protein level ratio,"2,3-dihydroxy-5-methylthio-4-pentenoate (DMTPA) (X-11564) levels",72 kDa inositol polyphosphate 5-phosphatase levels,Thymol sulfate levels,Thioproline levels,Phosphatidylinositol (18:0_22:5) (n3) levels,Metabolite levels (threonylphenylalanine),"2,3-dihydroxy-5-methylthio-4-pentenoate (dmtpa) levels",Serum levels of protein THPO,THP plasma levels,S-methyl-5-thioadenosine phosphorylase levels,Threonate levels,Metabolite levels (ethylmalonate),2-hydroxy-4-(methylthio)butanoic acid levels,HNMT/SETMAR protein level ratio,Methylthioribose-1-phosphate isomerase levels,Metabolite levels (sulfate),Phosphatidylinositol (18:0_22:6) levels,Phosphatidylinositol (18:0_22:5) (n6) levels,Phosphatidylinositol (18:0_22:4) levels,Metabolite levels (NMMA),Methylmalonate (mma) levels,Triosephosphate isomerase levels (TPI1.4309.59.3),Metabolite levels  (X-11787),Thymidine phosphorylase levels,Phospholysine phosphohistidine inorganic pyrophosphate phosphatase levels,AHSP/HMBS protein level ratio,"Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 levels",Metabolite levels (urate; cmh_urate; Uric_acid),MAVS/TDRKH protein level ratio,Myristoleoylcarnitine levels,ITGA6/THPO protein level ratio,Threonylphenylalanine levels,Urinary electrolytes (magnesium/calcium ratio),Mannonate levels,Phosphorus intake,Monohexosylceramide (d16:1/24:0) levels,"Type II inositol 1,4,5-trisphosphate 5-phosphatase levels",Phosphatidylinositol (16:0/16:0) levels,Metabolite levels (erythronate; erythronate/threonate),Phosphatidylinositol (15-MHDA_18:2) levels/Phosphatidylinositol (17:0_18:2) levels
Riboflavin (Reported Values: 5–100 nmol/L),Riboflavin kinase levels (RFK.13059.33.3),Riboflavin kinase levels,Metabolite levels (ribitol),Ribitol levels,Metabolite levels (ribose),Ribulonate/xylulonate/lyxonate levels,Ribonate levels,Riboflavin to 3-Indolepropionic acid ratio in coronary artery disease,Ribothymidine levels,Ribonate levels in elite athletes,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Nucleolin levels (NCL.13655.34.3),Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Ribitol levels in elite athletes,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,Linoleoylcarnitine levels,Metabolite levels (dihomo-linolenate (20:3n3 or n6); eicosatrienoate),5-methyluridine (ribothymidine) levels,Metabolite levels (isoleucylvaline),Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] levels,Urine ribonate levels in chronic kidney disease,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,Metabolite levels (biliverdin),1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [1] levels,40S ribosomal protein SA levels (RPSA.4957.1.2),Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,60S ribosomal protein L14 levels,Metabolite levels (dihomo-linoleoylcarnitine (C20:2)),60S ribosomal protein L30 levels (RPL30.12478.15.3),Ribose-5-phosphate isomerase levels (RPIA.12333.87.3),Metabolite levels (1-stearoyl-2-linoleoyl-GPI (18:0/18:2); C36:2 PI),Metabolite levels (linolenoylcarnitine (C18:3)),Metabolite levels (linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2]),Metabolite levels (linoleoyl ethanolamide),60S ribosomal protein L12 levels,Ribosyldihydronicotinamide dehydrogenase [quinone] levels,Metabolite levels (linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]; C36:4 DAG),Metabolite levels (erythritol),60S ribosomal protein L30 levels,Metabolite levels (1-linoleoyl-GPG (18:2)),Small nuclear ribonucleoprotein F levels,Ribose-5-phosphate isomerase levels
Flavin mononucleotide (Reported Values: 3–30 nmol/L),Flavin adenine dinucleotide (FAD) levels,Flavin reductase levels,Nucleolin levels (NCL.13655.34.3),Serum levels of protein FLNA,Vitrin levels (VIT.6234.74.3),Plasmin levels (PLG.4150.75.2),"N,N,N-trimethyl-5-aminovalerate levels",Palmitoleic acid (16:1n-7) levels,Flavonifractor sp002159265 abundance in stool,Ficolin-2 levels (FCN2.3313.21.2),Ficolin-1 levels (FCN1.3613.62.5),Flavonifractor sp900199495 abundance in stool,N-trimethyl 5-aminovalerate (X-21365) levels,ADpSGEGDFXAEGGGVR-to-X-14304--leucylalanine ratio,Filamin-A levels (FLNA.11124.9.3),FLT3/FLT3LG protein level ratio,rRNA 2-O-methyltransferase fibrillarin levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Fumarylacetoacetase levels (FAH.11424.4.3),1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,MLN/TNFRSF12A protein level ratio,Serum levels of protein FLRT1,Kynureninase levels (KYNU.4559.64.2),1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,N-formylanthranilic acid levels,Pirin levels (PIR.13634.209.3),Nucleobindin-1 levels,Plasma metabolome feature (c18_713) (Quinolinic acid),Leiomodin-1 levels (LMOD1:P29536:OID31416:v1),DNA-(apurinic or apyrimidinic site) lyase levels (APEX1.9849.13.3),Margaroylcarnitine (C17) levels,Triacylglycerol_52:5_[M+NH4]1+ levels,X-14189--leucylalanine levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,DNA-3-methyladenine glycosylase levels (MPG.12438.127.3),Leiomodin-1 levels (LMOD1:P29536:OID31014:v1),3-carboxy-4-methyl-5-propyl-2-furanpropanoate (cmpf) levels,Laminin levels (LAMA1.LAMB1.LAMC1.2728.62.2),Mucin-16 levels,N-linoleoyltaurine levels,Lipase member N levels (LIPN.8097.77.3),1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,Triacylglycerol_53:5_[M+NH4]1+ levels,Triacylglycerol_46:5_[M+NH4]1+ levels,Triacylglycerol_52:6_[M+NH4]1+ levels,5-acetylamino-6-amino-3-methyluracil levels,Flt3L levels,Phenylalanine levels (UKB data field 23468)
Neopterin (Reported Values: 5-50 nmol/L),Urine neopterin levels in chronic kidney disease,Neogenin levels (NEO1.8900.28.3),Serum levels of protein NEO1,Serum levels of protein NCMAP,Progonadoliberin-1 levels (GNRH1.5627.53.3),Nucleolin levels (NCL.13655.34.3),Progonadoliberin-2 levels (GNRH2.10708.3.3),Metabolite levels (N-acetyltryptophan),Serum levels of protein NTM,MME/NT5E protein level ratio,Serum levels of protein NMRAL1,Serum levels of protein NPPA,Metabolite levels (NMMA),NT5E protein levels,Serum levels of protein NT5C,Neudesin levels,Neuropilin-2 levels (NRP2.6590.54.3),Neogenin levels,N-acetylaspartate (naa) levels,Serum levels of protein NAGPA,ANPEP/NT5E protein level ratio,Prolargin levels (PRELP.5675.6.3),Serum levels of protein NPNT,Lymphotactin levels (XCL1.14078.69.3),Promotilin levels (MLN.5631.83.3),Serum levels of protein NPPB,Serum levels of protein NEURL4,N-acetyltryptophan levels,MGLL/PTPN6 protein level ratio,MCAM/NTRK3 protein level ratio,Protein MENT levels (MENT.5744.12.3),Metabolite levels (pterin),Kallistatin levels (SERPINA4.3449.58.2),Dihydrobiopterin levels,N-acetylproline levels,Neurexin-3 levels,Aminopeptidase N levels,N-acetyl neuraminic acid levels,Neurotrimin levels,Serum levels of protein NME2,Serum levels of protein NPW,Serum levels of protein GNMT,NBN/NMNAT1 protein level ratio,NT5C3A/NUB1 protein level ratio,NCF2/NMNAT1 protein level ratio,Serum levels of protein NMB,Progonadoliberin-1 levels,Serum levels of protein NDNF,Natriuretic peptide levels,Serum levels of protein NUP210
Cotinine (Reported Values: <3000 nmol/L),Cotinine levels in current smokers,"X-12442--5,8-tetradecadienoate levels",Tetradecadienoate (14:2) (X-12442) levels,Cotinine glucuronidation,Smoking intensity (cotinine levels/cigarettes per day),Tetradecenoylcarnitine levels,Trigonelline (n'-methylnicotinate) levels,Tetradecanedioate levels,Tetradecadienylcarnitine levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Cotinine levels in smokers with chronic obstructive pulmonary disease,Tetradecadienoate (14:2) levels,Oleoylcarnitine (C18:1) levels,Calnexin levels (CANX.8834.58.3),X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,Tetradecanoylcarnitine levels,X-12510--2-aminooctanoic acid levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Arachidonoylcarnitine (C20:4) levels,Serum levels of protein COTL1,Lignoceroylcarnitine (C24) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Oleoylcarnitine levels (Biocrates platform),1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Tartronate (hydroxymalonate) levels,Nervonoylcarnitine (C24:1) levels,Hexadecenoylcarnitine levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Metabolite levels (pregnenetriol sulfate),1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,Metabolite levels (C18:3 CE; C18_3_CE),Carnitine-to-X-12798 ratio,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Talin-2 levels (TLN2.14082.56.3),X-13431--nonanoylcarnitine levels,Ethylmalonate levels,Metabolite levels  (X-11787),Metabolite levels (ethylmalonate),Undecenoylcarnitine (c11:1) (X-17337) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Myristoleoylcarnitine (C14:1) levels,Metabolite levels (tetradecanedioate; tetradecanedioate (C14-DC)),Cotinine and 3'-hydroxycotinine levels in current smokers,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Cerotoylcarnitine (C26) levels,Linoleoylcarnitine (C18:2) levels
Trans hydroxycotinine (Reported Values: <1500 nmol/L),Hydroxycotinine levels,Metabolite levels (hydroxycotinine),trans-Hydroxyproline levels,Hydroxy-cmpf (X-02269) levels,Trans-4-hydroxyproline levels,2-hydroxyadipate levels,X-12441--12-hydroxyeicosatetraenoate 12-HETE levels,3-hydroxycotinine glucuronide levels,2-hydroxyoctanoate levels,3-hydroxyadipate levels,Metabolite levels  (X-11787),Metabolite levels (trans-4-hydroxyproline; hydroxyproline; cis_trans_hydroxyproline),2-hydroxydecanoate levels,X-11593--O-methylascorbate levels,Hydroxy-cmpf levels,3-hydroxyoctanoate levels,Metabolite levels (2-hydroxyoctanoate),Metabolite levels (2-hydroxystearate),2-hydroxystearate levels,Metabolite levels (3-hydroxyhexanoate),3-hydroxydecanoate levels,"X-12442--5,8-tetradecadienoate levels",1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4) levels,Metabolite levels (2-ethylhexanoate),Metabolite levels (3-hydroxyoctanoate),Alpha-hydroxyisocaproate levels,Metabolite levels (docosahexaenoate (DHA; 22:6n3); docosahexaenoate),1-palmitoyl-2-oleoyl-GPI (16:0/18:1) levels,"Hydroxy-N6,N6,N6-trimethyllysine levels",1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels,Monohexosylceramide (d16:1/22:0) levels,X-12510--2-aminooctanoic acid levels,Monohexosylceramide (d16:1/20:0) levels,"X-04499--3,4-dihydroxybutyrate levels",Plasma metabolome feature (hilic_5246) ((5Z7E)-(3S)-262626-trifluoro-27-nor-910-seco-5710(19)-cholestatriene-325-diol),3-hydroxyhexanoate levels,1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) levels,Monohexosylceramide (d16:1/18:0) levels,Monohexosylceramide (d16:1/24:0) levels,Plasma metabolome feature (c18_3925) ((5Z7E)-(3S)-262626272727-hexafluoro-910-seco-5710(19)16-cholestatetraen-23-yne-325-diol),3-hydroxyoleate levels,Metabolite levels (3-hydroxydecanoate),"Docosanoid 14S-HDHA, Docosanoid 17R-HDHA levels",1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,9-hydroxystearate levels,Monohexosylceramide (d18:1/16:0) levels,Monohexosylceramide (d18:1/22:0) levels,Monohexosylceramide (d18:1/20:0) levels,Metabolite levels (trans-2-hexenoylglycine),Metabolite levels (1-stearoyl-2-arachidonoyl-GPI (18:0/20:4); C38:4 PI)
Tryptophan (Reported Values: 40-90 µmol/L),Tryptophan levels,Tryptophan levels (Biocrates platform),N-acetyl-d-tryptophan levels,Metabolite levels (tryptophan),Tryptophan levels (Metabolon platform),Tryptophan levels in elite athletes,Metabolite levels (tryptophan betaine),Tryptophan betaine levels,Tryptophan betaine  levels,Plasma metabolome feature (hilic_2249) (L-Tryptophan),N-acetyltryptophan levels,Phenylalanyltryptophan levels,Gamma-glutamyltryptophan levels,Metabolite levels (N-acetyltryptophan),C-glycosyltryptophan levels,"Tryptophan 2,3-dioxygenase levels",X-12100--hydroxytryptophan levels,Gut bacterial pathway abundance (TRPSYN.PWY..L.tryptophan.biosynthesis),Tryptophan betaine levels in elite athletes,Urine tryptophan levels in chronic kidney disease,Metabolite levels (glycyltryptophan),5-bromotryptophan levels,Metabolite levels (5-bromotryptophan),"X-04499--3,4-dihydroxybutyrate-to-C-glycosyltryptophan ratio",N-acetyltryptophan levels in elite athletes,6-bromotryptophan levels,Gamma-glutamyltryptophan levels in elite athletes,Metabolite levels (6-bromotryptophan),Tryptase gamma levels (TPSG1.14103.12.3),Tryptase alpha/beta-1 levels,Plasma tryptophan betaine levels in chronic kidney disease,C-glycosyltryptophan-to-succinylcarnitine ratio,Tryptase beta-1 levels,N-acetylphenylalanine levels,Metabolite levels (tryptophylasparagine),Metabolite levels (histidylphenylalanine),5-bromotryptophan levels in elite athletes,Alkylphosphatidylethanolamine (O-16:0/20:3) levels,ADpSGEGDFXAEGGGVR-to-X-14304--leucylalanine ratio,Alkylphosphatidylethanolamine (O-18:0/22:5) levels,Alkylphosphatidylethanolamine (O-18:0/20:4) levels,Trypsin-3 levels,Tryptase delta levels,Alkylphosphatidylethanolamine (O-18:0/22:6) levels,Metabolite levels (aspartylphenylalanine),X-12798-to-phenylalanine ratio,Alkylphosphatidylethanolamine (O-16:0/22:6) levels,Alkylphosphatidylethanolamine (O-16:0/22:4) levels,Metabolite levels (threonylphenylalanine),L-Tryptophan to 3-Indolepropionic acid ratio in coronary artery disease
Kynenurine (Reported Values: 1.0-3.0 µmol/L),Kynurenate levels,Kynureninase levels (KYNU.4559.64.2),Kynureninase levels,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),KYNU level (plasma),1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Kynurenine levels,N-acetylkynurenine (2) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) levels,1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Linolenate [alpha or gamma; (18:3n3 or 6)] levels,X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) levels,1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels,Arachidonate 20:4n6-to-dihomo-linolenate 20:3n3 or n6 ratio,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,X-12798-to-phenylalanine ratio,"X-12442--5,8-tetradecadienoate levels",1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-linoleoyl-2-linolenoyl-GPC (18:2/18:3) levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Linoleoylcarnitine (C18:2) levels,1-palmitoyl-2-dihomo-linolenoyl-GPE (16:0/20:3) levels,Plasma metabolome feature (hilic_2278) (Kynurenine),Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-arachidoyl-2-arachidonoyl-GPC (20:0/20:4) levels,Dihomo-linolenate 20:3n3 or n6 levels,"N,n-dimethylalanine (X-23585) levels",Docosapentaenoate n3 DPA; 22:5n3-to-X-12627 ratio,Dihomo-linolenoylcarnitine (C20:3n3 or 6) levels,10-undecenoate 11:1n1-to-X-11438 ratio,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-arachidonoyl-GPE (20:4n6) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Dihomo-linolenate (20:3n3 or n6) levels
3Hydroxykynurenine (Reported Values: 25-80 nmol/L),Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Kynurenine levels,Kynurenate levels,Kynureninase levels (KYNU.4559.64.2),Plasma metabolome feature (hilic_2278) (Kynurenine),1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Stearidonate 18:4n3 levels,1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) levels,Stearidonate (18:4n3) levels,"N,n-dimethylalanine (X-23585) levels","X-04499--3,4-dihydroxybutyrate levels",1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,N-acetylkynurenine (2) levels,3-hydroxyoleoylcarnitine levels,1-stearoyl-2-meadoyl-GPC (18:0/20:3n9) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) levels,Kynureninase levels,N-trimethyl 5-aminovalerate (X-21365) levels,X-12244--N-acetylcarnosine levels,Docosatrienoate (22:3n3) levels,Nucleolin levels (NCL.13655.34.3),1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels,Urine 3-hydroxykynurenine levels in chronic kidney disease,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),"N,N,N-trimethyl-5-aminovalerate levels","X-12442--5,8-tetradecadienoate levels",4-hydroxyphenylacetoylcarnitine levels,1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,3-hydroxyoctanoylcarnitine (2) levels,X-12798-to-phenylalanine ratio,X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,3-hydroxyoctanoylcarnitine (1) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Hexadecenoylcarnitine levels,Undecenoylcarnitine (c11:1) (X-17337) levels,1-palmitoyl-2-alpha-linolenoyl-GPC (16:0/18:3n3) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) levels,N2-methylguanosine levels,Metabolite levels (stearidonate (18:4n3)),1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels
Kynurenic acid (Reported Values: 20-100 nmol/L),Kynurenate levels,Kynureninase levels (KYNU.4559.64.2),Kynureninase levels,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),Kynurenine levels,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),KYNU level (plasma),Vaccenic acid (18:1n-7) levels,N-acetyl neuraminic acid levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Gondoic acid (20:1n-9) levels,N-acetylaspartic acid levels,Kynurenate levels in elite athletes,N-acetyl-L-glutamic acid levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,X-12510--2-aminooctanoic acid levels,Plasma metabolome feature (hilic_2278) (Kynurenine),ADH4/KYNU protein level ratio,Metabolite levels (myristoleate (14:1n5); myristoleic acid),Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Oleic acid (18:1n-9) levels,N-acetylkynurenine (2) levels,Kynurenine--oxoglutarate transaminase 3 levels (CCBL2.12682.5.3),Stearic acid (18:0) levels,Acetoacetate levels (UKB data field 23476),Oxaloacetic acid levels,N-formylanthranilic acid levels,Urine kynurenate levels in chronic kidney disease,Serum levels of protein KYNU,Succinic acid/Methylmalonic acid levels,Urocanic acid levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,N-acetyltaurine levels,3-Indolepropionic acid to Kynurenic acid ratio in coronary artery disease,N-acetylneuraminate levels,X-12244--N-acetylcarnosine levels,Linoleic acid (18:2) levels,Plasma metabolome feature (c18_713) (Quinolinic acid),Nucleolin levels (NCL.13655.34.3),1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Kynurenine--oxoglutarate transaminase 3 levels,Plasma kynurenate levels in chronic kidney disease,Myristoleoylcarnitine levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Myristoleoylcarnitine (C14:1) levels,Kynurenine-oxoglutarate transaminase 1 levels,Linoleic acid levels (UKB data field 23449),1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels
Xanthurenic acid (Reported Values: 2-35 nmol/L),Xanthurenate levels,Metabolite levels (xanthurenate; cmh_xanthurenate; Xanthurenate),X-12510--2-aminooctanoic acid levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Vaccenic acid (18:1n-7) levels,Gondoic acid (20:1n-9) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,"X-12442--5,8-tetradecadienoate levels",Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Metabolite levels (xanthosine; Xanthosine),Docosahexaenoic acid (22:6) levels,Xanthurenate levels in elite athletes,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Ribulonate/xylulonate/lyxonate levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,Urine xanthurenate levels in chronic kidney disease,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,"2,6-dihydroxybenzoic acid (X-09789) levels",X-11593--O-methylascorbate levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,X-12798-to-phenylalanine ratio,1-margaroyl-2-arachidonoyl-GPC (17:0/20:4) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,1-arachidoyl-2-arachidonoyl-GPC (20:0/20:4) levels,Xanthosine levels,2-o-methylascorbic acid levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,Plasma xanthurenate levels in chronic kidney disease,"N,n-dimethylalanine (X-23585) levels",1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,Oleic acid (18:1n-9) levels,Docosahexaenoic acid levels (UKB data field 23450),Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) levels,Linoleic acid (18:2) levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Oxaloacetic acid levels
Anthralinic acid (Reported Values: 7-30 nmol/L),N-formylanthranilic acid levels,2-o-methylascorbic acid levels,Metabolite levels (N-formylanthranilic acid),Metabolite levels (myristoleate (14:1n5); myristoleic acid),Succinic acid/Methylmalonic acid levels,Vaccenic acid (18:1n-7) levels,N-acetylaspartic acid levels,Caprylic acid levels,Stearic acid (18:0) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,2-hydroxy-4-(methylthio)butanoic acid levels,FFA Arachidonic Acid a levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Orotic acid levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,"2,6-dihydroxybenzoic acid (X-09789) levels",Metabolite levels (arachidonate (20:4n6); arachidonate),Oxaloacetic acid levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Mannonate levels,Metabolite levels (ethylmalonate),Butyric acid levels,Metabolite levels (1-myristoyl-2-arachidonoyl-GPC (14:0/20:4); C34:4 PC; C34_4_PC),Metabolite levels (urate; cmh_urate; Uric_acid),Decadienedioic acid (c10:2-dc) (X-21792) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Oleic acid (18:1n-9) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,X-11593--O-methylascorbate levels,Metabolite levels (acisoga),FFA Arachidonic Acid c levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,X-12510--2-aminooctanoic acid levels,Urocanic acid levels,N-acetyl neuraminic acid levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,Ascorbic acid 3-sulfate (X-12206) levels,Docosahexaenoic acid (22:6) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,Gondoic acid (20:1n-9) levels,N-trimethyl 5-aminovalerate (X-21365) levels,"N,n-dimethylalanine (X-23585) levels",Linoleic acid (18:2) levels,1-margaroyl-2-arachidonoyl-GPC (17:0/20:4) levels,aparc-a2009s lh volume G-oc-temp-med-Lingual
Hydroxyanthralinic acid (Reported Values: 10-80 nmol/L),N-formylanthranilic acid levels,3-hydroxyhippurate levels,2-o-methylascorbic acid levels,2-hydroxy-4-(methylthio)butanoic acid levels,Metabolite levels (N-formylanthranilic acid),Docosahexaenoic acid (22:6) levels,Succinic acid/Methylmalonic acid levels,2-hydroxyhippurate (salicylurate) levels,Metabolite levels (3-hydroxyhexanoate),3-hydroxyhexanoate levels,Hydroxycholesterol_[M+H-2H2O]1+ levels,4-hydroxyphenylacetoylcarnitine levels,Dihydroxydocosapentaenoic acid levels,"2,6-dihydroxybenzoic acid (X-09789) levels",Metabolite levels (hypotaurine),Metabolite levels (5-HIAA),Metabolite levels (HVA/5-HIAA ratio),Alpha-hydroxyisocaproate levels,Docosahexaenoic acid levels (UKB data field 23450),4-hydroxyphenylacetate levels,2-hydroxyglutaric acid levels,dihydroferulic acid levels,Hydroxycotinine levels,Hypotaurine levels,3-hydroxyoleate levels,4-hydroxy-2-oxoglutaric acid levels,Metabolite levels (2-hydroxyphenylacetate),FFA Arachidonic Acid a levels,"3-hydroxyanthranilate 3,4-dioxygenase levels (HAAO.5861.78.3)",1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Stearic acid (18:0) levels,Docosahexaenoic acid levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Metabolite levels (5-HIAA/ MHPG Ratio),3-hydroxyadipate levels,Metabolite levels (urate; cmh_urate; Uric_acid),X-11593--O-methylascorbate levels,Oxaloacetic acid levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,2-hydroxyadipate levels,Metabolite levels (docosahexaenoate (DHA; 22:6n3); docosahexaenoate),Caprylic acid levels,Docosahexaenoate (DHA; 22:6n3) levels,Hydroxy-cmpf (X-02269) levels,"2,6-dihydroxybenzoic acid levels",Metabolite levels (myristoleate (14:1n5); myristoleic acid),3b-hydroxy-5-cholenoic acid levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,"Docosanoid 14S-HDHA, Docosanoid 17R-HDHA levels",2-hydroxyphenylacetate levels
Picolinic acid (Reported Values: 20-100 nmol/L),Picolinate levels,Metabolite levels (picolinate),Picolinoylglycine (X-12170) levels,Picolinoylglycine levels,Linoleic acid (18:2) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Gondoic acid (20:1n-9) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Vaccenic acid (18:1n-7) levels,Oxaloacetic acid levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Stearic acid (18:0) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,N-acetylaspartic acid levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,N-acetyl neuraminic acid levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Butyric acid levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Linoleoylcarnitine (C18:2) levels,Linoleic acid levels,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,Palmitic acid (16:0) levels,Caprylic acid levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Oleic acid (18:1n-9) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Plasma picolinate levels in chronic kidney disease,3-Indolepropionic acid to 2-Picolinic acid ratio in coronary artery disease,Succinic acid/Methylmalonic acid levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Urine picolinate levels in chronic kidney disease,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,X-12510--2-aminooctanoic acid levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,Salicylic acid levels,"3,5-dichloro-2,6-dihydroxybenzoic acid levels",Nucleolin levels (NCL.13655.34.3)
Quinolinic acid (Reported Values: 150-700 nmol/L),Quinolinate levels,Plasma metabolome feature (c18_713) (Quinolinic acid),Quinate levels,X-12510--2-aminooctanoic acid levels,Gondoic acid (20:1n-9) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),Kynureninase levels (KYNU.4559.64.2),Kynurenate levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,dihydroferulic acid levels,Ribosyldihydronicotinamide dehydrogenase [quinone] levels (NQO2.9754.33.3),"X-12442--5,8-tetradecadienoate levels","N,n-dimethylalanine (X-23585) levels",Quinate levels in elite athletes,Quinone oxidoreductase levels,X-12798-to-phenylalanine ratio,Vaccenic acid (18:1n-7) levels,N-formylanthranilic acid levels,Quinolinate levels in elite athletes,Metabolite peak levels (QI12000),N-acetyl neuraminic acid levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,"2,6-dihydroxybenzoic acid (X-09789) levels",Urocanic acid levels,Metabolite peak levels (QI12380),Metabolite peak levels (QI12663),Metabolite peak levels (QI12750),Metabolite peak levels (QI12128),Urine quinolinate levels in chronic kidney disease,Metabolite levels (myristoleate (14:1n5); myristoleic acid),Hydroquinone sulfate levels,N-trimethyl 5-aminovalerate (X-21365) levels,Metabolite peak levels (QI12768),NAD(P)H dehydrogenase [quinone] 1 levels (NQO1.9837.60.3),Caprylic acid levels,Metabolite peak levels (QI14354),Metabolite peak levels (QI12764),Metabolite peak levels (QI12147),Metabolite peak levels (QI1234),Metabolite peak levels (QI12470),Metabolite peak levels (QI12890),2-hydroxy-4-(methylthio)butanoic acid levels,Metabolite peak levels (QI2240),Nucleolin levels (NCL.13655.34.3),Metabolite peak levels (QI12472),"N,N,N-trimethyl-5-aminovalerate levels",Metabolite peak levels (QI4060),Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Laurylcarnitine levels (Biocrates platform)
Nicotinic acid (Reported Values: <20 nmol/L),Plasma metabolome feature (hilic_4134) (Nicotinic acid mononucleotide),Nicotinamide levels,N-acetyl neuraminic acid levels,N-acetylalanine levels,N-acetyl-L-glutamic acid levels,N-acetylaspartate (naa) levels,N-acetylvaline levels,Vaccenic acid (18:1n-7) levels,N-acetylaspartic acid levels,N-acetyl-2-aminoadipate levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Nicotinamide N-methyltransferase levels,Metabolite levels (N-acetylalanine),Oleic acid (18:1n-9) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,2-hydroxy-4-(methylthio)butanoic acid levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,N-formylanthranilic acid levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,N-acetylalliin levels,N-acetylarginine levels,Nucleolin levels (NCL.13655.34.3),1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,N-acetyl-2-aminooctanoate levels,Metabolite levels (N-acetylalliin),N-acetylproline levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Indoleacetoylcarnitine levels,X-12510--2-aminooctanoic acid levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,N-acetylglycine levels,Metabolite levels (N-acetylglutamate; acetylglutamic acid),Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,N-acetyl-aspartyl-glutamate (naag) levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [1] levels,"N,n-dimethylalanine (X-23585) levels",1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,"N2-acetyl,N6-methyllysine levels",1-palmitoyl-2-oleoyl-GPI (16:0/18:1) levels,N-acetylornithine levels,Gondoic acid (20:1n-9) levels
Nicotinamide (Reported Values: 100-600 nmol/L),Nicotinamide levels,Nicotinamide N-methyltransferase levels,Nicotinamide levels in elite athletes,Nicotinamide phosphoribosyltransferase levels (NAMPT.5011.11.1),Nucleolin levels (NCL.13655.34.3),Nervonoylcarnitine (C24:1) levels,Niacinamide levels,Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 levels,"N,n-dimethylalanine (X-23585) levels",Tetradecenoylcarnitine levels,1-methylnicotinamide levels,Urine nicotinamide riboside levels in chronic kidney disease,Oleoylcarnitine (C18:1) levels,Dihydroceramide (d18:0/22:0) levels,Nicotinamide riboside kinase 1 levels,Margaroylcarnitine (C17) levels,Dihydroceramide (d18:0/20:0) levels,Nonaylcarnitine levels,Dihydroceramide (d18:0/24:0) levels,Tetradecadienylcarnitine levels,Dihydroceramide (d18:0/18:0) levels,Dihydroceramide (d18:0/24:1) levels,Oleoylcarnitine levels,"N,N,N-trimethyl-5-aminovalerate levels",N-linoleoyl ethanolamide levels,"N,N-dimethylalanine levels",Oleoylcarnitine levels (Biocrates platform),Indoleacetoylcarnitine levels,Monohexosylceramide (d16:1/22:0) levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Monohexosylceramide (d16:1/20:0) levels,Metabolite levels (NMMA),Palmitoleoylcarnitine (C16:1) levels,"N2-acetyl,N6,N6-dimethyllysine levels",Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,N-trimethyl 5-aminovalerate (X-21365) levels,Monohexosylceramide (d16:1/24:0) levels,N-acetyl-2-aminoadipate levels,N-acetylalanine levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Triacylglyceroloxid(53:3)_[M+NH4]1+ levels,Myristoleoylcarnitine (C14:1) levels,Plasma metabolome feature (hilic_4134) (Nicotinic acid mononucleotide),Linoleoylcarnitine (C18:2) levels,Docosapentaenoylcarnitine (C22:5n3) levels,N-acetylaspartate (naa) levels,Monohexosylceramide (d16:1/18:0) levels,"N2-acetyl,N6-methyllysine levels",N-acetylornithine levels,(N(1) + N(8))-acetylspermidine levels
N1 methylnicotinamide (Reported Values: 20-250 nmol/L),1-methylnicotinamide levels,1-methylurate levels,Methylmalonate (mma) levels,Metabolite levels (1-methylurate),N1-methyladenosine levels,Metabolite levels (N1-methyladenosine; 1-methyladenosine),1-methylnicotinamide levels in elite athletes,"X-12442--5,8-tetradecadienoate levels","N,n-dimethylalanine (X-23585) levels",X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,Methylsuccinate levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),X-11593--O-methylascorbate levels,Metabolite levels (ethylmalonate),2-methylmalonylcarnitine (C4-DC) levels,N-linoleoyl ethanolamide levels,Metabolite levels (N('1)-acetylspermidine; N1-acetylspermidine),1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Trigonelline (n'-methylnicotinate) levels,Nervonoylcarnitine (C24:1) levels,Metabolite levels (NMMA),N1-acetylspermidine levels,Plasma 1-methylnicotinamide levels in chronic kidney disease,N-trimethyl 5-aminovalerate (X-21365) levels,N-methylpipecolate levels,N-methylproline levels,Margaroylcarnitine (C17) levels,Myristoleoylcarnitine (C14:1) levels,(N(1) + N(8))-acetylspermidine levels,Ethylmalonate levels,Metabolite levels ((N(1) + N(8))-acetylspermidine),Nicotinamide N-methyltransferase levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Monohexosylceramide (d16:1/22:0) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Triacylglyceroloxid(53:3)_[M+NH4]1+ levels,Monohexosylceramide (d16:1/20:0) levels,Monohexosylceramide (d16:1/24:0) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-stearoyl-2-meadoyl-GPC (18:0/20:3n9) levels,Metabolite levels (N-formylanthranilic acid),Metabolite levels (3-methylcytidine),Tartronate (hydroxymalonate) levels,N6-methyllysine levels,Niacinamide levels
Cystathionine (Reported Values: <0.4 µmol/L),Cystathionine levels,Metabolite levels (cystathionine; cmh_cystathionine),Cystine levels,Cystathionine beta-synthase levels,Cystatin M level (CSF),Cystatin-M levels (CST6.3303.23.2),Cystatin-8 levels (CST8.10572.65.3),Cystathionine levels in elite athletes,Cystatin-F levels (CST7.3302.58.1),Urine cystathionine levels in chronic kidney disease,Plasma cystathionine levels in chronic kidney disease,Cystatin-S levels,Cystatin-like 1 levels,"N2-acetyl,N6,N6-dimethyllysine levels","N,n-dimethylalanine (X-23585) levels",Cystatin-S level (brain),N-acetylornithine levels,Pregnenetriol disulfate (X-11440) levels,Docosatrienoate (22:3n6) levels,Docosatrienoate (22:3n3) levels,Threonine levels (Biocrates platform),Cystatin-SA levels,Cysteinylglycine disulfide levels,Cytohesin-2 levels (CYTH2.12533.135.3),Pregnenediol sulfate (C21H34O5S) levels,Pregnenediol disulfate (C21H34O8S2) levels,Metabolite levels (cysteinylglycine disulfide),1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Tetrahydrocortisol sulfate (1) levels,Methionine levels (Biocrates platform),Cystatin-SN levels,Metabolite levels (C18:3 CE; C18_3_CE),N-delta-acetylornithine levels,Sulfatide (d18:1/24:0(OH) levels) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Acetylornithine levels,"X-12442--5,8-tetradecadienoate levels",Metabolite levels (cytidine),Methionine sulfone levels,Cystatin-M levels,Sulfatide (d18:1/16:0(OH) levels) levels,Cystatin C levels (UKB data field 30720),Metabolite levels (N-acetylthreonine),Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),Semaphorin-3E levels (SEMA3E.5363.51.3),Metabolonic lactone sulfate (X-12063) levels,Semaphorin-5A levels (SEMA5A.13132.14.3),Metabolite levels (C16:0 CE; C16_0_CE),N-acetylthreonine levels,Metabolite levels (N-delta-acetylornithine)
Trigonelline (Reported Values: <25 µmol/L),Trigonelline (n'-methylnicotinate) levels,Treatment or medication use - glyceryl trinitrate (UKB data field 20003_1140860834),1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,"N,n-dimethylalanine (X-23585) levels",1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Triacylglycerol_58:10_[M+NH4]1+ levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,Tetradecenoylcarnitine levels,X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Docosatrienoate (22:3n3) levels,Ximenoylcarnitine (C26:1) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Triacylglycerol_58:7_[M+NH4]1+ levels,"X-12442--5,8-tetradecadienoate levels",Triacylglycerol(50:3)_[M+NH4]1+ levels,Docosatrienoate (22:3n6) levels,Carnitine-to-X-12798 ratio,Triacylglycerol_58:8_[M+NH4]1+ levels,Triacylglycerol_58:9_[M+NH4]1+ levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Trigonelline (N'-methylnicotinate) levels in elite athletes,1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Triacylglycerol(58:9)_[M+NH4]1+ levels,Trihexosylcermide (d18:1/16:0) levels,Trihexosylcermide (d18:1/20:0) levels,Tetradecadienoate (14:2) (X-12442) levels,1-arachidoyl-2-arachidonoyl-GPC (20:0/20:4) levels,1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels,Octadecenoylcarnitine levels,Trihexosylcermide (d18:1/22:0) levels,Triacylglycerol(56:5)_[M+NH4]1+ levels,Triacylglycerol(52:3)_[M+NH4]1+ levels,Dodecadienoate (12:2) (X-21343) levels,Triacylglycerol(53:3)_[M+NH4]1+ levels,1-arachidonoyl-gpc (20:4n6) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Triacylglycerol_56:7_[M+NH4]1+ levels,1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) levels,1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels,Triacylglycerol(51:3)_[M+NH4]1+ levels,Triacylglycerol(50:4)_[M+NH4]1+ levels,1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels
Folate (Reported Values: >7.5 nmol/L),Serum folate levels,Folate pathway vitamin levels,Folate receptor beta levels,Folate receptor alpha levels,Red blood cell folate levels,Folate receptor gamma levels,Plasma metabolome feature (hilic_5246) ((5Z7E)-(3S)-262626-trifluoro-27-nor-910-seco-5710(19)-cholestatriene-325-diol),Plasma metabolome feature (c18_3925) ((5Z7E)-(3S)-262626272727-hexafluoro-910-seco-5710(19)16-cholestatetraen-23-yne-325-diol),Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Glyco-beta-muricholate levels,Plasma metabolome feature (hilic_5950) (3-keto Fusidic acid),Metabolite levels (glyco-beta-muricholate),Tauro-beta-muricholate levels,Plasma metabolome feature (hilic_727) (5-Hydroxy-2-furoic acid),Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Glycolithocholate levels,Metabolite levels (N-linoleoyltaurine),Metabolite levels (C38_5_PC),Metabolite levels (pregnenetriol disulfate),Metabolite levels (dihomo-linolenate (20:3n3 or n6); eicosatrienoate),Lactotransferrin levels (LTF.2780.35.2),Metabolite levels  (X-11787),Triacylglycerol (50:4) [NL-14:0] levels,Metabolite levels (glycolithocholate sulfate),Metabolite levels (pregnenetriol sulfate),Metabolite levels (tauro-beta-muricholate; tauro-alpha-muricholate/tauro-beta-muricholate),Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Triacylglycerol (51:2) [NL-15:0] levels,Metabolite levels (1-linoleoyl-2-linolenoyl-GPC (18:2/18:3)),Metabolite levels (glycylproline),Metabolite levels (fumarate; fumarate/maleate; Fumarate),Metabolite levels (NMMA),Triacylglycerol (50:1) [NL-14:0] levels,Folate receptor alpha level in Chronic kidney disease with hypertension and no diabetes (17455_42),Glycohyocholate levels,Metabolite levels (linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]; C36:4 DAG),Triacylglycerol (49:1) [NL-15:0] levels,"3beta,7alpha-dihydroxy-5-cholestenoate levels",Flt3L levels,N-methylproline levels,3-carboxy-4-methyl-5-propyl-2-furanpropanoate (cmpf) levels,Triacylglycerol_58:10_[M+NH4]1+ levels,Vitamin levels,Metabolite levels (deoxycholic acid (12 or 24)-sulfate),Plasma metabolome feature (c18_783) (Phenylmethanesulfonyl fluoride),FOLR3/KLK8 protein level ratio,Metabolite levels (S-methylcysteine; methylcysteine),Fatty acids (15:0) levels,Triacylglycerol (50:3) [NL-14:1] levels,Metabolite levels (asparagylvaline)
Vitamin B12 (Reported Values: >150 pmol/L),Vitamin B12 levels,Vitamin B1 intake,Vitamin levels,Vitamin B2 intake,Transcobalamin-2 levels (TCN2.5584.21.3),Transcobalamin-2 levels,Transcobalamin-1 levels (TCN1.11232.46.3),Vitamin B9 levels,Transcobalamin-1 levels,Holo-Transcobalamin-2 levels,Retinol (Vitamin A) levels,Serpin B13 levels,Beta-crystallin B1 levels,Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),Protein MENT levels (MENT.5744.12.3),Vitamin C levels,Serum levels of protein MB,Serum total bilirubin levels,Protein FAM150B levels (FAM150B.6284.7.3),Vitamin D-binding protein levels (GC.6581.50.3),Serum lead levels,Promotilin levels (MLN.5631.83.3),Tauro-beta-muricholate levels,Total bilirubin levels,Bilirubin levels,Lamin-B1 levels,Metabolite levels (biliverdin),Folate pathway vitamin levels,Glyco-beta-muricholate levels,Vitamin E levels,"Metabolite levels (bilirubin (E,E))","Metabolite levels (bilirubin (E,Z or Z,E))",Vitamin D levels,Serum folate levels,Metabolite levels (C38_5_PC),Serum manganese levels,Haptoglobin levels (HP.3054.3.2),Myeloperoxidase levels (MPO.2580.83.2),Melanocyte protein PMEL levels (PMEL.6472.40.3),X-11793--oxidized bilirubin levels,Lamin-B1 levels (LMNB1.3889.64.2),Retinol levels,Ephrin-B1 levels,Calcium levels (UKB data field 30680),Protein DEPP levels (DEPP.7178.59.3),Vitrin levels (VIT.6234.74.3),Serum metabolite levels,Protein FAM3B levels (FAM3B.9177.6.3),High mobility group protein B1 levels (HMGB1.2524.56.3),Blood metabolite levels
Vitamin A (Reported Values: 1.46-2.84 µmol/L),Retinol (Vitamin A) levels,Vitamin levels,(S)-a-amino-omega-caprolactam levels,Retinol (Vitamin A) levels in elite athletes,Vitamin C levels,Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),FFA Arachidonic Acid a levels,Acylcarnitine (17:0) (a) levels,Acylcarnitine (15:0) (a) levels,Vitamin D-binding protein levels (GC.6581.50.3),Vitamin E levels,Vitamin D levels,Metabolite levels (C36:4 PC-A; C36_4_PC_A),Docosahexaenoic acid (22:6) levels,Vitrin levels (VIT.6234.74.3),25-Hydroxyvitamin D levels,4-oxo-retinoic acid levels,FFA Arachidonic Acid b levels,Palmitic acid (16:0) levels,2-o-methylascorbic acid levels,Metabolite levels (HVA/5-HIAA ratio),Acylcarnitine (17:0) (b) levels,Triglycerides (56:7)A levels,Metabolite levels (docosapentaenoate (n6 DPA; 22:5n6); docosapentaenoate),Metabolite levels (uracil; Uracil),Retinol levels,"Monounsaturated fatty acids (16:1, 18:1) levels",Serum lycopene concentrations,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),Metabolite levels (acisoga),Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),Fatty acid(22:5)_[M-H]1- levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Fatty acid(16:1)_[M-H]1- levels,Metabolite levels (HVA),Metabolite levels (docosahexaenoate (DHA; 22:6n3); docosahexaenoate),Fatty acid(22:6)_[M-H]1- levels,Eicosanoid 5S-HpETE a levels,Fatty acid(20:3)_[M-H]1- levels,Acylcarnitine (15:0) (b) levels,FFA Arachidonic Acid c levels,Lipoprotein (a) levels,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),Triglycerides (48:2)A levels,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),Monohexosylceramide (d16:1/24:0) levels,Fatty acids (20:5) levels,Metabolite levels (5-HIAA),Fatty acids (15:0) levels
Vitamin D2 (Reported Values: 0-30 nmol/L),Vitamin D levels,Vitamin D-binding protein levels (GC.6581.50.3),Vitamin D3 levels,25-Hydroxyvitamin D levels,Vitamin D levels (dietary vitamin D intake interaction),Vitamin D-binding protein levels,Vitamin D insufficiency,Serum vitamin D-binding protein levels,Vitamin levels,Serum 25-Hydroxyvitamin D levels,Bioavailable vitamin D levels in type 2 diabetes,Vitamin D3 receptor levels,Serum 25-Hydroxyvitamin D level variance,25-hydroxyvitamin D levels (skin colour stratified),Vitamin D-binding protein levels (adjusted for GC haplotype),Neonatal total 25-hydroxyvitamin D levels (cord blood),Dihydroceramide (d18:0/24:0) levels,Dihydroceramide (d18:0/20:0) levels,Dihydroceramide (d18:0/24:1) levels,Dihydroceramide (d18:0/22:0) levels,Vitamin D levels x vegetarianism interaction,Dihydroceramide (d18:0/18:0) levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Serum vitamin D-binding protein levels in type 2 diabetes,Depression score x vitamin D interaction,Vitamin D levels or COVID-19 (MTAG),Gamma-crystallin D levels,Retinol (Vitamin A) levels,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),DPP7/MCFD2 protein level ratio,Monohexosylceramide (d18:2/24:0) levels,Monohexosylceramide (d18:1/24:0) levels,Monohexosylceramide (d18:2/20:0) levels,Monohexosylceramide (d16:1/24:0) levels,Monohexosylceramide (d18:2/18:0) levels,Apolipoprotein D levels (APOD.4712.28.2),Monohexosylceramide (d16:1/20:0) levels,Monohexosylceramide (d18:1/24:1) levels,Vitamin D levels (adjusted for BMI) x vegetarianism interaction,25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Monohexosylceramide (d18:2/22:0) levels,Monohexosylceramide (d18:1/20:0) levels,DKK1/NID2 protein level ratio,Monohexosylceramide (d18:1/18:0) levels,Monohexosylceramide (d16:1/22:0) levels,Sulfatide (d18:1/24:0) levels,Monohexosylceramide (d16:1/18:0) levels,Dihexosylceramide (d18:1/24:0) levels,Dihexosylceramide (d18:2/24:1) levels
Vitamin D3 (Reported Values: 32.4-98.5 nmol/L),Vitamin D3 levels,Vitamin D levels,Vitamin D-binding protein levels (GC.6581.50.3),25-Hydroxyvitamin D levels,Vitamin D3 receptor levels,Vitamin D levels (dietary vitamin D intake interaction),Vitamin D-binding protein levels,Vitamin D insufficiency,Vitamin levels,Serum 25-Hydroxyvitamin D levels,Serum vitamin D-binding protein levels,25-hydroxyvitamin D levels (skin colour stratified),Serum 25-Hydroxyvitamin D level variance,Vitamin D-binding protein levels (adjusted for GC haplotype),Bioavailable vitamin D levels in type 2 diabetes,Neonatal total 25-hydroxyvitamin D levels (cord blood),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Dihydroceramide (d18:0/24:0) levels,Dihydroceramide (d18:0/24:1) levels,Vitamin D levels or COVID-19 (MTAG),Dihydroceramide (d18:0/20:0) levels,Vitamin D levels x vegetarianism interaction,Dihydroceramide (d18:0/18:0) levels,Dihydroceramide (d18:0/22:0) levels,25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Gamma-crystallin D levels,Retinol (Vitamin A) levels,Depression score x vitamin D interaction,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Vitamin D levels (adjusted for BMI) x vegetarianism interaction,Monohexosylceramide (d16:1/24:0) levels,Monohexosylceramide (d18:1/24:1) levels,Monohexosylceramide (d18:1/24:0) levels,Serum vitamin D-binding protein levels in type 2 diabetes,Monohexosylceramide (d18:2/24:0) levels,Monohexosylceramide (d16:1/20:0) levels,25-hydroxyvitamin D levels x skin colour (very fair vs. fair) interaction,Monohexosylceramide (d16:1/18:0) levels,Monohexosylceramide (d18:2/18:0) levels,Monohexosylceramide (d18:1/18:0) levels,Omega-3 fatty acids levels (UKB data field 23444),Monohexosylceramide (d18:1/20:0) levels,Trihexosylcermide (d18:1/24:1) levels,Monohexosylceramide (d18:2/20:0) levels,Trihexosylcermide (d18:1/24:0) levels,Monohexosylceramide (d16:1/22:0) levels,Phosphatidylinositol (18:0_22:5) (n3) levels,Monohexosylceramide (d18:1/16:0) levels,Serum 25-Hydroxyvitamin D levels x season interaction
Alpha tocopherol (Reported Values: 18.9-38.8.0 µmol/L),Alpha-tocopherol levels,Gamma-tocopherol/beta-tocopherol levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Phosphatidylinositol-O(36:0)_[M-H]1-/Phosphatidylglycerol(37:0)_[M+OAc]1- levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Alkyldiacylglycerol (O-52:0) [NL-16:0] levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Alkyldiacylglycerol (O-52:2) [NL-16:0] levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels,Alpha-hydroxyisocaproate levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Alkyldiacylglycerol (O-50:1) [NL-16:0] levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Phosphatidylinositol (18:0_22:5) (n3) levels,Phosphatidylinositol(36:0)_[M+OAc]1- levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Metabolite levels (oleoyl-oleoyl-glycerol (18:1/18:1)  [1]; C36:2 DAG; C36_2_DAG),Phosphatidylinositol (18:0_22:4) levels,Phosphatidylinositol (18:0_22:6) levels,Alpha-tocopherol levels in elite athletes,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,Phosphatidylinositol (18:0_20:3) levels,1-oleoyl-GPG (18:1) levels,1-stearoyl-2-oleoyl-gpc (18:0/18:1) levels,Phosphatidylinositol (18:0_20:3) (a) levels,Phosphatidylinositol-O(33:0)_[M-H]1- levels,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-palmitoyl-2-oleoyl-gpc (16:0/18:1) levels,Phosphatidylinositol (16:0_20:3) (a) levels,Phosphatidylinositol (18:0_22:5) (n6) levels
Gamma tocopherol (Reported Values: 2-11 µmol/L),Gamma-tocopherol/beta-tocopherol levels,Alpha-tocopherol levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Gamma-tocopherol/beta-tocopherol levels in elite athletes,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels,Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Gro-beta/gamma levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,"Metabolite levels (1-dihomo-linolenylglycerol (alpha, gamma); 1-dihomo-linolenylglycerol (20:3))",1-linoleoyl-2-linolenoyl-GPC (18:2/18:3) levels,1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-oleoyl-GPG (18:1) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,1-palmitoyl-2-oleoyl-gpc (16:0/18:1) levels,1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) levels,1-stearyl-GPC (O-18:0) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,1-stearoyl-2-oleoyl-gpc (18:0/18:1) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,Alkyldiacylglycerol (O-52:0) [NL-16:0] levels,Phosphatidylinositol-O(36:0)_[M-H]1-/Phosphatidylglycerol(37:0)_[M+OAc]1- levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels,Alkyldiacylglycerol (O-52:2) [NL-16:0] levels
Methylmalonic acid (Reported Values: <0.26 µmol/L),Succinic acid/Methylmalonic acid levels,Methylmalonate (mma) levels,2-o-methylascorbic acid levels,1-methylurate levels,Metabolite levels (1-methylurate),2-hydroxy-4-(methylthio)butanoic acid levels,X-11593--O-methylascorbate levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,Metabolite levels (ethylmalonate),Metabolite levels (myristoleate (14:1n5); myristoleic acid),Methylsuccinate levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-methylnicotinamide levels,Ethylmalonate levels,Plasma metabolome feature (c18_658) (Methylarsonic acid monosodium salt),Metabolite levels (N1-methyladenosine; 1-methyladenosine),1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,5-acetylamino-6-formylamino-3-methyluracil levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Margaroylcarnitine (C17) levels,Metabolite levels (methylsuccinate),Metabolite levels (N-formylanthranilic acid),1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,5-acetylamino-6-amino-3-methyluracil levels,N-formylanthranilic acid levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Metabolite levels (5-acetylamino-6-formylamino-3-methyluracil),Metabolite levels (5-acetylamino-6-amino-3-methyluracil),1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Metabolite levels (malate; cmh_malate; Malate),Decadienedioic acid (c10:2-dc) (X-21792) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Metabolonic lactone sulfate (X-12063) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Plasma metabolome feature (c18_410) (L-Malic acid),Tartronate (hydroxymalonate) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Stearic acid (18:0) levels,Mannonate levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,"X-12442--5,8-tetradecadienoate levels",Oleic acid (18:1n-9) levels,Metabolite levels (NMMA),Linoleic acid (18:2) levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,Metabolite levels (Dihydroxy docosatrienoic acid),1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Metabolite levels (1-myristoyl-2-arachidonoyl-GPC (14:0/20:4); C34:4 PC; C34_4_PC)
Total homocysteine (Reported Values: <15 µmol/L),Homocysteine levels,Plasma homocysteine levels,Plasma homocysteine levels (post-methionine load test),Cysteine levels,X-11786--methylcysteine levels,RBC levels of S-Adenosyl-L-homocysteine,Metabolite levels (S-methylcysteine; methylcysteine),S-methylcysteine levels,Cysteinylglycine levels,Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine),Metabolite levels (cysteinylglycine),Cysteine sulfinic acid levels,Plasma metabolome feature (hilic_5137) (Cysteineglutathione disulfide),AHCY/HSPA1A protein level ratio,Serum levels of protein HDAC8,Metabolite levels (HVA/5-HIAA ratio),Phosphopantothenoylcysteine decarboxylase levels,AHCY/FADD protein level ratio,AHCY/SNAP23 protein level ratio,Cysteine levels in elite athletes,RBC levels of [Similar to: gamma-Glutamylcysteine; deltaMass: -146.3080 Da],Metabolite levels (cysteinylglycine disulfide),AHCY/KYAT1 protein level ratio,S-methylcysteine sulfoxide levels,Cysteine-glutathione disulfide levels,Cysteinylglycine disulfide levels,Serum levels of protein HNF4A,4-hydroxyphenylacetoylcarnitine levels,Metabolite levels (cysteine-glutathione disulfide),S-methylmethionine--homocysteine S-methyltransferase BHMT2 levels,Metabolite levels (5-HIAA),Cyclin-H levels (CCNH.9848.22.3),7-alpha-hydroxy-3-oxo-4-cholestenoate (7-hoca) levels,Hydantoin-5-propionic acid levels,Haptoglobin levels (HP.3054.3.2),N-acetylthreonine levels,Cysteine-rich protein 1 levels,HAGH/HMBS protein level ratio,RBC levels of 14-HDoHE.1,Metabolite levels (HVA-5-HIAA Factor score),Protein MENT levels (MENT.5744.12.3),AHCY/FABP5 protein level ratio,HCC 4 plasma levels,Serum levels of protein HCAR2,Metabolite levels (12-HETE),Lactadherin levels (MFGE8.4455.89.2),Histidine betaine (hercynine) levels,3-hydroxybutyroylglycine levels,HGH level (plasma),DFFA/HCLS1 protein level ratio
Total cysteine (Reported Values: 150-350 µmol/L),Cysteine levels,Cysteine s-sulfate levels,Cysteine sulfinic acid levels,Cysteinylglycine disulfide levels,Metabolite levels (cysteinylglycine),Metabolite levels (cysteinylglycine disulfide),Cysteinylglycine levels,Cysteine levels in elite athletes,Cysteine-glutathione disulfide levels,X-11786--methylcysteine levels,Metabolite levels (cysteine-glutathione disulfide),Urine cysteine levels in chronic kidney disease,Cystine levels,Metabolite levels (S-methylcysteine; methylcysteine),Cysteine-rich protein 2 levels,Homocysteine levels,Phosphopantothenate--cysteine ligase levels,S-methylcysteine levels,Cysteine-rich protein 1 levels,Cysteine s-sulfate levels in elite athletes,Cysteine sulfinic acid levels in elite athletes,S-methylcysteine sulfoxide levels,CCDC80/CCL27 protein level ratio,Plasma metabolome feature (hilic_5137) (Cysteineglutathione disulfide),Phosphopantothenoylcysteine decarboxylase levels,Plasma cysteinylglycine disulfide* levels in chronic kidney disease,Cysteine protease ATG4A levels,Cyclin-C levels (CCNC.7817.36.3),Cystatin-8 levels (CST8.10572.65.3),Urine cysteinylglycine disulfide* levels in chronic kidney disease,Cystatin-F levels (CST7.3302.58.1),Cytidine levels,Metabolite levels (cytidine),Urine 3-S-cysteinyl-2-methylpropanoate* levels in chronic kidney disease,Cyclin-H levels (CCNH.9848.22.3),3-(cystein-S-yl)acetaminophen levels,Plasma cysteinylglycine levels in chronic kidney disease,Plasma homocysteine levels,Cystatin M level (CSF),Cystatin-M levels (CST6.3303.23.2),Cytohesin-2 levels (CYTH2.12533.135.3),Urine cysteinylglycine levels in chronic kidney disease,(S)-a-amino-omega-caprolactam levels,C2/SSC5D protein level ratio,CCL13/CCL8 protein level ratio,CXCL11/CXCL13 protein level ratio,Cysteine-glutathione disulfide levels in elite athletes,Metabolite levels (cystathionine; cmh_cystathionine),Cysteine and glycine-rich protein 2 levels,Cystatin-SA levels
Choline (Reported Values: 5-12 µmol/L),Choline levels,Total cholines levels,Choline phosphate levels,Cholate levels,Choline levels (advanced age),RBC levels of Choline,Choline levels in elite athletes,3-hydroxy-5-cholestenoic acid levels,Cholesteryl ester (22:5) (n3) levels,Cholesteryl ester (22:5) (n6) levels,Total cholines levels (UKB data field 23436),Choline levels (elderly offspring),Cholesteryl ester (20:3) levels,Cholesteryl ester (20:5) levels,Cholesteryl ester (20:0) levels,Cholesteryl ester (22:6) levels,Cholesteryl ester (22:0) levels,Cholesteryl ester (22:4) levels,Cholesteryl ester (18:3) levels,Cholesteryl ester (24:0) levels,Cholesteryl ester (20:4) levels,Cholesteryl ester(18:0)_[M+NH4]1+ levels,Cholic acid glucuronide levels,Cholesteryl ester (24:5) levels,Cholesteryl ester (18:0) levels,Metabolite levels (3b-hydroxy-5-cholenoic acid),Cholesteryl ester (24:6) levels,Cholesteryl ester (20:2) levels,4-cholesten-3-one levels,Cholesteryl ester (24:4) levels,Cholesteryl ester (18:2) levels,Cholesteryl ester (16:0) levels,Cholesteryl ester (15:0) levels,3b-hydroxy-5-cholenoic acid levels,Cholesteryl ester(16:0)_[M+NH4]1+ levels,Cholesteryl ester(20:5)_[M+NH4]1+ levels,Cholesteryl ester (20:1) levels,Cholesteryl ester (22:1) levels,Cholesteryl ester (24:1) levels,Cholesteryl ester_18:0_[M+NH4]1+ levels,Cholesteryl ester_22:6_[M+NH4]1+ levels,Cholesteryl ester_22:5_[M+NH4]1+ levels,Cholesteryl ester_20:5_[M+NH4]1+ levels,Cholesteryl ester_18:3_[M+NH4]1+ levels,Cholesteryl ester (17:0) levels,Cholesteryl ester(18:3)_[M+NH4]1+ levels,Cholesteryl ester (16:2) levels,Cholesteryl ester_17:0_[M+NH4]1+ levels,Cholesteryl ester(20:3)_[M+NH4]1+ levels,Cholesteryl ester(18:2)_[M+NH4]1+ levels
Betaine (Reported Values: 16-51 µmol/L),Betaine levels,Metabolite levels (betaine),Betaine-to-pyroglutamine ratio,Valine levels (Biocrates platform),Metabolite levels (beta-alanine; beta_alanine),Beta-alanine levels,Metabolite levels (valine),Betaine levels in elite athletes,Betaine levels in individuals undergoing cardiac evaluation,Beta-aminoisobutyric acid levels,Valine-to-proline ratio,Valine levels,Valine levels (Metabolon platform),Metabolite levels (N-acetyl-beta-alanine),N-acetyl-beta-alanine levels,Metabolite levels (tryptophan betaine),N-carbamoyl-beta-alanine levels,Plasma betaine levels in chronic kidney disease,Urine betaine levels in chronic kidney disease,Metabolite levels (beta-hydroxyisovalerate),Beta-trace protein levels,Valine-to-isovalerylcarnitine ratio,Beta-hydroxyisovaleroylcarnitine levels,Lithostathine-1-beta levels,Tryptophan betaine  levels,Tryptophan betaine levels,Metabolite levels (beta-hydroxyisovaleroylcarnitine),Metabolite levels (C18:3 CE; C18_3_CE),Beta-hydroxyisovalerate levels,Metabolite levels (beta-citrylglutamate),"Metabolite levels (ceramide (d16:1/24:1, d18:1/22:1))","Metabolite levels (ceramide (d18:1/20:0, d16:1/22:0, d20:1/18:0))",Branched-chain amino acid levels (Valine),Beta-crystallin B2 levels (CRYBB2.10000.28.3),Lithostathine-1-alpha levels,Metabolite levels (adrenate (22:4n6); adrenate),Beta-defensin 128 levels,Beta-defensin 110 levels,Ceramide (d17:1/24:0) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Alanine levels (UKB data field 23460),Ceramide (d16:1/24:0) levels,N-lactoyl valine levels,Beta-citrylglutamate levels,Metabolite levels  (X-11787),Metabolite levels (lysine),Beta-defensin 104 levels (DEFB104A.5763.67.3),Beta-defensin 128 levels (DEFB128.6360.7.3),Metabolite levels (glyco-beta-muricholate),Metabolite levels (alanine)
Dimethylglycine (Reported Values: 1.5–4 µmol/L),Dimethylglycine levels,Metabolite levels (dimethylglycine),Glycine levels (Biocrates platform),Isovalerylglycine levels,Picolinoylglycine (X-12170) levels,Metabolite levels (isovalerylglycine),Isobutyrylglycine levels,"N,n-dimethylalanine (X-23585) levels",Hexanoylglycine levels,Metabolite levels (isobutyrylglycine),Metabolite levels (N-acetylglycine; acetylglycine),Dimethylglycine levels in elite athletes,Isoleucylglycine levels,"Cis-3,4-methyleneheptanoylglycine levels","X-12442--5,8-tetradecadienoate levels",Metabolite levels (hexanoylglycine),Propionylglycine levels,Metabolite levels (isoleucylglycine),Metabolite levels (glycine),Glycine levels,Metabolite levels (3-hydroxybutyroylglycine),Metabolite levels (propionylglycine),Glycine levels (Metabolon platform),1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels,N-acetylglycine levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels,Dimethylglycine levels in chronic kidney disease,Diacylglycerol(36:3)_[M+NH4]1+ levels,Metabolite levels (trans-2-hexenoylglycine),1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6) levels,"N,N-dimethylalanine levels",1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) levels,Cysteinylglycine disulfide levels,3-hydroxybutyroylglycine levels,Metabolite levels (2-butenoylglycine),Diacylglycerol(36:4)_[M+NH4]1+ levels,Metabolite levels (tigloylglycine),Metabolite levels (cysteinylglycine disulfide),Metabolite levels (gamma-glutamylglycine),Docosapentaenoate (n6 DPA; 22:5n6) levels,Plasma dimethylglycine levels in chronic kidney disease,Metabolite levels (docosapentaenoate (n6 DPA; 22:5n6); docosapentaenoate),Glycine levels (UKB data field 23462),Diacylglycerol(36:2)_[M+NH4]1+ levels,Metabolite levels (leucylglycine),1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels,Metabolite levels (phenylalanylglycine),1-docosahexaenoyl-GPC (22:6) levels,Metabolite levels (cysteinylglycine)
Creatinine (Reported Values: <90 µmol/L),Creatinine levels,Serum creatinine levels,Creatinine levels (UKB data field 23478),Urinary creatinine levels,Creatinine levels (UKB data field 30700),Creatinine levels in elite athletes,Creatine levels,Urinary albumin-to-creatinine ratio,Urinary sodium to creatinine ratio,Glomerular filtration rate (creatinine),Urinary potassium to creatinine ratio,Creatinine clearance,Urinary uromodulin levels (indexed to creatinine),Estimated glomerular filtration rate (creatinine),Metabolite levels (creatine),Chronic kidney disease and serum creatinine levels,"Estimated glomerular filtration rate (creatinine, Rapid3)",Creatine kinase M-type levels (CKM.2670.67.4),Urinary magnesium-to-creatinine ratio,"Estimated glomerular filtration rate (creatinine, CKDi25)",Urinary albumin-to-creatinine ratio in non-diabetics,Plasma metabolome feature (hilic_502) (Creatinine),Glomerular filtration rate in non diabetics (creatinine),Cripto levels (serum),Peak creatinine levels in vancomycin therapy,Urine 6-hydroxymelatonin sulfate-to-creatinine ratio,Calnexin levels (CANX.8834.58.3),Serum levels of protein CROT,Serum urea levels,Urinary uric acid to urinary creatinine ratio,Serum levels of protein CRTAM,Endostatin levels (COL18A1.2201.17.6),Creatinine levels (adjusted for BMI) x vegetarianism interaction,Glucagon levels (GCG.4891.50.1),Ketonuria (moderate to severe),Creatine kinase levels,Serum levels of protein CRAT,Glomerular filtration rate in diabetics (creatinine),Creatine levels in elite athletes,Calpastatin levels (CAST.3026.5.2),Nephronectin levels,calreticulin level (plasma),Protein MENT levels (MENT.5744.12.3),Haptoglobin levels (HP.3054.3.2),Elafin levels (PI3.4982.54.1),Serum urate levels,Serum levels of protein CREB3L4,Bipolar disorder or glomerular filtration rate estimated from creatine (MTAG),Protein DEPP levels (DEPP.7178.59.3),Maximum creatine kinase levels in statin users
Methionine (Reported Values: 18-33 µmol/L),Methionine levels (Biocrates platform),Methionine levels,Methionine levels (Metabolon platform),Methioninesulfoxide levels,Methionine sulfone levels,Methionine synthase levels,Metabolite levels (methionine sulfone),Methionine sulfoxide levels,RBC levels of Methionine,Methionine levels in elite athletes,"N,n-dimethylalanine (X-23585) levels",Methoxychlor levels,Metabolite levels (3-methoxytyrosine),Metabolite levels (myristoleate (14:1n5); myristoleic acid),Metabolite levels (hypotaurine),Metabolite levels (N-acetylthreonine),Plasma metabolome feature (hilic_977) (Metenamine),3-methoxytyrosine levels,N-formylmethionine levels,Methionine sulfone levels in elite athletes,Metabolite levels (C18:3 CE; C18_3_CE),Metabolite levels  (X-11787),5-acetylamino-6-amino-3-methyluracil levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Metabolite levels (12-HETE),"3,4-methyleneheptanoate levels",Metabolite levels (N-formylmethionine; formylmethionine),Methionine aminopeptidase 2 levels,Metabolite levels (dimethylglycine),Methylmalonate (mma) levels,Threonine levels (Biocrates platform),"Metabolite levels (N6,N6-dimethyllysine; N6.N6-dimethyllysine)",Metabolite levels (3-methoxytyramine sulfate),Metabolite levels (threonine),Metabolite levels (isoleucylthreonine),Methionine sulfoxide levels in elite athletes,Metabolite levels (adrenate (22:4n6); adrenate),N-acetylthreonine levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,"N,N-dimethylalanine levels","5,6-dihydrouridine (X-11429) levels",5-acetylamino-6-formylamino-3-methyluracil levels,Metabolite levels (1-methylhistidine),Metabolite levels (C20:5 CE; C20_5_CE),Metabolite levels (5-HIAA),Alkylphosphatidylethanolamine (O-16:0/20:3) levels,Metabolite levels (5-acetylamino-6-amino-3-methyluracil),X-12798-to-phenylalanine ratio,5-methyluridine (ribothymidine) levels,Plasma homocysteine levels (post-methionine load test)
Methionine sulfoxide (Reported Values: not provided by bevital),Methionine sulfoxide levels,Methionine sulfone levels,Metabolite levels (methionine sulfone),Methioninesulfoxide levels,Sulfatide (d18:1/24:0(OH) levels) levels,Sulfatide (d18:1/16:0(OH) levels) levels,Methionine-R-sulfoxide reductase B3 levels,Methionine sulfoxide levels in elite athletes,Sulfatide (d18:1/24:1(OH) levels) levels,S-methylcysteine sulfoxide levels,Sulfatide (d18:1/24:0) levels,Sulfatide (d18:1/16:0) levels,Dimethyl sulfone levels,Sulfatide (d18:1/24:1) levels,Total Sulfatide levels,Urine methionine sulfoxide levels in chronic kidney disease,Methionine sulfone levels in elite athletes,"Methionine-R-sulfoxide reductase B2, mitochondrial levels",Pregnenediol disulfate (C21H34O8S2) levels,Methionine levels (Biocrates platform),Plasma metabolome feature (c18_1550) (Bis(methylsulfonylmethyl) disulfide),3-methoxytyramine sulfate levels,Mitochondrial peptide methionine sulfoxide reductase levels,RBC levels of 2S-5S-Methionine sulfoximine,Urine methionine sulfone levels in chronic kidney disease,Metabolite levels (3-methoxytyramine sulfate),Pregnenediol sulfate (C21H34O5S) levels,Methoxychlor levels,2-methoxyacetaminophen sulfate levels,Plasma methionine sulfone levels in chronic kidney disease,Dimethyl sulfone levels in elite athletes,Pregnenetriol disulfate (X-11440) levels,Plasma metabolome feature (c18_450) (Sulfoacetate),Perfluorooctanesulfonate (PFOS) levels,Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) levels,Sulfhydryl oxidase 2 levels (QSOX2.8397.147.3),6-hydroxyindole sulfate levels,Metabolite levels (pregnenetriol disulfate),Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),"5alpha-androstan-3beta,17beta-diol monosulfate (1) levels",Metabolite levels (3-methoxytyrosine),Metabolite levels (glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)),"4-androsten-3beta,17beta-diol monosulfate (1) levels","Androstenediol (3beta,17beta) disulfate (2) levels",Sulfiredoxin-1 levels,Methionine levels,2-hydroxyfluorene sulfate levels,"5alpha-androstan-3beta,17beta-diol monosulfate (2) levels","2,6-dihydroxybenzoic acid (X-09789) levels",4-methylcatechol sulfate levels
Arginine (Reported Values: 10-80 µmol/L),Arginine levels (Biocrates platform),Arginine levels,L-arginine levels,Metabolite levels (arginine),Arginine levels (Metabolon platform),Plasma metabolome feature (c18_789) (Arginine),Arginine levels in elite athletes,N-acetylarginine levels,Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Argininosuccinate synthase levels,Metabolite levels (homoarginine),Margaroylcarnitine (C17) levels,N-alpha-acetylarginine levels,Homoarginine levels,Acylcarnitine (10:0) levels,Acylcarnitine (14:0) levels,Piperine levels,Plasma arginine levels in chronic kidney disease,Alanine levels,Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),Acylcarnitine (15:0) (a) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Metabolite levels (alanine),Serine levels,N-acetylmethionine levels,Acylcarnitine (12:0) levels,Arginase-1 levels,Stearidonate (18:4n3) levels,Metabolite levels (serine),Acylcarnitine (10:1) levels,Acylcarnitine (17:0) (a) levels,Metabolite levels (adrenate (22:4n6); adrenate),Arginine/serine-rich protein 1 levels,Acylcarnitine (14:1) levels,Octadecadienylcarnitine levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Alanine levels (UKB data field 23460),Acylcarnitine (13:0) levels,Protein arginine N-methyltransferase 3 levels,Acylcarnitine (18:0) levels,Protein-arginine deiminase type-4 levels,Dimethylarginine (sdma + adma) levels,Acylcarnitine (16:0) levels,Valine levels,Protein-arginine deiminase type-2 levels,Stearidonate 18:4n3 levels,Valine-to-proline ratio,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Serine levels (Biocrates platform),Metabolite levels (N-acetylasparagine)
Asymmetric dimethylarginine (Reported Values: 0.4-1.0 µmol/L),Asymmetrical dimethylarginine levels,Serum dimethylarginine levels (asymmetric/symetric ratio),Symmetric dimethylarginine levels,Symmetrical dimethylarginine levels,Dimethylarginine (sdma + adma) levels,Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),Symmetric dimethylarginine levels in chronic kidney disease,"N,n-dimethylalanine (X-23585) levels","N,N-dimethylalanine levels","N2,n2-dimethylguanosine levels",Asymmetrical dimethylarginine levels in osteoarthritis,"Indoleacetate-to-N2,N2-dimethylguanosine ratio",Dimethylarginine dimethylaminohydrolase 1 levels,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 levels",Dimethylarginine (SDMA + ADMA) levels in elite athletes,"1,2-dilinoleoyl-GPC (18:2/18:2) levels",Docosapentaenoate n3 DPA; 22:5n3-to-X-12627 ratio,Docosatrienoate (22:3n3) levels,"1,2-dilinoleoyl-GPE (18:2/18:2) levels",Arginine levels (Biocrates platform),N-acetylarginine levels,1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n3) levels,Docosatrienoate (22:3n6) levels,Docosapentaenoate n3 DPA; 22:5n3 levels,1-oleoyl-GPG (18:1) levels,1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) levels,1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) levels,"N6,N6-dimethyllysine levels",1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) levels,Docosapentaenoate (n6 DPA; 22:5n6) levels,Docosapentaenoate (n3 DPA; 22:5n3) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Urine dimethylarginine (SDMA + ADMA) levels in chronic kidney disease,1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels,"N2,N5-diacetylornithine levels",1-methylguanosine levels,4-acetamidobutanoate-to-N1-methyladenosine ratio,1-palmitoyl-2-dihomo-linolenoyl-GPE (16:0/20:3) levels,1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,Plasma dimethylarginine (SDMA + ADMA) levels in chronic kidney disease,Stearidonate 18:4n3 levels,1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) levels,Tetradecenoylcarnitine levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Dodecadienoate (12:2) (X-21343) levels,"N2-acetyl,N6,N6-dimethyllysine levels",1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-palmitoyl-2-alpha-linolenoyl-GPC (16:0/18:3n3) levels
Symmetric dimethylarginine (Reported Values: 0.3-0.7 µmol/L),Symmetric dimethylarginine levels,Symmetrical dimethylarginine levels,Asymmetrical dimethylarginine levels,Serum dimethylarginine levels (asymmetric/symetric ratio),Dimethylarginine (sdma + adma) levels,Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),"N,n-dimethylalanine (X-23585) levels",Symmetric dimethylarginine levels in chronic kidney disease,"N,N-dimethylalanine levels","N2,n2-dimethylguanosine levels",Docosatrienoate (22:3n3) levels,Dimethylarginine dimethylaminohydrolase 1 levels,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 levels","Indoleacetate-to-N2,N2-dimethylguanosine ratio",Docosatrienoate (22:3n6) levels,Docosapentaenoate n3 DPA; 22:5n3-to-X-12627 ratio,"1,2-dilinoleoyl-GPC (18:2/18:2) levels",Docosapentaenoate n3 DPA; 22:5n3 levels,"1,2-dilinoleoyl-GPE (18:2/18:2) levels",1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n3) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) levels,Docosapentaenoate (n3 DPA; 22:5n3) levels,1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) levels,Arginine levels (Biocrates platform),Docosapentaenoate (n6 DPA; 22:5n6) levels,1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels,"N2,N5-diacetylornithine levels",1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-oleoyl-GPG (18:1) levels,Dimethylarginine (SDMA + ADMA) levels in elite athletes,Dodecadienoate (12:2) (X-21343) levels,N-acetylarginine levels,"X-12442--5,8-tetradecadienoate levels",1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) levels,Metabolite levels (5-dodecenoate (12:1n7); 5-dodecenoate),1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) levels,"N6,N6-dimethyllysine levels",1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels,1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels,Stearidonate 18:4n3 levels,1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels
Homoarginine (Reported Values: 2-6 µmol/L),Homoarginine levels,Metabolite levels (homoarginine),Arginine levels (Biocrates platform),L-arginine levels,Homoarginine levels in elite athletes,Metabolite levels (arginine),Arginine levels,Plasma homoarginine levels in chronic kidney disease,Urine homoarginine levels in chronic kidney disease,Arginine levels (Metabolon platform),4-hydroxyphenylacetoylcarnitine levels,Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Margaroylcarnitine (C17) levels,N-acetylarginine levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,"N,n-dimethylalanine (X-23585) levels",1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Metabolite levels (homostachydrine),1-methylguanosine levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,N-alpha-acetylarginine levels,"3,4-methyleneheptanoate levels",Plasma metabolome feature (c18_789) (Arginine),"N2,n2-dimethylguanosine levels",1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Metabolite levels (adrenate (22:4n6); adrenate),Serine levels,Metabolite levels (serine),1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,N-trimethyl 5-aminovalerate (X-21365) levels,Linoleoylcarnitine (C18:2) levels,Serine levels (Biocrates platform),1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),Semaphorin-4F levels,"Indoleacetate-to-N2,N2-dimethylguanosine ratio",3-hydroxyoleoylcarnitine levels,Semaphorin-5A levels (SEMA5A.13132.14.3),Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Stearidonate 18:4n3 levels,Metabolite levels (dihomo-linoleoylcarnitine (C20:2)),1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Stearidonate (18:4n3) levels,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,Metabolite levels (5-HIAA/ MHPG Ratio),1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Semaphorin-4C levels,"N,N,N-trimethyl-5-aminovalerate levels"
Trimethyllysine (Reported Values: not provided by bevital),Plasma trimethyllysine levels,"N6,n6,n6-trimethyllysine levels","Hydroxy-N6,N6,N6-trimethyllysine levels",Metabolite levels (glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)),Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) levels,"Metabolite levels (N-6-trimethyllysine; N6,N6,N6-trimethyllysine; N6.N6.N6-trimethyllysine)","1,3,7-trimethylurate levels","4-androsten-3beta,17beta-diol monosulfate (2) levels",Plasma metabolome feature (hilic_1401) (N(6)-Methyllysine),Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Cholesteryl esters in IDL (UKB data field 23527),Plasma metabolome feature (hilic_1381) (N(6)-Methyllysine),"4-androsten-3beta,17beta-diol disulfate 2 levels",Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,"4-androsten-3beta,17beta-diol monosulfate (1) levels","4-androsten-3beta,17beta-diol disulfate (2) levels",Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,Sterol ester (27:1/14:0) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,Metabolite levels (N6-methyllysine),Sterol ester (27:1/16:0) levels,1-stearoyl-2-oleoyl-GPE (18:0/18:1) levels,Metabolite levels (oleoyl-oleoyl-glycerol (18:1/18:1)  [1]; C36:2 DAG; C36_2_DAG),Sterol ester (27:1/22:6) levels,Sterol ester (27:1/18:0) levels,"DHEA-S-to-4-androsten-3beta,17beta-diol disulfate 2 ratio",Sterol ester (27:1/17:0) levels,Sterol ester (27:1/18:2) levels,Metabolite levels (lactosyl-N-behenoyl-sphingosine (d18:1/22:0)),Sterol ester (27:1/20:4) levels,"5alpha-androstan-3beta,17beta-diol monosulfate (2) levels",Sterol ester (27:1/20:5) levels,Sterol ester (27:1/20:2) levels,Sterol ester (27:1/18:3) levels,"4-androsten-3beta,17beta-diol disulfate (1) levels",Metabolite levels (1-stearoyl-2-oleoyl-GPE (18:0/18:1); C36:1 PE),Stearoyl-arachidonoyl-glycerol (18:0/20:4) [1] levels,Sterol ester (27:1/20:3) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Metabolite levels (glycosyl-N-stearoyl-sphingosine (d18:1/18:0)),N6-methyllysine levels,Sterol ester (27:1/16:1) levels,Metabolite levels (5-hydroxylysine),Palmitoyl-oleoyl-glycerol (16:0/18:1) [2] levels,Triglycerides in IDL (UKB data field 23529),Sterol ester (27:1/18:1) levels,Metabolite levels (oleoyl-arachidonoyl-glycerol (18:1/20:4) [2]),"5alpha-androstan-3beta,17beta-diol monosulfate (1) levels",Plasma metabolome feature (c18_1550) (Bis(methylsulfonylmethyl) disulfide),1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels
Histidine (Reported Values: not provided by bevital),Histidine levels (UKB data field 23463),Histidine levels (Biocrates platform),Histidine levels,Histidine betaine (hercynine) levels,Histidine levels (Metabolon platform),Histidine levels in elite athletes,Metabolite levels (histidylvaline),Histidine meal response (LMM),Urate-to-histidine ratio,1-methylhistidine levels,Histidine-rich glycoprotein levels,Urine histidine levels in chronic kidney disease,N-acetyl-3-methylhistidine levels,N-acetyl-1-methylhistidine levels,Metabolite levels (1-methylhistidine),N-acetylhistidine levels,Metabolite levels (histidylleucine),Glutamine-to-histidine ratio,Metabolite levels (N-acetylhistidine),L-Histidine to Uric acid ratio in coronary artery disease,Histidine meal response (OrNLSr),Metabolite levels (N-acetyl-1-methylhistidine),Metabolite levels (N-acetyl-3-methylhistidine),Fasting histidine,Serum levels of protein HIST2H2BE,Histatin-1 levels (HTN1.10608.9.3),Gamma-glutamylhistidine levels,Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Histatin-3 levels,L-Histidine to 3-Indolepropionic acid ratio in coronary artery disease,Pseudouridine levels,"5,6-dihydrouridine (X-11429) levels",Histatin-1 levels,Cytidine levels,Serum levels of protein HIST3H2A,1-methylhistidine levels in elite athletes,Orotidine levels,"5,6-dihydrouridine levels",Metabolite levels (cytidine),Metabolite levels (histidylphenylalanine),3-methylhistidine levels in elite athletes,Dihydroceramide (d18:0/20:0) levels,Dihydroceramide (d18:0/22:0) levels,Dihydroceramide (d18:0/18:0) levels,Metabolite levels (orotidine),Dihydroceramide (d18:0/24:0) levels,Pseudouridine levels in elite athletes,Behenoylcarnitine (C22) levels,Metabolite levels (2'-O-methylcytidine),Myristoylcarnitine levels
Trimethylamine N-oxide (Reported Values: not provided by bevital),Trimethylamine n-oxide levels,Plasma trimethylamine N-oxide levels,Trimethylamine N-oxide levels in elite athletes,Trimethylamine levels,"Hydroxy-N6,N6,N6-trimethyllysine levels","N6,n6,n6-trimethyllysine levels",3-Indolepropionic acid to Trimethylamine N-oxide ratio in coronary artery disease,"1,3,7-trimethylurate levels",N-trimethyl 5-aminovalerate (X-21365) levels,"Metabolite levels (N-6-trimethyllysine; N6,N6,N6-trimethyllysine; N6.N6.N6-trimethyllysine)",Metabolite levels (glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)),"N,N,N-trimethyl-5-aminovalerate levels","Metabolite levels (N,N,N-trimethyl-5-aminovalerate; N-trimethyl 5-aminovalerate)",Plasma trimethyllysine levels,Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) levels,Tyramine O-sulfate levels,Metabolite levels (10-undecenoate (11:1n1)),Metabolite levels (lactosyl-N-behenoyl-sphingosine (d18:1/22:0)),Docosatrienoate (22:3n3) levels,3-methoxytyramine sulfate levels,Metabolite levels (5-acetylamino-6-formylamino-3-methyluracil),Stearidonate 18:4n3 levels,Metabolite levels (N-formylanthranilic acid),N-formylanthranilic acid levels,Metabolite levels (5-dodecenoate (12:1n7); 5-dodecenoate),Metabolite levels (stearidonate (18:4n3)),Metabolite levels (N-stearoyl-sphingosine (d18:1/18:0)),"Metabolite levels (oleoyl sphingomyelin; sphingomyelin (d18:1/18:1, d18:2/18:0); C18:1 SM; C18_1_SM)","1,3,7-trimethylurate levels in elite athletes",Metabolite levels (docosapentaenoate (n3 DPA; 22:5n3)),Metabolite levels (N-oxalyl glycine (NOG)),Docosatrienoate (22:3n6) levels,Metabolite levels (adrenate (22:4n6); adrenate),Metabolite levels (N-oleoyltaurine),Metabolite levels (3-methoxytyramine sulfate),N-stearoyl-sphingadienine (d18:2/18:0) levels,N-behenoyl-sphingadienine (d18:2/22:0) levels in elite athletes,Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),Metabolite levels (pregnenolone sulfate),Metabolite levels (glycosyl-N-stearoyl-sphingosine (d18:1/18:0)),Stearidonate (18:4n3) levels,N-oleoyltaurine levels,N-stearoyl-sphinganine (d18:0/18:0) levels,Metabolite levels (glycosyl-N-(2-hydroxynervonoyl)-sphingosine (d18:1/24:1(2OH))),Eicosapentaenoate EPA; 20:5n3 levels,Estrone 3-sulfate levels,"Metabolite levels (euricoyl sphingomyelin; sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1); C22:1 SM; C22_1_SM)",Sulfatide (d18:1/24:0(OH) levels) levels,5-acetylamino-6-formylamino-3-methyluracil levels,Docosapentaenoate n3 DPA; 22:5n3 levels
Creatine (Reported Values: not provided by bevital),Creatine levels,Metabolite levels (creatine),Behenoylcarnitine (C22) levels in elite athletes,Creatine levels in elite athletes,Creatine kinase M-type levels (CKM.2670.67.4),Creatinine levels (UKB data field 23478),Creatinine levels (UKB data field 30700),Eicosenoylcarnitine (C20:1) levels in elite athletes,Creatinine levels in elite athletes,Serum creatinine levels,Carnitine levels in elite athletes,Creatinine levels,Propionylcarnitine (C3) levels in elite athletes,Plasma behenoylcarnitine (C22)* levels in chronic kidney disease,Creatine kinase levels,Isovalerylcarnitine (C5) levels in elite athletes,Behenoylcarnitine (C22) levels,Decanoylcarnitine (C10) levels in elite athletes,Laurylcarnitine (C12) levels in elite athletes,Carnitine levels (Biocrates platform),Cerotoylcarnitine (C26) levels in elite athletes,Creatine kinase B-type levels,Hexanoylcarnitine (C6) levels in elite athletes,3-hydroxybutyrylcarnitine (2) levels in elite athletes,Creatine kinase levels in off-statin users,Cis-4-decenoylcarnitine (C10:1) levels in elite athletes,3-Indolepropionic acid to Creatine ratio in coronary artery disease,Octanoylcarnitine (C8) levels in elite athletes,Nervonoylcarnitine (C24:1) levels in elite athletes,C9 Carnitine levels in chronic kidney disease,3-hydroxybutyrylcarnitine (1) levels in elite athletes,Urinary creatinine levels,Propionylcarnitine levels (Biocrates platform),Dihomo-linolenoylcarnitine (20:3n3 or 6) levels in elite athletes,Linolenoylcarnitine (C18:3) levels in elite athletes,Ximenoylcarnitine (C26:1) levels in elite athletes,Cripto levels (serum),Linoleoylcarnitine (C18:2) levels in elite athletes,Hexanoylcarnitine levels (Biocrates platform),Adipoylcarnitine (C6-DC) levels in elite athletes,Isobutyrylcarnitine (C4) levels in elite athletes,Urinary potassium to creatinine ratio,Metabolite levels (nonanoylcarnitine (C9); C9 carnitine; C9_carnitine),Creatine kinase M-type:Creatine kinase B-type heterodimer levels,Docosahexaenoylcarnitine (C22:6) levels in elite athletes,Glutarylcarnitine (C5-DC) levels in elite athletes,Lignoceroylcarnitine (C24) levels in elite athletes,Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),Isovalerylcarnitine levels (Biocrates platform),CRTAM/LY9 protein level ratio
1-Methylhistidine (Reported Values: 2.7-7 µmol/L),1-methylhistidine levels,Metabolite levels (1-methylhistidine),N-acetyl-1-methylhistidine levels,Metabolite levels (N-acetyl-1-methylhistidine),N-acetyl-3-methylhistidine levels,Metabolite levels (N-acetyl-3-methylhistidine),Metabolite levels (N-acetylhistidine),Histidine levels (Biocrates platform),N-acetylhistidine levels,Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Metabolite levels (1-methylhistamine; _1_methylhistamine),1-methylhistidine levels in elite athletes,Histidine levels (UKB data field 23463),Histidine levels,Histidine levels (Metabolon platform),"5,6-dihydrouridine (X-11429) levels",3-methylhistidine levels in elite athletes,Urine 1-methylhistidine levels in chronic kidney disease,Metabolite levels (histidylvaline),Urate-to-histidine ratio,Gamma-glutamylhistidine levels,Metabolite levels (2'-O-methyluridine),Metabolite levels (3-methylcytidine),Metabolite levels (2'-O-methylcytidine),"5,6-dihydrouridine levels",Metabolite levels (1-methylurate),Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),2'-o-methyluridine levels,N-acetyl-1-methylhistidine levels in elite athletes,Metabolite levels (orotidine),Metabolite levels ((N(1) + N(8))-acetylspermidine),Metabolite levels (histidylleucine),Metabolite levels (ethylmalonate),Metabolite levels (myristoleate (14:1n5); myristoleic acid),1-methylnicotinamide levels,Metabolite levels (hypotaurine),5-methyluridine (ribothymidine) levels,Metabolite levels (N('1)-acetylspermidine; N1-acetylspermidine),Plasma metabolome feature (hilic_1928) ((3S)-3-Hydroxy-L-enduracididine),Metabolite levels (histidylphenylalanine),1-methylurate levels,Metabolite levels (2-aminoadipate; cmh_aminoadipate),N-acetyl-3-methylhistidine levels in elite athletes,Glutamine-to-histidine ratio,2'-o-methylcytidine levels,Tartronate (hydroxymalonate) levels,Metabolite levels (1-methylxanthine),Histidine betaine (hercynine) levels,Myristoleoylcarnitine (C14:1) levels,Metabolite levels (cytidine)
3-Methylhistidine (Reported Values: 0.7-14 µmol/L),Metabolite levels (1-methylhistidine),1-methylhistidine levels,N-acetyl-3-methylhistidine levels,Metabolite levels (N-acetyl-3-methylhistidine),N-acetyl-1-methylhistidine levels,Metabolite levels (N-acetyl-1-methylhistidine),Metabolite levels (N-acetylhistidine),Histidine levels (Biocrates platform),Histidine levels (UKB data field 23463),N-acetylhistidine levels,3-methylhistidine levels in elite athletes,Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Histidine levels (Metabolon platform),Histidine levels,"5,6-dihydrouridine (X-11429) levels",Metabolite levels (3-methylcytidine),Metabolite levels (1-methylhistamine; _1_methylhistamine),1-methylhistidine levels in elite athletes,3-methylcytidine levels,Metabolite levels (histidylvaline),Urate-to-histidine ratio,Metabolite levels (2'-O-methyluridine),Plasma metabolome feature (hilic_1928) ((3S)-3-Hydroxy-L-enduracididine),Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),"5,6-dihydrouridine levels",Metabolite levels (C18:3 CE; C18_3_CE),Metabolite levels (histidylleucine),Metabolite levels (orotidine),Metabolite levels (ethylmalonate),Metabolite levels (hypotaurine),N-acetyl-3-methylhistidine levels in elite athletes,Gamma-glutamylhistidine levels,Metabolite levels (2'-O-methylcytidine),2'-o-methyluridine levels,Metabolite levels (2-aminoadipate; cmh_aminoadipate),Metabolite levels (histidylphenylalanine),Metabolite levels ((N(1) + N(8))-acetylspermidine),5-methyluridine (ribothymidine) levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),"3,4-methyleneheptanoate levels",Metabolite levels (3-methoxytyramine sulfate),Urine 1-methylhistidine levels in chronic kidney disease,Metabolite levels (1-methylurate),Tartronate (hydroxymalonate) levels,Metabolite levels (cytidine),Metabolite levels  (X-11787),X-11593--O-methylascorbate levels,Histidine betaine (hercynine) levels,Methylmalonate (mma) levels,Metabolite levels (5-HIAA)
Pyridoxal 5'-phosphate (Reported Values: 17–102 nmol//L),Pyridoxal 5'-phosphate levels,Plasma pyridoxal phosphate to pyridoxal ratio,Plasma pyridoxal phosphate levels,Phosphate-to-erythronate ratio,Plasma pyridoxic acid to pyridoxal phosphate ratio,Pyridoxal phosphate phosphatase levels,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,Pyridoxate levels,RBC levels of Pyridoxamine 5'-phosphate,Phosphate levels,Phosphatidylinositol (18:0_22:5) (n6) levels,Pyridoxine-5-phosphate oxidase levels,Pyridoxal phosphate homeostasis protein levels,Pyridoxal levels,Cerebrospinal fluid pyridoxal phosphate levels,Phosphatidylinositol (18:0_22:5) (n3) levels,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,Phosphatidylinositol (18:0_20:3) (a) levels,Phosphatidylinositol (16:0_20:3) (a) levels,Phosphatidylinositol (20:0_20:4) levels,Phosphatidylinositol (18:0_22:6) levels,Serum phosphate levels,Phosphatidylinositol (18:0_22:4) levels,72 kDa inositol polyphosphate 5-phosphatase levels,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels,Metabolite levels (5-oxoproline; pyroglutamic_acid),Phosphatidylinositol (18:0_20:3) levels,Phosphatidylinositol (18:0_20:4) levels,1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels,Phosphatidylinositol (16:0_20:4) levels,Phosphatidylinositol(40:5)_[M-H]1- levels,Phosphatidylinositol-O(33:0)_[M-H]1- levels,Phosphatidylinositol(36:3)_[M-H]1- levels,Phosphatidylinositol(36:4)_[M-H]1- levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels,Phosphatidylinositol (18:0_20:2) levels,Phosphatidylinositol (18:1_20:4) levels,Phosphatidylinositol(38:6)_[M-H]1- levels,Phosphatidylinositol (38:5) (a) levels,"Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 levels",1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (p-16:0/22:6) levels,Phosphatidylinositol(40:6)_[M-H]1- levels,Phosphatidylinositol (15-MHDA_20:4) levels/Phosphatidylinositol (17:0_20:4) levels,Phosphatidylinositol(36:2)_[M-H]1- levels,1-(1-enyl-stearoyl)-2-oleoyl-GPC (p-18:0/18:1) levels,Phosphatidylinositol(38:4)_[M-H]1- levels,Phosphatidylinositol(36:0)_[M+OAc]1- levels,Phosphatidylinositol_36:2_[M+H]1+ levels,Phosphatidylinositol(35:2)_[M-H]1- levels,"Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 levels"
Pyridoxal (Reported Values: 6–28 nmol/L),Pyridoxal levels,Pyridoxate levels,RBC levels of Pyridoxal,Pyridoxal 5'-phosphate levels,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Pyridoxamine levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels,Plasma pyridoxal phosphate to pyridoxal ratio,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels (advanced age),Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-(1-enyl-stearoyl)-2-linoleoyl-GPC (p-18:0/18:2) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels,Plasma pyridoxal phosphate levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels,Plasma pyridoxic acid to pyridoxal phosphate ratio,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,1-(1-enyl-oleoyl)-GPC (p-18:1) levels,1-(1-enyl-stearoyl)-2-oleoyl-GPC (p-18:0/18:1) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) levels
4-Pyridoxic acid (Reported Values: 11–88 nmol/L),Plasma pyridoxic acid to pyridoxal phosphate ratio,Pyridoxate levels,Pyroglutamic acid levels,Pyridoxal levels,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,3-Indolepropionic acid to 4-Pyridoxic acid ratio in coronary artery disease,Pyridoxal 5'-phosphate levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels (advanced age),1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels,Plasma metabolome feature (c18_20) (Pyruvic acid),X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Plasma metabolome feature (c18_343) (Pyrrolidonecarboxylic acid),Pyridoxamine levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels,4-acetamidophenol levels,X-11315-to-pyroglutamine ratio,Plasma metabolome feature (hilic_1348) (3-Pyridylacetic acid),1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (p-16:0/22:6) levels,Butyric acid levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Metabolite levels (5-oxoproline; pyroglutamic_acid),1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) levels,Phosphatidylcholine_37:6_[M+H]1+/Phosphatidylethanolamine_40:6_[M+H]1+/Phosphatidate_42:7_[M+NH4]1+ levels,Plasma pyridoxal phosphate levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Phosphatidylcholine_37:5_[M+H]1+/Phosphatidylethanolamine_40:5_[M+H]1+/Phosphatidate_42:6_[M+NH4]1+ levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (p-16:0/20:4) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,Phosphatidylcholine_34:0_[M+H]1+/Phosphatidylethanolamine_37:0_[M+H]1+/Phosphatidate_39:1_[M+NH4]1+ levels,Phosphatidylcholine_37:4_[M+H]1+/Phosphatidylethanolamine_40:4_[M+H]1+/Phosphatidate_42:5_[M+NH4]1+ levels,Metabolite levels (1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1)),Phosphatidylcholine_34:4_[M+H]1+/Phosphatidylethanolamine_37:4_[M+H]1+/Phosphatidate_39:5_[M+NH4]1+ levels,Phosphatidylcholine_35:6_[M+H]1+/Phosphatidylethanolamine_38:6_[M+H]1+/Phosphatidate_40:7_[M+NH4]1+ levels,Phosphatidylcholine_34:3_[M+H]1+/Phosphatidylethanolamine_37:3_[M+H]1+/Phosphatidate_39:4_[M+NH4]1+ levels,Phosphatidylcholine_32:0_[M+H]1+/Phosphatidylethanolamine_35:0_[M+H]1+/Phosphatidate_37:1_[M+NH4]1+ levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Phosphatidylcholine_36:5_[M+H]1+/Phosphatidylethanolamine_39:5_[M+H]1+/Phosphatidate_41:6_[M+NH4]1+ levels,Phosphatidylcholine_33:4_[M+H]1+/Phosphatidylethanolamine_36:4_[M+H]1+/Phosphatidate_38:5_[M+NH4]1+ levels,Phosphatidylcholine_34:2_[M+H]1+/Phosphatidylethanolamine_37:2_[M+H]1+/Phosphatidate_39:3_[M+NH4]1+ levels,Metabolite levels (1-myristoyl-2-arachidonoyl-GPC (14:0/20:4); C34:4 PC; C34_4_PC),Plasma pyridoxal phosphate to pyridoxal ratio
Pyridoxine (Reported Values: not provided by bevital),Pyridoxal levels,Pyridoxate levels,Pyridoxate levels in elite athletes,Pyridoxamine levels,RBC levels of Pyridoxal,Pyridoxine-5-phosphate oxidase levels,Plasma pyridoxic acid to pyridoxal phosphate ratio,RBC levels of Pyridoxamine,Pyridoxal levels in elite athletes,Calnexin levels (CANX.8834.58.3),Plasma pyridoxal phosphate levels,Cerebrospinal fluid pyridoxal phosphate levels,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,Plasma metabolome feature (c18_343) (Pyrrolidonecarboxylic acid),Plasma pyridoxal phosphate to pyridoxal ratio,Behenoylcarnitine (C22) levels,2-pyrrolidinone levels in elite athletes,Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) levels,Pyruvate levels (UKB data field 23472),Urine pyridoxal levels in chronic kidney disease,Metabolite levels (S-1-pyrroline-5-carboxylate),Plasma metabolome feature (c18_20) (Pyruvic acid),Behenoylcarnitine (C22) levels in elite athletes,Pyridoxal 5'-phosphate levels,Behenoyl dihydrosphingomyelin (d18:0/22:0) levels,Sulfiredoxin-1 levels,tricyclic pyrone compound response (IC50),Eotaxin levels (CCL11.5301.7.3),X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Radixin levels,Pyrraline levels in elite athletes,RBC levels of Pyridoxamine 5'-phosphate,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Metabolite levels (Pyroglutamine),Calnexin levels,Metabolite levels (glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)),"Metabolite levels (sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0))",Treatment or medication use - glyceryl trinitrate (UKB data field 20003_1140860834),S-1-pyrroline-5-carboxylate levels,Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),Dixin levels,"Metabolite levels (sphingomyelin (d18:1/17:0, d17:1/18:0, d19:1/16:0))","Metabolite levels (sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0))","Metabolite levels (sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0))",Metabolite levels (1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)),Sulfiredoxin-1 levels (SRXN1.14268.4.3),Pyridoxal kinase levels (PDXK.11098.1.3),Metabolite levels (erythritol),Neuropilin-2 levels (NRP2.6590.54.3),Butyrylcarnitine levels (Biocrates platform)
Thiamine (Reported Values: 7–16 nmol/L),Thiamine-triphosphatase levels,Thioproline levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),Vitamin levels,Threonate levels,Metabolite levels (threonylphenylalanine),Thiamin pyrophosphokinase 1 levels,Metabolite levels (ethylmalonate),Metabolite levels (erythronate; erythronate/threonate),Myristoleoylcarnitine levels,Metabolite levels (threonine),Triiodothyronine levels,Metabolite levels (ergothioneine),Methylmalonate (mma) levels,Myristoylcarnitine levels,Ethylmalonate levels,Metabolite levels  (X-11787),Metabolite levels (NMMA),Sodium levels,Gamma-glutamylhistidine levels,Metabolite levels (hypotaurine),Trigonelline (n'-methylnicotinate) levels,Protein MENT levels (MENT.5744.12.3),Ergothioneine levels,Metabolite levels (serine),MME/NT5E protein level ratio,Metabolite levels (1-methylhistidine),(S)-a-amino-omega-caprolactam levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-methylhistidine levels,Threonylphenylalanine levels,Mannonate levels,Threonine levels (Biocrates platform),Metabolite levels (arginine),Metabolite levels (lysine),"5,6-dihydrouridine (X-11429) levels",Thioredoxin levels,Metabolite levels (2-aminoadipate; cmh_aminoadipate),Metabolite levels (malate; cmh_malate; Malate),Free triiodothyronine (T3) levels,Metabolite levels (adrenate (22:4n6); adrenate),Vitrin levels (VIT.6234.74.3),Metabolite levels (valine),Plasma metabolome feature (hilic_901) (Dimethylphenylenediamine),Arginine levels (Biocrates platform),Urinary electrolytes (magnesium/calcium ratio),Urate-to-histidine ratio,Metabolite levels (thyroxine),Metabolite levels (N-acetylhistidine),"N,N,N-trimethyl-5-aminovalerate levels"
Thiamine monophosphate (Reported Values: 1–3 nmol/L),Thiamine-triphosphatase levels,Thiamin pyrophosphokinase 1 levels,Phosphate levels,Serum phosphate levels,Phosphorus levels,Phosphate-to-erythronate ratio,THPO protein levels,ESAM/THPO protein level ratio,Protein MENT levels (MENT.5744.12.3),Metabolite levels (myristoleate (14:1n5); myristoleic acid),Thymol sulfate levels,Thioproline levels,"2,3-dihydroxy-5-methylthio-4-pentenoate (DMTPA) (X-11564) levels",Metabolite levels (threonylphenylalanine),Phosphatidylinositol (18:0_22:5) (n3) levels,72 kDa inositol polyphosphate 5-phosphatase levels,HNMT/SETMAR protein level ratio,"2,3-dihydroxy-5-methylthio-4-pentenoate (dmtpa) levels",Serum levels of protein THPO,THP plasma levels,Threonate levels,Metabolite levels (ethylmalonate),Metabolite levels (NMMA),Methylthioribose-1-phosphate isomerase levels,2-hydroxy-4-(methylthio)butanoic acid levels,Myristoleoylcarnitine levels,S-methyl-5-thioadenosine phosphorylase levels,Metabolite levels (sulfate),Methylmalonate (mma) levels,Triosephosphate isomerase levels (TPI1.4309.59.3),Mannonate levels,MAVS/TDRKH protein level ratio,MME/NT5E protein level ratio,AHSP/HMBS protein level ratio,Phosphatidylinositol (18:0_22:5) (n6) levels,Urinary electrolytes (magnesium/calcium ratio),Threonylphenylalanine levels,Phosphatidylinositol (18:0_22:6) levels,Thymidine phosphorylase levels,Metabolite levels (urate; cmh_urate; Uric_acid),"Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 levels",ITGA6/THPO protein level ratio,Phosphatidylinositol (18:0_22:4) levels,Metabolite levels (erythronate; erythronate/threonate),"Type II inositol 1,4,5-trisphosphate 5-phosphatase levels",Metabolite levels  (X-11787),Metabolite levels (malate; cmh_malate; Malate),Ethylmalonate levels,Phosphorus intake,Choline phosphate levels
Riboflavin (Reported Values: 5–38 nmol/L),Riboflavin kinase levels (RFK.13059.33.3),Riboflavin kinase levels,Metabolite levels (ribitol),Ribitol levels,Metabolite levels (ribose),Riboflavin to 3-Indolepropionic acid ratio in coronary artery disease,Ribonate levels,Ribulonate/xylulonate/lyxonate levels,Ribothymidine levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Nucleolin levels (NCL.13655.34.3),Ribonate levels in elite athletes,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] levels,Metabolite levels (dihomo-linolenate (20:3n3 or n6); eicosatrienoate),Ribitol levels in elite athletes,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Metabolite levels (isoleucylvaline),Linoleoylcarnitine levels,5-methyluridine (ribothymidine) levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [1] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Urine ribonate levels in chronic kidney disease,Metabolite levels (linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]; C36:4 DAG),Metabolite levels (1-stearoyl-2-linoleoyl-GPI (18:0/18:2); C36:2 PI),Metabolite levels (linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2]),40S ribosomal protein SA levels (RPSA.4957.1.2),Ribose-5-phosphate isomerase levels (RPIA.12333.87.3),60S ribosomal protein L14 levels,Metabolite levels (biliverdin),Metabolite levels (linoleoyl ethanolamide),"Metabolite levels (4-androsten-3alpha,17alpha-diol monosulfate (3); androstenediol (3alpha, 17alpha) monosulfate (3))",Metabolite levels (linolenoylcarnitine (C18:3)),Metabolite levels (1-linoleoyl-GPG (18:2)),Metabolite levels (linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1]),Metabolite levels (1-linoleoyl-2-linolenoyl-GPC (18:2/18:3)),Metabolite levels (dihomo-linoleoylcarnitine (C20:2)),60S ribosomal protein L12 levels,Metabolite levels (oleoyl-linoleoyl-glycerol (18:1/18:2) [2]),60S ribosomal protein L30 levels (RPL30.12478.15.3),"Metabolite levels (4-androsten-3alpha,17alpha-diol monosulfate (2); androstenediol (3alpha, 17alpha) monosulfate (2))"
Flavin mononucleotide (Reported Values: 3–13 nmol/L),Flavin adenine dinucleotide (FAD) levels,Flavin reductase levels,Nucleolin levels (NCL.13655.34.3),Serum levels of protein FLNA,Vitrin levels (VIT.6234.74.3),Palmitoleic acid (16:1n-7) levels,Ficolin-1 levels (FCN1.3613.62.5),Ficolin-2 levels (FCN2.3313.21.2),Flavonifractor sp002159265 abundance in stool,"N,N,N-trimethyl-5-aminovalerate levels",Plasmin levels (PLG.4150.75.2),Flavonifractor sp900199495 abundance in stool,Filamin-A levels (FLNA.11124.9.3),MLN/TNFRSF12A protein level ratio,rRNA 2-O-methyltransferase fibrillarin levels,Serum levels of protein FLRT1,FLT3/FLT3LG protein level ratio,Fumarylacetoacetase levels (FAH.11424.4.3),N-trimethyl 5-aminovalerate (X-21365) levels,Mucin-16 levels,Triacylglycerol_52:5_[M+NH4]1+ levels,ADpSGEGDFXAEGGGVR-to-X-14304--leucylalanine ratio,Triacylglycerol_53:5_[M+NH4]1+ levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Pirin levels (PIR.13634.209.3),Nucleobindin-1 levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Triacylglycerol_52:6_[M+NH4]1+ levels,Triacylglycerol_46:5_[M+NH4]1+ levels,RBC levels of FA 16:1n7,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,X-14189--leucylalanine levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,3-carboxy-4-methyl-5-propyl-2-furanpropanoate (cmpf) levels,Leiomodin-1 levels (LMOD1:P29536:OID31416:v1),Triacylglycerol_56:5_[M+NH4]1+ levels,Triacylglycerol_52:1_[M+NH4]1+ levels,DNA-3-methyladenine glycosylase levels (MPG.12438.127.3),5-acetylamino-6-amino-3-methyluracil levels,Flt3L levels,Triacylglycerol(52:5)_[M+NH4]1+ levels,Lipase member N levels (LIPN.8097.77.3),Plasma metabolome feature (c18_713) (Quinolinic acid),Laminin levels (LAMA1.LAMB1.LAMC1.2728.62.2),Leucine-rich repeat transmembrane protein FLRT3 levels (FLRT3.13123.3.3),Triacylglycerol(53:2)_[M+NH4]1+ levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Leiomodin-1 levels (LMOD1:P29536:OID31014:v1),Serum levels of protein FLRT3,Triacylglycerol_51:2_[M+NH4]1+ levels
Neopterin (Reported Values: <20 nmol/L),Urine neopterin levels in chronic kidney disease,Serum levels of protein NEO1,Neogenin levels (NEO1.8900.28.3),Progonadoliberin-1 levels (GNRH1.5627.53.3),Progonadoliberin-2 levels (GNRH2.10708.3.3),Serum levels of protein NCMAP,Serum levels of protein NPPA,Serum levels of protein NMRAL1,Serum levels of protein NTM,Serum levels of protein NPPB,Serum levels of protein NT5C,Serum levels of protein NAGPA,Serum levels of protein NUP210,Dihydrobiopterin levels,Serum levels of protein NEURL4,Promotilin levels (MLN.5631.83.3),Serum levels of protein NPNT,Neuropilin-2 levels (NRP2.6590.54.3),Nucleolin levels (NCL.13655.34.3),Ena/VASP-like protein levels (EVL.11656.110.3),Neudesin levels,Neogenin levels,Prolargin levels (PRELP.5675.6.3),Progonadoliberin-1 levels,Protocadherin-17 levels,Lymphotactin levels (XCL1.14078.69.3),Metabolite levels (N-acetyltryptophan),Serum levels of protein CNTNAP5,Serum levels of protein NPTXR,Serum levels of protein TEX29,Serum levels of protein NME2,Neurexin-3 levels,Serum levels of protein CNP,Serum levels of protein NPW,Serum levels of protein GNMT,Serum levels of protein NME1,Protocadherin-9 levels,Uncharacterized protein KIAA0040 levels (KIAA0040.14603.51.3),Serum levels of protein NDNF,Kallistatin levels (SERPINA4.3449.58.2),Serum levels of protein NPIPB3,Serum levels of protein NAPB,Serum levels of protein NMB,Serum levels of protein RNPEP,Serum levels of protein HINT2,Serum levels of protein LOC652493,Lactadherin levels (MFGE8.4455.89.2),Aminopeptidase N levels,NT5E protein levels,Serum levels of protein TXNIP
Cotinine (Reported Values: not provided by bevital),Behenoylcarnitine (C22) levels,Cotinine levels in current smokers,Cotinine glucuronidation,Cotinine levels in smokers with chronic obstructive pulmonary disease,Smoking intensity (cotinine levels/cigarettes per day),Serum levels of protein COTL1,Plasma behenoylcarnitine (C22)* levels in chronic kidney disease,Tetradecenoylcarnitine levels,Isovalerylcarnitine levels (Biocrates platform),Treatment or medication use - glyceryl trinitrate (UKB data field 20003_1140860834),Propionylcarnitine levels (Biocrates platform),Cotinine and 3'-hydroxycotinine levels in current smokers,"X-12442--5,8-tetradecadienoate levels",Behenoylcarnitine (C22) levels in elite athletes,Kit ligand levels (KITLG.9377.25.3),Tetradecanedioate levels,X-13431--nonanoylcarnitine levels,Metabolite levels (pregnenetriol disulfate),Undecenoylcarnitine (c11:1) (X-17337) levels,Trigonelline (n'-methylnicotinate) levels,Tetradecadienylcarnitine levels,Cerotoylcarnitine (C26) levels,Calnexin levels (CANX.8834.58.3),Nervonoylcarnitine (C24:1) levels,Arecaidine levels,Isovalerylcarnitine levels (Metabolon platform),Metabolite levels (C18:3 CE; C18_3_CE),Tetradecanoylcarnitine levels,"Cis-3,4-methyleneheptanoylcarnitine levels",Oleoylcarnitine levels (Biocrates platform),2-tetradecenoyl carnitine levels (Biocrates platform),Tetradecadienoate (14:2) (X-12442) levels,Transcobalamin-2 levels (TCN2.5584.21.3),Butyrylcarnitine levels (Biocrates platform),Hexanoylcarnitine levels (Biocrates platform),Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),Metabolite levels (C16:0 CE; C16_0_CE),Hexadecenoylcarnitine levels,Docosapentaenoylcarnitine (C22:5n3) levels,Metabolite levels (glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)),Calbindin levels (CALB1.9918.23.3),Metabolite levels (tetradecanedioate; tetradecanedioate (C14-DC)),Metabolite levels (pregnenetriol sulfate),Beclin-1 levels,Metabolite levels (arachidonoylcarnitine (C20:4)),Isovalerylcarnitine levels,Metabolite levels (indoleacetoylcarnitine),Metabolite levels (C20:4 CE; C20_4_CE),Metabolite levels (C38:2 PC; C38_2_PC),Brorin levels (VWC2.11121.56.3)
Trans-3'-hydroxycotinine (Reported Values: not provided by bevital),Hydroxycotinine levels,Metabolite levels (hydroxycotinine),Metabolite levels (glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)),3-hydroxycotinine glucuronide levels,Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) levels,Hydroxy-cmpf (X-02269) levels,3-hydroxyadipate levels,Plasma metabolome feature (c18_3925) ((5Z7E)-(3S)-262626272727-hexafluoro-910-seco-5710(19)16-cholestatetraen-23-yne-325-diol),Metabolite levels (trans-2-hexenoylglycine),X-12441--12-hydroxyeicosatetraenoate 12-HETE levels,Plasma metabolome feature (hilic_5246) ((5Z7E)-(3S)-262626-trifluoro-27-nor-910-seco-5710(19)-cholestatriene-325-diol),Trans-4-hydroxyproline levels,Metabolite levels (glycosyl-N-(2-hydroxynervonoyl)-sphingosine (d18:1/24:1(2OH))),Glycosyl-N-tricosanoyl-sphingadienine (d18:2/23:0) levels,1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4) levels,Metabolite levels (1-stearoyl-2-arachidonoyl-GPI (18:0/20:4); C38:4 PI),trans-Hydroxyproline levels,Metabolite levels (3-hydroxybutyroylglycine),Metabolite levels (trans-4-hydroxyproline; hydroxyproline; cis_trans_hydroxyproline),Metabolite levels (1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6)),Plasma metabolome feature (c18_2759) (24-Dihydroxy-46-dimethoxy-3-prenylchalcone),Metabolite levels (3-hydroxyhexanoate),Plasma metabolome feature (hilic_1928) ((3S)-3-Hydroxy-L-enduracididine),Triacylglyceroloxid(53:3)_[M+NH4]1+ levels,Metabolite levels (1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4); C36:4 PI),1-palmitoyl-2-docosahexaenoyl-gpc (16:0/22:6) levels,Metabolite levels (3-hydroxydecanoate),1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels,Metabolite levels (1-stearoyl-2-oleoyl-GPI (18:0/18:1)),Metabolite levels (1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6); C38:6 PC; C38_6_PC),Metabolite levels (lactosyl-N-behenoyl-sphingosine (d18:1/22:0)),2-hydroxyadipate levels,1-palmitoyl-2-oleoyl-GPI (16:0/18:1) levels,Metabolite levels (1-palmitoyl-2-docosahexaenoyl-GPE (16:0/22:6)),3-hydroxydecanoate levels,Behenoylcarnitine (C22) levels,Metabolite levels (C18:3 CE; C18_3_CE),Metabolite levels (3-hydroxyoctanoate),Metabolite levels (1-palmitoyl-2-oleoyl-GPI (16:0/18:1); C34:1 PI),Metabolite levels (glycosyl-N-stearoyl-sphingosine (d18:1/18:0)),Plasma metabolome feature (c18_4546) (4-Hydroxyanigorootin),1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4) levels,1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6) levels,Monohexosylceramide (d18:2/22:0) levels,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) levels,3-hydroxyoctanoate levels,Plasma metabolome feature (hilic_4522) (3 5-Tetradecadiencarnitine),Monohexosylceramide (d18:2/24:0) levels,Metabolite levels  (X-11787),Plasma metabolome feature (hilic_4401) (Deacetylcolchicine)
Tryptophan (Reported Values: 43-89 µmol/L),Tryptophan levels,Tryptophan levels (Biocrates platform),N-acetyl-d-tryptophan levels,Metabolite levels (tryptophan),Tryptophan levels (Metabolon platform),Tryptophan levels in elite athletes,Plasma metabolome feature (hilic_2249) (L-Tryptophan),Metabolite levels (tryptophan betaine),Tryptophan betaine  levels,Tryptophan betaine levels,N-acetyltryptophan levels,Phenylalanyltryptophan levels,Gamma-glutamyltryptophan levels,Metabolite levels (N-acetyltryptophan),X-12100--hydroxytryptophan levels,C-glycosyltryptophan levels,"Tryptophan 2,3-dioxygenase levels",Gut bacterial pathway abundance (TRPSYN.PWY..L.tryptophan.biosynthesis),Tryptophan betaine levels in elite athletes,Urine tryptophan levels in chronic kidney disease,Metabolite levels (glycyltryptophan),5-bromotryptophan levels,Metabolite levels (5-bromotryptophan),"X-04499--3,4-dihydroxybutyrate-to-C-glycosyltryptophan ratio",6-bromotryptophan levels,N-acetyltryptophan levels in elite athletes,Metabolite levels (6-bromotryptophan),Tryptase gamma levels (TPSG1.14103.12.3),Tryptase alpha/beta-1 levels,Gamma-glutamyltryptophan levels in elite athletes,C-glycosyltryptophan-to-succinylcarnitine ratio,Plasma tryptophan betaine levels in chronic kidney disease,N-acetylphenylalanine levels,Tryptase beta-1 levels,Alkylphosphatidylethanolamine (O-18:0/22:5) levels,Alkylphosphatidylethanolamine (O-16:0/20:3) levels,Alkylphosphatidylethanolamine (O-18:0/22:6) levels,Alkylphosphatidylethanolamine (O-16:0/22:6) levels,Metabolite levels (histidylphenylalanine),Trypsin-3 levels,ADpSGEGDFXAEGGGVR-to-X-14304--leucylalanine ratio,Alkylphosphatidylethanolamine (O-18:0/20:4) levels,Alkylphosphatidylethanolamine (O-16:0/22:4) levels,X-12798-to-phenylalanine ratio,5-bromotryptophan levels in elite athletes,Metabolite levels (threonylphenylalanine),Metabolite levels (aspartylphenylalanine),Metabolite levels (tryptophylasparagine),Phosphatidylethanolamine (17:0_22:6) levels,Alkylphosphatidylethanolamine (O-38:5) (a) levels
Kynurenine (Reported Values: 1.0-2.9 µmol/L),Kynurenate levels,Kynurenine levels,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Kynureninase levels (KYNU.4559.64.2),Kynureninase levels,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),Plasma metabolome feature (hilic_2278) (Kynurenine),Kynurenine levels in elite athletes,Kynurenate levels in elite athletes,N-acetylkynurenine (2) levels,Kynurenine--oxoglutarate transaminase 3 levels (CCBL2.12682.5.3),Urine kynurenine levels in chronic kidney disease,KYNU level (plasma),X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,Plasma kynurenine levels in chronic kidney disease,Kynurenine--oxoglutarate transaminase 3 levels,Urine kynurenate levels in chronic kidney disease,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Kynurenine--oxoglutarate transaminase 1 levels,Metabolite levels (N-acetylkynurenine (2)),Kynurenine-oxoglutarate transaminase 1 levels,X-12798-to-phenylalanine ratio,Plasma kynurenate levels in chronic kidney disease,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,N-acetyl-isoputreanine (X-12688) levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Plasma kynurenine levels in major depressive disorder,Myristoleoylcarnitine (C14:1) levels,Myristoylcarnitine (C14) levels,Urinary potassium to creatinine ratio,N-acetyl-isoputreanine levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Nervonoylcarnitine (C24:1) levels,N-acetylmethionine levels,Undecenoylcarnitine (c11:1) (X-17337) levels,X-11315-to-pyroglutamine ratio,Kallistatin levels (SERPINA4.3449.58.2),Margaroylcarnitine (C17) levels,"5,6-dihydrouridine (X-11429) levels",X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Stearidonate 18:4n3 levels,Stearidonate (18:4n3) levels,Arginine levels (Biocrates platform),Alanine levels (UKB data field 23460),ADH4/KYNU protein level ratio,Octadecadienylcarnitine levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels
3-Hydroxykynurenine (Reported Values: 10-65 nmol/L),Plasma metabolome feature (hilic_2278) (Kynurenine),Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Kynurenine levels,Kynurenate levels,Kynureninase levels (KYNU.4559.64.2),Urine 3-hydroxykynurenine levels in chronic kidney disease,Stearidonate 18:4n3 levels,Stearidonate (18:4n3) levels,"X-04499--3,4-dihydroxybutyrate levels",N-acetylkynurenine (2) levels,1-stearoyl-2-dihomo-linolenoyl-GPC (18:0/20:3n3 or 6) levels,3-hydroxyoleoylcarnitine levels,4-hydroxyphenylacetoylcarnitine levels,X-12244--N-acetylcarnosine levels,3-hydroxyhexanoylcarnitine (1) levels,"N,n-dimethylalanine (X-23585) levels",3-hydroxyhexanoate levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Docosatrienoate (22:3n3) levels,N-trimethyl 5-aminovalerate (X-21365) levels,1-stearoyl-2-meadoyl-GPC (18:0/20:3n9) levels,3-hydroxyoctanoylcarnitine (1) levels,"X-12442--5,8-tetradecadienoate levels",3-hydroxyoctanoylcarnitine (2) levels,3-hydroxyoleate levels,3-hydroxylaurate levels,Kynureninase levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) levels,1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6) levels,1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels,Metabolite levels (3-hydroxyhexanoate),"Hydroxy-N6,N6,N6-trimethyllysine levels",Plasma metabolome feature (hilic_3740) (N-Acetyldehydroanonaine),3-hydroxybutyrate levels (UKB data field 23474),"N,N,N-trimethyl-5-aminovalerate levels",Plasma metabolome feature (hilic_5246) ((5Z7E)-(3S)-262626-trifluoro-27-nor-910-seco-5710(19)-cholestatriene-325-diol),3-hydroxyadipate levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,Docosatrienoate (22:3n6) levels,Triacylglyceroloxid(53:3)_[M+NH4]1+ levels,Metabolite levels (N-acetylkynurenine (2)),1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) levels,Plasma metabolome feature (c18_3925) ((5Z7E)-(3S)-262626272727-hexafluoro-910-seco-5710(19)16-cholestatetraen-23-yne-325-diol),X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,"3,4-methyleneheptanoate levels",Hexadecenoylcarnitine levels,Metabolite levels (3-hydroxylaurate)
Xanthurenic acid (Reported Values: 5-35 nmol/L),Xanthurenate levels,Metabolite levels (xanthurenate; cmh_xanthurenate; Xanthurenate),X-12510--2-aminooctanoic acid levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Vaccenic acid (18:1n-7) levels,Gondoic acid (20:1n-9) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,"X-12442--5,8-tetradecadienoate levels",Docosahexaenoic acid (22:6) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Metabolite levels (xanthosine; Xanthosine),Ribulonate/xylulonate/lyxonate levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Xanthurenate levels in elite athletes,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Urine xanthurenate levels in chronic kidney disease,1-margaroyl-2-arachidonoyl-GPC (17:0/20:4) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,"2,6-dihydroxybenzoic acid (X-09789) levels",X-11593--O-methylascorbate levels,"N,n-dimethylalanine (X-23585) levels",1-arachidoyl-2-arachidonoyl-GPC (20:0/20:4) levels,Xanthosine levels,Oleic acid (18:1n-9) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,X-12798-to-phenylalanine ratio,2-o-methylascorbic acid levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,Plasma xanthurenate levels in chronic kidney disease,Linoleic acid (18:2) levels,Docosahexaenoic acid levels (UKB data field 23450),Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-arachidonoyl-gpc (20:4n6) levels,Xanthine levels,1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels
Anthranilic acid (Reported Values: 7-30 nmol/L),N-formylanthranilic acid levels,Metabolite levels (N-formylanthranilic acid),2-o-methylascorbic acid levels,2-hydroxy-4-(methylthio)butanoic acid levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,Vaccenic acid (18:1n-7) levels,Metabolite levels (acisoga),Stearic acid (18:0) levels,"2,6-dihydroxybenzoic acid (X-09789) levels",Succinic acid/Methylmalonic acid levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,Metabolite levels (arachidonate (20:4n6); arachidonate),N-acetylaspartic acid levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),FFA Arachidonic Acid a levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Metabolite levels (1-myristoyl-2-arachidonoyl-GPC (14:0/20:4); C34:4 PC; C34_4_PC),Metabolite levels (docosapentaenoate (n6 DPA; 22:5n6); docosapentaenoate),Metabolite levels (docosapentaenoate (n3 DPA; 22:5n3)),Oxaloacetic acid levels,"N,n-dimethylalanine (X-23585) levels",Oleic acid (18:1n-9) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,Docosahexaenoic acid (22:6) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Metabolite levels (arabinose),1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Metabolite levels (ethylmalonate),1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,FFA Arachidonic Acid c levels,X-11593--O-methylascorbate levels,N-acetyl-L-glutamic acid levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Metabolite levels (Dihydroxy docosatrienoic acid),Metabolite levels (docosahexaenoate (DHA; 22:6n3); docosahexaenoate),1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Metabolite levels  (X-11787),Dihydroxydocosapentaenoic acid levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Gondoic acid (20:1n-9) levels,Metabolite levels (eicosapentaenoate (EPA; 20:5n3); eicosapentaenoate),1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels,Metabolite levels (1-stearoyl-2-arachidonoyl-GPI (18:0/20:4); C38:4 PI)
3-Hydroxyanthranilic acid (Reported Values: 7-50 nmol/L),3-hydroxyhippurate levels,N-formylanthranilic acid levels,2-hydroxy-4-(methylthio)butanoic acid levels,Metabolite levels (N-formylanthranilic acid),3-hydroxyoleate levels,Metabolite levels (3-hydroxyhexanoate),3-hydroxyhexanoate levels,2-o-methylascorbic acid levels,"3-hydroxyanthranilate 3,4-dioxygenase levels (HAAO.5861.78.3)","3-hydroxyanthranilate 3,4-dioxygenase levels",3-hydroxyadipate levels,Docosahexaenoic acid (22:6) levels,3b-hydroxy-5-cholenoic acid levels,Metabolite levels (5-HIAA),"3,4-methyleneheptanoate levels",3-hydroxy-5-cholestenoic acid levels,Triacylglycerol_58:10_[M+NH4]1+ levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,Metabolite levels (5-HIAA/ MHPG Ratio),2-hydroxyhippurate (salicylurate) levels,Metabolite levels (HVA/5-HIAA ratio),Triacylglycerol_51:3_[M+NH4]1+ levels,Metabolite levels (3b-hydroxy-5-cholenoic acid),Triacylglycerol(50:3)_[M+NH4]1+ levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,Metabolite levels (docosahexaenoate (DHA; 22:6n3); docosahexaenoate),Docosahexaenoic acid levels (UKB data field 23450),Triacylglycerol_52:3_[M+NH4]1+ levels,Triacylglycerol_58:9_[M+NH4]1+ levels,4-hydroxyphenylacetoylcarnitine levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Triacylglycerol(51:3)_[M+NH4]1+ levels,Docosahexaenoate (DHA; 22:6n3) levels,Triacylglycerol_50:3_[M+NH4]1+ levels,Triacylglycerol_58:8_[M+NH4]1+ levels,3-hydroxydecanoate levels,Triacylglycerol(50:4)_[M+NH4]1+ levels,Triacylglycerol_53:3_[M+NH4]1+ levels,Triacylglycerol_48:3_[M+NH4]1+ levels,Triacylglycerol(50:2)_[M+NH4]1+ levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,3-hydroxyhippurate levels in elite athletes,Triacylglycerol_52:5_[M+NH4]1+ levels,Triacylglycerol(53:3)_[M+NH4]1+ levels,3-hydroxyoleoylcarnitine levels,3-(3-hydroxyphenyl)propionate levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,Triacylglycerol(58:9)_[M+NH4]1+ levels,Triacylglycerol_58:7_[M+NH4]1+ levels
Picolinic acid (Reported Values: 90-370nmol/L),Picolinate levels,Metabolite levels (picolinate),Picolinoylglycine (X-12170) levels,Picolinoylglycine levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Linoleic acid (18:2) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Gondoic acid (20:1n-9) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Vaccenic acid (18:1n-7) levels,Oxaloacetic acid levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Stearic acid (18:0) levels,X-12510--2-aminooctanoic acid levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Butyric acid levels,"3,5-dichloro-2,6-dihydroxybenzoic acid levels",1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,"X-12442--5,8-tetradecadienoate levels",Oleic acid (18:1n-9) levels,Caprylic acid levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,Linoleoylcarnitine (C18:2) levels,"2,6-dihydroxybenzoic acid (X-09789) levels",1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,Palmitic acid (16:0) levels,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,3-Indolepropionic acid to 2-Picolinic acid ratio in coronary artery disease,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Lithocholate sulfate (1) (X-17469) levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Linoleic acid levels,"3-bromo-5-chloro-2,6-dihydroxybenzoic acid levels",1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Docosahexaenoic acid (22:6) levels,Succinic acid/Methylmalonic acid levels,Decadienedioic acid (C10:2-DC) levels,Acetylcarnitine levels (Biocrates platform)
Quinolinic acid (Reported Values: 134-384 nmol/L),Plasma metabolome feature (c18_713) (Quinolinic acid),Quinolinate levels,Quinate levels,X-12510--2-aminooctanoic acid levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,"X-12442--5,8-tetradecadienoate levels",1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,X-12798-to-phenylalanine ratio,X-13431--nonanoylcarnitine levels,Gondoic acid (20:1n-9) levels,Kynureninase levels (KYNU.4559.64.2),Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,"N,n-dimethylalanine (X-23585) levels",Nucleolin levels (NCL.13655.34.3),Kynurenate levels,Vaccenic acid (18:1n-7) levels,Ribosyldihydronicotinamide dehydrogenase [quinone] levels (NQO2.9754.33.3),1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Metabolite peak levels (QI12000),Metabolite peak levels (QI14354),Metabolite peak levels (QI12663),Metabolite peak levels (QI12380),2-hydroxy-4-(methylthio)butanoic acid levels,N-trimethyl 5-aminovalerate (X-21365) levels,"2,6-dihydroxybenzoic acid (X-09789) levels",Metabolite peak levels (QI12128),Metabolite peak levels (QI12750),"4,6-dinitro-o-cresol levels",1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Metabolite peak levels (QI12147),Metabolite peak levels (QI1483),Metabolite peak levels (QI1234),Metabolite peak levels (QI12764),Metabolite peak levels (QI12768),1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Carnitine-to-X-12798 ratio,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,N-acetyl neuraminic acid levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Metabolite peak levels (QI14556),Metabolite peak levels (QI12890),Nervonoylcarnitine (C24:1) levels,Laurylcarnitine levels (Biocrates platform),1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels
Nicotinamide (Reported Values: 92-388 nmol/L),Nicotinamide levels,Nicotinamide N-methyltransferase levels,Nicotinamide phosphoribosyltransferase levels (NAMPT.5011.11.1),Nicotinamide levels in elite athletes,Nucleolin levels (NCL.13655.34.3),Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 levels,Nervonoylcarnitine (C24:1) levels,Urine nicotinamide riboside levels in chronic kidney disease,Nicotinamide riboside kinase 1 levels,Tetradecenoylcarnitine levels,1-methylnicotinamide levels,"N,n-dimethylalanine (X-23585) levels",Dihydroceramide (d18:0/22:0) levels,Plasma metabolome feature (hilic_4134) (Nicotinic acid mononucleotide),Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Niacinamide levels,Oleoylcarnitine (C18:1) levels,Dihydroceramide (d18:0/20:0) levels,Margaroylcarnitine (C17) levels,Dihydroceramide (d18:0/24:0) levels,Triacylglyceroloxid(53:3)_[M+NH4]1+ levels,Dihydroceramide (d18:0/24:1) levels,Metabolite levels (NMMA),Dihydroceramide (d18:0/18:0) levels,NAD kinase levels (NADK.13624.17.3),X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Nonaylcarnitine levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,N-acetyl-2-aminoadipate levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,Triacylglycerol_58:10_[M+NH4]1+ levels,Monohexosylceramide (d16:1/22:0) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,"N,N,N-trimethyl-5-aminovalerate levels",1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Monohexosylceramide (d16:1/24:0) levels,Tetradecadienylcarnitine levels,N-linoleoyl ethanolamide levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,(N(1) + N(8))-acetylspermidine levels,Monohexosylceramide (d16:1/20:0) levels,Palmitoleoylcarnitine (C16:1) levels,"Metabolite levels (N2-acetyl,N6,N6-dimethyllysine)",Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Undecenoylcarnitine (c11:1) (X-17337) levels,Triacylglycerol(56:5)_[M+NH4]1+ levels
N1-methylnicotinamide (Reported Values: 27-221 nmol/L),1-methylnicotinamide levels,1-methylurate levels,Methylmalonate (mma) levels,Metabolite levels (1-methylurate),X-12095--N1-methyl-3-pyridone-4-carboxamide-to-X-12844 ratio,"X-12442--5,8-tetradecadienoate levels",Metabolite levels (N1-methyladenosine; 1-methyladenosine),1-methylnicotinamide levels in elite athletes,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,N1-methyladenosine levels,Metabolite levels (ethylmalonate),X-11593--O-methylascorbate levels,"N,n-dimethylalanine (X-23585) levels",Methylsuccinate levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Metabolite levels (N('1)-acetylspermidine; N1-acetylspermidine),2-methylmalonylcarnitine (C4-DC) levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),Metabolite levels ((N(1) + N(8))-acetylspermidine),Metabolite levels (NMMA),Trigonelline (n'-methylnicotinate) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Triacylglyceroloxid(53:3)_[M+NH4]1+ levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,N-trimethyl 5-aminovalerate (X-21365) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Margaroylcarnitine (C17) levels,Plasma 1-methylnicotinamide levels in chronic kidney disease,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Metabolite levels (docosapentaenoate (n3 DPA; 22:5n3)),Metabolite levels (3-methylcytidine),1-stearoyl-2-meadoyl-GPC (18:0/20:3n9) levels,Triacylglycerol_58:10_[M+NH4]1+ levels,(N(1) + N(8))-acetylspermidine levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,N-methylpipecolate levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Nervonoylcarnitine (C24:1) levels,Metabolite levels (1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6)),"2,3-dihydroxy-5-methylthio-4-pentenoate (DMTPA) (X-11564) levels",1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Triacylglycerol_58:9_[M+NH4]1+ levels,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels,Tartronate (hydroxymalonate) levels,Monohexosylceramide (d16:1/22:0) levels,N-methylproline levels,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels
Trigonelline (Reported Values: not provided by bevital),Trigonelline (n'-methylnicotinate) levels,Behenoylcarnitine (C22) levels,Triglycerides in IDL (UKB data field 23529),Treatment or medication use - glyceryl trinitrate (UKB data field 20003_1140860834),Metabolite levels (glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)),Triacylglycerol 56:6 levels,Trigonelline (N'-methylnicotinate) levels in elite athletes,Triglycerides in VLDL (UKB data field 23408),Triacylglycerol (56:3) levels,Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) levels,Triacylglycerol 56:2 levels,Triacylglycerol (58:8) [NL-22:6] levels,Triacylglycerol (58:7) levels,Plasma metabolome feature (c18_4599) (Glycerol triundecanoate),Triacylglycerol_58:9_[M+NH4]1+ levels,Triacylglycerol_58:7_[M+NH4]1+ levels,Total triglycerides levels (UKB data field 23407),Triacylglycerol (56:7) levels,Triacylglycerol_58:10_[M+NH4]1+ levels,Triacylglycerol (58:8) levels,Triacylglycerol (48:3) levels,Triacylglycerol (52:4) [NL-16:0] levels,Triacylglycerol(52:3)_[M+NH4]1+ levels,Triacylglycerol (56:5) levels,Octadecenoylcarnitine levels,Triacylglycerol(53:3)_[M+NH4]1+ levels,Triacylglycerol (56:4) levels,Triacylglycerol (54:3) levels,Triacylglycerol (53:3) levels,Triacylglycerol (56:6) levels,Triacylglycerol (56:8) levels,Triacylglyceroloxid(53:3)_[M+NH4]1+ levels,Triacylglycerol(54:3)_[M+NH4]1+ levels,Triacylglycerol (51:2) [NL-15:0] levels,Triacylglycerol (54:4) [NL-18:0] levels,Triacylglycerol(58:9)_[M+NH4]1+ levels,Triacylglycerol (52:3) levels,Triacylglycerol_58:8_[M+NH4]1+ levels,Dodecadienoate (12:2) (X-21343) levels,Triacylglycerol (54:7) levels,Tetradecenoylcarnitine levels,Triacylglycerol (53:2) [NL-17:0] levels,Triacylglycerol (49:1) [NL-15:0] levels,Triacylglycerol (54:0) [NL-18:0] levels,Triacylglycerol (52:2) [NL-16:0] levels,Triacylglycerol(56:7)_[M+NH4]1+ levels,Triacylglycerol(52:1)_[M+NH4]1+ levels,Triacylglycerol (50:0) [NL-18:0] levels,Triacylglycerol (54:2) [NL-18:0] levels,Triacylglycerol(48:3)_[M+NH4]1+ levels
Folate Comments,Serum folate levels,Folate pathway vitamin levels,Folate receptor alpha levels,Folate receptor beta levels,Folate receptor gamma levels,Red blood cell folate levels,Folate receptor alpha level in Chronic kidney disease with hypertension and no diabetes (17455_42),Folate receptor gamma level in Chronic kidney disease with hypertension and no diabetes (15495_9),Fumarate levels,FGF7 level (CSF),F9/FETUB protein level ratio,Fibulin-2 levels,Fibulin-5 levels,FAM3B/FUT3_FUT5 protein level ratio,Serum levels of protein FRS2,Lactotransferrin levels (LTF.2780.35.2),F0428 abundance in stool,F9/FURIN protein level ratio,Ficolin-2 levels (FCN2.3313.21.2),Plasma metabolome feature (c18_783) (Phenylmethanesulfonyl fluoride),Flt3L levels,F-carbohydrate liking (derived food-liking factor),F-lentils/beans liking (derived food-liking factor),F7/F9 protein level ratio,FYN-binding protein 1 levels,Lactotransferrin levels,Plasma metabolome feature (hilic_5246) ((5Z7E)-(3S)-262626-trifluoro-27-nor-910-seco-5710(19)-cholestatriene-325-diol),Plasma metabolome feature (hilic_727) (5-Hydroxy-2-furoic acid),Plasma metabolome feature (hilic_5950) (3-keto Fusidic acid),Serum levels of protein F7,Serum levels of protein F5,F2R/TNFRSF14 protein level ratio,Tyrosine-protein kinase Fyn levels (FYN.4550.3.2),FSC-A on CD14+ monocyte,FSC-A on monocyte,Serum levels of protein FTH1;FTL,FFA Eicosapentaenoic Acid c levels,Fumarylacetoacetase levels (FAH.11424.4.3),F3/KLK1 protein level ratio,Fructosamine levels,Fumarylacetoacetase levels,F-highly palatable foods liking (derived food-liking factor),"Fructose-1,6-bisphosphatase 1 levels (FBP1.7206.20.3)",Fasting insulin (dietary factor interaction),Olfactomedin-4 levels,Serum levels of protein F8,Metabolite levels (fumarate; fumarate/maleate; Fumarate),Serum levels of protein FN1,FHIT/PRTFDC1 protein level ratio,Fibulin-1 levels
Cobalamin (vitamin B12) (Reported Values: >150 pmol/L),Vitamin B12 levels,Vitamin B1 intake,Transcobalamin-2 levels (TCN2.5584.21.3),Transcobalamin-1 levels (TCN1.11232.46.3),Transcobalamin-2 levels,Transcobalamin-1 levels,Vitamin levels,Holo-Transcobalamin-2 levels,Serpin B13 levels,Vitamin B2 intake,Vitamin C levels,Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),X-11793--oxidized bilirubin levels,Vitamin B9 levels,"Metabolite levels (bilirubin (E,E))","Metabolite levels (bilirubin (E,Z or Z,E))",Retinol (Vitamin A) levels,Metabolite levels (biliverdin),Transcobalamin-1 level in Chronic kidney disease with hypertension and no diabetes (11232_46),Protein MENT levels (MENT.5744.12.3),Metabolite levels (C38_5_PC),Protein FAM150B levels (FAM150B.6284.7.3),Beta-crystallin B1 levels,Serum total bilirubin levels,Glyco-beta-muricholate levels,Transcobalamin-1 level in Chronic kidney disease with hypertension and no diabetes (19614_8),Bilirubin levels,Vitamin D-binding protein levels (GC.6581.50.3),Cofilin-2 levels,Holo-Transcobalamin-2 level in Chronic kidney disease with hypertension and no diabetes (5584_21),Folate pathway vitamin levels,Lamin-B1 levels,Promotilin levels (MLN.5631.83.3),Serum folate levels,"Metabolite levels (bilirubin (Z,Z); bilirubin; Bilirubin)",Total bilirubin levels,Metabolite levels  (X-11787),Haptoglobin levels (HP.3054.3.2),Vitamin E levels,Tauro-beta-muricholate levels,Serum metabolite levels (CMS),Vigilin levels (HDLBP.13570.43.3),Metabolite levels (glyco-beta-muricholate),Vitrin levels (VIT.6234.74.3),Periostin levels (POSTN.6650.20.3),Metabolite levels (C36:4 PC-A; C36_4_PC_A),High mobility group protein B1 levels (HMGB1.2524.56.3),Lamin-B1 levels (LMNB1.3889.64.2),Serum levels of protein MB,Serum levels of protein BAMBI
Vitamin B12 Comments,Vitamin B1 intake,Vitamin B12 levels,Vitamin B2 intake,Vitamin levels,Transcobalamin-2 levels (TCN2.5584.21.3),Transcobalamin-2 levels,Transcobalamin-1 levels (TCN1.11232.46.3),Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),Vitamin B9 levels,Serpin B13 levels,Holo-Transcobalamin-2 levels,Transcobalamin-1 levels,Response to Vitamin E supplementation,Beta-crystallin B1 levels,High mobility group protein B1 levels,Lamin-B1 levels,Ephrin-B1 levels,"Metabolite levels (bilirubin (Z,Z); bilirubin; Bilirubin)","Metabolite levels (bilirubin (E,E))","Metabolite levels (bilirubin (E,Z or Z,E))",Vitamin B levels in ischemic stroke,Vitamin D insufficiency,High mobility group protein B1 levels (HMGB1.2524.56.3),X-11793--oxidized bilirubin levels,Vitamin C levels,"Bilirubin degradation product, C17H20N2O5 (2) levels","Bilirubin degradation product, C16H18N2O5 (2) levels",Vitamin D-binding protein levels (GC.6581.50.3),"Bilirubin degradation product, C17H20N2O5 (1) levels","Bilirubin degradation product, C17H18N2O4 (2) levels",Folate pathway vitamin levels,"Bilirubin degradation product, C16H18N2O5 (4) levels",Complement C3b levels,Endophilin-B1 levels,"Bilirubin degradation product, C16H18N2O5 (3) levels",Bilirubin levels,"Bilirubin degradation product, C16H18N2O5 (1) levels",Direct bilirubin levels,"Bilirubin degradation product, C17H18N2O4 (3) levels","Bilirubin (E,E) levels","Bilirubin degradation product, C17H18N2O4 (1) levels",Metabolite levels (biliverdin),3-hydroxybutyrate (bhba) levels,Vitamin E levels,Vitamin D levels (dietary vitamin D intake interaction),Lamin-B1 levels (LMNB1.3889.64.2),Response to selenium supplementation (change in plasma selenium concentration),Plexin-B1 levels,Serum levels of protein BCAN,Biliverdin levels
All-trans retinol (Reported Values: 1.46-2.84 µmol/L),Retinol levels,Retinol (Vitamin A) levels,All-trans-retinol dehydrogenase levels,Retinol dehydrogenase 16 levels (RDH16.12881.17.3),All-trans-retinol dehydrogenase [NAD levels,Retinoschisin levels,4-oxo-retinoic acid levels,Retinoic acid receptor responder protein 3 levels (RARRES3.10961.15.3),Retinoic acid receptor responder protein 1 levels (RARRES1.8398.277.3),Retinol dehydrogenase 16 levels,Retinol-binding protein 1 levels,All-trans retinoic acid-induced differentiation factor levels,Retinoid-binding protein 7 levels (RBP7.14208.3.3),Retinol-binding protein 2 levels,Retinol-binding protein 5 levels,Retinoid-binding protein 7 levels,Retinol (Vitamin A) levels in elite athletes,Retinol-binding protein 4 levels,Retinoic acid receptor responder protein 1 levels,Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Retinoic acid receptor responder protein 3 levels,Cellular retinoic acid-binding protein 1 levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Phosphatidylinositol (16:0_20:3) (a) levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Cellular retinoic acid-binding protein 1 levels (CRABP1.11967.23.3),1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,Translin levels,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,Retinoic acid early transcript 1G protein levels,Phosphatidylinositol (18:0_20:3) (a) levels,Retinoic acid receptor responder protein 2 levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Transcobalamin-2 levels (TCN2.5584.21.3),Promotilin levels (MLN.5631.83.3),Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,Maximum retinal arteriolar tortuosity,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,Phosphatidylinositol (38:5) (a) levels
25-hydroxy vitamin D2 (Reported Values: 0-30 nmol/L),25-Hydroxyvitamin D levels,Serum 25-Hydroxyvitamin D levels,Vitamin D levels,Vitamin D-binding protein levels (GC.6581.50.3),Serum 25-Hydroxyvitamin D level variance,Vitamin D levels (dietary vitamin D intake interaction),25-hydroxyvitamin D levels (skin colour stratified),Vitamin D3 levels,Vitamin D-binding protein levels,Neonatal total 25-hydroxyvitamin D levels (cord blood),Vitamin D insufficiency,Serum vitamin D-binding protein levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Vitamin levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Dihydroceramide (d18:0/24:0) levels,Dihydroceramide (d18:0/20:0) levels,Dihydroceramide (d18:0/22:0) levels,Dihydroceramide (d18:0/24:1) levels,Bioavailable vitamin D levels in type 2 diabetes,Vitamin D-binding protein levels (adjusted for GC haplotype),Vitamin D3 receptor levels,25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Dihydroceramide (d18:0/18:0) levels,Serum 25-Hydroxyvitamin D levels x season interaction,Monohexosylceramide (d18:2/24:0) levels,Monohexosylceramide (d18:1/24:0) levels,25-hydroxyvitamin D levels x skin colour (very fair vs. fair) interaction,Monohexosylceramide (d18:1/24:1) levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Monohexosylceramide (d18:2/20:0) levels,Monohexosylceramide (d16:1/24:0) levels,Monohexosylceramide (d18:2/22:0) levels,Monohexosylceramide (d16:1/20:0) levels,Monohexosylceramide (d18:1/20:0) levels,Monohexosylceramide (d18:2/18:0) levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Monohexosylceramide (d18:1/22:0) levels,Monohexosylceramide (d16:1/22:0) levels,Monohexosylceramide (d18:1/18:0) levels,Dihexosylceramide (d18:1/24:0) levels,Monohexosylceramide (d18:1/16:0) levels,Dihexosylceramide (d18:2/24:1) levels,Monohexosylceramide (d16:1/18:0) levels,Dihexosylceramide (d18:1/24:1) levels,Dihexosylceramide (d18:1/20:0) levels,Apolipoprotein D levels (APOD.4712.28.2),Dihexosylceramide (d18:1/22:0) levels,Dihexosylceramide (d16:1/24:1) levels
25-hydroxy vitamin D3 (Reported Values: 32.4-98.5 nmol/L),25-Hydroxyvitamin D levels,Serum 25-Hydroxyvitamin D levels,Vitamin D3 levels,Vitamin D levels,Vitamin D-binding protein levels (GC.6581.50.3),Serum 25-Hydroxyvitamin D level variance,25-hydroxyvitamin D levels (skin colour stratified),Vitamin D levels (dietary vitamin D intake interaction),Vitamin D3 receptor levels,Vitamin D-binding protein levels,Neonatal total 25-hydroxyvitamin D levels (cord blood),Vitamin D insufficiency,Serum vitamin D-binding protein levels,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Vitamin levels,Vitamin D-binding protein levels (adjusted for GC haplotype),25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Dihydroceramide (d18:0/24:0) levels,Dihydroceramide (d18:0/24:1) levels,Dihydroceramide (d18:0/20:0) levels,Serum 25-Hydroxyvitamin D levels x season interaction,Dihydroceramide (d18:0/22:0) levels,Dihydroceramide (d18:0/18:0) levels,25-hydroxyvitamin D levels x skin colour (very fair vs. fair) interaction,Monohexosylceramide (d18:1/24:1) levels,Monohexosylceramide (d18:1/24:0) levels,Monohexosylceramide (d18:2/24:0) levels,Monohexosylceramide (d16:1/24:0) levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect),Monohexosylceramide (d16:1/20:0) levels,Bioavailable vitamin D levels in type 2 diabetes,Monohexosylceramide (d18:1/20:0) levels,Monohexosylceramide (d18:2/20:0) levels,Monohexosylceramide (d18:1/18:0) levels,Monohexosylceramide (d18:2/18:0) levels,Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect),Monohexosylceramide (d16:1/22:0) levels,Monohexosylceramide (d18:2/22:0) levels,Monohexosylceramide (d16:1/18:0) levels,Monohexosylceramide (d18:1/22:0) levels,Trihexosylcermide (d18:1/24:1) levels,Monohexosylceramide (d18:1/16:0) levels,Dihexosylceramide (d18:1/24:0) levels,Trihexosylcermide (d18:1/24:0) levels,Dihexosylceramide (d18:1/24:1) levels,Trihexosylcermide (d18:1/20:0) levels,Dihexosylceramide (d18:2/24:1) levels,Dihexosylceramide (d16:1/24:1) levels
alpha-tocopherol (Reported Values: 18.9-38.8.0 µmol/L),Alpha-tocopherol levels,Gamma-tocopherol/beta-tocopherol levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Phosphatidylinositol-O(36:0)_[M-H]1-/Phosphatidylglycerol(37:0)_[M+OAc]1- levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Alkyldiacylglycerol (O-52:0) [NL-16:0] levels,Alkyldiacylglycerol (O-52:2) [NL-16:0] levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,Alkyldiacylglycerol (O-50:1) [NL-16:0] levels,Metabolite levels (oleoyl-oleoyl-glycerol (18:1/18:1)  [1]; C36:2 DAG; C36_2_DAG),1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,Phosphatidylinositol(36:0)_[M+OAc]1- levels,Phosphatidylinositol-O(33:0)_[M-H]1- levels,Palmitoyl-oleoyl-glycerol (16:0/18:1) [2] levels,Phosphatidylinositol (18:0_22:5) (n3) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,1-oleoyl-GPG (18:1) levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] levels,1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels,1-stearoyl-2-oleoyl-gpc (18:0/18:1) levels,1-palmitoyl-2-oleoyl-gpc (16:0/18:1) levels,Alpha-hydroxyisocaproate levels,1-linoleoyl-2-linolenoyl-GPC (18:2/18:3) levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Stearoyl-arachidonoyl-glycerol (18:0/20:4) [1] levels,1-oleoyl-2-dihomo-linolenoyl-GPC (18:1/20:3) levels
gamma-tocopherol (Reported Values: 2-11 µmol/L),Gamma-tocopherol/beta-tocopherol levels,Alpha-tocopherol levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,1-linoleoyl-2-linolenoyl-GPC (18:2/18:3) levels,1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Phosphatidylinositol-O(36:0)_[M-H]1-/Phosphatidylglycerol(37:0)_[M+OAc]1- levels,Gamma-tocopherol/beta-tocopherol levels in elite athletes,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,"Metabolite levels (1-dihomo-linolenylglycerol (alpha, gamma); 1-dihomo-linolenylglycerol (20:3))",1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] levels,1-palmitoyl-2-oleoyl-gpc (16:0/18:1) levels,1-linoleoyl-gpc (18:2) levels,1-oleoyl-GPG (18:1) levels,1-stearyl-GPC (O-18:0) levels,1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels,1-stearoyl-2-oleoyl-gpc (18:0/18:1) levels,1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels
Total cholesterol [Assay Method: Colorimetric (Beckman AU5800)],Total cholesterol levels,Cholesterol levels,Serum total cholesterol levels,Total esterified cholesterol levels (UKB data field 23415),Total esterified cholesterol levels,Total cholesterol levels in medium HDL,"Cholesterol, total",Total cholesterol levels in HDL,Cholesterol in medium HDL (UKB data field 23568),Cholesterol levels in IDL,Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),"Remnant cholesterol (non-HDL, non-LDL -cholesterol)",Total cholesterol in very large HDL meal response (LMM),Postprandial total cholesterol in medium HDL,Esterified cholesterol levels,Total cholesterol levels in LDL,Total cholesterol in large HDL,Total Cholesterol in IDL,Total cholesterol in large LDL,"Remnant cholesterol (non-HDL, non-LDL -cholesterol) levels (UKB data field 23402)",Cholesterol_[M+H-H2O]1+ levels,Free cholesterol in medium HDL (UKB data field 23570),Non-HDL cholesterol levels,Total cholesterol levels in large HDL,Total cholesterol levels (MTAG),Total cholesterol in HDL2,Cholesterol levels in medium HDL,Total cholesterol in medium LDL,HDL Cholesterol - Triglycerides (HDLC-TG),Postprandial total cholesterol in HDL,HDL cholesterol,Cholesterol to total lipids in small HDL percentage (UKB data field 23645),Cholesterol efflux capacity (ABCA-1 dependent assay),Total cholesterol levels (UKB data field 23400),Total cholesterol levels in medium LDL,Cholesterol in medium LDL (UKB data field 23540),Total cholesterol minus HDL-C levels (UKB data field 23401),Cholesteryl ester (22:0) levels,Total cholesterol levels in large LDL,Postprandial total cholesterol in very large HDL,Total free cholesterol levels,Total cholesterol in HDL3,Total cholesterol levels in very large HDL,Cholesterol in small HDL (UKB data field 23575),Cholesterol in large HDL (UKB data field 23561),Postprandial total cholesterol in IDL,Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Postprandial total cholesterol in large HDL,Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642),Cholesterol
Triglycerides [Assay Method: Colorimetric (Beckman AU5800)],Triglyceride levels,Triglycerides (56:1) levels,Triglycerides (56:2) levels,Triglycerides (53:1) levels,Triglycerides,Triglycerides (44:1) levels,Triglycerides (51:3) levels,Triglycerides (56:9) levels,Triglycerides (48:1) levels,Triacylglyceride levels,Triglycerides (46:1) levels,Triglycerides (51:1) levels,Triglycerides (51:4) levels,Triglycerides (44:2) levels,Triacylglycerol 56:2 levels,Triglycerides (46:2) levels,Triglycerides (58:1) levels,Triglycerides (44:0) levels,Triglycerides (52:1) levels,Triglycerides (58:10) levels,Triglycerides (50:4) levels,Triglycerides (52:3) levels,Triglycerides (58:9) levels,Triglycerides (58:5) levels,Triglycerides (56:7)A levels,Triglyceride levels in IDL,Triglycerides (46:3)A levels,Triacylglycerol (50:0) [NL-18:0] levels,Triglycerides in IDL (UKB data field 23529),Triacylglycerol (56:8) [NL-20:4] levels,Triacylglycerol (56:3) levels,Triacylglycerol (50:3) [NL-16:1] levels,Triacylglycerol (56:6) [NL-20:4] levels,Triacylglycerol (58:8) [NL-22:6] levels,Triacylglycerol (56:7) levels,Triglyceride levels (MTAG),Triacylglycerol (49:1) [NL-15:0] levels,Triacylglycerol (50:3) [NL-18:1] levels,Triacylglycerol (51:2) [NL-15:0] levels,Triglycerides (54:7)B levels,Cholesterol and Triglycerides,Triglycerides (49:0) levels,Triacylglycerol (48:1) levels,Serum total triglyceride levels,Triacylglycerol (56:5) levels,Triacylglycerol (51:0) [NL-16:0] levels,Triacylglycerol (56:4) levels,Triacylglycerol (50:2) [NL-18:2] levels,Triacylglycerol (50:1) levels,Triacylglycerol (56:8) levels
High density lipoprotein cholesterol [Assay Method: Enzymatic (Beckman AU5800)],High density lipoprotein cholesterol levels,High-density lipoprotein levels,Cholesterol in large HDL (UKB data field 23561),Direct low density lipoprotein cholesterol levels,Cholesterol in medium HDL (UKB data field 23568),Low high density lipoprotein cholesterol levels,Cholesterol efflux capacity (ABCA-1 dependent assay),Total cholesterol in very large HDL meal response (LMM),Cholesterol levels in large HDL,High-density lipoprotein 2 cholesterol levels,HDL cholesterol,Cholesterol ester levels in very large HDL,Cholesterol esters in very large HDL meal response (LMM),Cholesterol in large LDL (UKB data field 23533),High-density lipoprotein 3 cholesterol levels,Cholesterol ester levels in medium HDL,Cholesterol levels in very large HDL,Cholesterol in very large HDL (UKB data field 23554),Total cholesterol in large HDL,Cholesterol efflux capacity (BHK stimulated assay),Total cholesterol levels in large HDL,Cholesterol levels in medium HDL,HDL Cholesterol - Triglycerides (HDLC-TG),Total cholesterol levels in very large HDL,Free cholesterol in large HDL,Free cholesterol in very large HDL meal response (LMM),Low density lipoprotein cholesterol levels,Free cholesterol levels in very large HDL,Free cholesterol in very large HDL,Total cholesterol levels in HDL,Fasting cholesterol esters in very large HDL,Free cholesterol in large HDL (UKB data field 23563),Free cholesterol in medium HDL (UKB data field 23570),High density lipoprotein cholesterol levels (UKB data field 30760),Free cholesterol in very large HDL (UKB data field 23556),Postprandial cholesterol esters in large HDL,Postprandial cholesterol esters in very large HDL,Free cholesterol in very large HDL meal response (OrNLSr),Free cholesterol levels in large HDL,Cholesteryl ester levels in large HDL,High-density lipoprotein mediated cholesterol efflux capacity,Cholesterol ester levels in large LDL,Total cholesterol levels in medium HDL,Cholesterol esters in large HDL,Cholesterol levels in large LDL,Cholesterol to total lipids ratio in large HDL,Cholesteryl ester levels in very large HDL,Cholesterol in medium LDL (UKB data field 23540),Cholesterol in small HDL (UKB data field 23575),Fasting cholesterol esters in large HDL
Low density lipoprotein cholesterol [Calculated using Friedwald equation: LDL = CHOL - HDL - TG/2.2. Note: Invalid (indicated by 8888) if triglycerides is more than or equals to 4.5],Low density lipoprotein cholesterol levels,Direct low density lipoprotein cholesterol levels,Low high density lipoprotein cholesterol levels,HDL Cholesterol - Triglycerides (HDLC-TG),High density lipoprotein cholesterol levels (UKB data field 30760),LDL (standard GWA),High density lipoprotein cholesterol levels,LDL cholesterol,LDL cholesterol levels (UKB data field 23405),Non-HDL cholesterol levels,Clinical LDL cholesterol levels (UKB data field 23404),Total cholesterol minus HDL-C levels (UKB data field 23401),HDL cholesterol,HDL cholesterol levels (UKB data field 23406),Low-density lipoprotein levels,Very low density lipoprotein cholesterol levels,Direct low density lipoprotein levels (UKB data field 30780),LDL cholesterol levels,Cholesterol to total lipids in small HDL percentage (UKB data field 23645),High-density lipoprotein 3 cholesterol levels,Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),Triglycerides in LDL (UKB data field 23409),VLDL cholesterol levels (UKB data field 23403),HDL cholesterol levels,Total cholesterol levels in LDL,Triglycerides to total lipids in medium LDL percentage (UKB data field 23623),Triglycerides to total lipids in small LDL percentage (UKB data field 23628),Clinical LDL cholesterol levels,Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642),Cholesterol to total lipids in medium LDL percentage (UKB data field 23620),Total lipids in LDL (UKB data field 23425),Cholesterol to total lipids in small LDL percentage (UKB data field 23625),HDL triglycerides levels,Triglyceride to HDL cholesterol ratio,Total lipids in medium LDL (UKB data field 23538),Total cholesterol levels,LDL triglycerides levels,Total cholesterol to total lipids ratio in IDL,Triglycerides to total lipids in small HDL percentage (UKB data field 23648),"Remnant cholesterol (non-HDL, non-LDL -cholesterol) levels (UKB data field 23402)",Triglycerides to total lipids in medium HDL percentage (UKB data field 23643),Triglycerides in medium LDL (UKB data field 23543),High-density lipoprotein levels,X-11820-to-cholesterol ratio,Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Cholesterol in medium LDL (UKB data field 23540),LDL cholesterol to HDL cholesterol ratio,Total cholesterol levels in medium HDL,Free cholesterol to total lipids in small HDL percentage (UKB data field 23647),Cholesterol in medium HDL (UKB data field 23568)
Derived Variable: Ratio of Total Cholesterol:High-density Lipoprotein Cholesterol,Cholesterol to total lipids ratio in IDL,Total cholesterol to total lipids ratio in IDL,High density lipoprotein cholesterol levels,Cholesterol to total lipids in large HDL percentage (UKB data field 23635),Total cholesterol to total lipids ratio in medium HDL,Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),LDL cholesterol to HDL cholesterol ratio,Cholesterol to total lipids ratio in medium HDL,Cholesterol to total lipids in small HDL percentage (UKB data field 23645),Cholesterol to total lipids in small VLDL percentage (UKB data field 23600),Cholesterol to total lipids in very large HDL percentage (UKB data field 23630),Cholesterol to total lipids in large VLDL percentage (UKB data field 23590),NHDL cholesterol to HDL cholesterol ratio,Total cholesterol to total lipids ratio in large HDL,Cholesterol to total lipids in large LDL percentage (UKB data field 23615),Cholesterol to total lipids ratio in large HDL,Free cholesterol to total lipids ratio in IDL,Free cholesterol to total lipids in large HDL percentage (UKB data field 23637),Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597),Free cholesterol to total lipids ratio in medium HDL,Total cholesterol to total lipids ratio in very large HDL,Total cholesterol to total lipids ratio in large LDL,Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632),Free cholesterol to total lipids in small VLDL percentage (UKB data field 23602),Free cholesterol to total lipids in large VLDL percentage (UKB data field 23592),Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642),Total cholesterol to total lipids ratio in medium LDL,Cholesterol to total lipids in very large VLDL percentage (UKB data field 23585),Cholesterol to total lipids ratio in very large HDL,Cholesterol to total lipids in very small VLDL percentage (UKB data field 23605),Cholesterol to total lipids in medium LDL percentage (UKB data field 23620),Direct low density lipoprotein cholesterol levels,HDL cholesterol,Cholesterol to total lipids ratio in large LDL,Cholesterol to total lipids in small LDL percentage (UKB data field 23625),Free cholesterol to total lipids in small HDL percentage (UKB data field 23647),High density lipoprotein cholesterol levels (UKB data field 30760),Free cholesterol to total lipids in very large VLDL percentage (UKB data field 23587),Free cholesterol to total lipids ratio in large HDL,Cholesterol to total lipids ratio in medium LDL,Free cholesterol to total lipids ratio in very large HDL,Cholesterol in IDL (UKB data field 23526),Free cholesterol to total lipids in large LDL percentage (UKB data field 23617),Free cholesterol to total lipids in very small VLDL percentage (UKB data field 23607),Total cholesterol to total lipids ratio in medium VLDL,X-11820-to-cholesterol ratio,Total esterified cholesterol levels (UKB data field 23415),Cholesterol to total lipids ratio in large VLDL,Cholesterol in medium HDL (UKB data field 23568)
Derived Variable: Ratio of Triglycerides:High-density Lipoprotein Cholesterol,Triglyceride to HDL cholesterol ratio,Triglycerides to total lipids in large HDL percentage (UKB data field 23638),Triglycerides to total lipids ratio in medium HDL,Triglycerides to total lipids in large LDL percentage (UKB data field 23618),Triglycerides to total lipids in medium HDL percentage (UKB data field 23643),Triglycerides to total lipids in small HDL percentage (UKB data field 23648),Triglycerides to total lipids ratio in IDL,Triglycerides to total lipids in very large HDL percentage (UKB data field 23633),Triglycerides to total lipids ratio in large LDL,Triglycerides to total lipids ratio in large HDL,Triglycerides to total lipids ratio in medium LDL,Triglycerides to total lipids in medium LDL percentage (UKB data field 23623),Triglycerides to total lipids in medium VLDL percentage (UKB data field 23598),Total cholesterol to total lipids ratio in IDL,Triglycerides to total lipids in small LDL percentage (UKB data field 23628),Cholesterol to total lipids ratio in IDL,Triglycerides to total lipids ratio in very large HDL,Triglycerides to total lipids in large VLDL percentage (UKB data field 23593),Triglycerides to total lipids in small VLDL percentage (UKB data field 23603),Total cholesterol to total lipids ratio in medium HDL,Triglycerides to phosphoglycerides ratio (UKB data field 23435),Triglycerides to total lipids ratio in small LDL,Ratio of diacylglycerol to triglycerides,High density lipoprotein cholesterol levels,Triglycerides to total lipids in very large VLDL percentage (UKB data field 23588),Cholesterol to total lipids ratio in medium HDL,Cholesterol to total lipids in large HDL percentage (UKB data field 23635),Triglycerides to total lipids ratio in small HDL,Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Triglycerides to total lipids in IDL percentage (UKB data field 23613),LDL cholesterol to HDL cholesterol ratio,Cholesterol to total lipids in small HDL percentage (UKB data field 23645),Cholesterol to total lipids in small VLDL percentage (UKB data field 23600),Total cholesterol to total lipids ratio in medium LDL,Triglycerides to total lipids in very small VLDL percentage (UKB data field 23608),Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),Cholesterol to total lipids in large LDL percentage (UKB data field 23615),Total cholesterol to total lipids ratio in large HDL,Cholesterol to total lipids in very large HDL percentage (UKB data field 23630),Triglycerides in LDL (UKB data field 23409),Total cholesterol to total lipids ratio in large LDL,Cholesterol to total lipids in large VLDL percentage (UKB data field 23590),HDL Cholesterol - Triglycerides (HDLC-TG),Cholesterol to total lipids ratio in large HDL,Free cholesterol to total lipids ratio in IDL,Total cholesterol to total lipids ratio in very large HDL,Free cholesterol to total lipids ratio in medium HDL,Cholesterol and Triglycerides,Cholesterol to total lipids ratio in very large HDL,HDL cholesterol and triglyceride levels
Insulin [Assay Method: Sandwich immunoassay (Beckman DxI 800)],Insulin receptor levels (INSR.3448.13.2),Insulin levels,Insulin-induced gene 1 protein levels,Insulin receptor levels,Insulin levels in response to oral glucose tolerance test (120 minutes),Insulin levels in response to oral glucose tolerance test (30 minutes),Insulin resistance/response,Insulin-related traits,Insulin levels in overweight individuals,Acute insulin response (insulin secretion adjusted),Diabetes related insulin traits,Insulin levels in response to oral glucose tolerance test (fasting),Corrected insulin response,Glucose-dependent insulinotropic peptide levels,Insulin resistance,Acute insulin response,Insulinogenic index,Insulin levels in lean individuals,Glucose-dependent insulinotropic peptide levels in type 2 diabetes,Insulin fold change during an oral glucose tolerance test,Insulin-like peptide INSL5 levels,Insulin-related traits (multivariate analysis),Modified Stumvoll Insulin Sensitivity Index,Area under the curve of insulin levels,2-hour postprandial insulin levels in prediabetes,Severe insulin-deficient type 2 diabetes,Incremental insulin,Insulin-degrading enzyme levels,Fasting insulin,Insulin-like peptide INSL6 levels,Pancreatic hormone levels (PPY.4588.1.2),Insulin disposition index,Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes,Fasting insulin levels in prediabetes,Fasting insulin (dietary factor interaction),Non-insulin-dependent diabetes mellitus (Union E11),Insulin-like growth factor I levels (IGF1.2952.75.2),Peak insulin response (insulin secretion adjusted),Insulin-like 3 levels,Insulin secretion rate,Treatment or medication use - insulin product (UKB data field 20003_1140883066),Insulin levels adjusted for BMI,Circulating leptin levels or fasting insulin levels,Insulin-like growth factor 1 receptor levels (IGF1R.4232.19.2),Regenerating islet-derived protein 4 levels (REG4.11102.22.3),Insulin-like growth factor I levels,Fasting blood insulin,Insulin sensitivity index,Glucagon levels in response to oral glucose tolerance test (120 minutes),Insulin fold change during an oral glucose tolerance test (adjusted for BMI)
Creatinine [Assay Method: Endpoint creatininase (Beckman AU5800) The creatinine assay calibration is traceable to an isotope dilution mass spectrometry (IDMS) reference method using the National Institutes of Standards and Technology (NIST) Standard Reference Material 967.],Creatinine levels (UKB data field 23478),Plasma metabolome feature (hilic_502) (Creatinine),Creatinine levels,Creatinine levels (UKB data field 30700),Serum creatinine levels,Urinary creatinine levels,Creatine kinase M-type levels (CKM.2670.67.4),Creatinine levels in elite athletes,Urinary albumin-to-creatinine ratio,Creatinine clearance,Protein CREG1 levels (CREG1.9357.4.3),Urinary uromodulin levels (indexed to creatinine),Metabolite levels (creatine),CRTAM/ICAM3 protein level ratio,Creatine kinase M-type:Creatine kinase B-type heterodimer levels,Crk-like protein levels (CRKL.9877.28.3),Creatine kinase levels,Estimated glomerular filtration rate (creatinine),Serine levels (Biocrates platform),Arginine levels (Biocrates platform),Chronic kidney disease and serum creatinine levels,"Estimated glomerular filtration rate (creatinine, CKDi25)",Alanine aminotransferase levels (UKB data field 30620),"Estimated glomerular filtration rate (creatinine, Rapid3)",Creatine levels,Serine/threonine-protein kinase/endoribonuclease IRE1 levels,Endostatin levels (COL18A1.2201.17.6),Glomerular filtration rate (creatinine),CRADD/EREG protein level ratio,Creatinine levels in ischemic stroke,CREB-binding protein levels (CREBBP.13614.6.3),Brevican core protein levels (BCAN.3461.58.1),CRADD/NT5C3A protein level ratio,Urinary uric acid to urinary creatinine ratio,Creatine kinase B-type levels,Serum levels of protein CRTAM,Endoglin levels (ENG.4908.6.1),ARSA/CREG1 protein level ratio,Serum levels of protein CRIM1,CREG1/NAAA protein level ratio,CRADD/EDAR protein level ratio,Serine levels (Metabolon platform),Calbindin levels (CALB1.9918.23.3),Metabolite levels (adrenate (22:4n6); adrenate),Metabolite levels (uridine; cmh_uridine; Uridine),Biochemical measures,Urinary potassium to creatinine ratio,Endostatin levels,CREB-binding protein levels,CRTAM/LY9 protein level ratio
High sensitivity C-reactive protein [Assay Method: Colorimetric (Beckman AU5800)]. Low values (<0.1) indicated by 8888,C-reactive protein levels (CRP.4337.49.2),High-sensitivity C-reactive protein levels,C-reactive protein levels,C-reactive protein,Serum C-reactive protein concentration,Serum C-reactive protein concentration in inactive individuals,C-reactive protein and white blood cell count,C-reactive protein levels (MTAG),High-sensitivity C-reactive protein levels in HIV infection,C-reactive protein levels or total cholesterol levels (pleiotropy),C-reactive protein (red blood cell fatty acid level interaction),C-reactive protein levels or HDL-cholesterol levels (pleiotropy),C-reactive protein levels or LDL-cholesterol levels (pleiotropy),Serum C-reactive protein concentration in non-obese individuals,C-reactive protein levels or triglyceride levels (pleiotropy),Serum levels of protein CCNC,Serum levels of protein CCDC126,C-reactive protein levels in ischemic stroke,C reactive protein levels x vegetarianism interaction,CD226 antigen levels (CD226.5721.1.3),CD63 antigen levels (CD63.9190.7.3),Serum levels of protein CCDC50,Complement C1q tumor necrosis factor-related protein 6 levels,Serum levels of protein CRP,Serum levels of protein CCL8,Serum levels of protein CCL1,Serum C-reactive protein concentration in low fat diet,Serum levels of protein CCL13,Serum C-reactive protein concentration in obesity,Serum levels of protein CD200R1L,Serum levels of protein C2orf66,Multiple sclerosis and C-reactive protein levels (pleiotropy),Protein CEI levels (C5orf38.6378.2.3),Serum levels of protein CCL3,Serum levels of protein C1QBP,Serum levels of protein CCM2,Complement C1q tumor necrosis factor-related protein 3 levels,Serum levels of protein CD200R1,Serum levels of protein CCL18,Serum levels of protein CCL23,Serum levels of protein CCL14,Serum C-reactive protein concentration in high fat diet,C reactive protein levels (adjusted for BMI) x vegetarianism interaction,Serum levels of protein CCL2,Serum levels of protein CCL28,Complement C1q tumor necrosis factor-related protein 1 levels,CD166 antigen levels (ALCAM.5451.1.3),Serum levels of protein C1RL,Complement factor I levels (CFI.2567.5.6),Serum levels of protein CD63
Alanine transaminase [Assay Method: Enzymatic (Beckman AU5800) without addition of pyridoxal-5-phosphate co-factor]. Low values (<6) indicated by 8888,Alanine transaminase levels,Liver enzyme levels (alanine transaminase),Alanine aminotransferase levels,Alanine transaminase levels in high alcohol intake,Alanine aminotransferase 1 levels,Alanine aminotransferase levels (UKB data field 30620),"Alanine--tRNA ligase, cytoplasmic levels (AARS.12340.17.3)",Glutamic oxaloacetic transaminase levels,Aspartate aminotransferase to alanine aminotransferase ratio,Serum glutamic-oxaloacetic transaminase levels,Serum glutamic-pyruvic transaminase levels,Kynurenine--oxoglutarate transaminase 3 levels (CCBL2.12682.5.3),Alanine levels,Metabolite levels (alanine),Liver enzyme levels (aspartate transaminase),Chronic elevation of alanine aminotransferase (cALT) levels,Glutamic pyruvic transaminase levels,"Alanine--tRNA ligase, cytoplasmic levels",Arylsulfatase K levels (ARSK.8269.327.3),Kynurenine--oxoglutarate transaminase 3 levels,Arylsulfatase B levels (ARSB.3172.28.2),Metabolite levels (beta-alanine; beta_alanine),Alanine aminotransferase levels x vegetarianism interaction,"Aspartate aminotransferase, cytoplasmic levels (GOT1.4912.17.1)",Metabolite levels (arabinose),Kynurenine-oxoglutarate transaminase 1 levels,Catalase levels (CAT.3488.64.2),"5'(3')-deoxyribonucleotidase, cytosolic type levels (NT5C.12560.9.3)",Alanine aminotransferase levels in low alcohol consumption,Transaldolase levels,N-acetylmuramoyl-L-alanine amidase levels,Transketolase levels (TKT.4306.4.2),Alanine levels in elite athletes,Arylsulfatase A level (CSF),Alanine aminotransferase levels in non-alcoholic fatty liver disease,Beta-Ala-His dipeptidase levels,Kynurenine--oxoglutarate transaminase 1 levels,L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase levels,Alanine aminotransferase levels in excessive alcohol consumption,Alpha-amylase 1 levels (AMY1A.7918.114.3),Serum levels of protein ASAH2,N-acetylated-alpha-linked acidic dipeptidase 2 levels (NAALAD2.7986.98.3),Formylglycine-generating enzyme levels,Beta-alanine levels,Alpha-L-iduronidase levels (IDUA.3169.70.2),Protocadherin alpha-4 levels (PCDHA4.7157.22.3),Aspartate aminotransferase levels,Fumarylacetoacetase levels (FAH.11424.4.3),Tryptase alpha/beta-1 levels,Alanine levels (UKB data field 23460)
Aspartate transaminase [Assay Method: Enzymatic (Beckman AU5800) without addition of pyridoxal-5-phosphate co-factor],"Aspartate aminotransferase, cytoplasmic levels (GOT1.4912.17.1)","Aspartate aminotransferase, cytoplasmic levels",Aspartate aminotransferase levels (UKB data field 30650),Aspartate aminotransferase levels,Aspartate transaminase levels in high alcohol intake,Aspartate aminotransferase to alanine aminotransferase ratio,Liver enzyme levels (aspartate transaminase),Aspartyl aminopeptidase levels,"Aspartate--tRNA ligase, cytoplasmic levels",Protein-L-isoaspartate(D-aspartate) O-methyltransferase levels,Aspartyl/asparaginyl beta-hydroxylase levels (ASPH.6998.106.3),Isoaspartyl peptidase/L-asparaginase levels,Aspartoacylase levels,"Aspartate--tRNA ligase, mitochondrial levels",N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase levels,Aspartate aminotransferase levels x vegetarianism interaction,Aspartate aminotransferase levels in non-alcoholic fatty liver disease,Aspartate aminotransferase to alanine aminotransferase ratio x alcohol consumption interaction,Phosphate-regulating neutral endopeptidase levels,Aspartate aminotransferase levels in low alcohol consumption,Aspartyl/asparaginyl beta-hydroxylase levels,Gut bacterial pathway abundance (ASPASN.PWY..superpathway.of.L.aspartate.and.L.asparagine.biosynthesis),"5'(3')-deoxyribonucleotidase, cytosolic type levels (NT5C.12560.9.3)",Gamma glutamyl transpeptidase,Glutamic oxaloacetic transaminase levels,Aspartate aminotransferase levels in excessive alcohol consumption,Aspartate aminotransferase levels in low dose methotrexate treatment,Aspartate levels,Aspartate levels in elite athletes,Serum glutamic-pyruvic transaminase levels,Serum glutamic-oxaloacetic transaminase levels,Glutamic pyruvic transaminase levels,N-acetylated-alpha-linked acidic dipeptidase 2 levels (NAALAD2.7986.98.3),Metabolite levels (aspartate),Retroviral-like aspartic protease 1 levels (ASPRV1.13023.8.3),"5'(3')-deoxyribonucleotidase, cytosolic type levels",Plasma aspartate levels in chronic kidney disease,N-acetylated-alpha-linked acidic dipeptidase 2 levels,Aspartylphenylalanine levels,"N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase, isoform C levels","Aspartate aminotransferase, mitochondrial level in Chronic kidney disease with hypertension and no diabetes (18233_10)",Kynurenine--oxoglutarate transaminase 3 levels (CCBL2.12682.5.3),"CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 levels",Metabolite levels (aspartylphenylalanine),Alanine transaminase levels,High aspartate aminotransferase or alanine aminotransferase levels in low dose methotrexate treatment,Aspartate aminotransferase levels x BMI interaction,"Asparagine--tRNA ligase, cytoplasmic levels",Acid ceramidase levels (ASAH1.5748.20.3),Membrane-bound aminopeptidase P levels
Gamma glutamyl transferase [Assay Method: Colorimetric (Beckman AU5800)]. Low values (<10) indicated by 8888,Gamma glutamyl transferase levels,Gamma-glutamyl transpeptidase levels,Liver enzyme levels (gamma-glutamyl transferase),Protein-glutamine gamma-glutamyltransferase 2 levels,Gamma glutamyl transpeptidase,Inactive gamma-glutamyltranspeptidase 2 levels (GGT2.6334.9.3),Protein-glutamine gamma-glutamyltransferase E levels,Inactive gamma-glutamyltranspeptidase 2 levels,Gamma-glutamyl hydrolase levels (GGH.9370.69.3),Gamma-glutamylcyclotransferase levels,Gamma-glutamylaminecyclotransferase levels,Gamma glutamyl transferase levels in low alcohol consumption,Gamma-glutamylleucine levels,Gamma-glutamyl hydrolase levels,Glutathione-specific gamma-glutamylcyclotransferase 2 levels,Glutathione S-transferase A4 levels (GSTA4.14645.253.3),Gamma-glutamyltyrosine levels,Gamma-glutamylisoleucine levels,Gamma glutamyl transferase levels in excessive alcohol consumption,Gamma-glutamylglycine levels,Gamma-glutamyl-alpha-lysine levels,Gamma-glutamylvaline levels,Glutamic oxaloacetic transaminase levels,Glutathione S-transferase A1 levels (GSTA1.12446.49.3),Gamma-glutamylphenylalanine levels,Gamma-glutamylmethionine levels,Gamma-glutamyltryptophan levels,Gamma-glutamylglutamate levels,Gamma-glutamylglutamine levels,Serum glutamic-oxaloacetic transaminase levels,Gamma-glutamylthreonine levels,Glutathione S-transferase P levels (GSTP1.4911.49.2),Gamma-glutamyl-epsilon-lysine levels,Glutathione S-transferase Mu 1 levels (GSTM1.7239.9.3),Glutathione S-transferase theta-1 levels,Metabolite levels (gamma-glutamylglutamate),Metabolite levels (gamma-glutamyllysine; gamma-glutamyl-epsilon-lysine),Metabolite levels (gamma-glutamylglutamine),Metabolite levels (gamma-glutamylglycine),Metabolite levels (gamma-glutamylthreonine),"Beta-1,4-galactosyltransferase 6 levels (B4GALT6.10832.24.3)",Glutathione S-transferase kappa 1 levels,RBC levels of [Similar to: gamma-Glutamylcysteine; deltaMass: -146.3080 Da],Glutathione S-transferase theta-2B levels,Glutaminyl-peptide cyclotransferase-like protein levels (QPCTL.8866.53.3),UDP-glucuronosyltransferase 1-8 levels,UDP-glucuronosyltransferase 1-6 levels,Metabolite levels (gamma-glutamyl-alpha-lysine),Gamma glutamyltransferase levels x vegetarianism interaction,Glutathione S-transferase A4 levels
Uric acid [Assay Method: Colorimetric (Beckman AU5800)]. Low values (<89) indicated by 8888,Uric acid levels,Urocanic acid levels,Serum uric acid levels,Urine uric Acid levels,Metabolite levels (urate; cmh_urate; Uric_acid),Metabolite levels (trans-urocanate; urocanic acid),RBC levels of Urate (uM),Serum uromodulin levels (antibody-based assay),Urate levels,Trans-urocanate levels,Urinary uromodulin levels (raw),Urinary uric acid excretion,Serum urate levels,Uracil levels,Uric acid clearance,Urinary uric acid to urinary creatinine ratio,Metabolite levels (uracil; Uracil),3-(3-amino-3-carboxypropyl)uridine levels,Metabolite levels (uridine; cmh_uridine; Uridine),Urinary uromodulin levels (indexed to creatinine),Uridine levels,Urea levels,Serum uromodulin levels (aptamer-based assay),Urinary uromodulin levels,Serum urea levels,Plasma trans-urocanate levels in chronic kidney disease,Fractional excretion of uric acid,L-urobilin levels,Uromodulin levels,Serum levels of protein UROS,Urine trans-urocanate levels in chronic kidney disease,Plasma metabolome feature (c18_2957) (Uranyl acetate),Serum uric acid levels in response to allopurinol in gout,Urine pH measurement,Glomerular load of uric acid,Trans-urocanate levels in elite athletes,Uroplakin-3b-like protein levels (UPK3BL.6633.43.3),Cis-urocanate levels in elite athletes,3-Indolepropionic acid to Uric acid ratio in coronary artery disease,N-acetyl neuraminic acid levels,L-Histidine to Uric acid ratio in coronary artery disease,RBC levels of Octadecenoic acid,Metabolite levels (3-ureidopropionate; N-carbamoyl-beta-alanine; n_carbamoyl_B_alanine; N_carbamoyl_beta_alanine),Urate levels in elite athletes,Serum uromodulin concentration,Urate-to-histidine ratio,Uromodulin-like 1 levels,3-Indolepropionic acid to Urocanic acid ratio in coronary artery disease,Ursodeoxycholate levels,Beta-ureidopropionase levels
Lipemia,Hypo-HDL-cholesterolemia,Dyslipidemia,Cholesterol,Disorders of lipid metabolism,Hyperlipidemia,LDL cholesterol,Aplastic anemia,Spontaneous adipocyte lipolysis,Serum levels of protein LIPA,Insulin resistance,LDL (oxidized),High serum lipase activity,Liver fat,Diabetes,Disease topic 09 (Anemia and fracture-plus),Lipid metabolism phenotypes,Lipid or lipoprotein levels,Metabolic syndrome,High cholesterol,Serum levels of protein LIPN,Low-density lipoprotein levels,Fatty liver,Hemoglobin,Red blood cell fatty acid levels,Severe aplastic anemia,ICD10 E78: Disorders of lipoprotein metabolism and other lipidemias,Lipoprotein lipase levels,Lipocalin-1 levels,Iron deficiency,HDL cholesterol,Serum lipase activity,Cardiovascular disease,High-density lipoprotein levels,Low high density lipoprotein cholesterol levels,Lipid traits (pleiotropy) (HIPO component 1),Visceral fat,Lipid traits (pleiotropy) (HIPO component 2),Serum linoleic acid concentration in metabolic syndrome,Low density lipoprotein cholesterol levels,Hyperglycemia,Stimulated adipocyte lipolysis,Lipid traits,Lipocalin-15 levels,Low HDL-cholesterol levels,Phospholipid levels (plasma),Total lipid levels in IDL,2-linoleoylglycerol (18:2) levels in elite athletes,Serum lipopolysaccharide activity,Fasting total lipids in small LDL,ICD10 D63.165.8: Anemia in chronic kidney disease
Icterus,IDP dMRI TBSS ICVF Cingulum cingulate gyrus L,IDP dMRI TBSS MD Cingulum cingulate gyrus L,IDP dMRI TBSS L3 Cingulum cingulate gyrus L,IDP dMRI TBSS L2 Cingulum cingulate gyrus L,IDP dMRI TBSS MD Cingulum cingulate gyrus R,IDP dMRI TBSS ICVF Cingulum cingulate gyrus R,Iritis,IDP dMRI TBSS FA Cingulum cingulate gyrus R,IDP dMRI TBSS MD Uncinate fasciculus L,IDP dMRI TBSS MD Uncinate fasciculus R,IDP dMRI TBSS ISOVF Cingulum cingulate gyrus R,IDP dMRI TBSS L3 Cingulum cingulate gyrus R,IDP dMRI TBSS L2 Cingulum cingulate gyrus R,IDP dMRI TBSS L1 Cingulum cingulate gyrus R,IDP dMRI TBSS FA Uncinate fasciculus L,Pollinosis,DTI TBSS MD Uncinate fasciculus R,DTI TBSS MD Cingulum cingulate gyrus L,DTI TBSS MD Uncinate fasciculus L,IDP dMRI TBSS FA Uncinate fasciculus R,IDUA level (brain),DTI TBSS MD Cingulum cingulate gyrus R,IDP dMRI TBSS ICVF Uncinate fasciculus L,DTI TBSS L3 Cingulum cingulate gyrus L,IDP dMRI TBSS ICVF Medial lemniscus L,DTI TBSS L2 Cingulum cingulate gyrus L,Insular cortex volume,DTI TBSS L1 Cingulum cingulate gyrus L,IDP dMRI TBSS ICVF Fornix cres+Stria terminalis L,IDP dMRI TBSS MO Medial lemniscus L,IDP dMRI TBSS L1 Uncinate fasciculus L,DTI TBSS FA Uncinate fasciculus L,IDP dMRI TBSS FA Tapetum L,IDP dMRI TBSS ICVF Medial lemniscus R,IDP dMRI TBSS MD Sagittal stratum L,IDP dMRI TBSS ICVF Uncinate fasciculus R,DTI TBSS FA Uncinate fasciculus R,IDP dMRI TBSS OD Tapetum R,Hypospadias,IDP dMRI ProbtrackX ICVF ilf l,T1 CAT volume R PrecentralGyrus,DTI TBSS L1 Cingulum cingulate gyrus R,Ringworm,IDP dMRI TBSS L2 Uncinate fasciculus L,DTI TBSS L3 Cingulum cingulate gyrus R,IDP dMRI TBSS MD Sagittal stratum R,IDP dMRI TBSS ICVF Sagittal stratum L,DTI TBSS L2 Cingulum cingulate gyrus R,IDP dMRI TBSS FA Tapetum R,IDP dMRI TBSS OD Cerebral peduncle L
Total cholesterol (Reference Range: < 5.2 mmol/L desirable; 5.2 - 6.1 mmol/L borderline high; ≥ 6.2 mmol/L high; Assay Method: Colorimetric (Beckman AU5800)),Non-HDL cholesterol levels,Total cholesterol levels,Cholesterol levels,Total esterified cholesterol levels (UKB data field 23415),Total cholesterol levels in medium HDL,"Cholesterol, total",Serum total cholesterol levels,Total cholesterol levels (MTAG),Total esterified cholesterol levels,Cholesteryl ester (22:6) levels,HDL cholesterol levels,Cholesterol in medium HDL (UKB data field 23568),Cholesteryl ester (24:5) levels,Cholesteryl ester (20:5) levels,Cholesteryl ester (24:0) levels,Cholesteryl ester (22:0) levels,Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),Cholesteryl ester (24:6) levels,Total cholesterol levels (UKB data field 23400),HDL cholesterol levels (UKB data field 23406),Cholesteryl ester (22:5) (n6) levels,Cholesteryl ester (22:1) levels,Cholesteryl ester (24:1) levels,Cholesteryl ester (22:4) levels,Cholesteryl ester (20:0) levels,Cholesteryl ester (20:1) levels,Cholesteryl ester (15:0) levels,Total cholesterol levels in HDL,Cholesterol levels in IDL,Cholesterol levels (UKB data field 30690),Clinical LDL cholesterol levels (UKB data field 23404),Cholesteryl ester (20:3) levels,Cholesteryl ester (24:4) levels,Cholesterol levels in medium HDL,3beta-hydroxy-5-cholestenoate levels,Total free cholesterol levels,Cholesteryl ester (20:4) levels,Cholesteryl ester (20:2) levels,VLDL cholesterol levels (UKB data field 23403),Cholesteryl ester (18:0) levels,Cholesteryl ester (16:0) levels,Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),X-11820-to-cholesterol ratio,Cholesteryl ester (17:1) levels,Cholesteryl ester (16:1) levels,Total cholesterol levels in medium VLDL,"3beta,7alpha-dihydroxy-5-cholestenoate levels",Free cholesterol in medium HDL (UKB data field 23570),Cholesteryl ester (17:0) levels,Cholesteryl ester (22:5) (n3) levels
Triglycerides (Reference Range: < 1.7 mmol/L optimal; 1.7 - 2.2 mmol/L desirable; 2.3 - 4.4 mmol/L high; ≥ 4.5 mmol/L very high; Assay Method: Colorimetric (Beckman AU5800)),Triglycerides (50:4) levels,Triglycerides (56:9) levels,Triglycerides (58:10) levels,Triglycerides (56:1) levels,Triglycerides (56:2) levels,Triglycerides (51:4) levels,Triglycerides (48:1) levels,Triglycerides (53:1) levels,Triglycerides (51:3) levels,Triglycerides (56:7)A levels,Triglycerides (52:3) levels,Triglycerides (58:5) levels,Triglycerides (58:9) levels,Triglycerides (44:1) levels,Triglycerides (52:1) levels,Triacylglycerol (56:8) [NL-20:4] levels,Triglycerides (58:1) levels,Triacylglycerol (50:3) [NL-16:1] levels,Triglycerides (46:1) levels,Triglycerides (51:1) levels,Triacylglycerol (56:6) [NL-20:4] levels,Triacylglycerol (58:8) [NL-22:6] levels,Triglycerides (44:2) levels,Triglycerides (46:2) levels,Triglyceride levels,Triglycerides (44:0) levels,Triacylglycerol (50:3) [NL-14:1] levels,Triacylglycerol (50:3) [NL-18:1] levels,Triacylglycerol (50:0) [NL-18:0] levels,Triacylglycerol (52:3) [NL-16:1] levels,Triglycerides (46:3)A levels,Triacylglycerol (50:4) [NL-14:0] levels,Triacylglycerol (50:2) [NL-18:2] levels,Triacylglycerol (50:1) [NL-18:1] levels,Triacylglycerol (52:3) [NL-18:2] levels,Triacylglycerol (50:1) [NL-14:0] levels,Triacylglycerol (50:5) levels,Triglycerides (48:2)A levels,Triacylglycerol (52:4) [NL-16:0] levels,Triacylglycerol (48:3) [NL-16:1] levels,Triacylglycerol (52:2) [NL-16:0] levels,Triacylglycerol (51:2) [NL-15:0] levels,Triacylglycerol (52:4) [NL-18:1] levels,Triacylglycerol (56:7) levels,Triacylglycerol (56:8) levels,Triacylglycerol (49:1) [NL-15:0] levels,Triacylglycerol (50:1) levels,Triacylglycerol (50:3) levels,Triacylglycerol (56:5) levels,Triacylglycerol (54:4) [NL-18:2] levels
High density lipoprotein cholesterol (Reference Range: < 1.0 mmol/L low; 1.0 - 1.5 mmol/L desirable; ≥ 1.6 mmol/L optimal; Assay Method: Enzymatic (Beckman AU5800)),Direct low density lipoprotein cholesterol levels,High density lipoprotein cholesterol levels,Low high density lipoprotein cholesterol levels,Low density lipoprotein cholesterol levels,Non-HDL cholesterol levels,High density lipoprotein cholesterol levels (UKB data field 30760),High-density lipoprotein levels,Cholesterol in medium HDL (UKB data field 23568),HDL cholesterol levels,HDL Cholesterol - Triglycerides (HDLC-TG),Direct low density lipoprotein levels (UKB data field 30780),Total cholesterol levels in medium HDL,HDL cholesterol levels (UKB data field 23406),Cholesterol levels in medium HDL,High-density lipoprotein 3 cholesterol levels,Free cholesterol in medium HDL (UKB data field 23570),Cholesterol in small HDL (UKB data field 23575),HDL cholesterol,Low-density lipoprotein levels,Cholesterol in large HDL (UKB data field 23561),Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),Free cholesterol in medium HDL,Total cholesterol levels in HDL,Very low density lipoprotein cholesterol levels,Free cholesterol levels in medium HDL,Total esterified cholesterol levels (UKB data field 23415),Clinical LDL cholesterol levels (UKB data field 23404),Cholesterol to total lipids in small HDL percentage (UKB data field 23645),Cholesterol in medium LDL (UKB data field 23540),Clinical LDL cholesterol levels,Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642),Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Cholesterol in very large HDL (UKB data field 23554),LDL (standard GWA),VLDL cholesterol levels (UKB data field 23403),NHDL cholesterol to HDL cholesterol ratio,Total lipid levels in medium HDL,High-density lipoprotein 2 cholesterol levels,Free cholesterol in large HDL (UKB data field 23563),Free cholesterol in small HDL (UKB data field 23577),Total lipid levels in HDL,LDL cholesterol levels (UKB data field 23405),Hydroxycholesterol_[M+H-2H2O]1+ levels,Free cholesterol in HDL (UKB data field 23422),Total cholesterol in very large HDL meal response (LMM),Cholesterol to total lipids in very large HDL percentage (UKB data field 23630),Cholesterol to total lipids in large HDL percentage (UKB data field 23635),Free cholesterol in very large HDL (UKB data field 23556),Cholesterol in large LDL (UKB data field 23533),Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597)
Low density lipoprotein cholesterol=CHOL-HDL-TG/2.2 (Reference Range: < 2.5 mmol/L optimal; 2.6 - 3.3 mmol/L desirable; 3.4 - 4.0 mmol/L borderline high; 4.1 - 4.8 mmol/L high; ≥ 4.9 mmol/L; Assay Method: Calculated LDL-C = CHOL - HDL-C - TG/2.2),Low density lipoprotein cholesterol levels,Direct low density lipoprotein cholesterol levels,Low high density lipoprotein cholesterol levels,Non-HDL cholesterol levels,Very low density lipoprotein cholesterol levels,Low-density lipoprotein levels,Clinical LDL cholesterol levels,High density lipoprotein cholesterol levels,Clinical LDL cholesterol levels (UKB data field 23404),Total cholesterol levels in medium HDL,High density lipoprotein cholesterol levels (UKB data field 30760),HDL cholesterol levels,HDL cholesterol levels (UKB data field 23406),LDL cholesterol levels (UKB data field 23405),Cholesterol levels in medium HDL,Total cholesterol levels in medium LDL,LDL cholesterol levels,Direct low density lipoprotein levels (UKB data field 30780),Total cholesterol levels in small HDL,HDL triglycerides levels,Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),Cholesterol to total lipids in small HDL percentage (UKB data field 23645),Cholesterol in medium HDL (UKB data field 23568),LDL (standard GWA),X-11820-to-cholesterol ratio,Total cholesterol levels in small LDL,Cholesterol in medium LDL (UKB data field 23540),VLDL cholesterol levels (UKB data field 23403),Total cholesterol to total lipids ratio in medium HDL,Free cholesterol levels in medium HDL,HDL2 cholesterol levels,Cholesterol in small LDL (UKB data field 23547),Total cholesterol to total lipids ratio in small HDL,High-density lipoprotein 3 cholesterol levels,Cholesterol to total lipids ratio in medium HDL,Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642),HDL Cholesterol - Triglycerides (HDLC-TG),Total cholesterol in medium LDL,Free cholesterol in medium HDL (UKB data field 23570),LDL cholesterol to HDL cholesterol ratio,Total cholesterol levels in HDL,Cholesterol in small HDL (UKB data field 23575),Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Cholesterol levels in medium LDL,Total cholesterol to total lipids ratio in medium LDL,Total lipid levels in medium HDL,Cholesterol to total lipids ratio in small HDL,HDL3 cholesterol levels,Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597),LDL triglycerides levels
Derived Variable: Ratio of Total Cholesterol:High-density Lipoprotein Cholesterol (Reference Range: > 4.5 high risk for CHD),High density lipoprotein cholesterol levels (UKB data field 30760),High density lipoprotein cholesterol levels,X-11820-to-cholesterol ratio,VLDL cholesterol levels (UKB data field 23403),HDL cholesterol levels (UKB data field 23406),X-08402-to-cholesterol ratio,Total esterified cholesterol levels (UKB data field 23415),Total cholesterol to total lipids ratio in IDL,Cholesterol in IDL (UKB data field 23526),Cholesterol to total lipids ratio in IDL,Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595),Cholesterol to total lipids in medium HDL percentage (UKB data field 23640),Total cholesterol levels (UKB data field 23400),LDL cholesterol levels (UKB data field 23405),Cholesterol to total lipids in large HDL percentage (UKB data field 23635),Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642),Free cholesterol to total lipids in medium VLDL percentage (UKB data field 23597),Cholesterol to total lipids in small HDL percentage (UKB data field 23645),Cholesterol to total lipids in very large HDL percentage (UKB data field 23630),NHDL cholesterol to HDL cholesterol ratio,Low high density lipoprotein cholesterol levels,Cholesterol to total lipids in small VLDL percentage (UKB data field 23600),High-density lipoprotein 3 cholesterol levels,Direct low density lipoprotein cholesterol levels,Free cholesterol to total lipids in large HDL percentage (UKB data field 23637),Low density lipoprotein cholesterol levels,Cholesterol to total lipids in large VLDL percentage (UKB data field 23590),LDL cholesterol to HDL cholesterol ratio,Cholesterol to total lipids in medium LDL percentage (UKB data field 23620),Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632),Non-HDL cholesterol levels,Cholesterol to total lipids in large LDL percentage (UKB data field 23615),Free cholesterol to total lipids ratio in IDL,Cholesterol levels (UKB data field 30690),Total cholesterol levels,"Remnant cholesterol (non-HDL, non-LDL -cholesterol) levels (UKB data field 23402)",Free cholesterol to total lipids in small VLDL percentage (UKB data field 23602),Free cholesterol to total lipids in small HDL percentage (UKB data field 23647),HDL cholesterol levels,Total cholesterol minus HDL-C levels (UKB data field 23401),Free cholesterol to total lipids in large VLDL percentage (UKB data field 23592),Total cholesterol to total lipids ratio in medium HDL,Free cholesterol in IDL (UKB data field 23528),Cholesterol in medium HDL (UKB data field 23568),Clinical LDL cholesterol levels (UKB data field 23404),Cholesterol to total lipids in very large VLDL percentage (UKB data field 23585),Total esterified cholesterol levels,Cholesterol to total lipids in very small VLDL percentage (UKB data field 23605),HDL cholesterol,High-density lipoprotein 2 cholesterol levels
Insulin (Reference Range: 0-25 mU/L; Assay Method: Sandwich immunoassay (Beckman DxI 800)),Insulin receptor levels (INSR.3448.13.2),Insulin levels,Insulin-related traits,Insulin resistance/response,Insulin-induced gene 1 protein levels,Insulin receptor levels,Insulin resistance,Diabetes related insulin traits,Insulin-like peptide INSL5 levels,Glucose-dependent insulinotropic peptide levels,Insulin-like 3 levels,Insulin-like growth factor I levels (IGF1.2952.75.2),Insulin-related traits (multivariate analysis),Corrected insulin response,Modified Stumvoll Insulin Sensitivity Index,Insulin-like growth factor 1 receptor levels (IGF1R.4232.19.2),Insulinogenic index,Treatment or medication use - insulin product (UKB data field 20003_1140883066),Non-insulin-dependent diabetes mellitus (Union E11),Severe insulin-deficient type 2 diabetes,Insulin-like peptide INSL6 levels,Acute insulin response (insulin secretion adjusted),Incremental insulin,Peak insulin response (insulin secretion adjusted),Glucose-dependent insulinotropic peptide levels in type 2 diabetes,Pancreatic hormone levels (PPY.4588.1.2),Severe insulin-resistant type 2 diabetes,Insulin levels in overweight individuals,Insulin growth factor-like family member 3 levels (IGFL3.6961.14.3),Insulin levels in response to oral glucose tolerance test (30 minutes),Insulin-like growth factor I levels,Insulin levels in response to oral glucose tolerance test (120 minutes),Acute insulin response,Insulin levels in lean individuals,Modified Stumvoll Insulin Sensitivity Index (adjusted for BMI),Peak insulin response (BMI and insulin secretion adjusted),Insulin sensitivity index,Insulin disposition index,Insulin-degrading enzyme levels,Regenerating islet-derived protein 4 levels (REG4.11102.22.3),Insulin-like growth factor-binding protein 3 levels (IGFBP3.2571.12.3),Insulin-like growth factor 1 levels,Insulin-like growth factors,Insulin growth factor-like family member 4 levels (IGFL4.6353.60.3),Area under the curve of insulin levels,Diabetes (standard GWA),Insulin-like growth factor-binding protein 7 levels (IGFBP7.3320.49.2),Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes,Fasting insulin (adjusted for BMI) or polycystic ovary syndrome (pleiotropy),Glucokinase levels (GCK.12960.9.3)
Creatinine (Reference Range: 50 – 90 umol/L; Assay Method: Endpoint creatininase (Beckman AU5800); Remarks: The creatinine assay calibration is traceable to an isotope dilution mass spectrometry (IDMS) reference method using the National Institutes of Standards and Technology (NIST) Standard Reference Material 967.),Creatinine levels,Creatinine levels (UKB data field 23478),Creatinine levels (UKB data field 30700),Serum creatinine levels,Plasma metabolome feature (hilic_502) (Creatinine),Urinary creatinine levels,Creatinine levels in elite athletes,Urinary albumin-to-creatinine ratio,Metabolite levels (creatine),Creatine kinase M-type levels (CKM.2670.67.4),Urinary uromodulin levels (indexed to creatinine),Creatine levels,Creatinine clearance,Protein CREG1 levels (CREG1.9357.4.3),Estimated glomerular filtration rate (creatinine),Chronic kidney disease and serum creatinine levels,Creatine kinase levels,Urinary sodium to creatinine ratio,CRTAM/ICAM3 protein level ratio,"Estimated glomerular filtration rate (creatinine, CKDi25)",Urinary uric acid to urinary creatinine ratio,"Estimated glomerular filtration rate (creatinine, Rapid3)",CRTAM/LY9 protein level ratio,Glomerular filtration rate (creatinine),Urinary potassium to creatinine ratio,Crk-like protein levels (CRKL.9877.28.3),Creatine kinase M-type:Creatine kinase B-type heterodimer levels,CRELD2/HYOU1 protein level ratio,CRADD/NT5C3A protein level ratio,Serine levels (Biocrates platform),Calbindin levels (CALB1.9918.23.3),CRADD/EREG protein level ratio,Urinary magnesium-to-creatinine ratio,CRELD2/NUCB2 protein level ratio,Urinary albumin-to-creatinine ratio in non-diabetics,CREG1/NAAA protein level ratio,Arginine levels (Biocrates platform),Metabolite levels (serine),Creatinine levels in ischemic stroke,Serum levels of protein CREB3L4,Creatine kinase B-type levels,CRTAM/TNFRSF9 protein level ratio,Creatine levels in elite athletes,Endoglin levels (ENG.4908.6.1),CREB-binding protein levels (CREBBP.13614.6.3),CRNN protein levels,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Serum levels of protein CRTAM,Alanine aminotransferase levels (UKB data field 30620),Metabolite levels (uridine; cmh_uridine; Uridine)
High sensitivity C-reactive protein (Reference Range: < 1 mg/L low risk; 1.0 - 3.0 mg/L average risk; > 3.0 mg/L high risk; Assay Method: Colorimetric (Beckman AU5800)). Low values (<0.1) indicated by 8888,High-sensitivity C-reactive protein levels,C-reactive protein levels (CRP.4337.49.2),C-reactive protein levels,Serum C-reactive protein concentration,C-reactive protein levels (MTAG),High-sensitivity C-reactive protein levels in HIV infection,Serum C-reactive protein concentration in inactive individuals,C-reactive protein,C-reactive protein (red blood cell fatty acid level interaction),C-reactive protein levels or total cholesterol levels (pleiotropy),C-reactive protein levels or HDL-cholesterol levels (pleiotropy),C-reactive protein levels or LDL-cholesterol levels (pleiotropy),C-reactive protein and white blood cell count,C-peptide levels,CD63 antigen levels (CD63.9190.7.3),Serum C-reactive protein concentration in non-obese individuals,CD70 protein levels,C-reactive protein levels or triglyceride levels (pleiotropy),Serum C-reactive protein concentration in low fat diet,CD226 antigen levels (CD226.5721.1.3),CD160 protein levels,CD300C/CLEC14A protein level ratio,CD30 Ligand level (CSF),Serum levels of protein CCDC50,Serum levels of protein CCNC,Serum levels of protein CCDC126,CD109 antigen levels (CD109.3290.50.2),CCL17/CD69 protein level ratio,CD70 antigen levels,CD300E/CXCL10 protein level ratio,Serum levels of protein C1RL,CD160 antigen levels,CD6 protein levels,CD300LG/CLEC14A protein level ratio,CD300C/LRRC25 protein level ratio,Serum levels of protein C2orf66,Serum C-reactive protein concentration in high fat diet,CD160/CXCL16 protein level ratio,CD166 antigen levels (ALCAM.5451.1.3),CD69/RHOC protein level ratio,Serum levels of protein CRP,CD69/CHMP1A protein level ratio,Complement factor I levels (CFI.2567.5.6),Calpastatin levels (CAST.3026.5.2),Serum levels of protein CCL13,CD209 antigen levels (CD209.3029.52.2),CDON/SCARA5 protein level ratio,CCDC80/CCL27 protein level ratio,CCL5/CD40LG protein level ratio,Serum levels of protein CCL23
Alanine transaminase (Reference Range: 10 – 70 U/L; Assay Method: Enzymatic (Beckman AU5800); Remarks: without addition of pyridoxal-5-phosphate co-factor). Low values (<6) indicated by 8888,Alanine transaminase levels,Liver enzyme levels (alanine transaminase),Alanine aminotransferase levels,Alanine aminotransferase 1 levels,Alanine aminotransferase levels (UKB data field 30620),Alanine transaminase levels in high alcohol intake,Glutamic oxaloacetic transaminase levels,"Alanine--tRNA ligase, cytoplasmic levels (AARS.12340.17.3)",Metabolite levels (alanine),Alanine levels,Serum glutamic-oxaloacetic transaminase levels,Liver enzyme levels (aspartate transaminase),Serum glutamic-pyruvic transaminase levels,Kynurenine--oxoglutarate transaminase 3 levels (CCBL2.12682.5.3),Aspartate aminotransferase to alanine aminotransferase ratio,Glutamic pyruvic transaminase levels,Transaldolase levels,Chronic elevation of alanine aminotransferase (cALT) levels,Metabolite levels (beta-alanine; beta_alanine),Catalase levels (CAT.3488.64.2),"Alanine--tRNA ligase, cytoplasmic levels",Arylsulfatase K levels (ARSK.8269.327.3),Arylsulfatase B levels (ARSB.3172.28.2),"Aspartate aminotransferase, cytoplasmic levels (GOT1.4912.17.1)",Transketolase levels (TKT.4306.4.2),Kynurenine--oxoglutarate transaminase 3 levels,Metabolite levels (arabinose),Kynurenine-oxoglutarate transaminase 1 levels,Aspartate aminotransferase levels,Alpha-amylase 1 levels (AMY1A.7918.114.3),Alanine levels in elite athletes,Alanine levels (UKB data field 23460),Arylsulfatase A level (CSF),N-acetylmuramoyl-L-alanine amidase levels,L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase levels,Beta-alanine levels,Serum levels of protein ASAH2,Alanine aminotransferase levels in low alcohol consumption,Beta-Ala-His dipeptidase levels,Tryptase alpha/beta-1 levels,"5'(3')-deoxyribonucleotidase, cytosolic type levels (NT5C.12560.9.3)",Serine--pyruvate aminotransferase levels,Kynurenine--oxoglutarate transaminase 1 levels,Metabolite levels (alanylleucine),Alpha-L-iduronidase levels (IDUA.3169.70.2),Aspartate aminotransferase levels (UKB data field 30650),Valine--tRNA ligase levels (VARS.13083.18.3),Endoplasmic reticulum aminopeptidase 2 levels (ERAP2.8960.3.3),Formylglycine-generating enzyme levels,"Aspartate aminotransferase, cytoplasmic levels"
Aspartate transaminase (Reference Range: 10 – 50 U/L; Assay Method: Enzymatic (Beckman AU5800); Remarks: without addition of pyridoxal-5-phosphate co-factor),"Aspartate aminotransferase, cytoplasmic levels (GOT1.4912.17.1)","Aspartate aminotransferase, cytoplasmic levels",Aspartate aminotransferase levels (UKB data field 30650),Aspartate aminotransferase levels,Aspartate aminotransferase to alanine aminotransferase ratio,"Aspartate--tRNA ligase, cytoplasmic levels",Aspartate transaminase levels in high alcohol intake,Liver enzyme levels (aspartate transaminase),Aspartyl aminopeptidase levels,"Aspartate--tRNA ligase, mitochondrial levels",Isoaspartyl peptidase/L-asparaginase levels,Protein-L-isoaspartate(D-aspartate) O-methyltransferase levels,Gamma glutamyl transpeptidase,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase levels,Aspartyl/asparaginyl beta-hydroxylase levels (ASPH.6998.106.3),Aspartoacylase levels,Gut bacterial pathway abundance (ASPASN.PWY..superpathway.of.L.aspartate.and.L.asparagine.biosynthesis),Aspartate levels,Phosphate-regulating neutral endopeptidase levels,"5'(3')-deoxyribonucleotidase, cytosolic type levels (NT5C.12560.9.3)",Glutamic oxaloacetic transaminase levels,Aspartate aminotransferase levels x vegetarianism interaction,Aspartate aminotransferase to alanine aminotransferase ratio x alcohol consumption interaction,Aspartyl/asparaginyl beta-hydroxylase levels,Aspartate aminotransferase levels in low alcohol consumption,"Asparagine--tRNA ligase, cytoplasmic levels",Aspartate aminotransferase levels in non-alcoholic fatty liver disease,Glutamic pyruvic transaminase levels,Aspartate levels in elite athletes,Aspartate aminotransferase levels in excessive alcohol consumption,Serum glutamic-pyruvic transaminase levels,Aspartate aminotransferase levels in low dose methotrexate treatment,"N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase, isoform C levels",Serum glutamic-oxaloacetic transaminase levels,Retroviral-like aspartic protease 1 levels (ASPRV1.13023.8.3),"CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 levels",Kynurenine--oxoglutarate transaminase 3 levels (CCBL2.12682.5.3),"5'(3')-deoxyribonucleotidase, cytosolic type levels",Metabolite levels (aspartate),N-acetylated-alpha-linked acidic dipeptidase 2 levels (NAALAD2.7986.98.3),Alanine transaminase levels,Aspartylphenylalanine levels,Catalase levels (CAT.3488.64.2),Asparagine levels,"Alpha-(1,3)-fucosyltransferase 10 levels",Membrane-bound aminopeptidase P levels,N-acetylated-alpha-linked acidic dipeptidase 2 levels,Inactive C-alpha-formylglycine-generating enzyme 2 levels,"Carbonic anhydrase 5A, mitochondrial levels (CA5A.8791.151.3)","Alpha-(1,3)-fucosyltransferase 10 levels (FUT10.7156.2.3)"
Gamma glutamyl transferase (Reference Range: 10 – 80 U/L; Assay Method: Colorimetric (Beckman AU5800)). Low values (<10) indicated by 8888,Gamma glutamyl transferase levels,Gamma-glutamyl transpeptidase levels,Liver enzyme levels (gamma-glutamyl transferase),Protein-glutamine gamma-glutamyltransferase 2 levels,Protein-glutamine gamma-glutamyltransferase E levels,Gamma-glutamyl hydrolase levels (GGH.9370.69.3),Inactive gamma-glutamyltranspeptidase 2 levels (GGT2.6334.9.3),Gamma glutamyl transpeptidase,Gamma-glutamylcyclotransferase levels,Gamma-glutamylaminecyclotransferase levels,Inactive gamma-glutamyltranspeptidase 2 levels,Gamma-glutamyl hydrolase levels,Gamma-glutamylleucine levels,Gamma glutamyl transferase levels in low alcohol consumption,Glutathione-specific gamma-glutamylcyclotransferase 2 levels,Gamma-glutamylisoleucine levels,Gamma-glutamyltyrosine levels,Gamma-glutamylglycine levels,Glutamic oxaloacetic transaminase levels,Gamma-glutamylvaline levels,Gamma-glutamyl-alpha-lysine levels,Gamma glutamyl transferase levels in excessive alcohol consumption,Gamma-glutamylphenylalanine levels,Gamma-glutamylmethionine levels,Gamma-glutamylglutamate levels,Gamma-glutamyltryptophan levels,Gamma-glutamylthreonine levels,Gamma-glutamylglutamine levels,Glutathione S-transferase A4 levels (GSTA4.14645.253.3),Serum glutamic-oxaloacetic transaminase levels,Gamma-glutamyl-epsilon-lysine levels,Glutathione S-transferase A1 levels (GSTA1.12446.49.3),Metabolite levels (gamma-glutamylglycine),Metabolite levels (gamma-glutamylthreonine),Metabolite levels (gamma-glutamylglutamine),Metabolite levels (gamma-glutamylglutamate),Metabolite levels (gamma-glutamyllysine; gamma-glutamyl-epsilon-lysine),Glutathione S-transferase theta-1 levels,Glutathione S-transferase P levels (GSTP1.4911.49.2),GMP synthase [glutamine-hydrolyzing] levels,Metabolite levels (gamma-glutamyl-alpha-lysine),Glutathione S-transferase Mu 1 levels (GSTM1.7239.9.3),Glutathione S-transferase kappa 1 levels,Glutaminyl-peptide cyclotransferase-like protein levels (QPCTL.8866.53.3),Glutathione S-transferase theta-2B levels,RBC levels of [Similar to: gamma-Glutamylcysteine; deltaMass: -146.3080 Da],"Beta-1,4-galactosyltransferase 6 levels (B4GALT6.10832.24.3)",UDP-glucuronosyltransferase 1-8 levels,UDP-glucuronosyltransferase 1-6 levels,Glutamine levels (Biocrates platform)
Uric acid (Reference Range: 150 – 370 umol/L; Assay Method: Colorimetric (Beckman AU5800)),Uric acid levels,Urocanic acid levels,Serum uric acid levels,Urine uric Acid levels,Metabolite levels (urate; cmh_urate; Uric_acid),Metabolite levels (trans-urocanate; urocanic acid),RBC levels of Urate (uM),Trans-urocanate levels,Urinary uromodulin levels (raw),Uric acid clearance,Urate levels,Urinary uric acid excretion,Uracil levels,Metabolite levels (uracil; Uracil),Serum uromodulin levels (antibody-based assay),Metabolite levels (uridine; cmh_uridine; Uridine),Urinary uric acid to urinary creatinine ratio,Serum urate levels,Uridine levels,3-(3-amino-3-carboxypropyl)uridine levels,Urinary uromodulin levels,L-urobilin levels,Urinary uromodulin levels (indexed to creatinine),Plasma metabolome feature (c18_2957) (Uranyl acetate),Urea levels,Trans-urocanate levels in elite athletes,Uromodulin levels,Cis-urocanate levels in elite athletes,Fractional excretion of uric acid,Serum uromodulin levels (aptamer-based assay),Glomerular load of uric acid,Plasma trans-urocanate levels in chronic kidney disease,Serum levels of protein UROS,Serum urea levels,Urine trans-urocanate levels in chronic kidney disease,Serum uric acid levels in response to allopurinol in gout,Urate levels in elite athletes,3-Indolepropionic acid to Uric acid ratio in coronary artery disease,Beta-ureidopropionase levels,Uromodulin-like 1 levels,Metabolite levels (3-ureidopropionate; N-carbamoyl-beta-alanine; n_carbamoyl_B_alanine; N_carbamoyl_beta_alanine),Succinic acid/Methylmalonic acid levels,Serum uromodulin concentration,3-ureidopropionate levels,3-Indolepropionic acid to Urocanic acid ratio in coronary artery disease,RBC levels of Arachidonic Acid,Urea transporter 2 levels (SLC14A2.12818.159.3),L-Histidine to Uric acid ratio in coronary artery disease,N-acetyl neuraminic acid levels,Urate-to-histidine ratio
Hemolysis (Reference Range: 50),Sickle cell anemia (haemolysis),hemolysis of donated blood (osmotic),Hematuria (moderate to severe),hemolysis of donated blood (oxidative),Hematocrit levels,ICD10 R31: Hematuria,End-stage coagulation,Hematuria,Hematological parameters,hemolysis of donated blood (cold-storage),Hemopexin level (plasma),HEMK2 level (plasma),Hematuria (mild),Hemicentin-2 levels,Hemojuvelin levels (HFE2.3332.57.1),RBC levels of ATP (consider breakdown) (uM),Osmotic hemolysis of cold stored red blood cells,Heme oxygenase 2 levels (HMOX2.2622.18.1),Hemopexin level (CSF),Hemorheological index (nd300 levels),Hemorheological index (nd30 levels),Haptoglobin levels (HP.3054.3.2),Hemojuvelin levels,Heme oxygenase 2 levels,Kidney Injury Molecule levels,Hyper-haemoglobinised percentage of red cells,Fibrinogen levels,Coagulation factor Xa levels (F10.3077.66.2),Coagulation Factor X levels (F10.4878.3.1),Thrombin levels,Hemorheological index (nd1 levels),Coagulation factor levels,Hemoglobin levels,Coagulation Factor V level (CSF),Acute kidney injury (model 3),Hematocrit,Fibrinogen levels or factor VII levels or factor XI levels or tissue plasminogen activator levels (pleiotropy),Relative index of whole blood hyposectomy,Heme oxygenase 1 levels,Acute kidney injury (model 2),HEMK2 level (CSF),Hemopexin levels,"Metabolite levels (Fibrinopeptide A, phosphono-ser(3); ADpSGEGDFXAEGGGVR)",aparc-a2009s lh volume G-oc-temp-med-Lingual,RBC levels of 15-HETE,Thrombin generation parameter (peak thrombin generation),"Haptoglobin, Mixed Type level (plasma)",Thrombomodulin levels,Coagulation Factor XI level (plasma),Acute kidney injury (model 1)
Lipemia (Reference Range: 40),Lipocalin-15 levels,Lipid or lipoprotein levels,Serum levels of protein LIPA,Low-density lipoprotein levels,High-density lipoprotein levels,Low high density lipoprotein cholesterol levels,Triacylglycerol (56:6) [NL-20:4] levels,Triacylglycerol (56:8) [NL-20:4] levels,Triacylglycerol (58:8) [NL-22:6] levels,Lipoprotein (a) levels,Fatty acids (20:5) levels,Triacylglycerol (52:3) [NL-18:2] levels,Triglycerides (49:0) levels,Triglycerides (44:0) levels,Lipoprotein lipase levels,Red blood cell fatty acid levels,Triacylglycerol (52:4) [NL-18:1] levels,Triacylglycerol (50:2) [NL-18:2] levels,Triglycerides (51:4) levels,Triacylglycerol (49:1) [NL-18:1] levels,Triacylglycerol (54:4) [NL-18:2] levels,Triglycerides (44:2) levels,Triacylglycerol (54:5) [NL-18:1] levels,Hypo-HDL-cholesterolemia,Triacylglycerol (50:3) [NL-18:1] levels,Triglycerides (58:10) levels,Triacylglycerol (54:3) [NL-18:1] levels,Triacylglycerol (52:3) [NL-16:1] levels,Triglycerides (44:1) levels,Triacylglycerol (49:1) [NL-16:0] levels,Triacylglycerol (50:0) [NL-18:0] levels,Triacylglycerol (52:2) [NL-16:0] levels,Triacylglycerol (50:1) [NL-18:1] levels,Triacylglycerol (52:4) [NL-16:0] levels,Lipocalin-1 levels,Diacylglycerol (16:0_20:4) levels,Triglycerides (58:5) levels,Triacylglycerol (54:2) [NL-18:0] levels,Triglycerides (51:1) levels,Triacylglycerol (54:4) [NL-18:0] levels,Triglycerides (58:1) levels,Low density lipoprotein cholesterol levels,Triacylglycerol (51:1) [NL-18:1] levels,Triacylglycerol (50:3) [NL-16:1] levels,Triglycerides (51:3) levels,Clinical LDL cholesterol levels (UKB data field 23404),Diacylglycerol (18:0_20:4) levels,Triglycerides (58:9) levels,Triacylglycerol (51:0) [NL-16:0] levels,Triacylglycerol (54:1) [NL-18:1] levels
Icterus (Reference Range: 2),T1 CAT volume R PrecentralGyrus,IDP dMRI TBSS L2 Cingulum cingulate gyrus L,IDP dMRI TBSS L3 Cingulum cingulate gyrus L,IDP dMRI TBSS MD Cingulum cingulate gyrus L,Cervical intraepithelial neoplasia grade 3,IDP dMRI TBSS ICVF Cingulum cingulate gyrus L,OTU97_95 (Cytophagales) prevalence,IDP dMRI TBSS L1 Cingulum cingulate gyrus R,OTU99_108 (Cytophagales) prevalence,Golgin subfamily A member 7 levels,IDP T1 FIRST right caudate volume,Golgin subfamily A member 3 levels,IDP dMRI TBSS L2 Cingulum cingulate gyrus R,Corneocyte area,IDP dMRI TBSS MD Uncinate fasciculus R,OTU99_13 (Subdoligranulum) prevalence,IDP dMRI TBSS MD Uncinate fasciculus L,OTU97_13 (Subdoligranulum) prevalence,Integral membrane protein 2A levels (ITM2A.7765.15.3),IDP dMRI TBSS FA Genu of corpus callosum,DTI TBSS L2 Cingulum cingulate gyrus L,IDP dMRI TBSS L3 Cingulum cingulate gyrus R,"ICD10 R16: Hepatomegaly and splenomegaly, not elsewhere classified",IDP T1 FIRST left caudate volume,DTI TBSS L1 Cingulum cingulate gyrus L,DTI TBSS L3 Cingulum cingulate gyrus L,IST1 homolog levels (IST1.12434.25.3),IDP dMRI TBSS MD Genu of corpus callosum,IDP dMRI TBSS ICVF Medial lemniscus L,T1 CAT volume R PostcentralGyrus,IDP dMRI TBSS MD Cingulum cingulate gyrus R,"ICD10 R16.1: Splenomegaly, not elsewhere classified",OTU99_53 (Aestuariispira) prevalence,IDP dMRI TBSS FA Middle cerebellar peduncle,IDP dMRI TBSS L1 Uncinate fasciculus L,DTI TBSS MD Uncinate fasciculus L,DTI TBSS MD Uncinate fasciculus R,DTI TBSS MD Cingulum cingulate gyrus L,DTI TBSS MD Genu of corpus callosum,Intracranial germ cell tumors,Indolin-2-one levels,OTU97_50 (Aestuariispira) prevalence,O_Selenomonadales prevalence,OTU97_130 (Butyrivibrio) prevalence,IDP dMRI TBSS ICVF Cingulum cingulate gyrus R,IDP dMRI TBSS L2 Anterior limb of internal capsule L,Gestational length in nulliparas,IDP dMRI TBSS FA Cingulum cingulate gyrus R,IDP dMRI TBSS L1 Anterior limb of internal capsule L,IDP dMRI TBSS L2 Retrolenticular part of internal capsule L
2-Hour Insulin. High values (>300) indicated by 8888,Treatment or medication use - insulin product (UKB data field 20003_1140883066),Insulin levels,Acute insulin response (insulin secretion adjusted),Insulin receptor levels (INSR.3448.13.2),Two-hour glucose,2-hour postprandial insulin levels in prediabetes,Peak insulin response (insulin secretion adjusted),Insulin-like 3 levels,Glucagon levels (GCG.4891.50.1),Incremental insulin,Modified Stumvoll Insulin Sensitivity Index,Acute insulin response,Insulin levels in response to oral glucose tolerance test (120 minutes),Diabetes (standard GWA),Severe insulin-deficient type 2 diabetes,Fasting insulin z-score (>85th percentile),Insulin disposition index,Corrected insulin response,Insulin levels in response to oral glucose tolerance test (30 minutes),Fasting insulin levels in prediabetes,Response to glipizide (Insulin levels at 30 minutes),Severe insulin-resistant type 2 diabetes,Peak insulin response (BMI and insulin secretion adjusted),Glucose levels (UKB data field 30740),Area under the curve of insulin levels,Two-hour glucose challenge,Pancreatic hormone levels (PPY.4588.1.2),Oral glucose tolerance test-2h,Fasting insulin z-score (>75th percentile),Response to metfomin (Insulin levels at 60 minutes),Fasting insulin,Insulin resistance/response,Insulin receptor levels,Peak insulin response,Glucose levels (Biocrates platform),Glucose levels (UKB data field 23470),Type 2 diabetes (time to event),Diabetes mellitus (UKB data field 2443),Fasting blood insulin,Insulin secretion rate,Glucose levels,Type ii diabetes,Blood glucose levels,Type 2 diabetes (age of onset),Fasting insulin z-score (>50th percentile),Fasting insulin z-score (<25th percentile),Modified Stumvoll Insulin Sensitivity Index (adjusted for BMI),Fasting insulin z-score (<15th percentile),Insulinogenic index,Insulin sensitivity index
Notes about data,Quantitative traits,Reading and spelling,Dimensional psychopathology (Social),Information processing speed,T1 CAT volume L VIIIb,Latent naming speed,T1 CAT volume L IX,Academic attainment (science),Social science traits (pleiotropy) (HIPO component 1),T1 CAT volume R IX,T1 CAT volume L VIIIa,IDP dMRI TBSS FA Tapetum L,Dimensional psychopathology (Positive),Personality dimensions,Dimensional psychopathology (Cognitive),aparc-DKTatlas lh volume lingual,aparc-Desikan lh volume lingual,Intelligence (MTAG),Beef consumption (UKB data field 1369),Dimensional psychopathology (Negative),T1 CAT volume L VIIb,ECG latent space,Systemising,Verbal-numerical reasoning,IDP dMRI TBSS MD Cingulum hippocampus R,aparc-DKTatlas rh volume lingual,T1 CAT volume R VIIb,IDP dMRI TBSS FA Tapetum R,DTI TBSS FA Tapetum L,Intelligence,Dimensional psychopathology (Arousal),Biomedical quantitative traits,aparc-Desikan rh volume lingual,Externalizing behaviour (multivariate analysis),Verbal learning,Mean corpuscular volume (UKB data field 30040),Loneliness (linear analysis),IDP dMRI TBSS MD Cingulum hippocampus L,IDP dMRI TBSS OD Tapetum R,Working memory,DTI autoptx FA ml l tract,DTI TBSS MD Tapetum L,DTI TBSS MD Tapetum R,Academic attainment (maths),Disease topic 34,Job SOC coding: Heavy goods vehicle drivers (UKB data field 22617_8211),"Alcohol consumption (drinks per month) (UKB data field 1578, 4424)",aparc-DKTatlas lh area lingual,IDP dMRI TBSS ICVF Tapetum L,Cholesterol in IDL (UKB data field 23526)
Choline (Reported Values: 5-15),Choline levels,Total cholines levels,Total cholines levels (UKB data field 23436),Choline levels (advanced age),RBC levels of Choline,Cholate levels,Choline phosphate levels,Choline levels (elderly offspring),Choline levels in elite athletes,4-cholesten-3-one levels,Postprandial total cholines,3-hydroxy-5-cholestenoic acid levels,Cholesteryl ester (15:0) levels,Cholesteryl ester (18:0) levels,Phosphatidylcholine and other choline levels,Cholesteryl ester (22:0) levels,Cholesteryl ester (20:0) levels,Cholesteryl ester (20:5) levels,Cholesteryl ester (16:0) levels,Cholesteryl ester (18:3) levels,Cholesteryl ester (22:6) levels,Cholesteryl ester (20:3) levels,Cholesteryl ester (24:0) levels,Cholesteryl ester (22:4) levels,Choline/ethanolamine kinase levels (CHKB.13117.232.3),Cholesteryl ester (18:2) levels,Cholesteryl ester (17:0) levels,Cholesteryl ester (20:4) levels,Cholesteryl ester (24:5) levels,Cholesteryl ester (14:0) levels,Cholesteryl ester (20:2) levels,Cholesteryl ester (24:6) levels,Total cholesterol levels (UKB data field 23400),Cholesteryl ester (22:5) (n6) levels,Cholesteryl ester (22:1) levels,Cholic acid glucuronide levels,Cholesteryl ester (20:1) levels,Urine choline levels in chronic kidney disease,Cholesteryl ester (16:2) levels,Cholesteryl ester (24:4) levels,Cholesteryl ester (16:1) levels,Metabolite levels (3b-hydroxy-5-cholenoic acid),Cholesterol levels (UKB data field 30690),Cholesteryl ester (24:1) levels,Cholesteryl ester (22:5) (n3) levels,Cholesteryl ester (17:1) levels,"Phosphatidylcholine (18:0/20:2, 20:0/18:2, 18:1/20:1) levels",Cholinesterase levels,Palmitoylcholine levels,Plasma choline levels in chronic kidney disease
Trimethylamineoxide (Reported Values: 0.5-60),Trimethylamine n-oxide levels,Trimethylamine levels,Plasma trimethylamine N-oxide levels,"1,3,7-trimethylurate levels","Hydroxy-N6,N6,N6-trimethyllysine levels","Metabolite levels (N-6-trimethyllysine; N6,N6,N6-trimethyllysine; N6.N6.N6-trimethyllysine)",Plasma trimethyllysine levels,Methioninesulfoxide levels,"N6,n6,n6-trimethyllysine levels",Trimethylamine N-oxide levels in elite athletes,"N,N,N-trimethyl-5-aminovalerate levels",Metabolite levels (3-methoxytyramine sulfate),"Metabolite levels (N,N,N-trimethyl-5-aminovalerate; N-trimethyl 5-aminovalerate)",N-trimethyl 5-aminovalerate (X-21365) levels,3-methoxytyramine sulfate levels,Metabolite levels (adrenate (22:4n6); adrenate),2-hydroxy-4-(methylthio)butanoic acid levels,"1,3,7-trimethylurate levels in elite athletes",1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Metabolite levels (eicosapentaenoate (EPA; 20:5n3); eicosapentaenoate),Metabolite levels (2-hydroxystearate),Methionine sulfoxide levels,Metabolite levels (5-acetylamino-6-formylamino-3-methyluracil),5-acetylamino-6-formylamino-3-methyluracil levels,Metabolite levels (hypotaurine),Metabolite levels (myristoleate (14:1n5); myristoleic acid),2-methoxyacetaminophen sulfate levels,Sulfatide (d18:1/24:0(OH) levels) levels,"3-hydroxyanthranilate 3,4-dioxygenase levels (HAAO.5861.78.3)",Metabolite levels (5-dodecenoate (12:1n7); 5-dodecenoate),Metabolite levels (C16:0 CE; C16_0_CE),Metabolite levels (methyl-4-hydroxybenzoate sulfate),Metabolite levels (N-formylanthranilic acid),Metabolite levels (C20:5 CE; C20_5_CE),Stearic acid (18:0) levels,Metabolite levels (methionine sulfone),Metabolite levels (ethylmalonate),Neutral ceramidase levels (ASAH2.3212.30.3),Metabolite levels  (X-11787),Sulfatide (d18:1/16:0(OH) levels) levels,Metabolite levels (docosapentaenoate (n3 DPA; 22:5n3)),Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),"Metabolite levels (ceramide (d18:1/20:0, d16:1/22:0, d20:1/18:0))",X-11593--O-methylascorbate levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Metabolite levels (3-methoxytyrosine),Metabolite levels (salicylate; Salicylate*),Sulfatide (d18:1/24:1(OH) levels) levels,Metabolite levels (dihydroorotate),Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels
Betaine (Reported Values: 20-60),Betaine levels,Metabolite levels (betaine),Beta-alanine levels,Metabolite levels (beta-alanine; beta_alanine),Betaine levels in individuals undergoing cardiac evaluation,Betaine levels in elite athletes,Plasma betaine levels in chronic kidney disease,Urine betaine levels in chronic kidney disease,N-acetyl-beta-alanine levels,Metabolite levels (N-acetyl-beta-alanine),Betaine-to-pyroglutamine ratio,Metabolite levels (valine),Beta-defensin 119 levels (DEFB119.13455.10.3),Metabolite levels (tryptophan betaine),Valine levels,N-carbamoyl-beta-alanine levels,Beta-aminoisobutyric acid levels,Beta-defensin 110 levels,Tryptophan betaine  levels,Tryptophan betaine levels,Beta-trace protein levels,Valine levels (Biocrates platform),Beta-defensin 104 levels (DEFB104A.5763.67.3),Beta-defensin 128 levels,Beta-defensin 116 levels,Beta-defensin 119 levels,Beta-defensin 128 levels (DEFB128.6360.7.3),Beta-klotho levels,Metabolite levels (beta-hydroxyisovalerate),Beta-defensin 105 levels (DEFB105A.10962.46.3),Beta-defensin 103 levels,Beta-defensin 113 levels,Metabolite levels (beta-citrylglutamate),Histidine betaine (hercynine) levels,Beta-defensin 106 levels,Beta-defensin 136 levels,Beta-defensin 135 levels,Metabolite levels (beta-hydroxyisovaleroylcarnitine),Beta-defensin 121 levels,Beta-defensin 104 levels,Beta-defensin 112 levels (DEFB112.5689.1.3),Beta-defensin 112 levels,Beta-defensin 132 levels,Beta-defensin 129 levels,Beta-crystallin B1 levels,Lithostathine-1-beta levels,Beta-hydroxyisovaleroylcarnitine levels,Beta-citrylglutamate levels,Dystrobrevin beta levels,Urine beta-alanine levels in chronic kidney disease
Dimethylglycine (Reported Values: 1.5-5),Dimethylglycine levels,Metabolite levels (dimethylglycine),Picolinoylglycine (X-12170) levels,Metabolite levels (isovalerylglycine),Metabolite levels (N-acetylglycine; acetylglycine),Hexanoylglycine levels,Glycine levels (Biocrates platform),Metabolite levels (glycine),Metabolite levels (hexanoylglycine),Metabolite levels (isobutyrylglycine),Isovalerylglycine levels,Propionylglycine levels,Isobutyrylglycine levels,Metabolite levels (3-hydroxybutyroylglycine),Dimethylglycine levels in elite athletes,Dihydroceramide (d18:0/20:0) levels,Dihydroceramide (d18:0/24:0) levels,"Cis-3,4-methyleneheptanoylglycine levels",Dihydroceramide (d18:0/22:0) levels,Dihydroceramide (d18:0/24:1) levels,Glycine levels,Dihydroceramide (d18:0/18:0) levels,Glycine levels (UKB data field 23462),"X-12442--5,8-tetradecadienoate levels",Metabolite levels (propionylglycine),3-hydroxybutyroylglycine levels,N-acetylglycine levels,Metabolite levels (isoleucylglycine),Metabolite levels (gamma-glutamylglycine),Isoleucylglycine levels,Metabolite levels (docosapentaenoate (n6 DPA; 22:5n6); docosapentaenoate),Metabolite levels (cysteinylglycine),Metabolite levels (trans-2-hexenoylglycine),Metabolite levels (2-butenoylglycine),"N,n-dimethylalanine (X-23585) levels",Picolinoylglycine levels,Metabolite levels (cysteinylglycine disulfide),Dimethylglycine levels in chronic kidney disease,Metabolite levels (cinnamoylglycine),Metabolite levels (5-dodecenoate (12:1n7); 5-dodecenoate),Metabolite levels (phenylalanylglycine),Metabolite levels (tigloylglycine),Cinnamoylglycine levels,Metabolite levels (leucylglycine),Decadienedioic acid (c10:2-dc) (X-21792) levels,N-(2-furoyl)glycine levels,Gamma-glutamylglycine levels,Metabolite levels (docosahexaenoate (DHA; 22:6n3); docosahexaenoate),Glycine levels (Metabolon platform),Butyrylglycine levels
Total homocysteine (Reported Values: 6-20),Homocysteine levels,Plasma homocysteine levels,Plasma homocysteine levels (post-methionine load test),Cysteine levels,RBC levels of S-Adenosyl-L-homocysteine,X-11786--methylcysteine levels,Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine),S-methylcysteine levels,Metabolite levels (S-methylcysteine; methylcysteine),Cysteinylglycine levels,AHCY/HSPA1A protein level ratio,Plasma metabolome feature (hilic_5137) (Cysteineglutathione disulfide),Serum levels of protein HDAC8,AHCY/SNAP23 protein level ratio,Metabolite levels (HVA/5-HIAA ratio),AHCY/FADD protein level ratio,Phosphopantothenoylcysteine decarboxylase levels,Metabolite levels (cysteinylglycine),Cysteine sulfinic acid levels,Serum levels of protein HNF4A,Haptoglobin levels (HP.3054.3.2),AHCY/KYAT1 protein level ratio,Cysteine levels in elite athletes,RBC levels of [Similar to: gamma-Glutamylcysteine; deltaMass: -146.3080 Da],Hydantoin-5-propionic acid levels,Cysteine-glutathione disulfide levels,Metabolite levels (HVA-5-HIAA Factor score),N-acetylthreonine levels,Serum levels of protein HCAR2,Metabolite levels (5-HIAA),AHCY/FABP5 protein level ratio,Metabolite levels (cysteine-glutathione disulfide),7-alpha-hydroxy-3-oxo-4-cholestenoate (7-hoca) levels,HCC 4 plasma levels,4-hydroxyphenylacetoylcarnitine levels,S-methylmethionine--homocysteine S-methyltransferase BHMT2 levels,Protein MENT levels (MENT.5744.12.3),Serum levels of protein DHFR,Serum levels of protein HHIP,Cyclin-H levels (CCNH.9848.22.3),Metabolite levels (cysteinylglycine disulfide),HAGH/HBQ1 protein level ratio,Hepatocyte growth factor levels (HGF.2681.23.2),S-methylcysteine sulfoxide levels,HAGH/HMBS protein level ratio,Serum levels of protein KLK8,Histidine betaine (hercynine) levels,Cysteine-rich protein 1 levels,Serum levels of protein HAAO,Holo-Transcobalamin-2 levels
Creatine (Reported Values: 10-100),Creatine levels,Metabolite levels (creatine),Creatine levels in elite athletes,Creatine kinase M-type levels (CKM.2670.67.4),Creatinine levels in elite athletes,Carnitine levels in elite athletes,Creatinine levels,Creatine kinase levels,Serum creatinine levels,Eicosenoylcarnitine (C20:1) levels in elite athletes,Myristoylcarnitine (C14) levels in elite athletes,Creatine kinase B-type levels,Creatinine levels (UKB data field 23478),Creatinine levels (UKB data field 30700),Glutarylcarnitine (C5-DC) levels in elite athletes,Deoxycarnitine levels in elite athletes,Decanoylcarnitine (C10) levels in elite athletes,Laurylcarnitine (C12) levels in elite athletes,Cerotoylcarnitine (C26) levels in elite athletes,Propionylcarnitine (C3) levels in elite athletes,Ximenoylcarnitine (C26:1) levels in elite athletes,Myristoleoylcarnitine (C14:1) levels in elite athletes,Isovalerylcarnitine (C5) levels in elite athletes,Urinary creatinine levels,Carnitine levels,Metabolite levels (carnitine),Creatine kinase levels in off-statin users,Creatine kinase M-type:Creatine kinase B-type heterodimer levels,Protein MENT levels (MENT.5744.12.3),Margaroylcarnitine levels in elite athletes,Protein DEPP levels (DEPP.7178.59.3),Acetylcarnitine (C2) levels in elite athletes,Octanoylcarnitine (C8) levels in elite athletes,Arachidonoylcarnitine (C20:4) levels in elite athletes,Linoleoylcarnitine (C18:2) levels in elite athletes,Maximum creatine kinase levels in statin users,Glucagon levels (GCG.4891.50.1),Cripto levels (serum),Hexanoylcarnitine (C6) levels in elite athletes,Adipoylcarnitine (C6-DC) levels in elite athletes,"Creatine kinase U-type, mitochondrial levels",Cis-4-decenoylcarnitine (C10:1) levels in elite athletes,3-hydroxybutyrylcarnitine (2) levels in elite athletes,Dihomo-linolenoylcarnitine (20:3n3 or 6) levels in elite athletes,Protein MENT levels,Stearoylcarnitine (C18) levels in elite athletes,10-nonadecenoate (19:1n9) levels in elite athletes,CRTAM/LY9 protein level ratio,Linolenoylcarnitine (C18:3) levels in elite athletes,3-hydroxybutyrylcarnitine (1) levels in elite athletes
Creatinine (Reported Values: 50-100),Creatinine levels,Serum creatinine levels,Urinary creatinine levels,Creatinine levels (UKB data field 23478),Creatinine levels (UKB data field 30700),Creatinine levels in elite athletes,Creatine levels,Chronic kidney disease and serum creatinine levels,Glomerular filtration rate (creatinine),Urinary potassium to creatinine ratio,Urinary albumin-to-creatinine ratio,Estimated glomerular filtration rate (creatinine),Urinary sodium to creatinine ratio,Urinary uromodulin levels (indexed to creatinine),"Estimated glomerular filtration rate (creatinine, Rapid3)","Estimated glomerular filtration rate (creatinine, CKDi25)",Creatine kinase M-type levels (CKM.2670.67.4),Creatinine clearance,Glomerular filtration rate in non diabetics (creatinine),Urinary albumin-to-creatinine ratio in non-diabetics,Metabolite levels (creatine),Creatinine levels (adjusted for BMI) x vegetarianism interaction,Urinary magnesium-to-creatinine ratio,Peak creatinine levels in vancomycin therapy,Plasma metabolome feature (hilic_502) (Creatinine),Serum levels of protein CROT,Glucagon levels (GCG.4891.50.1),Ketonuria (moderate to severe),Cripto levels (serum),Serum urea levels,Creatine kinase levels,Glomerular filtration rate in diabetics (creatinine),Calnexin levels (CANX.8834.58.3),Endostatin levels (COL18A1.2201.17.6),Creatine levels in elite athletes,Nephronectin levels,Serum levels of protein CRAT,Serum levels of protein CRTAM,Creatinine levels x vegetarianism interaction,Urine 6-hydroxymelatonin sulfate-to-creatinine ratio,Ketonuria (mild),Bipolar disorder or glomerular filtration rate estimated from creatine (MTAG),Proteinuria (moderate to severe),Urinary uric acid to urinary creatinine ratio,Maximum creatine kinase levels in statin users,Creatine kinase levels in statin users,Calpastatin levels (CAST.3026.5.2),Elafin levels (PI3.4982.54.1),Creatinine levels in ischemic stroke,Plasma serine levels in chronic kidney disease
Methionine (Reported Values: 18-50),Methionine levels,Methionine levels (Biocrates platform),Methionine synthase levels,Methionine levels (Metabolon platform),Methionine sulfone levels,Metabolite levels (methionine sulfone),RBC levels of Methionine,Methioninesulfoxide levels,Methionine sulfoxide levels,Methionine levels in elite athletes,Metabolite levels (N-acetylthreonine),Metabolite levels (3-methoxytyrosine),3-methoxytyrosine levels,Metabolite levels (hypotaurine),Metabolite levels  (X-11787),N-acetylthreonine levels,Methionine sulfone levels in elite athletes,Plasma homocysteine levels (post-methionine load test),Metabolite levels (threonine),Metabolite levels (12-HETE),Metabolite levels (5-HIAA),5-acetylamino-6-amino-3-methyluracil levels,Metabolite levels (dimethylglycine),Plasma metabolome feature (hilic_977) (Metenamine),Methionine sulfoxide levels in elite athletes,Methionine aminopeptidase 2 levels,Methoxychlor levels,Metabolite levels (HWESASLLR),"Metabolite levels (N6,N6-dimethyllysine; N6.N6-dimethyllysine)",5-methyluridine (ribothymidine) levels,Metabolite levels (C20:5 CE; C20_5_CE),"Metabolite levels (sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0))",Metabolite levels (myristoleate (14:1n5); myristoleic acid),Metabolite levels (C18:3 CE; C18_3_CE),5-acetylamino-6-formylamino-3-methyluracil levels,"Metabolite levels (sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0))",RBC levels of 2S-5S-Methionine sulfoximine,Hypotaurine levels,Metabolite levels (3-methoxytyramine sulfate),Metabolite levels (C38_5_PC),"Metabolite levels (sphingomyelin (d18:1/17:0, d17:1/18:0, d19:1/16:0))","Metabolite levels (sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0))",Metabolite levels (homostachydrine),Metabolite levels (isoleucylthreonine),Threonine levels (Biocrates platform),Metabolite levels (1-methylhistidine),Alkylphosphatidylethanolamine (O-18:0/22:5) levels,Metabolite peak levels (QI9368),Metabolite peak levels (QI15965),Metabolite levels (2-aminoadipate; cmh_aminoadipate)
Methionine sulfoxide (Reported Values: 0.5-5),Methionine sulfoxide levels,Methionine sulfone levels,Metabolite levels (methionine sulfone),Methioninesulfoxide levels,Sulfatide (d18:1/24:0(OH) levels) levels,Sulfatide (d18:1/16:0(OH) levels) levels,Sulfatide (d18:1/24:1(OH) levels) levels,Sulfatide (d18:1/24:0) levels,Sulfatide (d18:1/16:0) levels,Dimethyl sulfone levels,Sulfatide (d18:1/24:1) levels,Methionine sulfoxide levels in elite athletes,S-methylcysteine sulfoxide levels,3-methoxytyramine sulfate levels,Total Sulfatide levels,RBC levels of 2S-5S-Methionine sulfoximine,Metabolite levels (3-methoxytyramine sulfate),Methionine-R-sulfoxide reductase B3 levels,2-methoxyacetaminophen sulfate levels,Methionine levels (Biocrates platform),Methionine sulfone levels in elite athletes,Metabolite levels (3-methoxytyrosine),Urine methionine sulfoxide levels in chronic kidney disease,Sulfhydryl oxidase 2 levels (QSOX2.8397.147.3),3-methoxytyrosine levels,Pregnenediol sulfate (C21H34O5S) levels,Sulfiredoxin-1 levels,Methoxychlor levels,Methionine levels,4-methylcatechol sulfate levels,X-11593--O-methylascorbate levels,O-methylcatechol sulfate levels,Metabolite levels (sulfate),Mitochondrial peptide methionine sulfoxide reductase levels,"1,2,3-benzenetriol sulfate (2) levels",5-hydroxy-2-methylpyridine sulfate levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),Dimethyl sulfone levels in elite athletes,Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),Lithocholate sulfate (1) (X-17469) levels,3-methyl catechol sulfate (1) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Metabolite levels (lithocholate sulfate (1)),Plasma metabolome feature (c18_450) (Sulfoacetate),Perfluorooctanesulfonate (PFOS) levels,Plasma metabolome feature (c18_1550) (Bis(methylsulfonylmethyl) disulfide),Sulfhydryl oxidase 1 levels (QSOX1.6217.23.3),"2,6-dihydroxybenzoic acid (X-09789) levels",Pregnenediol disulfate (C21H34O8S2) levels,Plasma metabolome feature (c18_1507) (5-Sulfo-13-benzenedicarboxylic acid)
Total cysteine (Reported Values: 150-400),Cysteine levels,Cysteine s-sulfate levels,Cysteine sulfinic acid levels,Cysteinylglycine levels,Cysteine levels in elite athletes,Metabolite levels (cysteinylglycine),X-11786--methylcysteine levels,Metabolite levels (cysteinylglycine disulfide),Cysteine-glutathione disulfide levels,Cysteinylglycine disulfide levels,Metabolite levels (cysteine-glutathione disulfide),Cysteine-rich protein 2 levels,Urine cysteine levels in chronic kidney disease,Homocysteine levels,Cystine levels,S-methylcysteine levels,Metabolite levels (S-methylcysteine; methylcysteine),Phosphopantothenate--cysteine ligase levels,Cysteine-rich protein 1 levels,Plasma metabolome feature (hilic_5137) (Cysteineglutathione disulfide),Cystatin-8 levels (CST8.10572.65.3),Plasma cysteinylglycine disulfide* levels in chronic kidney disease,Cysteine s-sulfate levels in elite athletes,Cystatin-F levels (CST7.3302.58.1),Cysteine sulfinic acid levels in elite athletes,CCDC80/CCL27 protein level ratio,Cyclin-C levels (CCNC.7817.36.3),Urine cysteinylglycine disulfide* levels in chronic kidney disease,Phosphopantothenoylcysteine decarboxylase levels,Cytohesin-2 levels (CYTH2.12533.135.3),Plasma homocysteine levels,Urine 3-S-cysteinyl-2-methylpropanoate* levels in chronic kidney disease,Plasma cysteinylglycine levels in chronic kidney disease,Cytidine levels,Cysteine protease ATG4A levels,Cystatin-M levels (CST6.3303.23.2),S-methylcysteine sulfoxide levels,Urine cysteinylglycine levels in chronic kidney disease,Serum levels of protein C2orf66,Plasma homocysteine levels (post-methionine load test),Cysteine and glycine-rich protein 2 levels,Cystatin M level (CSF),Cystatin-SA levels,Protein MENT levels (MENT.5744.12.3),Metabolite levels (cytidine),Cystatin C levels (UKB data field 30720),Cyclin-H levels (CCNH.9848.22.3),Vitamin levels,Cystatin-8 levels,Cystatin-F levels
Histidine (Reported Values: 50-100),Histidine levels,Histidine levels (UKB data field 23463),Histidine levels (Biocrates platform),Histidine betaine (hercynine) levels,Histidine levels (Metabolon platform),Histidine levels in elite athletes,Metabolite levels (histidylvaline),Metabolite levels (histidylleucine),Urine histidine levels in chronic kidney disease,Glutamine-to-histidine ratio,Metabolite levels (1-methylhistidine),Metabolite levels (N-acetylhistidine),1-methylhistidine levels,N-acetylhistidine levels,Histidine meal response (LMM),Metabolite levels (N-acetyl-1-methylhistidine),N-acetyl-1-methylhistidine levels,Histidine-rich glycoprotein levels,N-acetyl-3-methylhistidine levels,Metabolite levels (N-acetyl-3-methylhistidine),Urate-to-histidine ratio,Gamma-glutamylhistidine levels,Fasting histidine,Histatin-3 levels,Histatin-1 levels (HTN1.10608.9.3),Histatin-1 levels,Metabolite levels (histidylphenylalanine),Orotidine levels,Histidine meal response (OrNLSr),L-Histidine to Uric acid ratio in coronary artery disease,"5,6-dihydrouridine (X-11429) levels",Metabolite levels (orotidine),Myristoylcarnitine levels,Pseudouridine levels,Serum levels of protein HIST3H2A,"5,6-dihydrouridine levels",Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Cytidine levels,5-methyluridine (ribothymidine) levels,Serum levels of protein HIST2H2BE,Metabolite levels (cytidine),1-methylhistidine levels in elite athletes,Myocilin levels,Dihydroceramide (d18:0/20:0) levels,Myristoleoylcarnitine levels,Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),Gamma-glutamylhistidine levels in elite athletes,Dihydroceramide (d18:0/18:0) levels,Dihydroceramide (d18:0/24:0) levels,Dihydroceramide (d18:0/22:0) levels
3-Methylhistidine (3-MH) (Reported Values: 2.7-10),Metabolite levels (1-methylhistidine),1-methylhistidine levels,N-acetyl-3-methylhistidine levels,Metabolite levels (N-acetyl-3-methylhistidine),Metabolite levels (N-acetyl-1-methylhistidine),N-acetyl-1-methylhistidine levels,Metabolite levels (N-acetylhistidine),3-methylhistidine levels in elite athletes,Plasma metabolome feature (c18_1013) (N-Acetylhistidine),1-methylhistidine levels in elite athletes,Histidine levels (UKB data field 23463),N-acetylhistidine levels,Histidine levels (Biocrates platform),Histidine levels,Histidine levels (Metabolon platform),Metabolite levels (1-methylhistamine; _1_methylhistamine),N-acetyl-3-methylhistidine levels in elite athletes,"5,6-dihydrouridine (X-11429) levels",Metabolite levels (hypotaurine),Metabolite levels (3-methylcytidine),Metabolite levels (2-aminoadipate; cmh_aminoadipate),Plasma metabolome feature (hilic_1928) ((3S)-3-Hydroxy-L-enduracididine),Metabolite levels (histidylvaline),Metabolite levels (C18:3 CE; C18_3_CE),Metabolite levels (5-HIAA),Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),Metabolite levels (malate; cmh_malate; Malate),"5,6-dihydrouridine levels",Metabolite levels (histidylphenylalanine),Metabolite levels (2'-O-methyluridine),N-acetyl-1-methylhistidine levels in elite athletes,3-methylcytidine levels,Metabolite levels (ethylmalonate),Metabolite levels (histidylleucine),Metabolite levels (3-methoxytyramine sulfate),Gamma-glutamylhistidine levels,Plasma metabolome feature (hilic_300) (()-2-Methylthiazolidine),Urine 1-methylhistidine levels in chronic kidney disease,Metabolite levels (myristoleate (14:1n5); myristoleic acid),5-methyluridine (ribothymidine) levels,Metabolite levels (HWESASLLR),Metabolite levels (2'-O-methylcytidine),Metabolite levels (HVA/5-HIAA ratio),2'-o-methyluridine levels,Plasma N-acetyl-3-methylhistidine* levels in chronic kidney disease,Urate-to-histidine ratio,Metabolite levels (5-HIAA/ MHPG Ratio),"3,4-methyleneheptanoate levels",Metabolite levels (uridine; cmh_uridine; Uridine),Metabolite levels  (X-11787)
1-Methylhistidine (1-MH); <Limit Of Detection indicated by 8881 (Reported Values: 0.5-15),1-methylhistidine levels,Metabolite levels (1-methylhistidine),N-acetyl-1-methylhistidine levels,N-acetyl-3-methylhistidine levels,Metabolite levels (N-acetyl-1-methylhistidine),Metabolite levels (1-methylhistamine; _1_methylhistamine),Metabolite levels (N-acetyl-3-methylhistidine),Plasma metabolome feature (c18_1013) (N-Acetylhistidine),Metabolite levels (N-acetylhistidine),1-methylhistidine levels in elite athletes,Histidine levels (UKB data field 23463),"5,6-dihydrouridine (X-11429) levels",Histidine levels (Biocrates platform),N-acetylhistidine levels,Histidine levels (Metabolon platform),Plasma metabolome feature (hilic_1928) ((3S)-3-Hydroxy-L-enduracididine),Urine 1-methylhistidine levels in chronic kidney disease,Gamma-glutamylhistidine levels,Histidine levels,1-methylnicotinamide levels,Plasma metabolome feature (hilic_956) (NaNa-Dimethylhistamine),Metabolite levels (2-aminoadipate; cmh_aminoadipate),3-methylhistidine levels in elite athletes,1-methylurate levels,Metabolite levels (hypotaurine),Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),1-methylxanthine levels,2'-o-methyluridine levels,"5,6-dihydrouridine levels",Phosphatidate_34:2_[M-H]1- levels,Metabolite levels (1-methylurate),5-methyluridine (ribothymidine) levels,Monohexosylceramide (d16:1/22:0) levels,Metabolite levels (ethylmalonate),Metabolite levels (1-methylxanthine),Lysophosphatidylethanolamine_16:0_[M-H]1- levels,Methylmalonate (mma) levels,Plasma metabolome feature (hilic_901) (Dimethylphenylenediamine),Metabolite levels (histidylvaline),Metabolite levels  (X-11787),Metabolite levels (histidylphenylalanine),Monohexosylceramide (d16:1/24:0) levels,Hydroxycholesterol_[M+H-2H2O]1+ levels,N-acetyl-1-methylhistidine levels in elite athletes,Metabolite levels (2'-O-methyluridine),Plasma metabolome feature (hilic_300) (()-2-Methylthiazolidine),Monohexosylceramide (d16:1/18:0) levels,Lysophosphatidylethanolamine_20:0_[M-H]1- levels,Monohexosylceramide (d16:1/20:0) levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels
Citrulline (Reported Values: 10-60),Citrulline levels,Treatment or medication use - codeine (UKB data field 20003_1140884444),RBC levels of Citrate,Metabolite levels (N-acetylcitrulline),Calpastatin levels (CAST.3026.5.2),N-acetylcitrulline levels,Calretinin levels,Acylcarnitine (10:0) levels,Calnexin levels (CANX.8834.58.3),X-12244--N-acetylcarnosine levels,Acylcarnitine (14:0) levels,Acylcarnitine (12:0) levels,Metabolite levels (beta-citrylglutamate),Cerotoylcarnitine (C26) levels,Metabolite levels (cinnamoylglycine),Acylcarnitine (10:1) levels,Acylcarnitine (18:0) levels,Kallistatin levels (SERPINA4.3449.58.2),Response to citalopram treatment,Acylcarnitine (13:0) levels,Acylcarnitine (14:1) levels,Treatment or medication use - elleste duet conti tablet (UKB data field 20003_1141156644),"Metabolite levels (ceramide (d16:1/24:1, d18:1/22:1))",Metabolite levels  (X-11787),Metabolite levels (C38_5_PC),Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),Acylcarnitine (18:1) levels,L-Citrulline to 3-Indolepropionic acid ratio in coronary artery disease,Treatment or medication use - maxalt 5mg tablet (UKB data field 20003_1141167940),Calcineurin levels,Acylcarnitine (15:0) (a) levels,Acylcarnitine (14:2) levels,X-12510--2-aminooctanoic acid levels,Metabolite levels (indoleacetoylcarnitine),X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Cortolone glucuronide (1) (X-17359) levels,Postprandial citrate,Metabolite levels (N-acetylputrescine),Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Acylcarnitine (16:0) levels,Metabolite levels (N-acetylhomocitrulline),Thioproline levels,Cinnamoylglycine levels,Indoleacetoylcarnitine levels,Cystatin-8 levels (CST8.10572.65.3),Metabolite levels (homocitrulline),Treatment or medication use - atorvastatin (UKB data field 20003_1141146234),Acylcarnitine (17:0) (a) levels,Calcipressin-1 levels (RCAN1.13465.5.3),Acetylcarnitine (c2) levels
Ornithine (Reported Values: 30-90),Ornithine levels,Ornithine levels (Biocrates platform),Metabolite levels (ornithine),Ornithine levels in elite athletes,Ornithine levels (Metabolon platform),Plasma metabolome feature (c18_389) (Ornithine),Ornithine decarboxylase levels,Urine ornithine levels in chronic kidney disease,Docosatrienoate (22:3n3) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Docosatrienoate (22:3n6) levels,Stearidonate (18:4n3) levels,1-arachidonoyl-GPA (20:4) levels,Ceramide (d17:1/24:0) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,1-margaroyl-2-arachidonoyl-GPC (17:0/20:4) levels,Stearidonate 18:4n3 levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Ceramide (d17:1/20:0) levels,Ceramide (d17:1/24:1) levels,Metabolite levels  (X-11787),Nisinate (24:6n3) levels,Ceramide (d18:2/26:0) levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Ceramide (d17:1/18:0) levels,Metabolite levels (10-undecenoate (11:1n1)),Ceramide (d17:1/22:0) levels,Arachidonate (20:4n6) levels (advanced age),2-oxoarginine levels,Ceramide (d19:1/26:0) levels,Ceramide (d18:2/24:0) levels,1-arachidoyl-2-arachidonoyl-GPC (20:0/20:4) levels,Ceramide (d18:1/26:0) levels,Butyrobetaine levels,"4,6-dinitro-o-cresol levels",1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,Ceramide (d18:2/14:0) levels,Ceramide (d18:1/24:0) levels,1-arachidonoyl-GPI (20:4) levels,Ceramide (d19:1/24:0) levels,Ceramide (d18:2/24:1) levels,1-arachidonoyl-GPC (20:4) levels,N-acetylornithine levels,Androstenedione levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,N-alpha-acetylornithine levels,Ceramide (d17:1/16:0) levels,Treatment or medication use - glyceryl trinitrate (UKB data field 20003_1140860834),1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels
Arginine (Reported Values: 40-100),Arginine levels,Arginine levels (Biocrates platform),L-arginine levels,Metabolite levels (arginine),Arginine levels (Metabolon platform),Arginine levels in elite athletes,Plasma metabolome feature (c18_789) (Arginine),Plasma arginine levels in chronic kidney disease,N-acetylarginine levels,Argininosuccinate synthase levels,N-alpha-acetylarginine levels,Alanine levels,Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Homoarginine levels,X-12244--N-acetylcarnosine levels,Metabolite levels (homoarginine),Plasma argininate* levels in chronic kidney disease,Piperine levels,Protein-arginine deiminase type-2 levels,Metabolite levels (alanine),Protein-arginine deiminase type-4 levels,Metabolite levels (N-acetylcarnosine),N-acetylmethionine levels,Kynurenine levels,Acylcarnitine (14:0) levels,Acylcarnitine (10:0) levels,N-acetylcarnosine levels,Alanine levels (UKB data field 23460),Metabolite levels (N-acetylasparagine),3-amino-2-piperidone levels,Arginine/serine-rich protein 1 levels,Valine levels,Acylcarnitine (12:0) levels,Argininate levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Urine argininate* levels in chronic kidney disease,Protein arginine N-methyltransferase 3 levels,Acylcarnitine (18:0) levels,Arginase-1 levels,Acylcarnitine (14:1) levels,Acylcarnitine (10:1) levels,Acylcarnitine (13:0) levels,N-acetyl-isoputreanine (X-12688) levels,Neugrin levels,X-12510--2-aminooctanoic acid levels,Metabolite levels (valine),Acylcarnitine (16:0) levels,Metabolite levels (10-undecenoate (11:1n1)),N-acetyl-beta-alanine levels,N-acetylvaline levels
Asymmetric dimethylarginine (Reported Values: 0.4-0.8),Asymmetrical dimethylarginine levels,Serum dimethylarginine levels (asymmetric/symetric ratio),Symmetrical dimethylarginine levels,Symmetric dimethylarginine levels,Dimethylarginine (sdma + adma) levels,Symmetric dimethylarginine levels in chronic kidney disease,Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),Asymmetrical dimethylarginine levels in osteoarthritis,"N2,n2-dimethylguanosine levels","N,n-dimethylalanine (X-23585) levels",Dimethylarginine dimethylaminohydrolase 1 levels,Dimethylarginine (SDMA + ADMA) levels in elite athletes,"N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 levels","N,N-dimethylalanine levels",N-acetylarginine levels,Arginine levels (Biocrates platform),"Indoleacetate-to-N2,N2-dimethylguanosine ratio",Docosatrienoate (22:3n3) levels,"1,2-dilinoleoyl-GPE (18:2/18:2) levels",Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),Metabolite levels (5-dodecenoate (12:1n7); 5-dodecenoate),Docosatrienoate (22:3n6) levels,N-alpha-acetylarginine levels,"1,2-dilinoleoyl-GPC (18:2/18:2) levels",Urine dimethylarginine (SDMA + ADMA) levels in chronic kidney disease,"N6,N6-dimethyllysine levels",1-methylguanosine levels,N2-methylguanosine levels,Dimethylglycine levels,Stearidonate 18:4n3 levels,Plasma dimethylarginine (SDMA + ADMA) levels in chronic kidney disease,Stearidonate (18:4n3) levels,Docosapentaenoate (n6 DPA; 22:5n6) levels,"N2,N5-diacetylornithine levels",Dodecadienoate (12:2) (X-21343) levels,Tetradecenoylcarnitine levels,Docosapentaenoate (n3 DPA; 22:5n3) levels,"N2-acetyl,N6,N6-dimethyllysine levels",Asparagine levels,N1-methyladenosine levels,1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n3) levels,1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels,Docosapentaenoate n3 DPA; 22:5n3 levels,Homoarginine levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,L-arginine levels,Tetradecadienylcarnitine levels,Dihydroceramide (d18:0/20:0) levels,"X-12442--5,8-tetradecadienoate levels",Decadienedioic acid (c10:2-dc) (X-21792) levels
Symmetric dimethylarginine (Reported Values: 0.4-0.9),Symmetric dimethylarginine levels,Symmetrical dimethylarginine levels,Asymmetrical dimethylarginine levels,Serum dimethylarginine levels (asymmetric/symetric ratio),Dimethylarginine (sdma + adma) levels,Metabolite levels (dimethylarginine (SDMA + ADMA); ADMA),Symmetric dimethylarginine levels in chronic kidney disease,"N2,n2-dimethylguanosine levels","N,n-dimethylalanine (X-23585) levels",Dimethylarginine dimethylaminohydrolase 1 levels,Docosatrienoate (22:3n3) levels,"N,N-dimethylalanine levels","N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 levels",Docosatrienoate (22:3n6) levels,N-acetylarginine levels,Dimethylarginine (SDMA + ADMA) levels in elite athletes,Metabolite levels (5-dodecenoate (12:1n7); 5-dodecenoate),Arginine levels (Biocrates platform),Asymmetrical dimethylarginine levels in osteoarthritis,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,"1,2-dilinoleoyl-GPE (18:2/18:2) levels",Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),"N2,N5-diacetylornithine levels",Dodecadienoate (12:2) (X-21343) levels,"1,2-dilinoleoyl-GPC (18:2/18:2) levels","N6,N6-dimethyllysine levels",Docosapentaenoate (n6 DPA; 22:5n6) levels,"X-12442--5,8-tetradecadienoate levels",N-alpha-acetylarginine levels,Dimethylglycine levels,1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Stearidonate (18:4n3) levels,Stearidonate 18:4n3 levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,"Indoleacetate-to-N2,N2-dimethylguanosine ratio",Docosapentaenoate (n3 DPA; 22:5n3) levels,Docosapentaenoate n3 DPA; 22:5n3 levels,Metabolite levels (dimethylglycine),Dihydroceramide (d18:0/20:0) levels,1-methylguanosine levels,"N2-acetyl,N6,N6-dimethyllysine levels",Diglycerides (36:3) levels,N2-methylguanosine levels,Urine dimethylarginine (SDMA + ADMA) levels in chronic kidney disease,Dihydroceramide (d18:0/22:0) levels,1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3) levels,Metabolite levels (arginine),Plasma dimethylarginine (SDMA + ADMA) levels in chronic kidney disease
Homoarginine (Reported Values: 1-6),Homoarginine levels,Metabolite levels (homoarginine),Homoarginine levels in elite athletes,Arginine levels (Biocrates platform),Plasma homoarginine levels in chronic kidney disease,L-arginine levels,Urine homoarginine levels in chronic kidney disease,Arginine levels,Metabolite levels (arginine),Homostachydrine levels,Metabolite levels (homostachydrine),N-acetylarginine levels,Arginine levels (Metabolon platform),Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),N-alpha-acetylarginine levels,4-hydroxyphenylacetoylcarnitine levels,2-aminoheptanoate levels,Alanine levels (UKB data field 23460),Plasma metabolome feature (c18_789) (Arginine),Arginine levels in elite athletes,Serum dimethylarginine levels (asymmetric/symetric ratio),Asymmetrical dimethylarginine levels,Metabolite levels (5-HIAA/ MHPG Ratio),Metabolite levels (adrenate (22:4n6); adrenate),Metabolite levels (5-HIAA),1-methylguanosine levels,Urine homocarnosine levels in chronic kidney disease,Haptoglobin levels (HP.3054.3.2),Piperine levels,"3,4-methyleneheptanoate levels",Serine levels,Glucuronide of piperine metabolite C17H21NO3 (4) levels,"N2,n2-dimethylguanosine levels","N,N,N-trimethyl-5-aminovalerate levels",X-12244--N-acetylcarnosine levels,Glucuronide of piperine metabolite C17H21NO3 (5) levels,Metabolite levels (HVA/5-HIAA ratio),Alanine levels,Arginine/serine-rich protein 1 levels,3-hydroxyoleoylcarnitine levels,Stearidonate (18:4n3) levels,Metabolite levels (serine),Semaphorin-6A levels (SEMA6A.7945.10.3),Glucuronide of piperine metabolite C17H21NO3 (3) levels,Stearidonate 18:4n3 levels,Adrenate (22:4n6) levels,Homocitrulline levels,Margaroylcarnitine (C17) levels,Metabolite levels (alanine),N-acetylcarnosine levels
Trimethyllysine (Reported Values: 0.3-2),Plasma trimethyllysine levels,"N6,n6,n6-trimethyllysine levels","Hydroxy-N6,N6,N6-trimethyllysine levels","1,3,7-trimethylurate levels","Metabolite levels (N-6-trimethyllysine; N6,N6,N6-trimethyllysine; N6.N6.N6-trimethyllysine)",1-stearoyl-2-oleoyl-GPE (18:0/18:1) levels,Sterol ester (27:1/20:4) levels,Sterol ester (27:1/20:5) levels,Sterol ester (27:1/22:6) levels,Sterol ester (27:1/20:3) levels,Sterol ester (27:1/18:3) levels,Sterol ester (27:1/20:2) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,Sterol ester (27:1/16:0) levels,Sterol ester (27:1/18:2) levels,Sterol ester (27:1/14:0) levels,Sterol ester (27:1/17:0) levels,Sterol ester (27:1/18:0) levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels,Sterol ester (27:1/16:1) levels,1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels,1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) levels,Sulfatide (d18:1/16:0(OH) levels) levels,Sulfatide (d18:1/24:0(OH) levels) levels,Sterol ester (27:1/18:1) levels,Sterol ester (27:1/17:1) levels,Metabolite levels (glycosyl-N-stearoyl-sphingosine (d18:1/18:0)),Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) levels,Sulfatide (d18:1/24:1(OH) levels) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,Trimethylamine levels,1-stearoyl-2-oleoyl-GPI (18:0/18:1) levels,Metabolite levels (5-hydroxylysine),1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,1-palmitoyl-2-oleoyl-GPE (16:0/18:1) levels,Sulfatide (d18:1/24:0) levels,Sulfatide (d18:1/16:0) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,Metabolite levels (N6-methyllysine),1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,"4-androsten-3beta,17beta-diol monosulfate (2) levels",1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) levels,4-ethylphenylsulfate levels,Sulfatide (d18:1/24:1) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,Metabolite levels (2-hydroxystearate)
Butyrobetaine; <Limit Of Detection indicated by 8881 (Reported Values: 0.4-2),Butyrobetaine levels,Biglycan levels (BGN.13690.26.3),OTU99_155 (Butyrivibrio) abundance,OTU97_130 (Butyrivibrio) abundance,Semaphorin-6A levels (SEMA6A.7945.10.3),1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-oleoyl-2-docosahexaenoyl-GPE (18:1/22:6) levels,Semaphorin-3G levels (SEMA3G.5628.21.3),1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Progonadoliberin-2 levels,Nidogen-2 levels (NID2.3633.70.5),Progonadoliberin-2 levels (GNRH2.10708.3.3),Semaphorin-5A levels (SEMA5A.13132.14.3),Dodecadienoate (12:2) (X-21343) levels,Docosatrienoate (22:3n6) levels,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Calnexin levels (CANX.8834.58.3),1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,Metabolite levels (deoxycarnitine; butyrobetaine),1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Semaphorin-3E levels (SEMA3E.5363.51.3),OTU97_130 (Butyrivibrio) prevalence,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,1-palmitoyl-2-docosahexaenoyl-GPE (16:0/22:6) levels,1-stearoyl-2-oleoyl-GPE (18:0/18:1) levels,1-palmitoyl-2-oleoyl-GPE (16:0/18:1) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,"4-androsten-3beta,17beta-diol disulfate 2 levels",Docosatrienoate (22:3n3) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Butyrate/isobutyrate (4:0) levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Nucleolin levels (NCL.13655.34.3),Treatment or medication use - glyceryl trinitrate (UKB data field 20003_1140860834),Semaphorin-3C levels (SEMA3C.6448.36.3),Talin-2 levels (TLN2.14082.56.3),"X-12442--5,8-tetradecadienoate levels",1-(1-enyl-palmitoyl)-2-oleoyl-GPE (p-16:0/18:1) levels,Progonadoliberin-1 levels,1-(1-enyl-stearoyl)-2-oleoyl-GPE (p-18:0/18:1) levels,Semaphorin-3B levels (SEMA3B.5667.3.3),1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels,OTU99_155 (Butyrivibrio) prevalence,Spread type: Flora Pro-Active/Benecol (UKB data field 1428_2),Butyrylcarnitine levels (Biocrates platform),UPF0696 protein C11orf68 levels (C11orf68.8307.47.3),Granulins levels (GRN.4992.49.1)
Carnitine (Reported Values: 20-80),Carnitine levels,Carnitine C10 levels,Carnitine levels (Biocrates platform),Carnitine-to-X-12798 ratio,Metabolite levels (carnitine),Carnitine C12 levels,Carnitine C8 levels,Carnitine C18:2 levels,Carnitine C14:1 levels,Carnitine levels (Metabolon platform),Carnitine C9 levels,Carnitine C6 levels,Carnitine C4 levels,Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),2-tetradecenoyl carnitine levels (Biocrates platform),RBC levels of L-Carnitine,RBC levels of L-Carnitine.1,Glutaroyl carnitine levels (Biocrates platform),Carnitine C14:2 levels,Metabolite levels (nonanoylcarnitine (C9); C9 carnitine; C9_carnitine),Glutaroyl carnitine levels,Hydroxyisovaleroyl carnitine levels (Biocrates platform),Metabolite levels (acetylcarnitine; acetylcarnitine (C2); C2 carnitine; C2_carnitine),Carnitine levels in elite athletes,Hydroxyisovaleroyl carnitine levels,Acylcarnitine (18:0) levels,Metabolite levels (octanoylcarnitine; octanoylcarnitine (C8); C8 carnitine; C8_carnitine),2-tetradecenoyl carnitine levels (Metabolon platform),Acylcarnitine (14:0) levels,Acylcarnitine (18:1) levels,Metabolite levels (propionylcarnitine; propionylcarnitine (C3); C3 carnitine; C3_carnitine),RBC levels of acetyl-carnitine,Metabolite levels (tiglyl carnitine; tiglylcarnitine (C5:1-DC); C5:1 carnitine; C5_1_carnitine),Acylcarnitine (10:0) levels,Metabolite levels (butyrylcarnitine; butyrylcarnitine (C4); C4 carnitine; C4_carnitine),Carnitine O-acetyltransferase levels,Metabolite levels (decanoylcarnitine; decanoylcarnitine (C10); C10 carnitine; C10_carnitine),Acylcarnitine (14:1) levels,Metabolite levels (hexanoylcarnitine; hexanoylcarnitine (C6); C6 carnitine; C6_carnitine),Acylcarnitine (12:0) levels,Acylcarnitine (10:1) levels,Metabolite levels (cis-4-decenoyl carnitine; cis-4-decenoylcarnitine (C10:1)),Metabolite levels (linoleoylcarnitine; linoleoylcarnitine (C18:2); C18:2 carnitine; C18_2_carnitine),Acylcarnitine (13:0) levels,Metabolite levels (oleoylcarnitine; oleoylcarnitine (C18:1); C18:1 carnitine; C18_1_carnitine),Metabolite levels (laurylcarnitine; laurylcarnitine (C12); C12 carnitine; C12_carnitine),RBC levels of Undecanoyl carnitine,Acylcarnitine (18:2) levels,Total Acylcarnitine levels,Decanoylcarnitine (C10) levels
Acetylcarnitine (Reported Values: 3-15),Acetylcarnitine levels,Acetylcarnitine (c2) levels,Acetylcarnitine levels (Biocrates platform),Acylcarnitine (15:0) (a) levels,Acylcarnitine (18:0) levels,Acylcarnitine (18:1) levels,Acylcarnitine (17:0) (a) levels,Acylcarnitine (14:0) levels,Acylcarnitine (13:0) levels,Acylcarnitine (16:0) levels,Acylcarnitine (14:1) levels,Acylcarnitine (18:2) levels,Acylcarnitine (16:1) levels,Acylcarnitine (12:0) levels,Acylcarnitine (14:2) levels,Acylcarnitine (10:0) levels,Acylcarnitine (10:1) levels,Octadecenoylcarnitine levels,Acylcarnitine (15:0) (b) levels,Octadecandienylcarnitine levels,3-hydroxyoctanoylcarnitine (2) levels,Palmitoleoylcarnitine (C16:1) levels,Octadecadienylcarnitine levels,X-12244--N-acetylcarnosine levels,3-hydroxyoctanoylcarnitine (1) levels,Acylcarnitine (17:0) (b) levels,Oleoylcarnitine (C18:1) levels,Lignoceroylcarnitine (C24) levels,Acetylcarnitine levels (Metabolon platform),Nervonoylcarnitine (C24:1) levels,Cerotoylcarnitine (C26) levels,Arachidonoylcarnitine (C20:4) levels,Margaroylcarnitine (C17) levels,Metabolite levels (acetylcarnitine; acetylcarnitine (C2); C2 carnitine; C2_carnitine),Phenylacetylcarnitine levels,Acetylcarnitine-to-hexanoylcarnitine ratio,Metabolite levels (arachidonoylcarnitine (C20:4)),Hexadecenoylcarnitine levels,Eicosenoylcarnitine (C20:1) levels,N-acetylcarnosine levels,Metabolite levels (N-acetylcarnosine),Ximenoylcarnitine (C26:1) levels,Total Acylcarnitine levels,Succinylcarnitine levels,3-hydroxyoleoylcarnitine levels,Myristoylcarnitine (C14) levels,Acetylcarnitine (C2) levels in elite athletes,Tetradecenoylcarnitine levels,Tiglylcarnitine (C5:1-DC) levels,Linoleoylcarnitine (C18:2) levels
Propionylcarnitine (Reported Values: 0.2-1.5),Propionylcarnitine levels,Propionylcarnitine levels (Biocrates platform),Propionylcarnitine (c3) levels,Metabolite levels (propionylcarnitine; propionylcarnitine (C3); C3 carnitine; C3_carnitine),Undecenoylcarnitine (c11:1) (X-17337) levels,Propionylcarnitine levels (Metabolon platform),Undecenoylcarnitine (C11:1) levels,Metabolite levels (nonanoylcarnitine (C9); C9 carnitine; C9_carnitine),Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),Acylcarnitine (12:0) levels,Metabolite levels (suberoylcarnitine (C8-DC)),Acylcarnitine (18:0) levels,Laurylcarnitine (C12) levels,Pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels,Acylcarnitine (10:0) levels,Metabolite levels (pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC)),Acylcarnitine (14:0) levels,Carnitine C10 levels,Propionylcarnitine-to-isovalerylcarnitine ratio,Suberoylcarnitine (C8-DC) levels,Acylcarnitine (18:1) levels,Decanoylcarnitine (C10) levels,Octadecanedioylcarnitine (C18-DC) levels,Acylcarnitine (13:0) levels,Acylcarnitine (10:1) levels,Arachidoylcarnitine (C20) levels,Acylcarnitine (14:1) levels,Acylcarnitine (15:0) (a) levels,Docosapentaenoylcarnitine (C22:5n3) levels,Carnitine C14:1 levels,Stearoylcarnitine (C18) levels,Metabolite levels (methylsuccinoylcarnitine),Acylcarnitine (17:0) (a) levels,Linolenoylcarnitine (C18:3) levels,Pimelylcarnitine levels,Nonanoylcarnitine (C9) levels,Carnitine C12 levels,Carnitine C18:2 levels,Metabolite levels (dihomo-linolenoylcarnitine (C20:3n3 or 6)),Docosahexaenoylcarnitine (C22:6) levels,Acylcarnitine (16:0) levels,Metabolite levels (isobutyrylcarnitine; isobutyrylcarnitine (C4)),Carnitine-to-X-12798 ratio,Acetylcarnitine (c2) levels,Butyrylcarnitine (C4) levels,Acylcarnitine (18:2) levels,Hexanoylcarnitine (C6) levels,Metabolite levels (octanoylcarnitine; octanoylcarnitine (C8); C8 carnitine; C8_carnitine),Metabolite levels (linolenoylcarnitine (C18:3)),Methylsuccinoylcarnitine levels
Butyrylcarnitine (Reported Values: 0.1-0.5),Butyrylcarnitine levels,Butyrylcarnitine levels (Biocrates platform),Butyrylcarnitine (C4) levels,Butyrylcarnitine levels (Metabolon platform),Metabolite levels (deoxycarnitine; butyrobetaine),Metabolite levels (butyrylcarnitine; butyrylcarnitine (C4); C4 carnitine; C4_carnitine),Undecenoylcarnitine (c11:1) (X-17337) levels,Acylcarnitine (14:0) levels,Acylcarnitine (15:0) (a) levels,Acylcarnitine (14:1) levels,Acylcarnitine (10:0) levels,Acylcarnitine (18:0) levels,Acylcarnitine (17:0) (a) levels,Acylcarnitine (16:0) levels,Acylcarnitine (12:0) levels,Nervonoylcarnitine (C24:1) levels,Acylcarnitine (18:1) levels,Undecenoylcarnitine (C11:1) levels,Acylcarnitine (10:1) levels,Acylcarnitine (16:1) levels,Acylcarnitine (13:0) levels,Carnitine-to-X-12798 ratio,Metabolite levels (nonanoylcarnitine (C9); C9 carnitine; C9_carnitine),Acylcarnitine (15:0) (b) levels,Metabolite levels (suberoylcarnitine (C8-DC)),Acylcarnitine (17:0) (b) levels,Acylcarnitine (14:2) levels,Laurylcarnitine levels (Biocrates platform),Metabolite levels (methylsuccinoylcarnitine),Myristoylcarnitine (C14) levels,Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),Suberoylcarnitine (C8-DC) levels,Acylcarnitine (18:2) levels,Metabolite levels (pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC)),Lignoceroylcarnitine (C24) levels,Hexanoylcarnitine levels (Biocrates platform),Carnitine C10 levels,Margaroylcarnitine (C17) levels,Carnitine C18:2 levels,Carnitine C14:1 levels,Docosapentaenoylcarnitine (C22:5n3) levels,Propionylcarnitine levels (Biocrates platform),Pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels,Total Acylcarnitine levels,Linolenoylcarnitine (C18:3) levels,Metabolite levels (linolenoylcarnitine (C18:3)),Methylsuccinoylcarnitine levels,X-13431--nonanoylcarnitine levels,Myristoleoylcarnitine (C14:1) levels,Stearoylcarnitine levels (Biocrates platform)
Isovalerylcarnitine; <Limit Of Detection indicated by 8881 (Reported Values: 0.06-0.2),Isovalerylcarnitine levels,Isovalerylcarnitine levels (Biocrates platform),Isovalerylcarnitine (C5) levels,Isobutyrylcarnitine levels,Isovalerylcarnitine levels (Metabolon platform),Isobutyrylcarnitine (c4) levels,Undecenoylcarnitine (c11:1) (X-17337) levels,Hydroxyvalerylcarnitine levels,Oleoylcarnitine (C18:1) levels,Hexadecenoylcarnitine levels,Isovalerylglycine levels,Undecenoylcarnitine (C11:1) levels,Octadecenedioylcarnitine (C18:1-DC) levels,Metabolite levels (isobutyrylcarnitine; isobutyrylcarnitine (C4)),Arachidoylcarnitine (C20) levels,Arachidonoylcarnitine (C20:4) levels,Octadecadienylcarnitine levels,Lignoceroylcarnitine (C24) levels,Octadecanedioylcarnitine (C18-DC) levels,Octadecenoylcarnitine levels,Octadecandienylcarnitine levels,"X-12442--5,8-tetradecadienoate levels",Tetradecenoylcarnitine levels,Laurylcarnitine levels (Biocrates platform),Tetradecadienylcarnitine levels,Suberoylcarnitine (C8-DC) levels,X-13431--nonanoylcarnitine levels,Beta-hydroxyisovaleroylcarnitine levels,Hydroxyisovaleroyl carnitine levels,Succinylcarnitine (C4DC) levels,Valerylcarnitine levels,Laurylcarnitine (C12) levels,Metabolite levels (isovalerylcarnitine; isovalerylcarnitine (C5); C5 carnitine; C5_carnitine),Hydroxyisovaleroyl carnitine levels (Biocrates platform),3-hydroxyoctanoylcarnitine (2) levels,3-hydroxyoctanoylcarnitine (1) levels,Eicosenoylcarnitine (C20:1) levels,Linoleoylcarnitine (C18:2) levels,Myristoleoylcarnitine (C14:1) levels,Myristoylcarnitine (C14) levels,Propionylcarnitine-to-isovalerylcarnitine ratio,Ximenoylcarnitine (C26:1) levels,Metabolite levels (isovalerylglycine),Succinylcarnitine (c4-dc) levels,Oleoylcarnitine levels (Biocrates platform),Laurylcarnitine levels,Stearoylcarnitine (C18) levels,Nervonoylcarnitine (C24:1) levels,(S)-3-hydroxybutyrylcarnitine levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels
Glutarylcarnitine; <Limit Of Detection indicated by 8881 (Reported Values: <0.05),Lignoceroylcarnitine (C24) levels,Glutarylcarnitine (C5) levels,Glutarylcarnitine (c5-dc) levels,Octadecenoylcarnitine levels,Nonaylcarnitine levels,Hexadecenoylcarnitine levels,Tiglylcarnitine levels,Octadecadienylcarnitine levels,Margaroylcarnitine (C17) levels,Octadecandienylcarnitine levels,Eicosenoylcarnitine (C20:1) levels,Nervonoylcarnitine (C24:1) levels,Tetradecenoylcarnitine levels,3-methylglutarylcarnitine (2) levels,Succinylcarnitine levels,Methylglutarylcarnitine levels,Oleoylcarnitine (C18:1) levels,Acetylcarnitine levels (Biocrates platform),Levulinoylcarnitine levels,Glutaroyl carnitine levels (Biocrates platform),Tetradecadienylcarnitine levels,3-hydroxyoctanoylcarnitine (1) levels,Myristoylcarnitine (C14) levels,3-hydroxyoctanoylcarnitine (2) levels,Oleoylcarnitine levels (Biocrates platform),Myristoylcarnitine levels,Glutaroyl carnitine levels,Cerotoylcarnitine (C26) levels,Succinylcarnitine (C4DC) levels,Acylcarnitine (17:0) (a) levels,Acetylcarnitine (c2) levels,Linoleoylcarnitine levels,Undecenoylcarnitine (c11:1) (X-17337) levels,succinylcarnitine measurement (advanced age),Acetylcarnitine levels,Palmitoleoylcarnitine (C16:1) levels,Metabolite levels (3-methylglutarylcarnitine (2)),3-hydroxyoleoylcarnitine levels,Oleoylcarnitine levels,X-13431--nonanoylcarnitine levels,Linoleoylcarnitine (C18:2) levels,Acylcarnitine (17:0) (b) levels,Laurylcarnitine levels (Biocrates platform),Ximenoylcarnitine (C26:1) levels,Arachidonoylcarnitine (C20:4) levels,Myristoleoylcarnitine (C14:1) levels,Isovalerylcarnitine levels (Biocrates platform),Acylcarnitine (15:0) (a) levels,Cortolone glucuronide (1) (X-17359) levels,Tiglylcarnitine (C5:1-DC) levels
Hexanoylcarnitine (Reported Values: 0.01-1.2),Hexanoylcarnitine levels,Hexanoylcarnitine levels (Biocrates platform),Hexadecanoylcarnitine levels,Hexanoylcarnitine (C6) levels,Hexadecenoylcarnitine levels,Hexanoylcarnitine-to-octanoylcarnitine ratio,Acetylcarnitine-to-hexanoylcarnitine ratio,Undecenoylcarnitine (c11:1) (X-17337) levels,3-hydroxyhexanoylcarnitine (1) levels,Metabolite levels (hexanoylcarnitine; hexanoylcarnitine (C6); C6 carnitine; C6_carnitine),Hexanoylcarnitine levels (Metabolon platform),Undecenoylcarnitine (C11:1) levels,Carnitine-to-X-12798 ratio,Carnitine C18:2 levels,Hydroxyhexadecanoylcarnitine levels,Carnitine C14:1 levels,Octadecanedioylcarnitine (C18-DC) levels,3-hydroxydecanoylcarnitine levels,Carnitine C10 levels,Metabolite levels (nonanoylcarnitine (C9); C9 carnitine; C9_carnitine),Acylcarnitine (10:0) levels,Docosahexaenoylcarnitine (C22:6) levels,Acylcarnitine (14:0) levels,Acylcarnitine (15:0) (a) levels,Linolenoylcarnitine (C18:3) levels,Metabolite levels (dihomo-linolenoylcarnitine (C20:3n3 or 6)),Metabolite levels (suberoylcarnitine (C8-DC)),Suberoylcarnitine (C8-DC) levels,Acylcarnitine (18:0) levels,Acylcarnitine (16:0) levels,Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),Acylcarnitine (14:1) levels,Acylcarnitine (10:1) levels,Octanoylcarnitine levels (Biocrates platform),Acylcarnitine (18:1) levels,Acylcarnitine (12:0) levels,Decanoylcarnitine (C10) levels,Docosapentaenoylcarnitine (C22:5n3) levels,Metabolite levels (octanoylcarnitine; octanoylcarnitine (C8); C8 carnitine; C8_carnitine),5-dodecenoylcarnitine (C12:1) levels,Arachidoylcarnitine (C20) levels,Octanoylcarnitine (c8) levels,Acylcarnitine (16:1) levels,Acylcarnitine (17:0) (a) levels,X-13431--nonanoylcarnitine levels,Octadecenedioylcarnitine (C18:1-DC) levels,(R)-3-hydroxybutyrylcarnitine levels,3-hydroxybutyrylcarnitine (1) levels,Butyrylcarnitine (C4) levels,Nonanoylcarnitine (C9) levels
Octanoylcarnitine (Reported Values: 0.06-0.3),Octanoylcarnitine levels (Biocrates platform),Octanoylcarnitine levels,Octadecanoylcarnitine levels,Octadecadienylcarnitine levels,Octadecenoylcarnitine levels,Octanoylcarnitine (c8) levels,Octadecandienylcarnitine levels,Octadecanedioylcarnitine (C18-DC) levels,Octadecenedioylcarnitine (C18:1-DC) levels,Octanoylcarnitine-to-X-13435 ratio,Metabolite levels (octanoylcarnitine; octanoylcarnitine (C8); C8 carnitine; C8_carnitine),Hexanoylcarnitine-to-octanoylcarnitine ratio,Octanoylcarnitine levels (Metabolon platform),Acylcarnitine (10:0) levels,Acylcarnitine (18:0) levels,Undecenoylcarnitine (c11:1) (X-17337) levels,Acylcarnitine (12:0) levels,Acylcarnitine (18:1) levels,Hexanoylcarnitine (C6) levels,Carnitine C6 levels,Acylcarnitine (10:1) levels,Acylcarnitine (15:0) (a) levels,Carnitine C18:2 levels,Acylcarnitine (14:0) levels,Acylcarnitine (16:0) levels,Metabolite levels (nonanoylcarnitine (C9); C9 carnitine; C9_carnitine),Hexanoylcarnitine levels (Biocrates platform),Carnitine-to-X-12798 ratio,Carnitine C8 levels,Undecenoylcarnitine (C11:1) levels,Acylcarnitine (13:0) levels,Acylcarnitine (18:2) levels,Acylcarnitine (14:1) levels,Decanoylcarnitine (C10) levels,Acylcarnitine (17:0) (a) levels,Nonanoylcarnitine (C9) levels,Acylcarnitine (16:1) levels,Carnitine C10 levels,Suberoylcarnitine (C8-DC) levels,Carnitine C14:1 levels,Arachidoylcarnitine (C20) levels,Acylcarnitine (15:0) (b) levels,Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),Linolenoylcarnitine (C18:3) levels,Docosahexaenoylcarnitine (C22:6) levels,Arachidonoylcarnitine (C20:4) levels,Metabolite levels (hexanoylcarnitine; hexanoylcarnitine (C6); C6 carnitine; C6_carnitine),Docosapentaenoylcarnitine (C22:5n3) levels,Decanoylcarnitine levels (Biocrates platform),Metabolite levels (suberoylcarnitine (C8-DC))
Decanoylcarnitine (Reported Values: 0.2-1),Decanoylcarnitine (C10) levels,Decanoylcarnitine levels (Biocrates platform),Decanoylcarnitine levels,Decenoylcarnitine levels,Undecenoylcarnitine (c11:1) (X-17337) levels,Cis-4-decenoylcarnitine (C10:1) levels,Undecenoylcarnitine (C11:1) levels,Metabolite levels (decanoylcarnitine; decanoylcarnitine (C10); C10 carnitine; C10_carnitine),3-decenoylcarnitine levels,Metabolite levels (cis-4-decenoyl carnitine; cis-4-decenoylcarnitine (C10:1)),Decanoylcarnitine levels (Metabolon platform),5-dodecenoylcarnitine (C12:1) levels,Octadecenedioylcarnitine (C18:1-DC) levels,Octadecanedioylcarnitine (C18-DC) levels,Carnitine C14:1 levels,Suberoylcarnitine (C8-DC) levels,2-tetradecenoyl carnitine levels (Biocrates platform),Dodecanoylcarnitine levels,Docosapentaenoylcarnitine (C22:5n3) levels,Carnitine C18:2 levels,Nonanoylcarnitine (C9) levels,Dodecenoylcarnitine levels,Lignoceroylcarnitine (C24) levels,Metabolite levels (nonanoylcarnitine (C9); C9 carnitine; C9_carnitine),Nervonoylcarnitine (C24:1) levels,Docosahexaenoylcarnitine (C22:6) levels,Cis-4-decenoyl carnitine levels,Octanoylcarnitine levels (Biocrates platform),Carnitine C10 levels,Carnitine C14:2 levels,Metabolite levels (suberoylcarnitine (C8-DC)),Tetradecenoylcarnitine levels,Octanoylcarnitine (c8) levels,Hexanoylcarnitine levels (Biocrates platform),Hexadecenoylcarnitine levels,Butyrylcarnitine (C4) levels,Carnitine C9 levels,X-13431--nonanoylcarnitine levels,Tetradecadienylcarnitine levels,Acylcarnitine (10:0) levels,Propionylcarnitine levels (Biocrates platform),Arachidoylcarnitine (C20) levels,Carnitine-to-X-12798 ratio,Tetradecanoylcarnitine levels,Carnitine C8 levels,Carnitine C4 levels,Octanoylcarnitine levels,Pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels,Acylcarnitine (10:1) levels,Arachidonoylcarnitine (C20:4) levels
Dodecanoylcarnitine (Reported Values: <0.4),Dodecanoylcarnitine levels,Dodecenoylcarnitine levels,5-dodecenoylcarnitine (C12:1) levels,Decanoylcarnitine levels (Biocrates platform),Decanoylcarnitine (C10) levels,Undecenoylcarnitine (C11:1) levels,Tetradecadienylcarnitine levels,Decanoylcarnitine levels,Undecenoylcarnitine (c11:1) (X-17337) levels,Laurylcarnitine levels (Biocrates platform),Tetradecenoylcarnitine levels,2-tetradecenoyl carnitine levels (Biocrates platform),3-dehydrocarnitine levels,Docosapentaenoylcarnitine (C22:5n3) levels,Octadecadienylcarnitine levels,Octadecanedioylcarnitine (C18-DC) levels,X-13431--nonanoylcarnitine levels,Hexanoylcarnitine levels (Biocrates platform),Docosahexaenoylcarnitine (C22:6) levels,Tetradecanoylcarnitine levels,Decenoylcarnitine levels,Octadecandienylcarnitine levels,Deoxycarnitine levels,Carnitine C10 levels,Octadecenoylcarnitine levels,3-hydroxydecanoylcarnitine levels,Arachidoylcarnitine (C20) levels,Acylcarnitine (14:0) levels,Hexadecenoylcarnitine levels,3-decenoylcarnitine levels,Butyrylcarnitine levels,Carnitine C14:1 levels,Metabolite levels (suberoylcarnitine (C8-DC)),Nervonoylcarnitine (C24:1) levels,Metabolite levels (cis-4-decenoyl carnitine; cis-4-decenoylcarnitine (C10:1)),Suberoylcarnitine (C8-DC) levels,Butyrylcarnitine levels (Biocrates platform),Acylcarnitine (10:0) levels,Metabolite levels (dodecanedioate; dodecanedioate (C12-DC)),Nonanoylcarnitine (C9) levels,Laurylcarnitine levels,Acylcarnitine (14:1) levels,Octadecanoylcarnitine levels,Isovalerylcarnitine levels (Biocrates platform),Carnitine levels (Biocrates platform),Octanoylcarnitine levels (Biocrates platform),Hexanoylcarnitine levels,Stearoylcarnitine levels (Biocrates platform),Acylcarnitine (12:0) levels,Acylcarnitine (13:0) levels
Pyridoxal 5'-phosphate (Reported Values: 15-150),Pyridoxal 5'-phosphate levels,Plasma pyridoxal phosphate levels,RBC levels of Pyridoxamine 5'-phosphate,Pyridoxal phosphate phosphatase levels,Plasma pyridoxal phosphate to pyridoxal ratio,Plasma pyridoxic acid to pyridoxal phosphate ratio,Pyridoxate levels,Phosphate levels,Phosphate-to-erythronate ratio,Serum phosphate levels,Pyridoxine-5-phosphate oxidase levels,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,Pyridoxal levels,Pyridoxal phosphate homeostasis protein levels,Metabolite levels (5-oxoproline; pyroglutamic_acid),Cerebrospinal fluid pyridoxal phosphate levels,RBC levels of 5-Deoxyribose-1-phosphate,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Metabolite levels (S-1-pyrroline-5-carboxylate),72 kDa inositol polyphosphate 5-phosphatase levels,Phosphatidylinositol (18:0_22:6) levels,Phosphatidylinositol (18:0_22:5) (n6) levels,Phosphatidylinositol (18:0_22:4) levels,Phosphatidylinositol (18:0_20:3) levels,RBC levels of Pyridoxal,"Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 levels",Phosphorus levels,Pyridoxamine levels,Phosphatidylinositol (20:0_20:4) levels,Phosphatidylinositol (18:0_20:4) levels,Phosphatidylinositol (16:0_20:4) levels,Phosphatidylinositol (18:0_20:3) (a) levels,Phosphatidylinositol (16:0_20:3) (a) levels,5-oxoproline levels,Phosphatidylinositol (18:0_22:5) (n3) levels,Phosphatidylinositol (18:0_20:2) levels,Phosphatidylinositol (16:0/16:0) levels,"Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A levels",Phosphatidylinositol (16:0_18:2) levels,Phospholysine phosphohistidine inorganic pyrophosphate phosphatase levels,S-1-pyrroline-5-carboxylate levels,"Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 levels",Phosphatidylinositol (18:1_20:4) levels,Phosphatidylinositol (18:0_18:2) levels,Ribose-5-phosphate isomerase levels (RPIA.12333.87.3),2'-deoxynucleoside 5'-phosphate N-hydrolase 1 levels,6-oxopiperidine-2-carboxylic acid levels,Phosphatidylinositol (16:0_16:1) levels,Phosphatidylinositol (16:0_18:1) levels,Phosphatidylinositol (18:0_18:1) levels
Pyridoxal (Reported Values: 5-150),Pyridoxal levels,RBC levels of Pyridoxal,Pyridoxamine levels,Pyridoxate levels,RBC levels of Pyridoxamine,Pyridoxal 5'-phosphate levels,Plasma pyridoxal phosphate levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Pyridoxal levels in elite athletes,Plasma metabolome feature (c18_343) (Pyrrolidonecarboxylic acid),Urine pyridoxal levels in chronic kidney disease,RBC levels of Pyridoxamine 5'-phosphate,Metabolite levels (S-1-pyrroline-5-carboxylate),Plasma pyridoxic acid to pyridoxal phosphate ratio,Pyridoxate levels in elite athletes,Metabolite levels (5-oxoproline; pyroglutamic_acid),Plasma pyridoxal phosphate to pyridoxal ratio,Metabolite levels  (X-11787),1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Peroxiredoxin-6 level (CSF),Dihexosylceramide (d18:1/18:0) levels,Dihexosylceramide (d18:2/16:0) levels,Cerebrospinal fluid pyridoxal phosphate levels,Dihexosylceramide (d16:1/16:0) levels,Dihexosylceramide (d18:1/24:0) levels,Pyridoxal kinase levels (PDXK.11098.1.3),Dihexosylceramide (d18:1/20:0) levels,Dihexosylceramide (d16:1/24:1) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,Dihexosylceramide (d18:1/16:0) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Metabolite peak levels (QI4775),Peroxiredoxin-6 levels,Metabolite peak levels (QI9368),Paxillin levels,Dihexosylceramide (d18:1/22:0) levels,Dihexosylceramide (d18:2/24:1) levels,Metabolite levels (erythritol),Metabolite peak levels (QI15965),Metabolite peak levels (QI4755),Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,Metabolite peak levels (QI9738),Metabolite peak levels (QI9710),X-12244--N-acetylcarnosine levels,Metabolite peak levels (QI9810),Metabolite peak levels (QI6455),N-acetyl-isoputreanine (X-12688) levels,N1-methyl-2-pyridone-5-carboxamide levels,Metabolite peak levels (QI9376)
4-Pyridoxic acid (Reported Values: 10-200),Plasma pyridoxic acid to pyridoxal phosphate ratio,Pyridoxate levels,Pyroglutamic acid levels,Pyridoxal levels,Pyridoxamine levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Plasma pyridoxal phosphate levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Plasma metabolome feature (c18_343) (Pyrrolidonecarboxylic acid),4-acetamidophenol levels,Plasma metabolome feature (c18_20) (Pyruvic acid),Pyridoxal 5'-phosphate levels,Metabolite levels (5-oxoproline; pyroglutamic_acid),Pyridoxine-5-phosphate oxidase levels,3-Indolepropionic acid to 4-Pyridoxic acid ratio in coronary artery disease,RBC levels of Pyridoxal,RBC levels of Pyridoxamine,RBC levels of Pyridoxamine 5'-phosphate,6-oxopiperidine-2-carboxylic acid levels,Palmitic acid (16:0) levels,Butyric acid levels,Pyridoxate levels in elite athletes,Plasma metabolome feature (hilic_1348) (3-Pyridylacetic acid),Metabolite levels (N4-acetylcytidine),Metabolite levels (C36:4 PC-A; C36_4_PC_A),4-oxo-retinoic acid levels,Metabolite levels (Pyroglutamine),N4-acetylcytidine levels,4-hydroxy-2-oxoglutaric acid levels,Metabolite levels (S-1-pyrroline-5-carboxylate),4-hydroxyphenylacetoylcarnitine levels,Cerebrospinal fluid pyridoxal phosphate levels,X-12244--N-acetylcarnosine levels,"X-04499--3,4-dihydroxybutyrate levels",X-12510--2-aminooctanoic acid levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels (advanced age),4-acetamidobutanoate levels,FFA Arachidonic Acid a levels,Pyruvate levels (UKB data field 23472),Pyroglutamine levels,Plasma pyridoxal phosphate to pyridoxal ratio,Metabolite levels (C20:4 CE; C20_4_CE),Metabolite levels (4-acetamidobutanoate),Metabolite levels (pyruvate; cmh_pyruvate; Pyruvate),Metabolite levels  (X-11787),Lysoalkenylphosphatidylethanolamine (P-16:0) levels,Peroxiredoxin-4 levels,Metabolite levels (4-guanidinobutanoate; 4-guanidinobutanoic acid),"2,6-dihydroxybenzoic acid (X-09789) levels",Metabolite levels (1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0))
Thiamine (Reported Values: 2-50),Thiamine-triphosphatase levels,Vitamin levels,Thioproline levels,Metabolite levels (threonine),Thiamin pyrophosphokinase 1 levels,Triiodothyronine levels,Protein MENT levels (MENT.5744.12.3),Metabolite levels (threonylphenylalanine),Metabolite levels (erythronate; erythronate/threonate),Metabolite levels (ergothioneine),Thioredoxin levels,Metabolite levels (hypotaurine),Ergothioneine levels,Metabolite levels (2-aminoadipate; cmh_aminoadipate),Threonine levels,Metabolite levels  (X-11787),Threonate levels,Histidine levels,Metabolite levels (thyroxine),Serum levels of protein THRA,Gamma-glutamylhistidine levels,Hypotaurine levels,Metabolite levels (glutamine),Metabolite levels (valine),Threonine levels (Biocrates platform),Metabolite levels (betaine),Metabolite levels (1-methylhistidine),Metabolite levels (5-HIAA),Metabolite levels (gamma-glutamylthreonine),Metabolite levels (alanine),Transcobalamin-2 levels (TCN2.5584.21.3),Metabolite levels (HWESASLLR),Vitrin levels (VIT.6234.74.3),Metabolite levels (alliin),Metabolite levels (N-acetylhistidine),Metabolite levels (malate; cmh_malate; Malate),Metabolite levels (serine),(S)-a-amino-omega-caprolactam levels,Metabolite levels (lysine),Metabolite levels (homostachydrine),Sodium levels,Metabolite levels (arginine),Metabolite levels (homoarginine),Glucagon levels (GCG.4891.50.1),Metabolite levels (glycine),Potassium levels,Metabolite levels (ethylmalonate),Metabolite levels (carnitine),1-methylhistidine levels,Metabolite levels (histidylleucine)
Thiamine monophosphate (Reported Values: 2-15),Thiamine-triphosphatase levels,Thiamin pyrophosphokinase 1 levels,Serum phosphate levels,Phosphate levels,Protein MENT levels (MENT.5744.12.3),THPO protein levels,Phosphorus levels,Vitamin levels,Serum levels of protein THPO,72 kDa inositol polyphosphate 5-phosphatase levels,"Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 levels",S-methyl-5-thioadenosine phosphorylase levels,THP plasma levels,ESAM/THPO protein level ratio,Metabolite levels (threonylphenylalanine),Thioproline levels,Inosine-5-monophosphate dehydrogenase 2 levels,"Type II inositol 1,4,5-trisphosphate 5-phosphatase levels",Thymidine phosphorylase levels,Metabolite levels  (X-11787),3-phosphoglycerate levels,Phosphorus intake,Phospholysine phosphohistidine inorganic pyrophosphate phosphatase levels,Metabolite levels (HWESASLLR),Phosphate levels in elite athletes,Metabolite levels (erythronate; erythronate/threonate),Phosphate levels (adjusted for BMI) x vegetarianism interaction,Metabolite levels (threonine),Protein DEPP levels (DEPP.7178.59.3),Inosine-5'-monophosphate dehydrogenase 2 levels,"2,3-dihydroxy-5-methylthio-4-pentenoate (dmtpa) levels",Metabolite levels (urate; cmh_urate; Uric_acid),Monohexosylceramide (d16:1/24:0) levels,Phosphatidylinositol (18:0_22:6) levels,Phosphate-to-erythronate ratio,Metabolite levels (thyroxine),Metabolite levels (ergothioneine),Choline phosphate levels,Metabolite levels (hypotaurine),Inositol polyphosphate 1-phosphatase levels,Metabolite levels (MHPG),Metabolite levels (5-HIAA),ITGA6/THPO protein level ratio,Sphinganine-1-phosphate levels,"Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 levels",Calcium levels (UKB data field 30680),Vitamin D-binding protein levels (GC.6581.50.3),Phosphatidylinositol (18:0_22:4) levels,Gamma-glutamylhistidine levels,Monohexosylceramide (d16:1/22:0) levels
Riboflavin (Reported Values: 5-100),Riboflavin kinase levels (RFK.13059.33.3),Riboflavin kinase levels,Metabolite levels (ribitol),Metabolite levels (ribose),Ribitol levels,Ribothymidine levels,Riboflavin to 3-Indolepropionic acid ratio in coronary artery disease,Ribulonate/xylulonate/lyxonate levels,Ribonate levels,Ribonate levels in elite athletes,Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),5-methyluridine (ribothymidine) levels,Ribitol levels in elite athletes,Urine ribonate levels in chronic kidney disease,Metabolite levels (biliverdin),60S ribosomal protein L30 levels (RPL30.12478.15.3),Calpastatin levels (CAST.3026.5.2),Ribose-5-phosphate isomerase levels (RPIA.12333.87.3),Plasma ribitol levels in chronic kidney disease,Elafin levels (PI3.4982.54.1),Osteocalcin levels (BGLAP.11067.13.3),Metabolite peak levels (QI10958),Metabolite peak levels (QI15965),Urine ribitol levels in chronic kidney disease,RS-10-hydroxywarfarin levels,Metabolite peak levels (QI10834),Metabolite peak levels (QI10664),40S ribosomal protein SA levels (RPSA.4957.1.2),Vigilin levels (HDLBP.13570.43.3),Metabolite peak levels (QI10057),Metabolite peak levels (QI4060),Metabolite levels (isoleucylvaline),Metabolite peak levels (QI4775),Metabolite peak levels (QI1565),Ribose-5-phosphate isomerase levels,Metabolite peak levels (QI15625),Metabolite peak levels (QI10969),Metabolite peak levels (QI15633),Metabolite peak levels (QI6455),Metabolite peak levels (QI3754),Metabolite peak levels (QI3785),Metabolite peak levels (QI4144),Metabolite peak levels (QI10309),Metabolite peak levels (QI10992),Metabolite peak levels (QI10980),Metabolite peak levels (QI3710),Metabolite peak levels (QI409),Metabolite peak levels (QI1087),"Metabolite levels (bilirubin (E,E))",Ribothymidine levels in chronic kidney disease
Flavin mononucleotide (Reported Values: 3-30),Flavin adenine dinucleotide (FAD) levels,Flavin reductase levels,Serum levels of protein FLNA,Ficolin-1 levels (FCN1.3613.62.5),Ficolin-2 levels (FCN2.3313.21.2),Serum levels of protein FLRT1,Serum levels of protein FLRT3,Filamin-A levels (FLNA.11124.9.3),Vitrin levels (VIT.6234.74.3),Serum levels of protein FLT3,Serum levels of protein FLRT2,Ficolin-3 levels,Ficolin-2 levels,Serum levels of protein FLT4,Ficolin-1 levels,Fumarylacetoacetase levels (FAH.11424.4.3),Protein FAM177A1 levels (FAM177A1.8039.41.3),Flavonifractor sp900199495 abundance in stool,Flavonifractor sp002159265 abundance in stool,rRNA 2-O-methyltransferase fibrillarin levels,Cryptic protein levels (CFC1.3294.55.2),Protein FAM163A levels (FAM163A.6260.14.3),Protein FAM171B levels (FAM171B.8851.42.3),Receptor-type tyrosine-protein kinase FLT3 levels (FLT3.3437.80.3),Protein FAM151A levels (FAM151A.7856.51.3),Elafin levels (PI3.4982.54.1),Ficolin 3 plasma levels,Protein FAM107A levels (FAM107A.2760.2.2),Fibulin-1 levels,Protein FAM3B levels (FAM3B.9177.6.3),Beta-defensin 104 levels (DEFB104A.5763.67.3),UPF0696 protein C11orf68 levels (C11orf68.8307.47.3),Protein FAM3D levels (FAM3D.13102.1.3),Nucleolin levels (NCL.13655.34.3),Pirin levels (PIR.13634.209.3),FLT4 protein levels,UPF0454 protein C12orf49 levels (C12orf49.9387.13.3),Palmitoleic acid (16:1n-7) levels,Serum levels of protein F13B,Nucleobindin-1 levels,Arfaptin-1 levels (ARFIP1.13488.3.3),Fc receptor-like protein 4 levels (FCRL4.8973.23.3),Beta-defensin 105 levels (DEFB105A.10962.46.3),Serum levels of protein F10,Fc receptor-like protein 3 levels (FCRL3.4440.15.2),Leucine-rich repeat transmembrane protein FLRT3 levels (FLRT3.13123.3.3),Serum levels of protein FBN3,Serum levels of protein F5,Riboflavin kinase levels (RFK.13059.33.3),RBC levels of FA 16:1n7
Cystathionine (Reported Values: <0.4),Cystathionine levels,Metabolite levels (cystathionine; cmh_cystathionine),Cystine levels,Cystathionine beta-synthase levels,Cystatin-8 levels (CST8.10572.65.3),Cystatin-F levels (CST7.3302.58.1),Cystatin-M levels (CST6.3303.23.2),Cystatin M level (CSF),Cystathionine levels in elite athletes,Urine cystathionine levels in chronic kidney disease,Plasma cystathionine levels in chronic kidney disease,Cystatin-S levels,Cytohesin-2 levels (CYTH2.12533.135.3),Cystatin-S level (brain),Cystatin-like 1 levels,Cystatin-SA levels,Cystatin-SN levels,Cystatin C levels (UKB data field 30720),Cystatin-F levels,Cystatin-C levels,Cystatin-8 levels,Cystatin-M levels,Cyclin-H levels (CCNH.9848.22.3),Cyclin-C levels (CCNC.7817.36.3),Metabolite levels (cysteinylglycine disulfide),Metabolite levels (cytidine),Cystatin C levels,Metabolite levels (N-acetylthreonine),Calnexin levels (CANX.8834.58.3),Cytidine levels,Cysteinylglycine disulfide levels,N-acetylthreonine levels,Cystatin-B levels,Cystine levels in elite athletes,Metabolite levels  (X-11787),Di-N-acetylchitobiase levels (CTBS.6115.40.3),Cystatin-D levels,Mesothelin levels (MSLN.3893.55.2),"Metabolite levels (sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0))",Metabolite levels (C16:0 CE; C16_0_CE),Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),Cystatin C plasma levels,"Metabolite levels (sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0))",X-12244--N-acetylcarnosine levels,Metabolite levels (cysteine-glutathione disulfide),"Metabolite levels (sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0))","Metabolite levels (sphingomyelin (d18:1/17:0, d17:1/18:0, d19:1/16:0))",Metabolite levels (C18:3 CE; C18_3_CE),Deoxycytidine kinase levels (DCK.9836.20.3),Pregnenediol sulfate (C21H34O5S) levels
Neopterin (Reported Values: 5-50),Urine neopterin levels in chronic kidney disease,Neogenin levels (NEO1.8900.28.3),Serum levels of protein NEO1,Progonadoliberin-1 levels (GNRH1.5627.53.3),Serum levels of protein NCMAP,Serum levels of protein NT5C,Progonadoliberin-2 levels (GNRH2.10708.3.3),Neogenin levels,Serum levels of protein CNTNAP5,Serum levels of protein NPPA,Serum levels of protein TEX29,Promotilin levels (MLN.5631.83.3),Neuropilin-2 levels (NRP2.6590.54.3),Neurexin-3 levels,Protocadherin-9 levels,Progonadoliberin-1 levels,Serum levels of protein NUP210,Protocadherin-7 levels,Lymphotactin levels (XCL1.14078.69.3),Serum levels of protein NPPB,Kallistatin levels (SERPINA4.3449.58.2),Prepronociceptin levels,Protocadherin-17 levels,Serum levels of protein C15orf48,Serum levels of protein CNP,NT5E protein levels,Neuroendocrine secretory protein 55 levels,Serum levels of protein NAGPA,Serum levels of protein TIRAP,Neuregulin-4 levels,Prolargin levels (PRELP.5675.6.3),Serum levels of protein LOC652493,Ena/VASP-like protein levels (EVL.11656.110.3),Serum levels of protein HINT2,Serum levels of protein NTM,Serum levels of protein INPP5B,Serum levels of protein INPP5E,Serum levels of protein CEP57,Serum levels of protein RNPEP,Serum levels of protein NPW,Serum levels of protein NPTXR,Neudesin levels,Protocadherin-12 levels,Dihydrobiopterin levels,Serum levels of protein KCNIP1,Serum levels of protein NPNT,Elafin levels (PI3.4982.54.1),Nucleolar protein 56 levels,Calpastatin levels (CAST.3026.5.2),Serum levels of protein NEURL4
Tryptophan (Reported Values: 40-90),Tryptophan levels,Tryptophan levels (Biocrates platform),N-acetyl-d-tryptophan levels,Metabolite levels (tryptophan),Tryptophan levels in elite athletes,Tryptophan levels (Metabolon platform),Tryptophan betaine  levels,Tryptophan betaine levels,Metabolite levels (tryptophan betaine),N-acetyltryptophan levels,Plasma metabolome feature (hilic_2249) (L-Tryptophan),Gamma-glutamyltryptophan levels,Tryptophan betaine levels in elite athletes,X-12100--hydroxytryptophan levels,Phenylalanyltryptophan levels,Metabolite levels (N-acetyltryptophan),C-glycosyltryptophan levels,"Tryptophan 2,3-dioxygenase levels",Urine tryptophan levels in chronic kidney disease,Metabolite levels (glycyltryptophan),5-bromotryptophan levels,Gut bacterial pathway abundance (TRPSYN.PWY..L.tryptophan.biosynthesis),Metabolite levels (5-bromotryptophan),N-acetyltryptophan levels in elite athletes,Tryptase gamma levels (TPSG1.14103.12.3),6-bromotryptophan levels,Plasma tryptophan betaine levels in chronic kidney disease,Gamma-glutamyltryptophan levels in elite athletes,Tryptase alpha/beta-1 levels,Protein DEPP levels (DEPP.7178.59.3),Metabolite levels (6-bromotryptophan),Tryptase beta-1 levels,5-bromotryptophan levels in elite athletes,Tryptase beta-2 levels,Tryptase beta-2 levels (TPSB2.3403.1.2),Trypsin-3 levels,"X-04499--3,4-dihydroxybutyrate-to-C-glycosyltryptophan ratio",Tryptase delta levels,Protein MENT levels (MENT.5744.12.3),Phosphatidylethanolamine (17:0_22:6) levels,Cathepsin H levels (CTSH.8465.52.3),C-glycosyltryptophan levels in elite athletes,N-acetylphenylalanine levels,Phosphatidylethanolamine (38:5) (a) levels,Gastrotropin levels,Phosphatidylethanolamine (38:4)A levels,Phosphatidylethanolamine (16:0_20:5) levels,Metabolite levels (tryptophylasparagine),Metabolite levels (histidylphenylalanine),Phosphatidylethanolamine (18:0_22:6) levels
Kynurenine (Reported Values: 1.0-3.0),Kynurenine levels,Kynurenate levels,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Kynureninase levels (KYNU.4559.64.2),Kynureninase levels,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),Kynurenine levels in elite athletes,Kynurenate levels in elite athletes,Plasma metabolome feature (hilic_2278) (Kynurenine),Urine kynurenine levels in chronic kidney disease,Plasma kynurenine levels in chronic kidney disease,Urine kynurenate levels in chronic kidney disease,Kynurenine--oxoglutarate transaminase 3 levels (CCBL2.12682.5.3),Plasma kynurenate levels in chronic kidney disease,Kallistatin levels (SERPINA4.3449.58.2),KYNU level (plasma),Kynurenine--oxoglutarate transaminase 3 levels,Plasma kynurenine levels in major depressive disorder,Kynurenine-oxoglutarate transaminase 1 levels,N-acetylkynurenine (2) levels,Kynurenine--oxoglutarate transaminase 1 levels,Serum levels of protein KYNU,Metabolite levels (N-acetylkynurenine (2)),X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Kallikrein-8 levels (KLK8.13708.56.3),Urinary potassium to creatinine ratio,Alanine levels (UKB data field 23460),X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,3-amino-2-piperidone levels,Kallistatin levels,Kallikrein-8 levels,N-acetyl-isoputreanine (X-12688) levels,Creatinine levels (UKB data field 30700),"Bradykinin, des-arg 9 levels",Creatinine levels (UKB data field 23478),Potassium levels,Kallikrein-6 levels,Metabolite peak levels (QI9810),X-12244--N-acetylcarnosine levels,Kallikrein-14 levels (KLK14.8620.56.3),Metabolite peak levels (QI9710),Plasma kynurenine to tryptophan ratio in major depressive disorder,Kallikrein-7 levels (KLK7.3378.49.2),N-acetylmethionine levels,Kallikrein-15 levels,Kallikrein-7 levels,ADH4/KYNU protein level ratio,Metabolite peak levels (QI9845),Metabolite peak levels (QI9993),Metabolite peak levels (QI9777)
Kynurenic acid (Reported Values: 20-100),Kynurenate levels,Kynureninase levels (KYNU.4559.64.2),Kynureninase levels,Kynurenine levels,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Kynurenate levels in elite athletes,Serum levels of protein KYNU,Urine kynurenate levels in chronic kidney disease,KYNU level (plasma),Plasma kynurenate levels in chronic kidney disease,Kynurenine--oxoglutarate transaminase 3 levels (CCBL2.12682.5.3),X-12244--N-acetylcarnosine levels,Plasma metabolome feature (hilic_2278) (Kynurenine),Kallistatin levels (SERPINA4.3449.58.2),Vaccenic acid (18:1n-7) levels,X-12510--2-aminooctanoic acid levels,Urine kynurenine levels in chronic kidney disease,Urocanic acid levels,N-acetyl neuraminic acid levels,Stearic acid (18:0) levels,Kynurenine-oxoglutarate transaminase 1 levels,Kynurenine levels in elite athletes,Kynurenine--oxoglutarate transaminase 1 levels,Kynurenine--oxoglutarate transaminase 3 levels,Plasma kynurenine levels in chronic kidney disease,N-acetylaspartic acid levels,N-acetylkynurenine (2) levels,Uric acid levels,Potassium levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Acetoacetate levels (UKB data field 23476),N-acetylputrescine levels,3-Indolepropionic acid to Kynurenic acid ratio in coronary artery disease,N-acetyl-L-glutamic acid levels,Gondoic acid (20:1n-9) levels,Oxaloacetic acid levels,Metabolite levels (N-acetylkynurenine (2)),N-acetylcarnosine levels,Kallikrein-8 levels (KLK8.13708.56.3),Plasma metabolome feature (c18_713) (Quinolinic acid),Metabolite peak levels (QI9810),Metabolite peak levels (QI9710),Metabolite peak levels (QI9738),Metabolite peak levels (QI9993),Metabolite peak levels (QI10958),Metabolite peak levels (QI9963),Metabolite peak levels (QI9778),Metabolite peak levels (QI10834),Metabolite peak levels (QI9777)
Quinaldic acid (Reported Values: 0.2-100),Quinate levels,Quinolinate levels,Plasma metabolome feature (c18_713) (Quinolinic acid),Metabolite peak levels (QI12000),Decadienedioic acid (c10:2-dc) (X-21792) levels,Quinate levels in elite athletes,X-12510--2-aminooctanoic acid levels,Metabolite peak levels (QI12750),Metabolite peak levels (QI12663),Metabolite peak levels (QI12128),Metabolite peak levels (QI12768),Metabolite peak levels (QI12380),Metabolite peak levels (QI12890),Metabolite peak levels (QI12147),Metabolite peak levels (QI10664),Metabolite peak levels (QI10057),Metabolite peak levels (QI12764),Metabolite peak levels (QI12470),Metabolite peak levels (QI1087),Metabolite peak levels (QI1483),Metabolite peak levels (QI13773),Metabolite peak levels (QI10834),Metabolite peak levels (QI12070),Metabolite peak levels (QI14793),Metabolite peak levels (QI14127),Metabolite peak levels (QI4060),Metabolite peak levels (QI10524),Metabolite peak levels (QI12472),Metabolite peak levels (QI14354),Metabolite peak levels (QI1027),Metabolite peak levels (QI1234),Metabolite peak levels (QI9810),Metabolite peak levels (QI9777),Metabolite peak levels (QI2240),Metabolite peak levels (QI9710),Metabolite peak levels (QI9873),Metabolite peak levels (QI9774),Metabolite peak levels (QI409),Metabolite peak levels (QI12680),Metabolite peak levels (QI1478),Metabolite peak levels (QI10992),Metabolite peak levels (QI7380),Metabolite peak levels (QI9738),Metabolite peak levels (QI750),Metabolite peak levels (QI10958),Metabolite peak levels (QI14045),Metabolite peak levels (QI9778),Metabolite peak levels (QI13343),Metabolite peak levels (QI9993),Metabolite peak levels (QI12506)
Anthranilic acid (Reported Values: 7-30),Metabolite levels (N-formylanthranilic acid),2-o-methylascorbic acid levels,N-formylanthranilic acid levels,FFA Arachidonic Acid a levels,Docosahexaenoic acid (22:6) levels,Metabolite levels (acisoga),Stearic acid (18:0) levels,"2,6-dihydroxybenzoic acid (X-09789) levels",Metabolite levels (5-HIAA),FFA Arachidonic Acid b levels,Metabolite levels (arachidonate (20:4n6); arachidonate),Vaccenic acid (18:1n-7) levels,Metabolite levels (docosapentaenoate (n6 DPA; 22:5n6); docosapentaenoate),Metabolite levels (arabinose),FFA Arachidonic Acid c levels,Metabolite levels (docosahexaenoate (DHA; 22:6n3); docosahexaenoate),Metabolite levels (deoxycholic acid (12 or 24)-sulfate),Metabolite levels  (X-11787),Oxaloacetic acid levels,Metabolite levels (aminoisobutyric_acid; 2-aminoisobutyric acid),Metabolite levels (docosapentaenoate (n3 DPA; 22:5n3)),Metabolite levels (aspartylphenylalanine),Metabolite levels (1-arachidonoylglyercophosphate; 1-arachidonoyl-GPA (20:4)),Metabolite levels (Dihydroxy docosatrienoic acid),Metabolite levels (urate; cmh_urate; Uric_acid),Decadienedioic acid (c10:2-dc) (X-21792) levels,Dihydroxydocosapentaenoic acid levels,2-hydroxy-4-(methylthio)butanoic acid levels,Metabolite levels (C16:0 CE; C16_0_CE),Metabolite levels (C18:3 CE; C18_3_CE),Metabolite levels (alanine),"3-hydroxyanthranilate 3,4-dioxygenase levels (HAAO.5861.78.3)",N-acetylaspartic acid levels,Metabolite levels (1-myristoyl-2-arachidonoyl-GPC (14:0/20:4); C34:4 PC; C34_4_PC),Metabolite levels (C38_5_PC),"Metabolite levels (N,N,N-trimethyl-5-aminovalerate; N-trimethyl 5-aminovalerate)",Metabolite levels (3b-hydroxy-5-cholenoic acid),4-hydroxy-2-oxoglutaric acid levels,Metabolite levels (hypotaurine),Metabolite levels (C36:4 PC-A; C36_4_PC_A),Palmitic acid (16:0) levels,Metabolite levels (eicosapentaenoate (EPA; 20:5n3); eicosapentaenoate),"2,6-dihydroxybenzoic acid levels",Metabolite levels (adrenate (22:4n6); adrenate),Metabolite levels (HWESASLLR),Metabolite levels (1-stearoyl-2-arachidonoyl-GPC (18:0/20:4); C38:4 PC; C38_4_PC),"Metabolite levels (3,5-dichloro-2,6-dihydroxybenzoic acid)",Ascorbic acid 3-sulfate (X-12206) levels,Metabolite levels (1-stearoyl-2-arachidonoyl-GPI (18:0/20:4); C38:4 PI),6-oxopiperidine-2-carboxylic acid levels
3-Hydroxykynurenine (Reported Values: 25-80),Urine 3-hydroxykynurenine levels in chronic kidney disease,Metabolite levels (kynurenine; cmh_kynurenine; Kynurenine),Kynurenine levels,Plasma metabolome feature (hilic_2278) (Kynurenine),X-12244--N-acetylcarnosine levels,"X-04499--3,4-dihydroxybutyrate levels",4-hydroxyphenylacetoylcarnitine levels,Metabolite levels (3-hydroxyhexanoate),Kynurenate levels,3-hydroxyhexanoylcarnitine (1) levels,3-hydroxylaurate levels,3-hydroxybutyrate levels (UKB data field 23474),3-hydroxyhexanoate levels,Stearidonate (18:4n3) levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Metabolite levels (N-acetylkynurenine (2)),Kynureninase levels (KYNU.4559.64.2),N-acetylkynurenine (2) levels,3-hydroxyadipate levels,3-hydroxyoctanoylcarnitine (2) levels,3-hydroxyoctanoylcarnitine (1) levels,Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),Stearidonate 18:4n3 levels,3-methoxytyrosine levels,3-hydroxyoleoylcarnitine levels,3-Hydroxybutyrate levels,Metabolite levels (3-methoxytyrosine),(S)-3-hydroxybutyrylcarnitine levels,Alkylphosphatidylethanolamine (O-18:0/22:5) levels,Metabolite levels (3-hydroxylaurate),Alkylphosphatidylethanolamine (O-18:0/22:6) levels,3-hydroxybutyrylcarnitine (1) levels,N-acetylcarnosine levels,Alkylphosphatidylethanolamine (O-18:0/20:4) levels,Alkylphosphatidylethanolamine (O-16:0/20:3) levels,Dihydroceramide (d18:0/22:0) levels,Kynureninase levels,Alkylphosphatidylethanolamine (O-16:0/22:6) levels,3-hydroxybutyroylglycine levels,N-acetyl-isoputreanine (X-12688) levels,Dihydroceramide (d18:0/20:0) levels,Alkylphosphatidylethanolamine (O-16:0/22:4) levels,1-stearoyl-2-adrenoyl-GPC (18:0/22:4) levels,N-trimethyl 5-aminovalerate (X-21365) levels,3-(3-amino-3-carboxypropyl)uridine levels,Metabolite levels (2'-deoxyuridine; __deoxyuridine),Metabolite levels (N-acetylthreonine),Metabolite levels (stearidonate (18:4n3)),Metabolite levels (N-acetylcarnosine),N-acetylthreonine levels
Xanthurenic acid (Reported Values: 2-35),Xanthurenate levels,Metabolite levels (xanthurenate; cmh_xanthurenate; Xanthurenate),X-12510--2-aminooctanoic acid levels,Xanthurenate levels in elite athletes,Urine xanthurenate levels in chronic kidney disease,Plasma xanthurenate levels in chronic kidney disease,Metabolite levels (xanthosine; Xanthosine),Docosahexaenoic acid (22:6) levels,Xanthosine levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Vaccenic acid (18:1n-7) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Gondoic acid (20:1n-9) levels,"2,6-dihydroxybenzoic acid (X-09789) levels","X-12442--5,8-tetradecadienoate levels",X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,FFA Arachidonic Acid a levels,Docosahexaenoic acid levels (UKB data field 23450),2-o-methylascorbic acid levels,Ribulonate/xylulonate/lyxonate levels,RBC levels of (7Z-10Z-13Z-16Z-19Z)-Docosa-7-10-13-16-19-pentaenoic acid,Palmitic acid (16:0) levels,4-hydroxy-2-oxoglutaric acid levels,Docosahexaenoic acid levels,X-12244--N-acetylcarnosine levels,X-11593--O-methylascorbate levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,RBC levels of Docosahexaenoic Acid,Xanthine levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,FFA Arachidonic Acid b levels,Metabolite levels  (X-11787),1-arachidonoyl-GPA (20:4) levels,Urocanic acid levels,RBC levels of Arachidonic Acid,Oxaloacetic acid levels,FFA Arachidonic Acid c levels,Stearic acid (18:0) levels,X-12100--hydroxytryptophan levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,1-margaroyl-2-arachidonoyl-GPC (17:0/20:4) levels,"X-04499--3,4-dihydroxybutyrate levels",RBC levels of Octadecenoic acid,X-12990--docosapentaenoic acid n6-DPA levels,1-arachidoyl-2-arachidonoyl-GPC (20:0/20:4) levels,Ascorbic acid 3-sulfate (X-12206) levels,RBC levels of Tetradecanoic acid,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,RBC levels of Octanoic acid (caprylate),Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels
3-Hydroxyanthranilic acid (Reported Values: 10-80),3-hydroxyhippurate levels,"3-hydroxyanthranilate 3,4-dioxygenase levels (HAAO.5861.78.3)",Metabolite levels (3-hydroxyhexanoate),"3-hydroxyanthranilate 3,4-dioxygenase levels",Docosahexaenoic acid (22:6) levels,3-hydroxyadipate levels,3-hydroxyhexanoate levels,Metabolite levels (N-formylanthranilic acid),Metabolite levels (5-HIAA),N-formylanthranilic acid levels,3-hydroxyoleate levels,2-o-methylascorbic acid levels,3b-hydroxy-5-cholenoic acid levels,Metabolite levels (3b-hydroxy-5-cholenoic acid),3-hydroxy-5-cholestenoic acid levels,Metabolite levels (HVA/5-HIAA ratio),2-hydroxy-4-(methylthio)butanoic acid levels,"Docosanoid 14S-HDHA, Docosanoid 17R-HDHA levels",Metabolite levels (docosahexaenoate (DHA; 22:6n3); docosahexaenoate),Docosahexaenoic acid levels (UKB data field 23450),4-hydroxyphenylacetate levels,Metabolite levels (5-HIAA/ MHPG Ratio),Metabolite levels (2-hydroxyphenylacetate),4-hydroxy-2-oxoglutaric acid levels,"3,4-methyleneheptanoate levels",3-hydroxyhippurate levels in elite athletes,Metabolite levels (3-hydroxydecanoate),Plasma metabolome feature (hilic_1348) (3-Pyridylacetic acid),3-hydroxylaurate levels,4-hydroxyphenylacetoylcarnitine levels,Metabolite levels (hypotaurine),Stearic acid (18:0) levels,Metabolite levels (16a-hydroxy DHEA 3-sulfate),"2,6-dihydroxybenzoic acid (X-09789) levels",Metabolite levels (3-hydroxylaurate),2-hydroxyhippurate (salicylurate) levels,3-hydroxybutyrate levels (UKB data field 23474),Docosahexaenoate (DHA; 22:6n3) levels,Dihydroxydocosapentaenoic acid levels,Metabolite levels (Dihydroxy docosatrienoic acid),Metabolite levels (3-hydroxysebacate),Metabolite levels (urate; cmh_urate; Uric_acid),3-hydroxydecanoate levels,FFA Arachidonic Acid a levels,3-hydroxyoleoylcarnitine levels,Docosahexaenoic acid levels,Metabolite levels (HWESASLLR),3-hydroxybutyrate (bhba) levels,2-hydroxyglutaric acid levels,Plasma metabolome feature (c18_1951) (6-Hydroxypentadecanedioic acid)
Picolinic acid (Reported Values: 20-100),Picolinate levels,Metabolite levels (picolinate),Picolinoylglycine (X-12170) levels,Picolinoylglycine levels,Stearic acid (18:0) levels,Oxaloacetic acid levels,Gondoic acid (20:1n-9) levels,Palmitic acid (16:0) levels,Vaccenic acid (18:1n-7) levels,X-12510--2-aminooctanoic acid levels,Plasma picolinate levels in chronic kidney disease,Urine picolinate levels in chronic kidney disease,Butyric acid levels,Linoleic acid (18:2) levels,6-oxopiperidine-2-carboxylic acid levels,Decadienedioic acid (c10:2-dc) (X-21792) levels,Urocanic acid levels,Docosahexaenoic acid (22:6) levels,3-Indolepropionic acid to 2-Picolinic acid ratio in coronary artery disease,"2,6-dihydroxybenzoic acid (X-09789) levels",X-12244--N-acetylcarnosine levels,Ascorbic acid 3-sulfate (X-12206) levels,RBC levels of Octadecenoic acid,"3,5-dichloro-2,6-dihydroxybenzoic acid levels",N-acetylaspartic acid levels,RBC levels of (7Z-10Z-13Z-16Z-19Z)-Docosa-7-10-13-16-19-pentaenoic acid,N-acetyl neuraminic acid levels,Caprylic acid levels,Acylcarnitine (18:0) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Deoxycholic acid (12 or 24)-sulfate levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Orotic acid levels,Glycochenodeoxycholic acid levels,Acylcarnitine (10:0) levels,2-o-methylascorbic acid levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Decadienedioic acid (C10:2-DC) levels,3-hydroxy-5-cholestenoic acid levels,Dihydroxydocosapentaenoic acid levels,Acetylcarnitine levels (Biocrates platform),Salicylic acid levels,Acylcarnitine (15:0) (a) levels,Octadecadienylcarnitine levels,FFA Arachidonic Acid a levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,4-hydroxy-2-oxoglutaric acid levels,Acylcarnitine (12:0) levels,Stearic acid levels
Quinolinic acid (Reported Values: 150-700),Plasma metabolome feature (c18_713) (Quinolinic acid),Quinolinate levels,Quinate levels,X-12510--2-aminooctanoic acid levels,Metabolite peak levels (QI12000),Quinate levels in elite athletes,Metabolite peak levels (QI12750),Metabolite peak levels (QI12663),Metabolite peak levels (QI12768),Metabolite levels (kynurenate; kynurenic acid; kynurenic_acid; Kynurenic_acid),Metabolite peak levels (QI12380),Ribosyldihydronicotinamide dehydrogenase [quinone] levels (NQO2.9754.33.3),Metabolite peak levels (QI12764),Metabolite peak levels (QI12128),Metabolite peak levels (QI12890),Metabolite peak levels (QI12470),Metabolite peak levels (QI12147),Metabolite peak levels (QI10057),Metabolite peak levels (QI1234),Metabolite peak levels (QI14354),Metabolite peak levels (QI12070),Metabolite peak levels (QI10664),Metabolite peak levels (QI12680),Metabolite peak levels (QI13773),Metabolite peak levels (QI12472),Quinone oxidoreductase levels,Metabolite peak levels (QI2240),Metabolite peak levels (QI12506),Urocanic acid levels,Metabolite peak levels (QI14793),Metabolite peak levels (QI1483),Metabolite peak levels (QI6840),Metabolite peak levels (QI4060),Metabolite peak levels (QI7638),Metabolite peak levels (QI3504),Metabolite peak levels (QI1565),Metabolite peak levels (QI6333),Metabolite peak levels (QI750),Metabolite peak levels (QI3710),Metabolite peak levels (QI13343),Metabolite peak levels (QI6762),Metabolite peak levels (QI15625),Metabolite peak levels (QI7380),Metabolite peak levels (QI14556),Metabolite peak levels (QI12942),Metabolite peak levels (QI14127),Metabolite peak levels (QI15563),Metabolite peak levels (QI6383),Metabolite peak levels (QI12743),Metabolite peak levels (QI2727)
Nicotinic acid (Reported Values: <20),Nicotinamide levels,Plasma metabolome feature (hilic_4134) (Nicotinic acid mononucleotide),N-acetyl neuraminic acid levels,N-acetyl-L-glutamic acid levels,N-acetyl-2-aminoadipate levels,N-acetylvaline levels,N-acetylaspartate (naa) levels,N-acetylarginine levels,N-acetylglycine levels,N-acetylalanine levels,Metabolite levels (N-acetylthreonine),Cinnamoylglycine levels,Nicotinamide N-methyltransferase levels,N-acetylalliin levels,N-alpha-acetylarginine levels,Metabolite levels (N-acetylalliin),N-acetylaspartic acid levels,Metabolite levels (N-acetylalanine),N-acetylthreonine levels,N-acetylcarnosine levels,Metabolite levels (N-acetylglutamate; acetylglutamic acid),Vaccenic acid (18:1n-7) levels,X-12244--N-acetylcarnosine levels,Metabolite levels (N-acetylglycine; acetylglycine),Acetoacetate levels,Metabolite levels (N-acetylneuraminate),N-acetyl-2-aminooctanoate levels,Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 levels,Metabolite levels (N-acetylarginine; N-alpha-acetylarginine),X-12510--2-aminooctanoic acid levels,Palmitic acid (16:0) levels,Indoleacetoylcarnitine levels,N-acetylproline levels,N-acetylmethionine levels,Periostin levels (POSTN.6650.20.3),Metabolite levels (cinnamoylglycine),Nicotinamide phosphoribosyltransferase levels (NAMPT.5011.11.1),Metabolite levels (N-acetylcarnosine),N-acetylleucine levels,N-acetyl-aspartyl-glutamate (naag) levels,N-acetyl-2-aminooctanoate (X-12511) levels,Triacylglycerol (54:0) [NL-18:0] levels,Nicalin levels,Stearic acid (18:0) levels,Triacylglycerol (54:4) [NL-18:0] levels,N-acetyl-beta-alanine levels,Triacylglycerol (50:0) [NL-18:0] levels,Very long-chain saturated fatty acid levels (fatty acid 20:0),Triacylglycerol (54:2) [NL-18:0] levels,Acetoacetate levels (UKB data field 23476)
Nicotinamide (Reported Values: 100-600),Nicotinamide levels,Nicotinamide levels in elite athletes,Nicotinamide N-methyltransferase levels,Nicotinamide phosphoribosyltransferase levels (NAMPT.5011.11.1),Urine nicotinamide riboside levels in chronic kidney disease,Niacinamide levels,Dihydroceramide (d18:0/22:0) levels,Dihydroceramide (d18:0/20:0) levels,Dihydroceramide (d18:0/24:0) levels,Dihydroceramide (d18:0/18:0) levels,Dihydroceramide (d18:0/24:1) levels,Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 levels,N-acetylputrescine levels,Nicotinamide riboside kinase 1 levels,Metabolite levels (N-acetylputrescine),Metabolite levels (N-acetylglycine; acetylglycine),X-12095--N1-methyl-3-pyridone-4-carboxamide levels,N-acetylglycine levels,Nucleolin levels (NCL.13655.34.3),Nervonoylcarnitine (C24:1) levels,Metabolite levels (N-acetylneuraminate),N-acetyl-2-aminoadipate levels,Monohexosylceramide (d18:2/24:0) levels,Monohexosylceramide (d16:1/18:0) levels,Monohexosylceramide (d18:2/18:0) levels,Monohexosylceramide (d16:1/20:0) levels,Nonaylcarnitine levels,Monohexosylceramide (d16:1/24:0) levels,Plasma metabolome feature (hilic_4134) (Nicotinic acid mononucleotide),Monohexosylceramide (d16:1/22:0) levels,Monohexosylceramide (d18:2/22:0) levels,Indoleacetoylcarnitine levels,Monohexosylceramide (d18:2/20:0) levels,Total Dihydroceramide levels,Metabolite levels (N4-acetylcytidine),Monohexosylceramide (d18:1/18:0) levels,Monohexosylceramide (d18:1/24:0) levels,NAD kinase levels (NADK.13624.17.3),Monohexosylceramide (d18:1/22:0) levels,Monohexosylceramide (d18:1/20:0) levels,"Metabolite levels (N2-acetyl,N6,N6-dimethyllysine)",Metabolite levels (N-acetyltaurine),N4-acetylcytidine levels,Metabolite levels (N-acetylthreonine),1-methylnicotinamide levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Monohexosylceramide (d18:1/16:0) levels,Metabolite levels  (X-11787),Metabolite levels (indoleacetoylcarnitine),Metabolite levels (N-acetylkynurenine (2))
N1-methylnicotinamide (Reported Values: 20-250),1-methylnicotinamide levels,1-methylnicotinamide levels in elite athletes,Metabolite levels (N1-methyladenosine; 1-methyladenosine),N1-methyladenosine levels,Metabolite levels (1-methylurate),1-methylurate levels,Plasma 1-methylnicotinamide levels in chronic kidney disease,Methylmalonate (mma) levels,X-11593--O-methylascorbate levels,X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Metabolite levels (2'-O-methylcytidine),Methylsuccinate levels,Metabolite levels (3-methylcytidine),Metabolite levels (NMMA),Metabolite levels (N('1)-acetylspermidine; N1-acetylspermidine),Nicotinamide N-methyltransferase levels,Monohexosylceramide (d16:1/20:0) levels,"Metabolite levels (ceramide (d16:1/24:1, d18:1/22:1))",Monohexosylceramide (d16:1/24:0) levels,Monohexosylceramide (d16:1/22:0) levels,Monohexosylceramide (d18:1/18:0) levels,Monohexosylceramide (d18:1/24:0) levels,Monohexosylceramide (d16:1/18:0) levels,Monohexosylceramide (d18:1/22:0) levels,Monohexosylceramide (d18:1/20:0) levels,Metabolite levels  (X-11787),Metabolite levels (ethylmalonate),Monohexosylceramide (d18:1/16:0) levels,2'-o-methylcytidine levels,Monohexosylceramide (d18:2/24:0) levels,Plasma metabolome feature (c18_2068) (Methylmercuric dicyanamide),5-methyluridine (ribothymidine) levels,Metabolite levels (5-methyluridine (ribothymidine); ribothymidine),Metabolite levels (N-methylpipecolate),Monohexosylceramide (d18:2/20:0) levels,Metabolite levels ((N(1) + N(8))-acetylspermidine),Monohexosylceramide (d18:2/18:0) levels,Monohexosylceramide (d18:2/22:0) levels,Trihexosylcermide (d18:1/22:0) levels,"Metabolite levels (N,N,N-trimethyl-5-aminovalerate; N-trimethyl 5-aminovalerate)",2-methylmalonylcarnitine (C4-DC) levels,Trihexosylcermide (d18:1/20:0) levels,Dihydroceramide (d18:0/20:0) levels,Monohexosylceramide (d18:1/24:1) levels,Dihydroceramide (d18:0/22:0) levels,N1-acetylspermidine levels,Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),Trigonelline (n'-methylnicotinate) levels,Metabolite levels (N6-methyllysine),Metabolite levels (1-methylxanthine)
Cotinine (Reported Values: <3000),Smoking intensity (cotinine levels/cigarettes per day),Cotinine levels in current smokers,Calnexin levels (CANX.8834.58.3),Cotinine levels in smokers with chronic obstructive pulmonary disease,"X-12442--5,8-tetradecadienoate levels",Metabolite levels  (X-11787),Tetradecenoylcarnitine levels,Cotinine glucuronidation,Metabolite levels (C18:3 CE; C18_3_CE),X-12510--2-aminooctanoic acid levels,Tetradecadienoate (14:2) (X-12442) levels,Metabolite levels (C16:0 CE; C16_0_CE),Metabolite levels (tetradecanedioate; tetradecanedioate (C14-DC)),Metabolite levels (C20:4 CE; C20_4_CE),Tetradecanedioate levels,Calpastatin levels (CAST.3026.5.2),Cerotoylcarnitine (C26) levels,Tetradecadienylcarnitine levels,Metabolite levels (C20:5 CE; C20_5_CE),"Metabolite levels (ceramide (d16:1/24:1, d18:1/22:1))",Trigonelline (n'-methylnicotinate) levels,X-13431--nonanoylcarnitine levels,Metabolite peak levels (QI10958),Promotilin levels (MLN.5631.83.3),Metabolite peak levels (QI15965),Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),"Metabolite levels (ceramide (d18:1/20:0, d16:1/22:0, d20:1/18:0))",Metabolite levels (C38_5_PC),Cotinine and 3'-hydroxycotinine levels in current smokers,Metabolite peak levels (QI9368),Metabolite peak levels (QI6455),Metabolite levels (pregnenetriol sulfate),Tetradecanoylcarnitine levels,Metabolite peak levels (QI4775),Metabolite peak levels (QI10969),Metabolite levels (deoxycarnitine; butyrobetaine),Metabolite peak levels (QI10309),Metabolite peak levels (QI10834),Metabolite peak levels (QI10980),Metabolite peak levels (QI9710),Metabolite peak levels (QI15625),Metabolite peak levels (QI2799),Metabolite peak levels (QI6558),Metabolite peak levels (QI9810),Metabolite peak levels (QI14798),Metabolite peak levels (QI15633),Metabolite peak levels (QI9376),Metabolite levels (arachidonoylcarnitine (C20:4)),Metabolite peak levels (QI9738),Metabolite peak levels (QI15932)
Trans-3'-hydroxycotinine (Reported Values: <1500),Hydroxycotinine levels,Metabolite levels (hydroxycotinine),3-hydroxycotinine glucuronide levels,Hydroxy-cmpf (X-02269) levels,3-hydroxyadipate levels,Metabolite levels (3-hydroxyhexanoate),trans-Hydroxyproline levels,Trans-4-hydroxyproline levels,Metabolite levels (3-hydroxyoctanoate),3-hydroxyoctanoate levels,Metabolite levels  (X-11787),Metabolite levels (3-hydroxydecanoate),Metabolite levels (2-hydroxystearate),X-12441--12-hydroxyeicosatetraenoate 12-HETE levels,Metabolite levels (2-hydroxyoctanoate),Metabolite levels (trans-2-hexenoylglycine),Metabolite levels (trans-4-hydroxyproline; hydroxyproline; cis_trans_hydroxyproline),Metabolite levels (2-ethylhexanoate),Plasma metabolome feature (c18_3925) ((5Z7E)-(3S)-262626272727-hexafluoro-910-seco-5710(19)16-cholestatetraen-23-yne-325-diol),3-hydroxydecanoate levels,X-11593--O-methylascorbate levels,Metabolite levels (3-hydroxy-2-ethylpropionate),2-hydroxyadipate levels,Plasma metabolome feature (hilic_4401) (Deacetylcolchicine),2-hydroxyoctanoate levels,Glycosyl-N-tricosanoyl-sphingadienine (d18:2/23:0) levels,Metabolite levels (3-methoxytyrosine),Plasma metabolome feature (hilic_5246) ((5Z7E)-(3S)-262626-trifluoro-27-nor-910-seco-5710(19)-cholestatriene-325-diol),3-hydroxy-2-ethylpropionate levels,X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,3-hydroxyhexanoate levels,Metabolite levels (1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6)),Metabolite levels (16a-hydroxy DHEA 3-sulfate),3-hydroxyoleate levels,Plasma metabolome feature (c18_2759) (24-Dihydroxy-46-dimethoxy-3-prenylchalcone),Monohexosylceramide (d18:2/22:0) levels,Cotinine and 3'-hydroxycotinine levels in current smokers,Trihexosylcermide (d18:1/22:0) levels,Monohexosylceramide (d18:2/18:0) levels,"3-hydroxyanthranilate 3,4-dioxygenase levels (HAAO.5861.78.3)",Monohexosylceramide (d18:2/24:0) levels,Monohexosylceramide (d16:1/18:0) levels,Metabolite peak levels (QI15965),Monohexosylceramide (d18:2/20:0) levels,Monohexosylceramide (d16:1/22:0) levels,Monohexosylceramide (d18:1/22:0) levels,Plasma metabolome feature (hilic_2525) (Buthionine sulfoximine),2-hydroxystearate levels,Metabolite levels (3beta-hydroxy-5-cholestenoate),Metabolite peak levels (QI15633)
Trigonelline (Reported Values: <25),Trigonelline (n'-methylnicotinate) levels,Triacylglycerol (58:8) [NL-22:6] levels,Triacylglycerol 56:6 levels,Triacylglycerol (56:5) levels,Triacylglycerol (56:3) levels,Triacylglycerol (58:7) levels,Triacylglycerol (56:7) levels,Triacylglycerol (58:8) levels,Triacylglycerol 56:2 levels,Triacylglycerol (56:8) [NL-20:4] levels,Triacylglycerol (56:6) [NL-20:4] levels,Triacylglycerol (56:8) levels,Triacylglycerol (49:1) [NL-15:0] levels,Triglycerides (58:10) levels,Triacylglycerol (56:6) levels,Triacylglycerol (56:4) levels,Triacylglycerol (51:2) [NL-15:0] levels,Triacylglycerol (52:3) levels,Triacylglycerol (52:3) [NL-18:2] levels,Triacylglycerol (50:3) levels,Triacylglycerol (50:0) [NL-18:0] levels,Triglycerides (56:9) levels,Triglycerides (58:9) levels,Triacylglycerol (52:4) [NL-16:0] levels,Triacylglycerol (52:5) levels,Triacylglycerol (50:5) levels,Triacylglycerol (50:3) [NL-18:1] levels,Triglycerides (58:5) levels,Triacylglycerol (51:3) levels,Triacylglycerol (52:3) [NL-16:1] levels,Triacylglycerol (52:6) levels,Triacylglycerol (50:3) [NL-16:1] levels,Triacylglycerol (53:3) levels,Triglycerides (44:0) levels,Triacylglycerol (50:4) [NL-14:0] levels,Triacylglycerol (46:1) levels,Triacylglycerol (54:7) levels,Triacylglycerol (50:3) [NL-14:1] levels,Triacylglycerol (52:2) [NL-16:0] levels,Triacylglycerol (48:3) levels,Triacylglycerol (54:4) [NL-18:0] levels,Triacylglycerol (53:2) [NL-17:0] levels,Triacylglycerol (54:0) [NL-18:0] levels,Triacylglycerol (50:1) levels,Triacylglycerol (52:4) [NL-18:1] levels,Triacylglycerol (54:5) [NL-18:1] levels,Triacylglycerol (54:3) [NL-18:1] levels,Triacylglycerol (46:2) levels,Triacylglycerol (48:1) levels,Triacylglycerol (49:1) [NL-16:0] levels
Imidazole propionate; <Limit Of Detection indicated by 8881 (Reported Values: 3-500),Imidazole propionate levels,1-methyl-5-imidazoleacetate (X-14838) levels,Imidazole propionate levels in elite athletes,1-ribosyl-imidazoleacetate (X-11334) levels,Metabolite levels (1-methylimidazoleacetate; 1-methyl-4-imidazoleacetate; methylimidazoleacetic acid),1-methyl-4-imidazoleacetate levels,1-methyl-5-imidazoleacetate levels,Progonadoliberin-2 levels,1-methylimidazoleacetate levels,Metabolite levels (imidazole lactate; imidazolelactate),X-12095--N1-methyl-3-pyridone-4-carboxamide levels,Imidazole lactate levels,Progonadoliberin-1 levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,Semaphorin-6A levels (SEMA6A.7945.10.3),Octadecadienylcarnitine levels,Picolinoylglycine (X-12170) levels,Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate),1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-ribosyl-imidazoleacetate levels,Semaphorin-3G levels (SEMA3G.5628.21.3),Octadecenoylcarnitine levels,"X-12442--5,8-tetradecadienoate levels",Semaphorin-3C levels (SEMA3C.6448.36.3),Metabolite levels  (X-11787),Progonadoliberin-2 levels (GNRH2.10708.3.3),Semaphorin-5A levels (SEMA5A.13132.14.3),Octadecandienylcarnitine levels,Treatment or medication use - glyceryl trinitrate (UKB data field 20003_1140860834),X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Metabolite levels (picolinate),1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,X-12510--2-aminooctanoic acid levels,Metabolite levels (indoleacetoylcarnitine),Semaphorin-3A levels (SEMA3A.3222.11.2),Semaphorin-6B levels,Semaphorin-3A levels,Apo-CIII0c levels,Azelaoyltaurine levels,Treatment or medication use - maxalt 5mg tablet (UKB data field 20003_1141167940),"2,6-dihydroxybenzoic acid (X-09789) levels",1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4) levels,1-pentadecanoyl-2-arachidonoyl-GPC (15:0/20:4) levels,Prolargin levels (PRELP.5675.6.3),1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6) levels,1-palmityl-2-arachidonoyl-GPC (o-16:0/20:4) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,Semaphorin-3F levels
3-Indoxyl sulfate (Reported Values: 0.9-30),3-indoxyl sulfate levels,6-hydroxyindole sulfate levels,5-hydroxyindole sulfate levels,3-indoxyl sulfate levels in elite athletes,3-indoleglyoxylic acid levels,Metabolite levels (indolelactate; Indole_3_lactate),Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate),Metabolite levels (indole-3-carboxylic acid; indole-3-carboxylate; Indole_3_carboxylate),Indoleacetate levels,Indole-3-carboxylic acid levels,Indole-3-carboxylate levels,Metabolite levels (indolebutyrate),Indole-3-lactic acid levels,RBC levels of Indoxyl,Metabolite levels (indoleacetoylcarnitine),Indolelactate levels,Metabolite levels (indoleacetylglutamine),3-hydroxyadipate levels,3-ethylcatechol sulfate (1) levels,Metabolite levels (sulfate),4-allylcatechol sulfate levels,Indolepropionate levels,6-hydroxyindole sulfate levels in elite athletes,RBC levels of Indole-3-acetate,3-methoxytyramine sulfate levels,"Indoleamine 2,3-dioxygenase 1 levels (IDO1.9759.13.3)",RBC levels of Indole-3-acetate.1,Indoleacetoylcarnitine levels,Serum sulfate level,Plasma metabolome feature (hilic_5468) (Indol-3-ylacetyl-myo-inositol L-arabinoside),3-methyl-2-oxindole levels,Metabolite levels (3-methoxytyramine sulfate),Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),Indolebutyrate levels,Metabolite levels (1-methylimidazoleacetate; 1-methyl-4-imidazoleacetate; methylimidazoleacetic acid),Urine 3-hydroxyindolin-2-one sulfate levels in chronic kidney disease,Metabolite levels (pregnenetriol sulfate),2-acetamidophenol sulfate levels,3-methyl catechol sulfate (1) levels,Sterol ester (27:1/18:0) levels,Sterol ester (27:1/18:3) levels,1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels,Metabolite levels (glycocholenate sulfate),4-acetylphenol sulfate levels,Sterol ester (27:1/18:2) levels,Sterol ester (27:1/17:0) levels,Indoleacetylglutamine levels,Sterol ester (27:1/14:0) levels,Indolin-2-one levels,Sterol ester (27:1/20:3) levels
Indole-3-acetamide; <Limit Of Detection indicated by 8881 (Reported Values: 0-10),RBC levels of Indole.1,RBC levels of Indole-3-acetate.1,Indole-3-carboxylate levels,RBC levels of Indole-3-acetate,Indole-3-carboxylic acid levels,Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate),Indolin-2-one levels,Indolepropionate levels,Metabolite levels (indolebutyrate),Indolebutyrate levels,Metabolite levels (indole-3-carboxylic acid; indole-3-carboxylate; Indole_3_carboxylate),3-indoxyl sulfate levels,Indolelactate levels,Plasma metabolome feature (hilic_4314) (Indole-3-acetic-acid-O-glucuronide),3-indoleglyoxylic acid levels,Indoleacetate levels,Metabolite levels (indoleacetoylcarnitine),Metabolite levels (indolelactate; Indole_3_lactate),Indoleacetoylcarnitine levels,Indole-3-lactic acid levels,RBC levels of Indoxyl,"Indoleamine 2,3-dioxygenase 1 levels (IDO1.9759.13.3)",Plasma metabolome feature (hilic_5468) (Indol-3-ylacetyl-myo-inositol L-arabinoside),X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels,Plasma metabolome feature (hilic_1399) (Indole ethanol (Tryptophanol)),Metabolite levels (indoleacetylglutamine),3-methyl-2-oxindole levels,Indoleacetylglutamine levels,6-hydroxyindole sulfate levels,N-acetyl-2-aminoadipate levels,"Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID31474:v1)","Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID30563:v1)","Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID30230:v1)","Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID31050:v1)",1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4) levels,N-acetyl-isoputreanine (X-12688) levels,"Indoleamine 2,3-dioxygenase 1 levels",N-acetyl-isoputreanine levels,1-palmitoyl-2-oleoyl-GPI (16:0/18:1) levels,5-hydroxyindole sulfate levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels (advanced age),1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels,Octadecadienylcarnitine levels,Indole-3-carboxylic acid levels in elite athletes,"5,6-dihydroxyindole-2-carboxylic acid oxidase levels",Nidogen-2 levels (NID2.3633.70.5),1-ribosyl-imidazoleacetate (X-11334) levels,Undecenoylcarnitine (c11:1) (X-17337) levels,Octadecenoylcarnitine levels,N-acetylcitrulline levels
Indole-3-acetate (Reported Values: 0.3-23),Indole-3-carboxylic acid levels,Indole-3-carboxylate levels,Metabolite levels (indolelactate; Indole_3_lactate),Indole-3-lactic acid levels,Metabolite levels (indole-3-carboxylic acid; indole-3-carboxylate; Indole_3_carboxylate),Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate),RBC levels of Indole-3-acetate,RBC levels of Indole-3-acetate.1,Indolelactate levels,3-indoleglyoxylic acid levels,Indoleacetate levels,3-indoxyl sulfate levels,Metabolite levels (indolebutyrate),Indolebutyrate levels,RBC levels of Indole.1,Indolin-2-one levels,Indolepropionate levels,Metabolite levels (indoleacetoylcarnitine),Plasma metabolome feature (hilic_4314) (Indole-3-acetic-acid-O-glucuronide),Indoleacetoylcarnitine levels,"Indoleacetate-to-N2,N2-dimethylguanosine ratio",Indole-3-carboxylic acid levels in elite athletes,"Indoleamine 2,3-dioxygenase 1 levels (IDO1.9759.13.3)",6-hydroxyindole sulfate levels,Metabolite levels (indoleacetylglutamine),RBC levels of Indoxyl,Plasma metabolome feature (hilic_5468) (Indol-3-ylacetyl-myo-inositol L-arabinoside),3-methyl-2-oxindole levels,5-hydroxyindole sulfate levels,3-Indolepropionic acid to Indole-5-carboxylic acid ratio in coronary artery disease,"Indoleamine 2,3-dioxygenase 1 levels",Indoleacetylglutamine levels,"5,6-dihydroxyindole-2-carboxylic acid oxidase levels",3-Indolepropionic acid to Isonicotinamide ratio in coronary artery disease,Acetoacetate levels (UKB data field 23476),3-Indolepropionic acid to N-acetylglycine ratio in coronary artery disease,Plasma metabolome feature (hilic_1399) (Indole ethanol (Tryptophanol)),3-Indolepropionic acid to 3-Hydroxybutyrate ratio in coronary artery disease,3-Indolepropionic acid to Hypoxanthine ratio in coronary artery disease,3-Indolepropionic acid to Myoinositol ratio in coronary artery disease,N-acetyl-2-aminoadipate levels,3-Indolepropionic acid to L-Arginine ratio in coronary artery disease,3-Indolepropionic acid to SubericAcid ratio in coronary artery disease,3-Indolepropionic acid to Azelaic acid ratio in coronary artery disease,3-Indolepropionic acid levels in coronary artery disease,"Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID30563:v1)",3-indoxyl sulfate levels in elite athletes,Sterol ester (27:1/18:3) levels,"Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID31474:v1)",Acetate levels (UKB data field 23475)
Indole-3-aldehyde; <Limit Of Detection indicated by 8881 (Reported Values: 0.01-0.20),Indole-3-carboxylate levels,Indole-3-carboxylic acid levels,RBC levels of Indole.1,3-indoleglyoxylic acid levels,Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate),RBC levels of Indole-3-acetate.1,Indolin-2-one levels,Metabolite levels (indole-3-carboxylic acid; indole-3-carboxylate; Indole_3_carboxylate),RBC levels of Indole-3-acetate,Indolebutyrate levels,"Indoleamine 2,3-dioxygenase 1 levels (IDO1.9759.13.3)",Metabolite levels (indolebutyrate),Indolelactate levels,Plasma metabolome feature (hilic_4314) (Indole-3-acetic-acid-O-glucuronide),Indoleacetate levels,3-indoxyl sulfate levels,Indolepropionate levels,Indoleacetoylcarnitine levels,Metabolite levels (indolelactate; Indole_3_lactate),Indole-3-lactic acid levels,Plasma metabolome feature (hilic_1399) (Indole ethanol (Tryptophanol)),RBC levels of Indoxyl,Metabolite levels (indoleacetoylcarnitine),Plasma metabolome feature (hilic_5468) (Indol-3-ylacetyl-myo-inositol L-arabinoside),"Indoleamine 2,3-dioxygenase 1 levels","Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID30563:v1)","Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID31474:v1)","Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID30230:v1)","5,6-dihydroxyindole-2-carboxylic acid oxidase levels",3-methyl-2-oxindole levels,"Indoleamine 2,3-dioxygenase 1 levels (IDO1:P14902:OID31050:v1)",3-formylindole (X-16071) levels,6-hydroxyindole sulfate levels,1-palmitoyl-2-oleoyl-GPI (16:0/18:1) levels,Metabolite levels (indoleacetylglutamine),1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4) levels,Indoleacetylglutamine levels,"Indoleacetate-to-N2,N2-dimethylguanosine ratio",5-hydroxyindole sulfate levels,1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels,1-stearoyl-2-oleoyl-GPI (18:0/18:1) levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels (advanced age),1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) levels,1-(1-enyl-palmitoyl)-2-oleoyl-gpc (p-16:0/18:1) levels,1-ribosyl-imidazoleacetate (X-11334) levels,3-formylindole levels,3-Indolepropionic acid to 4-Hydroxybenzaldehyde ratio in coronary artery disease,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,Indole-3-carboxylic acid levels in elite athletes
Indole-3-lactate (Reported Values: 0.08-5),Indole-3-lactic acid levels,Metabolite levels (indolelactate; Indole_3_lactate),Indolelactate levels,Indole-3-carboxylic acid levels,Metabolite levels (indole-3-carboxylic acid; indole-3-carboxylate; Indole_3_carboxylate),Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate),Indoleacetate levels,Metabolite levels (indolebutyrate),Indole-3-carboxylate levels,Imidazole lactate levels,RBC levels of Indole-3-acetate,Indolebutyrate levels,RBC levels of Indole-3-acetate.1,3-indoleglyoxylic acid levels,Metabolite levels (imidazole lactate; imidazolelactate),3-indoxyl sulfate levels,Metabolite levels (indoleacetoylcarnitine),RBC levels of Indole.1,Lactate levels (UKB data field 23471),Plasma metabolome feature (hilic_4314) (Indole-3-acetic-acid-O-glucuronide),Metabolite levels (indoleacetylglutamine),Indoleacetoylcarnitine levels,Indolin-2-one levels,Lactate levels,Plasma metabolome feature (hilic_5468) (Indol-3-ylacetyl-myo-inositol L-arabinoside),Indolepropionate levels,Indole-3-carboxylic acid levels in elite athletes,3-(4-hydroxyphenyl)lactate levels,3-(4-hydroxyphenyl) lactate levels,6-hydroxyindole sulfate levels,Indolelactate levels in elite athletes,5-hydroxyindole sulfate levels,"Indoleacetate-to-N2,N2-dimethylguanosine ratio",3- 4-hydroxyphenyl lactate-to-alpha-hydroxyisovalerate ratio,"Indoleamine 2,3-dioxygenase 1 levels (IDO1.9759.13.3)",Metabolite levels (1-methylimidazoleacetate; 1-methyl-4-imidazoleacetate; methylimidazoleacetic acid),Metabolite levels (inosine; cmh_inosine; Inosine),Indoleacetylglutamine levels,Plasma lactate levels,"5,6-dihydroxyindole-2-carboxylic acid oxidase levels",Imidazole lactate levels in elite athletes,Metabolonic lactone sulfate (X-12063) levels,Plasma metabolome feature (hilic_1399) (Indole ethanol (Tryptophanol)),Inositol monophosphatase 3 levels (IMPAD1.9231.23.3),Metabolite levels (orotate; cmh_orotate; Orotate),RBC levels of Indoxyl,Metabolite levels (N-acetylcitrulline),3-indoxyl sulfate levels in elite athletes,Urine indolelactate levels in chronic kidney disease,Metabolonic lactone sulfate levels
Indole-3-propionate (Reported Values: 0.5-12),Metabolite levels (indolepropionate; indole-3-propionate; cmh_indole_pro; Indole_3_propanoate),Indole-3-carboxylic acid levels,Metabolite levels (indolelactate; Indole_3_lactate),Indole-3-carboxylate levels,Metabolite levels (indole-3-carboxylic acid; indole-3-carboxylate; Indole_3_carboxylate),Indole-3-lactic acid levels,Metabolite levels (indolebutyrate),3-indoleglyoxylic acid levels,Imidazole propionate levels,Indolelactate levels,Indolepropionate levels,Indolebutyrate levels,3-indoxyl sulfate levels,Metabolite levels (indoleacetoylcarnitine),Indolin-2-one levels,Indoleacetate levels,RBC levels of Indole.1,RBC levels of Indole-3-acetate.1,RBC levels of Indole-3-acetate,Indoleacetoylcarnitine levels,Plasma metabolome feature (hilic_4314) (Indole-3-acetic-acid-O-glucuronide),3-Indolepropionic acid to Isonicotinamide ratio in coronary artery disease,6-hydroxyindole sulfate levels,Metabolite levels (indoleacetylglutamine),3-Indolepropionic acid to Indole-5-carboxylic acid ratio in coronary artery disease,Plasma metabolome feature (hilic_5468) (Indol-3-ylacetyl-myo-inositol L-arabinoside),"Indoleamine 2,3-dioxygenase 1 levels (IDO1.9759.13.3)",3-(3-hydroxyphenyl)propionate levels,3-Indolepropionic acid to SubericAcid ratio in coronary artery disease,"Indoleacetate-to-N2,N2-dimethylguanosine ratio",3-Indolepropionic acid to L-Arginine ratio in coronary artery disease,5-hydroxyindole sulfate levels,3-Indolepropionic acid levels in coronary artery disease,Indole-3-carboxylic acid levels in elite athletes,3-Indolepropionic acid to Hypoxanthine ratio in coronary artery disease,3-Indolepropionic acid to Dodecanedioic aicd ratio in coronary artery disease,3-Indolepropionic acid to Kinurenine ratio in coronary artery disease,"3-Indolepropionic acid to N,N-Dimethylglycine ratio in coronary artery disease",3-Indolepropionic acid to Myoinositol ratio in coronary artery disease,3-Indolepropionic acid to 3-Hydroxybutyrate ratio in coronary artery disease,3-methyl-2-oxindole levels,3-Indolepropionic acid to beta-Pseudouridine ratio in coronary artery disease,3-Indolepropionic acid to Phenylpyruvic acid ratio in coronary artery disease,3-Indolepropionic acid to Homovanillic acid ratio in coronary artery disease,3-Indolepropionic acid to Creatinine ratio in coronary artery disease,3-Indolepropionic acid to Pipecolinic acid ratio in coronary artery disease,3-Indolepropionic acid to Hippuric acid ratio in coronary artery disease,RBC levels of Indoxyl,"Indoleamine 2,3-dioxygenase 1 levels",3-Indolepropionic acid to Creatine ratio in coronary artery disease
Folate (s-Folate) (Reported Values: >7.5),Serum folate levels,Folate pathway vitamin levels,Folate receptor beta levels,Folate receptor alpha levels,Folate receptor gamma levels,Red blood cell folate levels,Metabolite levels (S-methylcysteine; methylcysteine),Metabolite levels (glycolithocholate sulfate),Plasma metabolome feature (hilic_5950) (3-keto Fusidic acid),Plasma metabolome feature (hilic_5246) ((5Z7E)-(3S)-262626-trifluoro-27-nor-910-seco-5710(19)-cholestatriene-325-diol),Metabolite levels (glyco-beta-muricholate),(S)-a-amino-omega-caprolactam levels,Glycolithocholate levels,Plasma metabolome feature (hilic_727) (5-Hydroxy-2-furoic acid),Metabolite levels (deoxycholic acid (12 or 24)-sulfate),Metabolite levels (C38_5_PC),Metabolite levels (glycodeoxycholate 3-sulfate; glycodeoxycholate sulfate),Plasma metabolome feature (c18_3925) ((5Z7E)-(3S)-262626272727-hexafluoro-910-seco-5710(19)16-cholestatetraen-23-yne-325-diol),Glutathione S-transferase omega-1 levels (GSTO1.12436.84.3),Lactotransferrin levels (LTF.2780.35.2),Tauro-beta-muricholate levels,Glyco-beta-muricholate levels,Metabolite levels (tauro-beta-muricholate; tauro-alpha-muricholate/tauro-beta-muricholate),Folate receptor alpha level in Chronic kidney disease with hypertension and no diabetes (17455_42),Metabolite levels  (X-11787),Folate receptor gamma level in Chronic kidney disease with hypertension and no diabetes (15495_9),Cystatin-F levels (CST7.3302.58.1),Metabolite levels (isoursodeoxycholate sulfate (2)),Metabolite levels (C36:4 PC-A; C36_4_PC_A),Metabolite levels (HVA-5-HIAA Factor score),Tyrosine-protein kinase Fyn levels (FYN.4550.3.2),Metabolite levels (methionine sulfone),Plasma metabolome feature (c18_1507) (5-Sulfo-13-benzenedicarboxylic acid),Plasma metabolome feature (c18_783) (Phenylmethanesulfonyl fluoride),Fumarylacetoacetase levels (FAH.11424.4.3),Metabolite levels (C38:2 PC; C38_2_PC),Metabolite levels (S-allylcysteine),Vitamin levels,Glycohyocholate levels,Transcobalamin-2 levels (TCN2.5584.21.3),Fatty acids (15:0) levels,Metabolite levels (asparagylvaline),Metabolite levels (S-adenosylhomocysteine (SAH); ___adenosylhomocysteine; S_Ado_homocysteine),Metabolite levels (pregnenetriol disulfate),S-methylcysteine levels,Metabolite levels (glycochenodeoxycholate 3-sulfate; glycochenodeoxycholate sulfate),Metabolite levels (hypotaurine),Metabolite levels (pregn steroid monosulfate; pregnenediol sulfate (C21H34O5S); pregn steroid monosulfate C21H34O5S),Metabolite levels (glycylproline),3-carboxy-4-methyl-5-propyl-2-furanpropanoate (cmpf) levels
"Cobalamin (vitamin B12, s-B12) (Reported Values: >150)",Transcobalamin-2 levels (TCN2.5584.21.3),Transcobalamin-1 levels (TCN1.11232.46.3),Transcobalamin-2 levels,Vitamin B1 intake,Vitamin B12 levels,Transcobalamin-1 levels,Holo-Transcobalamin-2 levels,Vitamin levels,Serpin B13 levels,Vitamin B2 intake,X-11793--oxidized bilirubin levels,Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),Vitamin C levels,Cofilin-2 levels,Protein MENT levels (MENT.5744.12.3),Transcobalamin-1 level in Chronic kidney disease with hypertension and no diabetes (11232_46),"Metabolite levels (bilirubin (E,Z or Z,E))","Metabolite levels (bilirubin (E,E))",Vitamin D-binding protein levels (GC.6581.50.3),Transcobalamin-1 level in Chronic kidney disease with hypertension and no diabetes (19614_8),Protein FAM150B levels (FAM150B.6284.7.3),Holo-Transcobalamin-2 level in Chronic kidney disease with hypertension and no diabetes (5584_21),Retinol (Vitamin A) levels,Vitamin B9 levels,Bilirubin levels,Metabolite levels (biliverdin),(S)-a-amino-omega-caprolactam levels,Brevican core protein levels (BCAN.3461.58.1),Endostatin levels (COL18A1.2201.17.6),Reticulocalbin-3 levels,Metabolite levels (C38_5_PC),"Metabolite levels (bilirubin (Z,Z); bilirubin; Bilirubin)",High mobility group protein B1 levels (HMGB1.2524.56.3),Serum total bilirubin levels,Vigilin levels (HDLBP.13570.43.3),Vitrin levels (VIT.6234.74.3),Metabolite levels  (X-11787),Haptoglobin levels (HP.3054.3.2),Serum levels of protein C2,Periostin levels (POSTN.6650.20.3),Promotilin levels (MLN.5631.83.3),Biliverdin levels in elite athletes,Beta-crystallin B1 levels,Lamin-B1 levels,Biliverdin reductase A levels (BLVRA.11382.5.3),RBC levels of [Similar to: L-Glutathione (reduced); deltaMass: 0.9383 Da],Total bilirubin levels,Folate pathway vitamin levels,Serum levels of protein BAMBI,Glyco-beta-muricholate levels
All-trans retinol (Vit. A) (Reported Values: 1.46-2.84),Retinol (Vitamin A) levels,Retinol levels,Retinol dehydrogenase 16 levels (RDH16.12881.17.3),All-trans-retinol dehydrogenase [NAD levels,All-trans-retinol dehydrogenase levels,Retinoschisin levels,Retinoic acid receptor responder protein 1 levels (RARRES1.8398.277.3),Retinoic acid receptor responder protein 3 levels (RARRES3.10961.15.3),All-trans retinoic acid-induced differentiation factor levels,Retinol-binding protein 1 levels,Retinoid-binding protein 7 levels (RBP7.14208.3.3),Retinol dehydrogenase 16 levels,4-oxo-retinoic acid levels,Retinol-binding protein 5 levels,Retinol (Vitamin A) levels in elite athletes,Retinol-binding protein 2 levels,Retinoid-binding protein 7 levels,Retinoic acid receptor responder protein 1 levels,Retinol-binding protein 4 levels,Cellular retinoic acid-binding protein 1 levels,Vitrin levels (VIT.6234.74.3),Retinoic acid receptor responder protein 3 levels,Treatment or medication use - vitamin e product (UKB data field 20003_1140871112),Cellular retinoic acid-binding protein 1 levels (CRABP1.11967.23.3),Retinoic acid early transcript 1G protein levels,Retinoic acid receptor responder protein 2 levels,Promotilin levels (MLN.5631.83.3),Cellular retinoic acid-binding protein 2 levels,RET protein levels,Translin levels,Vitamin levels,Transthyretin levels,Vigilin levels (HDLBP.13570.43.3),Phosphatidylinositol (16:0_20:3) (a) levels,Transcobalamin-2 levels (TCN2.5584.21.3),Estriol levels,Serum levels of protein RET,Phosphatidylinositol (38:5) (a) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Transcobalamin-1 levels (TCN1.11232.46.3),Serum levels of protein RELT,Phosphatidylinositol (18:0_20:3) (a) levels,Serum levels of protein VIT,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Vitamin D-binding protein levels (GC.6581.50.3),Retinoid-inducible serine carboxypeptidase levels,Phosphatidylinositol (16:0_20:3) (b) levels
25-hydroxyvitamin-D2 (25OH-D2) (Reported Values: 0-30),25-Hydroxyvitamin D levels,Serum 25-Hydroxyvitamin D levels,Serum 25-Hydroxyvitamin D level variance,25-hydroxyvitamin D levels (skin colour stratified),Vitamin D-binding protein levels (GC.6581.50.3),Vitamin D levels,Dihydroceramide (d18:0/24:0) levels,Dihydroceramide (d18:0/22:0) levels,Dihydroceramide (d18:0/20:0) levels,Dihydroceramide (d18:0/24:1) levels,Dihydroceramide (d18:0/18:0) levels,Serum 25-Hydroxyvitamin D levels x season interaction,Neonatal total 25-hydroxyvitamin D levels (cord blood),Vitamin D levels (dietary vitamin D intake interaction),Midgestational total 25-hydroxyvitamin D levels (antenatal blood),25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Dihexosylceramide (d18:1/24:0) levels,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Dihexosylceramide (d18:1/24:1) levels,Dihexosylceramide (d18:2/24:1) levels,Vitamin levels,25-hydroxyvitamin D levels x skin colour (very fair vs. fair) interaction,Dihexosylceramide (d18:1/20:0) levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Monohexosylceramide (d18:2/24:0) levels,Dihexosylceramide (d18:1/22:0) levels,Dihexosylceramide (d16:1/24:1) levels,Monohexosylceramide (d18:1/24:0) levels,Vitamin D insufficiency,Vitamin D3 levels,Dihexosylceramide (d18:2/16:0) levels,Monohexosylceramide (d16:1/24:0) levels,Monohexosylceramide (d18:1/24:1) levels,Dihexosylceramide (d18:1/16:0) levels,Dihexosylceramide (d18:1/18:0) levels,Monohexosylceramide (d16:1/20:0) levels,Monohexosylceramide (d18:2/20:0) levels,Monohexosylceramide (d18:1/20:0) levels,Monohexosylceramide (d18:2/22:0) levels,Vitamin D-binding protein levels,Monohexosylceramide (d18:2/18:0) levels,Monohexosylceramide (d16:1/22:0) levels,Dihexosylceramide (d16:1/16:0) levels,Monohexosylceramide (d18:1/22:0) levels,Metabolite levels (deoxycholic acid (12 or 24)-sulfate),Monohexosylceramide (d18:1/18:0) levels,Monohexosylceramide (d16:1/18:0) levels,Monohexosylceramide (d18:1/16:0) levels,Serum vitamin D-binding protein levels,Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect)
25-hydroxyvitamin-D3 (25OH-D3) (Reported Values: 32.4-98.5),25-Hydroxyvitamin D levels,Serum 25-Hydroxyvitamin D levels,Serum 25-Hydroxyvitamin D level variance,25-hydroxyvitamin D levels (skin colour stratified),Vitamin D-binding protein levels (GC.6581.50.3),Vitamin D levels,Vitamin D3 levels,Vitamin D levels (dietary vitamin D intake interaction),Dihydroceramide (d18:0/24:0) levels,Dihydroceramide (d18:0/24:1) levels,Dihydroceramide (d18:0/20:0) levels,Dihydroceramide (d18:0/22:0) levels,25-hydroxyvitamin D levels x skin colour (very fair vs. light olive) interaction,Neonatal total 25-hydroxyvitamin D levels (cord blood),Vitamin levels,Dihydroceramide (d18:0/18:0) levels,Serum 25-Hydroxyvitamin D levels x season interaction,25-hydroxyvitamin D levels x skin colour (very fair vs. fair) interaction,Midgestational total 25-hydroxyvitamin D levels (antenatal blood),Vitamin D-binding protein levels,Serum vitamin D-binding protein levels,Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect),Vitamin D insufficiency,Dihexosylceramide (d18:1/24:0) levels,Dihexosylceramide (d18:1/24:1) levels,Vitamin D3 receptor levels,Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect),Dihexosylceramide (d16:1/24:1) levels,Monohexosylceramide (d16:1/24:0) levels,Dihexosylceramide (d18:2/24:1) levels,Dihexosylceramide (d18:1/20:0) levels,Monohexosylceramide (d18:1/24:0) levels,Monohexosylceramide (d18:1/24:1) levels,Monohexosylceramide (d18:2/24:0) levels,Monohexosylceramide (d16:1/20:0) levels,Dihexosylceramide (d18:1/22:0) levels,Dihexosylceramide (d18:1/18:0) levels,Dihexosylceramide (d18:1/16:0) levels,Vitamin D-binding protein levels (adjusted for GC haplotype),Dihexosylceramide (d18:2/16:0) levels,Monohexosylceramide (d18:1/20:0) levels,Monohexosylceramide (d18:2/20:0) levels,Monohexosylceramide (d16:1/22:0) levels,Dihexosylceramide (d16:1/16:0) levels,Trihexosylcermide (d18:1/24:0) levels,Trihexosylcermide (d18:1/24:1) levels,Monohexosylceramide (d16:1/18:0) levels,Monohexosylceramide (d18:1/18:0) levels,Monohexosylceramide (d18:2/18:0) levels,Monohexosylceramide (d18:2/22:0) levels
Alfa-tocopherol (Vit. E) (Reported Values: 18.9-38.8.0),Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,Alpha-tocopherol levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Gamma-tocopherol/beta-tocopherol levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels,Stearoyl-arachidonoyl-glycerol (18:0/20:4) [1] levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,Palmitoyl-oleoyl-glycerol (16:0/18:1) [2] levels,Metabolite levels (oleoyl-oleoyl-glycerol (18:1/18:1)  [1]; C36:2 DAG; C36_2_DAG),1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2] levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) levels,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Phosphatidylinositol (18:0_20:3) (a) levels,Phosphatidylinositol (18:0_22:5) (n3) levels,1-stearoyl-2-oleoyl-gpc (18:0/18:1) levels,1-palmitoyl-2-oleoyl-gpc (16:0/18:1) levels,"5alpha-androstan-3beta,17beta-diol monosulfate (2) levels","5alpha-androstan-3alpha,17beta-diol monosulfate (2) levels",1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Phosphatidylinositol (18:0_22:4) levels,Phosphatidylinositol (18:0_22:6) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,"5alpha-androstan-3alpha,17beta-diol monosulfate (1) levels",1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Phosphatidylinositol (18:0_22:5) (n6) levels,Phosphatidylinositol (16:0_20:3) (a) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels,1-palmitoyl-2-oleoyl-GPE (16:0/18:1) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) levels,Phosphatidylinositol (15-MHDA_20:4) levels/Phosphatidylinositol (17:0_20:4) levels
Gamma-tocopherol (Vit. E) (Reported Values: 2-11),Gamma-tocopherol/beta-tocopherol levels,Alpha-tocopherol levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] levels,Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) levels,"Metabolite levels (1-dihomo-linolenylglycerol (alpha, gamma); 1-dihomo-linolenylglycerol (20:3))",1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Phosphatidylinositol (18:0_22:5) (n6) levels,Palmitoyl-oleoyl-glycerol (16:0/18:1) [2] levels,Phosphatidylinositol(36:0)_[M+OAc]1- levels,Phosphatidylinositol-O(36:0)_[M-H]1-/Phosphatidylglycerol(37:0)_[M+OAc]1- levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2] levels,1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels,1-stearoyl-2-linoleoyl-GPE (18:0/18:2) levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [1] levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Phosphatidylinositol (18:0_22:5) (n3) levels,Stearoyl-arachidonoyl-glycerol (18:0/20:4) [1] levels,Gamma-enolase levels (ENO2.11083.23.3),Phosphatidylinositol (18:0_22:6) levels,Metabolite levels (oleoyl-oleoyl-glycerol (18:1/18:1)  [1]; C36:2 DAG; C36_2_DAG),Phosphatidylinositol(36:1)_[M+OAc]1- levels,Phosphatidylinositol-O(33:0)_[M-H]1- levels,Phosphatidylinositol (18:0_22:4) levels,1-palmitoyl-2-oleoyl-GPE (16:0/18:1) levels,Phosphatidylinositol (18:0_20:3) (a) levels,Gamma-tocopherol/beta-tocopherol levels in elite athletes
Phylloquinone (Vit. K1); <Limit Of Detection indicated by 8881 (Reported Values: 0.1-8.7),Circulating phylloquinone levels,Kallikrein-8 levels (KLK8.13708.56.3),Kynureninase levels (KYNU.4559.64.2),Leiomodin-1 levels (LMOD1:P29536:OID31416:v1),Spread type: Flora Pro-Active/Benecol (UKB data field 1428_2),Kallikrein-14 levels (KLK14.8620.56.3),NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 levels (NDUFB4.10677.9.3),Leiomodin-1 levels (LMOD1:P29536:OID31014:v1),Kallikrein-12 levels (KLK12.3199.54.2),Quinone oxidoreductase-like protein 1 levels (CRYZL1.9207.60.3),NAD(P)H dehydrogenase [quinone] 1 levels (NQO1.9837.60.3),Plasma metabolome feature (c18_713) (Quinolinic acid),Ribosyldihydronicotinamide dehydrogenase [quinone] levels (NQO2.9754.33.3),1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels,Leiomodin-1 levels (LMOD1:P29536:OID30212:v1),Ubiquinone levels,Leiomodin-1 levels (LMOD1:P29536:OID30547:v1),NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 levels,Carboxypeptidase Q levels,Plasma metabolome feature (hilic_4665) (1-Amino-24-dibromoanthraquinone),NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 levels,Kallikrein-7 levels (KLK7.3378.49.2),1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels,NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 levels,Gut bacterial pathway abundance (PWY.6708..ubiquinol.8.biosynthesis..prokaryotic.),1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (p-16:0/20:4) levels,1-palmitoyl-2-dihomo-linolenoyl-GPE (16:0/20:3) levels,1-(1-enyl-stearoyl)-2-linoleoyl-GPE (p-18:0/18:2) levels,Phosphomevalonate kinase levels (PMVK.12450.42.3),Kallikrein-6 levels,Kallikrein-15 levels,Coenzyme Q10 levels,Kynurenine--oxoglutarate transaminase 3 levels (CCBL2.12682.5.3),Kallikrein-8 levels,Hydroquinone sulfate levels,Kallikrein-12 levels,Phosphatidylinositol(38:6)_[M-H]1- levels,Kininogen-1 levels,1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) levels,Phosphatidylinositol-O(33:0)_[M-H]1- levels,1-(1-enyl-stearoyl)-2-linoleoyl-GPC (p-18:0/18:2) levels,Phosphatidylinositol(34:0)_[M-H]1- levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels (advanced age),Total Ubiquinone levels,Phosphatidylinositol_38:0_[M-H]1- levels,Quinone oxidoreductase-like protein 1 levels,Phosphatidylinositol(38:4)_[M-H]1- levels,1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (p-18:0/20:4) levels,Phosphatidylinositol(36:2)_[M-H]1- levels,1-(1-enyl-palmitoyl)-2-arachidonoyl-gpc (p-16:0/20:4) levels
Myristoylcarnitine (Reported Values: 0.01-0.1),Myristoleoylcarnitine levels,Myristoylcarnitine levels,Myristoleoylcarnitine (C14:1) levels,Myristoylcarnitine (C14) levels,Myristoleate (14:1n5) levels,Metabolite levels (myristoleate (14:1n5); myristoleic acid),1-myristoyl-GPC (14:0) levels,1-myristoyl-2-eicosapentaenoyl-GPC (14:0/20:5) levels,2-myristoyl-GPC (14:0) levels,Myristoleate 14:1n5 levels,Myristoleoylcarnitine (C14:1) levels in elite athletes,1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Rac-glycerol 1-myristate levels,Myristoylcarnitine (C14) levels in elite athletes,Metabolite levels (1-myristoyl-2-arachidonoyl-GPC (14:0/20:4); C34:4 PC; C34_4_PC),Nervonoylcarnitine (C24:1) levels,1-myristoylglycerol (14:0) levels,1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) levels,Myristate 14:0-to-myristoleate 14:1n5 ratio,Tetradecenoylcarnitine levels,Octadecenoylcarnitine levels,Eicosenoylcarnitine (C20:1) levels,1-myristoylglycerophosphocholine levels (Biocrates platform),Acetylcarnitine levels (Biocrates platform),Myristate (14:0) levels in elite athletes,1-(1-enyl-palmitoyl)-2-myristoyl-GPC (p-16:0/14:0) levels,3-hydroxyoctanoylcarnitine (2) levels,Myristoleate (14:1n5) levels in elite athletes,Margaroylcarnitine (C17) levels,Acylcarnitine (10:0) levels,X-13431--nonanoylcarnitine levels,Lignoceroylcarnitine (C24) levels,Butyrylcarnitine levels (Biocrates platform),Oleoylcarnitine levels (Biocrates platform),Isovalerylcarnitine levels (Biocrates platform),Acylcarnitine (14:0) levels,Acylcarnitine (13:0) levels,Carnitine-to-X-12798 ratio,Linoleoylcarnitine (C18:2) levels,3-hydroxyoctanoylcarnitine (1) levels,Histidine levels (Biocrates platform),Arachidonoylcarnitine (C20:4) levels,Carnitine levels (Biocrates platform),Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),Octadecandienylcarnitine levels,Acylcarnitine (12:0) levels
Palmitoylcarnitine (Reported Values: 0.05-0.25),Palmitoylcarnitine levels,Palmitoleoylcarnitine levels,Palmitoylcarnitine levels (Biocrates platform),Palmitoylcarnitine (C16) levels,Palmitoleoylcarnitine (C16:1) levels,Palmitoylcarnitine levels (Metabolon platform),RBC levels of L-Palmitoylcarnitine,Metabolite levels (1-palmitoyl-2-stearoyl-GPC (16:0/18:0); C34:0 PC),Metabolite levels (palmitoleate (16:1n7); palmitoleate),1-palmitoyl-2-stearoyl-gpc (16:0/18:0) levels,1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,1-palmityl-2-palmitoyl-GPC (O-16:0/16:0) levels,Metabolite levels (1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6)),1-palmitoyl-2-palmitoleoyl-gpc (16:0/16:1) levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,1-myristoyl-2-palmitoyl-gpc (14:0/16:0) levels,1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5) levels,Metabolite levels (1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4); C36:4 PI),Metabolite levels (1-palmitoyl-2-docosahexaenoyl-GPC (16:0/22:6); C38:6 PC; C38_6_PC),N-palmitoylserine levels,1-palmitoleoyl-GPC (16:1) levels,Metabolite levels (1-palmitoylglycerophosphocholine (16:0); 1-palmitoyl-GPC (16:0); C16:0 LPC; C16_0_LPC),Stearoylcarnitine levels (Biocrates platform),1-palmitoyl-2-meadoyl-GPC (16:0/20:3n9) levels,1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) levels,Palmitoyl-linoleoyl-glycerol (16:0/18:2) [2] levels,Metabolite levels (1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3)),Metabolite levels (1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6)),1-palmitoyl-GPA (16:0) levels,Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2] levels,Metabolite levels (1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4)),Metabolite levels (1-palmitoyl-2-linoleoyl-GPI (16:0/18:2); C34:2 PI),Palmitoleoyl-linoleoyl-glycerol (16:1/18:2) [1] levels,Metabolite levels (1-palmitoyl-2-linoleoyl-GPC (16:0/18:2); C34:2 PC; C34_2_PC),Palmitoyl-linoleoyl-glycerol (16:0/18:2) [1] levels,Palmitoylcholine levels,1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Metabolite levels (1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)),Palmitoylcarnitine (C16) levels in elite athletes,1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) levels,1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2) levels,Metabolite levels (1-palmitoleoylglycerophosphocholine (16:1); 1-palmitoleoyl-GPC (16:1); C16:1 LPC; C16_1_LPC),2-palmitoleoyl-GPC (16:1) levels,Pimelylcarnitine levels,Metabolite levels (1-palmitoyl-2-oleoyl-GPC (16:0/18:1); C34:1 PC; C34_1_PC),1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4) levels,Palmitoleoylcarnitine (C16:1) levels in elite athletes,N-palmitoylglycine levels,Metabolite levels (N-palmitoyl glycine; N-palmitoylglycine),1-palmitoyl-2-docosahexaenoyl-gpc (16:0/22:6) levels
Stearoylcarnitine (Reported Values: 0.03-0.1),Stearoylcarnitine levels,Stearoylcarnitine (C18) levels,Stearoylcarnitine levels (Biocrates platform),Stearoylcarnitine levels (Metabolon platform),Undecenoylcarnitine (C11:1) levels,Laurylcarnitine (C12) levels,Eicosenoylcarnitine (C20:1) levels,1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels,Undecenoylcarnitine (c11:1) (X-17337) levels,Acylcarnitine (10:0) levels,Metabolite levels (methylsuccinoylcarnitine),Acylcarnitine (14:0) levels,Methylsuccinoylcarnitine levels,Metabolite levels (nonanoylcarnitine (C9); C9 carnitine; C9_carnitine),Succinylcarnitine levels,Acylcarnitine (13:0) levels,Acylcarnitine (12:0) levels,Metabolite levels (cerotoylcarnitine (C26); C26 carnitine; C26_carnitine),Margaroylcarnitine (C17) levels,Metabolite levels (linolenoylcarnitine (C18:3)),Linolenoylcarnitine (C18:3) levels,Acylcarnitine (10:1) levels,Carnitine C10 levels,Acylcarnitine (14:1) levels,Acylcarnitine (18:0) levels,Stearic acid (18:0) levels,Acylcarnitine (15:0) (a) levels,Acylcarnitine (16:0) levels,Metabolite levels (suberoylcarnitine (C8-DC)),Acylcarnitine (17:0) (a) levels,1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) levels,Metabolite levels (succinylcarnitine; succinylcarnitine (C4-DC)),Acylcarnitine (18:1) levels,Oleoylcarnitine (C18:1) levels,Laurylcarnitine levels (Biocrates platform),Acylcarnitine (16:1) levels,Acetylcarnitine (c2) levels,Myristoylcarnitine (C14) levels,1-stearoyl-gpc (18:0) levels,1-stearoyl-2-meadoyl-GPC (18:0/20:3n9) levels,Arachidoylcarnitine (C20) levels,Nonanoylcarnitine (C9) levels,Nervonoylcarnitine (C24:1) levels,Decanoylcarnitine (C10) levels,Laurylcarnitine levels,1-palmityl-2-stearoyl-GPC (O-16:0/18:0) levels,Palmitoylcarnitine (C16) levels,Metabolite levels (linoleoylcarnitine; linoleoylcarnitine (C18:2); C18:2 carnitine; C18_2_carnitine),1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels,Docosapentaenoylcarnitine (C22:5n3) levels
Oleoylcarnitine (Reported Values: 0.04-0.2),Oleoylcarnitine (C18:1) levels,Oleoylcarnitine levels,Oleoylcarnitine levels (Biocrates platform),Oleoylcarnitine levels (Metabolon platform),Tetradecenoylcarnitine levels,Octadecenoylcarnitine levels,Metabolite levels (oleoylcarnitine; oleoylcarnitine (C18:1); C18:1 carnitine; C18_1_carnitine),Linoleoylcarnitine (C18:2) levels,Lignoceroylcarnitine (C24) levels,Arachidonoylcarnitine (C20:4) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [2] levels,Nervonoylcarnitine (C24:1) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,Eicosenoylcarnitine (C20:1) levels,1-oleoyl-2-arachidonoyl-GPE (18:1/20:4) levels,Oleoyl-arachidonoyl-glycerol (18:1/20:4) [1] levels,1-oleoyl-2-eicosapentaenoyl-GPC (18:1/20:5) levels,Octadecandienylcarnitine levels,Metabolite levels (arachidonoylcarnitine (C20:4)),Linoleoylcarnitine levels,Ximenoylcarnitine (C26:1) levels,Tetradecadienylcarnitine levels,3-hydroxyoctanoylcarnitine (2) levels,3-hydroxyoctanoylcarnitine (1) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] levels,Margaroylcarnitine (C17) levels,1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels,3-hydroxyoleoylcarnitine levels,1-oleoyl-3-linoleoyl-glycerol (18:1/18:2) levels,1-stearoyl-2-oleoyl-GPI (18:0/18:1) levels,1-stearoyl-2-oleoyl-gpc (18:0/18:1) levels,Octadecadienylcarnitine levels,1-oleoyl-2-linoleoyl-glycerol (18:1/18:2) levels,Hexadecenoylcarnitine levels,Myristoleoylcarnitine (C14:1) levels,1-oleoyl-2-linoleoyl-GPE (18:1/18:2) levels,Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] levels,1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6) levels,Oleoyl-oleoyl-glycerol (18:1/18:1) [2] levels,Metabolite levels (1-stearoyl-2-oleoyl-GPI (18:0/18:1)),1-palmityl-2-oleoyl-GPC (o-16:0/18:1) levels,Oleoyl-oleoyl-glycerol (18:1/18:1)  [1] levels,Acetylcarnitine levels (Biocrates platform),Palmitoleoylcarnitine (C16:1) levels,1-oleoyl-GPI (18:1) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Oleoylcarnitine (C18:1) levels in elite athletes,Myristoylcarnitine (C14) levels,1-oleoyl-GPC (18:1) levels,1-margaroyl-2-oleoyl-GPC (17:0/18:1) levels
Linoleylcarnitine (Reported Values: 0.01-0.1),Linolenoylcarnitine (C18:3) levels,Linoleoylcarnitine (C18:2) levels,Linoleoylcarnitine levels,Metabolite levels (linolenoylcarnitine (C18:3)),Dihomo-linolenoylcarnitine (C20:3n3 or 6) levels,Metabolite levels (dihomo-linolenoylcarnitine (C20:3n3 or 6)),Dihomo-linoleoylcarnitine (C20:2) levels,Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2] levels,Metabolite levels (dihomo-linoleoylcarnitine (C20:2)),1-linoleoyl-2-linolenoyl-GPC (18:2/18:3) levels,1-pentadecanoyl-2-linoleoyl-GPC (15:0/18:2) levels,Metabolite levels (linoleoylcarnitine; linoleoylcarnitine (C18:2); C18:2 carnitine; C18_2_carnitine),1-stearoyl-2-linoleoyl-gpc (18:0/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2] levels,Linoleoyl-linoleoyl-glycerol (18:2/18:2) [1] levels,Lignoceroylcarnitine (C24) levels,1-myristoyl-2-linoleoyl-GPC (14:0/18:2) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [2] levels,1-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levels,1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) levels,1-linoleoyl-gpc (18:2) levels,1-palmityl-2-linoleoyl-GPC (O-16:0/18:2) levels,Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels,Metabolite levels (1-linoleoyl-2-linolenoyl-GPC (18:2/18:3)),1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6) levels,1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3) levels,Myristoyl-linoleoyl-glycerol (14:0/18:2) [1] levels,Myristoleoylcarnitine (C14:1) levels,1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels,Laurylcarnitine levels (Biocrates platform),1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) levels,Laurylcarnitine (C12) levels,Acylcarnitine (17:0) (a) levels,2-linoleoyl-GPC (18:2) levels,Carnitine-to-X-12798 ratio,Acylcarnitine (16:0) levels,Oleoylcarnitine (C18:1) levels,1-oleoyl-2-linoleoyl-GPC (18:1/18:2) levels,1-linolenoyl-GPC (18:3) levels,Linolenoylcarnitine (C18:3) levels in elite athletes,1-margaroyl-2-linoleoyl-GPC (17:0/18:2) levels,1-stearoyl-2-linoleoyl-GPE (18:0/18:2) levels,Linoleoylcarnitine (C18:2) levels in elite athletes,Acylcarnitine (16:1) levels,Undecenoylcarnitine (c11:1) (X-17337) levels,Metabolite levels (1-stearoyl-2-linoleoyl-GPI (18:0/18:2); C36:2 PI),Acylcarnitine (10:0) levels,Metabolite levels (1-stearoyl-2-linoleoyl-GPC (18:0/18:2); C36:2 PC; C36_2_PC),1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2) levels,Myristoylcarnitine (C14) levels
